|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Deoxycytidine Monophosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 2'-deoxyguanosine 5'-phosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of CEBPA protein |
CTD |
PMID:19427183 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of DLK1 mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of FABP4 mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of FAS mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of glucosamine 6-phosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of glucosamine 6-phosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of LEP mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases expression |
ISO |
glucosamine 6-phosphate results in increased expression of LIPE mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of LPL mRNA |
CTD |
PMID:19427183 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of PPARG protein |
CTD |
PMID:19427183 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of SREBF1 protein |
CTD |
PMID:19427183 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of TNF mRNA |
CTD |
PMID:19427183 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Tymp |
thymidine phosphorylase |
increases abundance |
ISO |
TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate |
CTD |
PMID:11103787 |
|
NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
|
G |
Tymp |
thymidine phosphorylase |
increases abundance |
ISO |
TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate |
CTD |
PMID:11103787 |
|
NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression multiple interactions |
ISO |
Cyclic AMP results in increased expression of ABCA1 mRNA; Cyclic AMP results in increased expression of ABCA1 protein [HCAR2 protein results in decreased abundance of Cyclic AMP] which results in decreased expression of ABCA1 protein |
CTD |
PMID:20339114 PMID:20655299 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport multiple interactions affects uptake |
ISO |
ABCC4 protein results in increased transport of Cyclic AMP Probenecid affects the reaction [ABCC4 protein affects the uptake of Cyclic AMP analog] |
CTD |
PMID:11856762 PMID:28587784 |
|
NCBI chr15:101,948,387...102,182,912
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
ISO |
[ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:7733904 |
|
NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases abundance |
ISO |
ADIPOQ protein results in increased abundance of Cyclic AMP |
CTD |
PMID:18931039 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases abundance |
EXP |
ADM protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP] ADM protein results in increased abundance of Cyclic AMP; ADM results in increased abundance of Cyclic AMP |
CTD |
PMID:10374718 PMID:17306419 |
|
NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
multiple interactions |
ISO |
ADRA1B protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP] |
CTD |
PMID:12649302 |
|
NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,255,025...28,312,919
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions increases abundance affects abundance |
ISO EXP |
[3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Bupranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ADRB1 protein polymorphism affects the reaction [[Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP]; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; Isoproterenol promotes the reaction [ADRB1 protein results in increased abundance of Cyclic AMP]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP] ADRB1 protein affects the abundance of Cyclic AMP; ADRB1 protein polymorphism affects the abundance of Cyclic AMP ADRB1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] |
CTD |
PMID:11562432 PMID:12761341 PMID:14502278 PMID:14730417 PMID:15060759 PMID:17200720 PMID:18378355 PMID:18787115 PMID:19419905 More...
|
|
NCBI chr 1:265,777,103...265,780,114
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases chemical synthesis increases abundance affects abundance |
EXP ISO |
[Terbutaline results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; ADRB2 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] ADRB2 protein polymorphism results in increased chemical synthesis of Cyclic AMP; ADRB2 protein results in increased chemical synthesis of Cyclic AMP [Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [BRL 37344 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [carvedilol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Isoproterenol results in increased activity of ADRB2 protein] which results in increased chemical synthesis of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metaproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Nadolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Oxprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Practolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Propranolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Sotalol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP] ADRB2 protein results in increased abundance of Cyclic AMP ADRB2 protein affects the abundance of Cyclic AMP |
CTD |
PMID:10516654 PMID:10857765 PMID:10952688 PMID:11562432 PMID:12920204 PMID:14730417 PMID:16036225 PMID:16980553 PMID:17925438 PMID:18378355 PMID:19419905 PMID:21868359 PMID:27825928 More...
|
|
NCBI chr18:57,912,760...57,914,802
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions affects abundance |
ISO |
3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [[SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP]; [Albuterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [BRL 37344 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP ADRB3 protein affects the abundance of Cyclic AMP |
CTD |
PMID:10952688 PMID:14730417 |
|
NCBI chr16:71,544,603...71,547,410
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Ahcyl1 |
adenosylhomocysteinase-like 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of AHCYL1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:197,982,335...198,016,770
Ensembl chr 2:195,294,153...195,345,815
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions decreases expression |
EXP ISO |
AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer] 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA Cyclic AMP results in decreased expression of AHR protein |
CTD |
PMID:12859982 PMID:32781018 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Alpp |
alkaline phosphatase, placental |
multiple interactions |
ISO |
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of ALPP mRNA |
CTD |
PMID:16036225 |
|
NCBI chr 9:95,213,763...95,216,509
Ensembl chr 9:87,765,860...87,768,606
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANGPTL4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ank2 |
ankyrin 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANK2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:218,052,555...218,628,414
Ensembl chr 2:215,379,680...215,862,923
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions increases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]; N-(2-aminoethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA] |
CTD |
PMID:12542607 |
|
NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Cyclic AMP results in decreased expression of AQP5 protein]; Cyclic AMP affects the expression of and results in increased phosphorylation of and results in increased localization of AQP5 protein |
CTD |
PMID:15536076 |
|
NCBI chr 7:132,601,528...132,605,060
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Armh4 |
armadillo-like helical domain containing 4 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ARMH4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr15:25,455,478...25,556,569
Ensembl chr15:22,975,895...23,076,949
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
EXP |
Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein] |
CTD |
PMID:12859982 |
|
NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein |
CTD |
PMID:25191754 |
|
NCBI chr10:55,645,539...55,653,485
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atf5 |
activating transcription factor 5 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ATF5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:104,432,094...104,437,611
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
ISO |
[AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:20683494 |
|
NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Avpr2 |
arginine vasopressin receptor 2 |
multiple interactions increases abundance |
ISO |
[AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP AVPR2 protein results in increased abundance of Cyclic AMP |
CTD |
PMID:20683494 PMID:33638691 |
|
NCBI chr X:156,785,009...156,787,477
Ensembl chr X:151,633,522...151,635,989
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein |
CTD |
PMID:33713149 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
increases activity multiple interactions |
ISO EXP |
Cyclic AMP results in increased activity of BRAF protein [Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein |
CTD |
PMID:21693435 |
|
NCBI chr 4:69,329,772...69,476,931
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
C13h1orf115 |
similar to human chromosome 1 open reading frame 115 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C13H1ORF115 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:98,953,841...98,963,577
Ensembl chr13:96,422,302...96,432,068
|
|
G |
C1qtnf5 |
C1q and TNF related 5 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C1QTNF5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:53,347,754...53,349,912
Ensembl chr 8:44,451,154...44,453,074
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases abundance multiple interactions |
ISO EXP |
CALCA protein modified form results in increased abundance of Cyclic AMP; CALCA protein results in increased abundance of Cyclic AMP CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]] Isoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]; sevoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP] |
CTD |
PMID:15297469 PMID:17295025 PMID:17306419 PMID:18463244 |
|
NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Carm1 |
coactivator-associated arginine methyltransferase 1 |
multiple interactions increases phosphorylation |
ISO |
[Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] |
CTD |
PMID:20360387 |
|
NCBI chr 8:28,373,370...28,418,056
Ensembl chr 8:20,097,254...20,147,689
|
|
G |
Cckbr |
cholecystokinin B receptor |
multiple interactions |
ISO |
CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP] |
CTD |
PMID:11880531 |
|
NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:159,771,733...159,814,881
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] |
CTD |
PMID:9863660 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CCN2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP ISO |
[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein; sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein] |
CTD |
PMID:21693435 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd3e |
CD3 epsilon subunit of T-cell receptor complex |
decreases phosphorylation |
ISO |
Cyclic AMP results in decreased phosphorylation of CD3E protein |
CTD |
PMID:2824607 |
|
NCBI chr 8:54,200,617...54,211,770
Ensembl chr 8:45,303,852...45,315,022
|
|
G |
Cd3g |
CD3 gamma subunit of T-cell receptor complex |
decreases phosphorylation |
ISO |
Cyclic AMP results in decreased phosphorylation of CD3G protein |
CTD |
PMID:2824607 |
|
NCBI chr 8:54,177,572...54,184,087
Ensembl chr 8:45,281,204...45,287,147
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP ISO |
[Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; Sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein] |
CTD |
PMID:21693435 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases response to substance |
ISO |
CEBPB protein results in increased susceptibility to Cyclic AMP |
CTD |
PMID:23097472 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions increases activity |
ISO EXP |
Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Bicarbonates]; Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Chlorides] CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]; Cyclic AMP affects the localization of and results in increased activity of CFTR protein; Nitric Oxide inhibits the reaction [CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]]; Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]; Primaquine inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein] Cyclic AMP results in increased activity of CFTR protein Genistein promotes the reaction [Cyclic AMP results in increased activity of CFTR protein mutant form] |
CTD |
PMID:11786964 PMID:12529251 PMID:12556293 PMID:12612912 PMID:15229107 PMID:15371258 More...
|
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions affects secretion increases abundance |
EXP ISO |
[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of CGA mRNA CGA protein affects the secretion of Cyclic AMP CGA protein results in increased abundance of Cyclic AMP [CGA protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [CGA protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; [CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]]; DDT inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:8404651 PMID:20378682 PMID:21642635 PMID:23071612 PMID:26895433 PMID:31132478 PMID:33638691 PMID:37552060 More...
|
|
NCBI chr 5:54,283,109...54,295,464
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chsy1 |
chondroitin sulfate synthase 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CHSY1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:129,100,088...129,161,167
Ensembl chr 1:119,686,350...119,750,601
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP ISO |
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP (1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:10422789 PMID:11730719 PMID:17953657 PMID:27429655 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:17558435 PMID:27429655 |
|
NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Cntn1 |
contactin 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 7:125,142,638...125,440,397
Ensembl chr 7:123,372,792...123,558,541
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CP mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; [Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer] |
CTD |
PMID:12859982 PMID:22676303 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein] |
CTD |
PMID:20360387 |
|
NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
ISO EXP |
[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Cholera Toxin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Manganese results in increased chemical synthesis of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:2153673 PMID:20702571 |
|
NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
multiple interactions |
ISO |
[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:20702571 |
|
NCBI chr10:89,540,192...89,583,466
Ensembl chr10:89,040,203...89,083,481
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr13:87,694,062...87,695,978
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression |
ISO |
Cyclic AMP results in increased expression of CSF3 protein |
CTD |
PMID:7540958 |
|
NCBI chr10:84,157,485...84,159,860
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
ISO |
CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Terbutaline results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]] |
CTD |
PMID:1699227 |
|
NCBI chr 8:66,925,650...66,944,861
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Cstb |
cystatin B |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CSTB mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:10,245,157...10,247,199
Ensembl chr20:10,245,462...10,247,526
|
|
G |
Ctsa |
cathepsin A |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CTSA mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:173,988,443...173,994,320
Ensembl chr 3:153,568,381...153,576,215
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Cyclic AMP results in increased expression of CYP11A1 mRNA Cyclic AMP results in increased expression of CYP11A1 mRNA; Cyclic AMP results in increased expression of CYP11A1 protein myricetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA] |
CTD |
PMID:25576683 PMID:28668616 PMID:29228121 |
|
NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions increases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of CYP11B1 mRNA] |
CTD |
PMID:22172629 |
|
NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
[acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein Cyclic AMP results in increased expression of CYP17A1 mRNA |
CTD |
PMID:23084589 PMID:25576683 |
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Cyclic AMP results in increased expression of CYP19A1 mRNA; Cyclic AMP results in increased expression of CYP19A1 protein [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:29228121 PMID:31953017 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA |
CTD |
PMID:32781018 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO EXP |
Cyclic AMP results in increased expression of CYP1B1 mRNA; Cyclic AMP results in increased expression of CYP1B1 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer] |
CTD |
PMID:12859982 PMID:32781018 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Cyclic AMP results in increased expression of CYP51 mRNA |
CTD |
PMID:25576683 |
|
NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression decreases activity |
EXP |
Cyclic AMP results in decreased expression of CYP7B1 mRNA Cyclic AMP results in decreased activity of CYP7B1 protein |
CTD |
PMID:12029625 |
|
NCBI chr 2:102,419,011...102,586,047
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Dap |
death-associated protein |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DAP mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:83,910,113...83,962,673
Ensembl chr 2:82,199,280...82,251,752
|
|
G |
Ddt |
D-dopachrome tautomerase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DDT mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:12,883,025...12,886,121
Ensembl chr20:12,884,243...12,888,482
|
|
G |
Disc1 |
DISC1 scaffold protein |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein] |
CTD |
PMID:16293762 |
|
NCBI chr19:69,911,548...70,120,970
Ensembl chr19:53,014,616...53,219,778
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
affects response to substance |
ISO |
DKK1 protein affects the susceptibility to Cyclic AMP |
CTD |
PMID:21546446 |
|
NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
increases abundance |
EXP |
DLD protein results in increased abundance of Cyclic AMP |
CTD |
PMID:25981801 |
|
NCBI chr 6:53,631,686...53,655,059
Ensembl chr 6:47,903,914...47,924,795
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr10:55,239,397...55,267,780
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
ISO EXP |
A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP] [SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP; A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]; SCH 23390 inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Spiperone inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]] |
CTD |
PMID:8558425 PMID:15711596 |
|
NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] [quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP; CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP] |
CTD |
PMID:11880531 PMID:17958328 |
|
NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd4 |
dopamine receptor D4 |
multiple interactions |
ISO |
[3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine binds to and results in decreased activity of DRD4 protein] inhibits the reaction [Naloxone results in increased abundance of Cyclic AMP] |
CTD |
PMID:15542745 |
|
NCBI chr 1:205,825,937...205,829,124
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
E2f2 |
E2F transcription factor 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 5:153,682,789...153,706,087
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:17295779 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[[Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA |
CTD |
PMID:12767924 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Ehd2 |
EH-domain containing 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of EHD2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:85,767,757...85,786,974
Ensembl chr 1:76,637,482...76,658,783
|
|
G |
Endod1 |
endonuclease domain containing 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENDOD1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:19,490,615...19,520,007
Ensembl chr 8:11,211,110...11,238,892
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENO2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Epo |
erythropoietin |
increases expression |
EXP |
Cyclic AMP results in increased expression of EPO protein |
CTD |
PMID:18621143 |
|
NCBI chr12:24,841,285...24,844,725
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
increases expression |
EXP |
Cyclic AMP results in increased expression of ERRFI1 mRNA |
CTD |
PMID:1472065 |
|
NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:161,323,998...161,337,282
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity |
ISO |
[Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased activity of ESR1 protein] |
CTD |
PMID:19766106 PMID:20360387 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:19766106 PMID:20378682 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
[C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [C186 65 binds to and results in increased activity of F2R protein] which results in decreased chemical synthesis of Cyclic AMP |
CTD |
PMID:22207716 |
|
NCBI chr 2:28,604,066...28,620,579
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [F2RL1 protein results in increased transport of Chlorides] |
CTD |
PMID:11804840 |
|
NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
F2rl3 |
F2R like thrombin or trypsin receptor 3 |
multiple interactions |
ISO |
[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] which results in decreased chemical synthesis of Cyclic AMP |
CTD |
PMID:22207716 |
|
NCBI chr16:17,151,516...17,153,509
Ensembl chr16:17,117,441...17,119,472
|
|
G |
Fam20c |
FAM20C, golgi associated secretory pathway kinase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FAM20C mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr12:20,940,654...20,999,072
Ensembl chr12:15,826,871...15,884,543
|
|
G |
Fcgr2a |
Fc gamma receptor 2A |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FCGR3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:85,813,516...85,830,269
Ensembl chr13:83,280,784...83,295,967
|
|
G |
Fdx1 |
ferredoxin 1 |
multiple interactions increases expression |
ISO |
myricetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA] |
CTD |
PMID:28668616 |
|
NCBI chr 8:61,164,839...61,183,645
Ensembl chr 8:52,268,536...52,287,414
|
|
G |
Fig4 |
FIG4 phosphoinositide 5-phosphatase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FIG4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:46,183,225...46,306,686
Ensembl chr20:44,600,603...44,723,844
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
[Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA Cyclic AMP results in increased expression of FOS mRNA |
CTD |
PMID:10064622 PMID:10711420 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 4:163,325,628...163,338,100
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA] FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]] |
CTD |
PMID:26847930 PMID:31953017 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions increases abundance increases secretion |
EXP ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of FSHB mRNA; fulvestrant inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Methoxychlor inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP] FSHB protein results in increased secretion of Cyclic AMP NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]] [FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:8404651 PMID:18535249 PMID:23137853 PMID:23583632 PMID:25549949 PMID:26895433 More...
|
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:26895433 |
|
NCBI chr 6:10,952,329...11,160,288
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Fzd10 |
frizzled class receptor 10 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr12:33,734,364...33,737,559
Ensembl chr12:28,098,371...28,101,566
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP ISO |
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA] [Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein] |
CTD |
PMID:22676303 PMID:26847930 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gabpb1 |
GA binding protein transcription factor subunit beta 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GABPB1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:134,333,339...134,380,239
Ensembl chr 3:113,879,973...113,923,696
|
|
G |
Gabra2 |
gamma-aminobutyric acid type A receptor subunit alpha 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr14:37,451,218...37,587,458
Ensembl chr14:37,097,279...37,228,944
|
|
G |
Gbp2 |
guanylate binding protein 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GBP2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Gcg |
glucagon |
multiple interactions increases chemical synthesis increases abundance |
ISO EXP |
[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP GCG protein results in increased chemical synthesis of Cyclic AMP Dietary Fats promotes the reaction [GCG protein results in increased chemical synthesis of Cyclic AMP]; Niclosamide inhibits the reaction [GCG protein results in increased abundance of Cyclic AMP] [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:6312992 PMID:18669601 PMID:20074626 PMID:25191754 PMID:26964897 |
|
NCBI chr 3:67,522,489...67,531,533
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
ISO |
3,9-bis((ethylthio)methyl)-K-252a inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein; [GDNF protein co-treated with Cyclic AMP] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; [GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium; Mazindol inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; vanoxerine inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:19647008 PMID:33713149 |
|
NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA |
CTD |
PMID:33713149 |
|
NCBI chr10:88,352,987...88,361,661
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ghrh |
growth hormone releasing hormone |
multiple interactions |
ISO |
[GH-RH(1-29), desaminotyrosyl(1)-ornithyl(12,21)-alpha-aminobutryic acid(15)-norleucyl(27)-aspartyl(28)-agmatine(29)- binds to and results in increased activity of GHRH protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:22308467 |
|
NCBI chr 3:166,412,763...166,432,519
Ensembl chr 3:145,992,763...146,011,889
|
|
G |
Gip |
gastric inhibitory polypeptide |
multiple interactions |
ISO |
[GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:25191754 |
|
NCBI chr10:81,465,070...81,473,216
Ensembl chr10:80,968,352...80,976,503
|
|
G |
Gipr |
gastric inhibitory polypeptide receptor |
multiple interactions |
ISO |
[GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:25191754 |
|
NCBI chr 1:87,932,316...87,956,084
Ensembl chr 1:78,805,593...78,814,462
|
|
G |
Gli1 |
GLI family zinc finger 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 7:65,042,237...65,054,888
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Glipr2 |
GLI pathogenesis-related 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GLIPR2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:62,966,163...62,998,016
Ensembl chr 5:58,170,425...58,202,272
|
|
G |
Glp1r |
glucagon-like peptide 1 receptor |
multiple interactions |
ISO EXP |
[danuglipron results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP; [GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP; [Liraglutide results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP [Exenatide results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP |
CTD |
PMID:18669601 PMID:25191754 PMID:39395609 |
|
NCBI chr20:8,973,393...9,011,622
Ensembl chr20:8,972,004...9,010,241
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
multiple interactions |
ISO |
[[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP |
CTD |
PMID:20713914 |
|
NCBI chr 8:117,167,045...117,187,652
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Gnal |
G protein subunit alpha L |
multiple interactions |
ISO |
[[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:15598656 |
|
NCBI chr18:62,892,257...63,032,510
Ensembl chr18:60,622,311...60,762,599
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO |
[[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP] [[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:11895442 PMID:15598656 PMID:23022524 |
|
NCBI chr 3:183,489,648...183,554,570
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
multiple interactions |
ISO |
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP [Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Lithocholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:17963371 PMID:23022524 |
|
NCBI chr 9:83,309,895...83,312,397
Ensembl chr 9:75,860,677...75,863,168
|
|
G |
Gpc3 |
glypican 3 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GPC3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr X:136,789,770...137,157,598
Ensembl chr X:131,868,990...132,236,798
|
|
G |
Greb1l |
GREB1 like retinoic acid receptor coactivator |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GREB1L mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr18:1,665,468...1,902,291
Ensembl chr18:1,392,725...1,628,067
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 3:28,501,836...28,528,754
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA |
CTD |
PMID:33713149 |
|
NCBI chr10:6,136,458...6,560,003
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein] |
CTD |
PMID:25191754 |
|
NCBI chr 1:211,010,259...211,031,013
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Grn |
granulin precursor |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GRN mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:87,887,834...87,893,938
Ensembl chr10:87,387,638...87,393,775
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
GSK3B protein affects the reaction [Deamino Arginine Vasopressin results in increased abundance of Cyclic AMP] |
CTD |
PMID:20056751 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gtpbp2 |
GTP binding protein 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GTPBP2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:22,311,532...22,321,405
Ensembl chr 9:14,813,964...14,823,241
|
|
G |
Gypc |
glycophorin C |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GYPC mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr18:24,434,921...24,467,592
Ensembl chr18:24,160,739...24,193,204
|
|
G |
Hcar2 |
hydroxycarboxylic acid receptor 2 |
multiple interactions decreases abundance |
ISO |
[3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] HCAR2 protein results in decreased abundance of Cyclic AMP |
CTD |
PMID:17124637 PMID:19223991 PMID:20655299 |
|
NCBI chr12:38,387,163...38,389,149
Ensembl chr12:32,726,184...32,728,504
|
|
G |
Hdac2 |
histone deacetylase 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HDAC2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:42,101,815...42,126,486
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac6 |
histone deacetylase 6 |
affects abundance |
ISO |
HDAC6 protein affects the abundance of Cyclic AMP |
CTD |
PMID:28887310 |
|
NCBI chr X:17,222,538...17,244,373
Ensembl chr X:14,551,044...14,572,441
|
|
G |
Hes3 |
hes family bHLH transcription factor 3 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 5:168,076,337...168,082,270
Ensembl chr 5:162,794,367...162,796,261
|
|
G |
Hist2h2be |
histone cluster 2 H2B family member E |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIST2H2BE mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:186,469,452...186,471,899
|
|
G |
Hivep2 |
HIVEP zinc finger 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIVEP2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:10,176,880...10,376,089
Ensembl chr 1:8,359,289...8,555,993
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [HNF4A protein binds to CYP2A5 promoter] |
CTD |
PMID:18602936 |
|
NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hoxb1 |
homeo box B1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr10:81,827,915...81,830,404
Ensembl chr10:81,331,507...81,332,836
|
|
G |
Hp |
haptoglobin |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr19:54,449,151...54,453,701
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO |
1-Methyl-3-isobutylxanthine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]]; HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]; Triprolidine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]] |
CTD |
PMID:2419744 |
|
NCBI chr 4:149,120,511...149,204,267
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Hrh2 |
histamine receptor H 2 |
increases abundance multiple interactions |
ISO |
HRH2 protein results in increased abundance of Cyclic AMP [Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cyclic AMP; [Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; [Histamine binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cimetidine]; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in increased activity of HRH2 protein] which results in increased abundance of Histamine]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]; HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP] |
CTD |
PMID:9187264 PMID:9681472 PMID:15843518 |
|
NCBI chr17:10,371,083...10,412,979
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions |
EXP |
[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:21276809 |
|
NCBI chr 3:187,569,174...187,575,263
Ensembl chr 3:167,191,558...167,196,642
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression |
ISO |
Cyclic AMP results in increased expression of HSD3B1 mRNA |
CTD |
PMID:25576683 |
|
NCBI chr 2:188,858,574...188,864,694
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
increases expression |
ISO |
Cyclic AMP results in increased expression of HSD3B2 mRNA |
CTD |
PMID:18490834 |
|
NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
[JB-788 binds to and results in increased activity of HTR1A protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Melitten inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11356925 PMID:20580787 |
|
NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
multiple interactions |
ISO |
HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11134654 |
|
NCBI chr 8:91,395,405...91,414,815
Ensembl chr 8:82,517,360...82,534,549
|
|
G |
Htr6 |
5-hydroxytryptamine receptor 6 |
increases abundance multiple interactions |
ISO |
HTR6 protein results in increased abundance of Cyclic AMP Serotonin promotes the reaction [HTR6 protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:11406289 |
|
NCBI chr 5:156,579,901...156,595,147
Ensembl chr 5:151,296,662...151,311,912
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
increases abundance multiple interactions |
ISO |
HTR7 results in increased abundance of Cyclic AMP [3,N-dimethyl-N-(1-methyl-3-(4-methylpiperidin-1-yl)propyl)benzenesulfonamide binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [5-carboxamidotryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Clozapine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Ketanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] which results in decreased abundance of Cyclic AMP; [Methoxydimethyltryptamines binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Mianserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Ritanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Serotonin binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Spiperone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [volinanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP] |
CTD |
PMID:10720076 PMID:14578406 PMID:19509219 |
|
NCBI chr 1:243,049,064...243,173,636
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HTRA1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:194,928,069...194,977,619
Ensembl chr 1:185,497,735...185,547,379
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Cyclic AMP] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein |
CTD |
PMID:32781018 |
|
NCBI chr16:74,133,259...74,145,328
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions affects response to substance |
EXP ISO |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IER3 mRNA] IER3 protein affects the susceptibility to Cyclic AMP [[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP; IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; Pertussis Toxin affects the reaction [IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]] |
CTD |
PMID:19414516 PMID:20713914 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]] |
CTD |
PMID:32781018 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
ISO |
2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] |
CTD |
PMID:31953017 PMID:32446389 PMID:32781018 |
|
NCBI chr14:86,261,277...86,266,344
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IGFBP5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein] |
CTD |
PMID:15843518 |
|
NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein] |
CTD |
PMID:15843518 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il15ra |
interleukin 15 receptor subunit alpha |
multiple interactions decreases expression |
ISO |
[Metformin co-treated with Cyclic AMP] results in decreased expression of IL15RA mRNA; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr17:71,712,141...71,742,072
Ensembl chr17:66,802,334...66,832,278
|
|
G |
Il17re |
interleukin 17 receptor E |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IL17RE mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:148,160,384...148,173,830
Ensembl chr 4:146,605,526...146,618,206
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance |
ISO |
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Ibuprofen inhibits the reaction [IL1B protein results in increased abundance of Cyclic AMP]; KT 5720 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; KT 5823 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; Rolipram promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP] Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA]; Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA]; Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA] |
CTD |
PMID:8904084 PMID:17709599 PMID:22117073 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions increases expression |
ISO |
Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]; Cyclic AMP promotes the reaction [Metformin results in increased expression of IL1RN mRNA]; Metformin promotes the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA] |
CTD |
PMID:22117073 |
|
NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il4 |
interleukin 4 |
increases chemical synthesis multiple interactions |
ISO |
IL4 protein results in increased chemical synthesis of Cyclic AMP Ketoconazole inhibits the reaction [IL4 protein results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:12230500 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
increases expression |
EXP |
Cyclic AMP analog results in increased expression of IL6 mRNA |
CTD |
PMID:10469353 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhba |
inhibin subunit beta A |
increases secretion |
ISO |
Cyclic AMP results in increased secretion of INHBA protein |
CTD |
PMID:20074812 |
|
NCBI chr17:53,787,159...53,810,942
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Inhbe |
inhibin subunit beta E |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 7:65,061,531...65,064,519
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP ISO |
[Theophylline co-treated with INS1 protein] results in decreased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with Norepinephrine] results in increased abundance of Cyclic AMP]; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP] [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein] |
CTD |
PMID:4306506 PMID:26847930 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IQGAP1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:144,088,788...144,178,989
Ensembl chr 1:134,679,586...134,769,755
|
|
G |
Irf6 |
interferon regulatory factor 6 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IRF6 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:107,200,876...107,220,083
Ensembl chr13:104,672,179...104,691,386
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ITGB1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr19:73,602,277...73,650,271
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA |
CTD |
PMID:10711420 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnd2 |
potassium voltage-gated channel subfamily D member 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KCND2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:49,776,246...50,277,728
|
|
G |
Kif15 |
kinesin family member 15 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KIF15 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:131,479,340...131,550,209
Ensembl chr 8:122,601,897...122,672,750
|
|
G |
Kng1 |
kininogen 1 |
increases abundance |
EXP |
KNG1 results in increased abundance of Cyclic AMP |
CTD |
PMID:15750287 |
|
NCBI chr11:91,317,354...91,340,148
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LAMP1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr16:83,058,131...83,082,843
Ensembl chr16:76,355,984...76,381,883
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lep |
leptin |
increases abundance multiple interactions increases expression |
ISO |
LEP protein results in increased abundance of Cyclic AMP 3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrile inhibits the reaction [Cyclic AMP analog results in increased expression of LEP mRNA] |
CTD |
PMID:11342529 PMID:27381457 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions increases abundance increases chemical synthesis affects secretion |
EXP ISO |
5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; [Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of LHB mRNA; [LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP; CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Sphingosine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Tetradecanoylphorbol Acetate inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP] CGB3 protein results in increased chemical synthesis of Cyclic AMP; LHB protein results in increased chemical synthesis of Cyclic AMP LHB protein affects the secretion of Cyclic AMP [LHB protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [LHB protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; DDT inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:2153673 PMID:6430271 PMID:8404651 PMID:23071612 PMID:33638691 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
ISO |
[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:19766106 PMID:20378682 |
|
NCBI chr 6:11,415,361...11,480,834
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases activity |
ISO |
Cyclic AMP results in increased activity of LIPE protein |
CTD |
PMID:7155675 |
|
NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lmna |
lamin A/C |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LMNA mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:176,237,564...176,265,301
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Lurap1l |
leucine rich adaptor protein 1-like |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LURAP1L mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:100,402,921...100,455,479
Ensembl chr 5:95,362,005...95,409,438
|
|
G |
Man1a1 |
mannosidase, alpha, class 1A, member 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MAN1A mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr20:33,745,158...33,928,584
Ensembl chr20:33,202,517...33,385,824
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein |
CTD |
PMID:33713149 |
|
NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mc2r |
melanocortin 2 receptor |
multiple interactions |
ISO |
[acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased expression of MC2R mRNA |
CTD |
PMID:23084589 |
|
NCBI chr18:64,279,878...64,291,775
Ensembl chr18:62,004,948...62,015,488
|
|
G |
Msantd3 |
Myb/SANT DNA binding domain containing 3 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MSANTD3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:67,661,551...67,687,971
Ensembl chr 5:62,866,022...62,888,859
|
|
G |
Ndufb11 |
NADH:ubiquinone oxidoreductase subunit B11 |
increases phosphorylation multiple interactions |
ISO |
Cyclic AMP results in increased phosphorylation of NDUFB11 protein Zalcitabine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]; Zidovudine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein] |
CTD |
PMID:17904600 |
|
NCBI chr X:4,126,317...4,128,575
Ensembl chr X:1,572,785...1,575,062
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
EXP |
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA; [Isoproterenol results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA Cyclic AMP results in increased expression of NGF mRNA |
CTD |
PMID:2174743 PMID:2853697 |
|
NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nog |
noggin |
multiple interactions |
ISO |
NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:23137853 |
|
NCBI chr10:74,625,874...74,627,501
Ensembl chr10:74,128,712...74,130,339
|
|
G |
Npl |
N-acetylneuraminate pyruvate lyase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NPL mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:68,205,602...68,247,940
Ensembl chr13:65,655,118...65,697,372
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression multiple interactions |
ISO |
Cyclic AMP results in decreased expression of NR0B1 mRNA Verapamil promotes the reaction [Cyclic AMP results in decreased expression of NR0B1 mRNA] |
CTD |
PMID:19822634 |
|
NCBI chr X:54,707,658...54,711,786
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Ntan1 |
N-terminal asparagine amidase |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NTAN1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:2,618,239...2,633,185
|
|
G |
Oat |
ornithine aminotransferase |
increases activity multiple interactions increases expression |
EXP |
Cyclic AMP results in increased activity of OAT protein Deoxyglucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Dihydroxyacetone inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased expression of OAT mRNA]; Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glycerol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Inositol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Rhamnose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Xylitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2824512 PMID:2827574 |
|
NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
[7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [[Naloxone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [[Naltrexone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [chlornaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [clocinnamox binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [nalmefene binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP |
CTD |
PMID:11413242 |
|
NCBI chr 1:45,565,371...45,818,722
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
Or51a41 |
olfactory receptor family 51 subfamily A member 41 |
multiple interactions |
ISO |
[pelargonic acid results in increased activity of OR51A5 protein] which results in increased abundance of Cyclic AMP; octanoic acid promotes the reaction [[pelargonic acid results in increased activity of OR51A5 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:15598656 |
|
NCBI chr 1:166,866,293...166,867,300
Ensembl chr 1:157,454,041...157,456,953
|
|
G |
Or5d18 |
olfactory receptor family 5 subfamily D member 18 |
multiple interactions |
ISO |
[[Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA; [Eugenol binds to and results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP; [Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:12767924 PMID:15716417 |
|
NCBI chr 3:93,972,754...93,973,695
Ensembl chr 3:73,516,364...73,519,858 Ensembl chr 3:73,516,364...73,519,858
|
|
G |
Or6e1 |
olfactory receptor family 6 subfamily E member 1 |
multiple interactions |
ISO |
[citronellal results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP [[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP; [[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:15598656 |
|
NCBI chr15:31,703,919...31,704,863
Ensembl chr15:27,729,827...27,736,945
|
|
G |
Os9 |
OS9, endoplasmic reticulum lectin |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of OS9 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 7:64,802,517...64,829,185
Ensembl chr 7:62,915,515...62,943,745
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression multiple interactions |
EXP ISO |
Cyclic AMP results in increased expression of PCK1 mRNA [Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein] [Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; ochratoxin A inhibits the reaction [Cyclic AMP results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA] |
CTD |
PMID:2569870 PMID:8971075 PMID:10446394 PMID:22117073 PMID:22676303 PMID:26847930 More...
|
|
NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pde10a |
phosphodiesterase 10A |
multiple interactions increases hydrolysis |
ISO |
Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10373451 |
|
NCBI chr 1:54,313,343...54,765,668
Ensembl chr 1:51,770,132...52,216,563
|
|
G |
Pde11a |
phosphodiesterase 11A |
increases hydrolysis |
ISO |
PDE11A protein results in increased hydrolysis of Cyclic AMP |
CTD |
PMID:10725373 |
|
NCBI chr 3:81,320,822...81,704,397
Ensembl chr 3:60,913,562...61,297,158
|
|
G |
Pde4b |
phosphodiesterase 4B |
multiple interactions |
ISO |
[[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; [S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP [Bresol results in decreased activity of PDE4B protein] which results in increased abundance of Cyclic AMP; Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein] |
CTD |
PMID:16293762 PMID:21266552 PMID:21854221 |
|
NCBI chr 5:122,028,956...122,598,267
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pde7a |
phosphodiesterase 7A |
multiple interactions increases hydrolysis |
ISO |
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10618442 PMID:10814504 |
|
NCBI chr 2:103,631,655...103,723,057
Ensembl chr 2:101,718,444...101,806,681
|
|
G |
Pde7b |
phosphodiesterase 7B |
increases hydrolysis multiple interactions |
ISO |
PDE7B protein results in increased hydrolysis of Cyclic AMP 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; E 4021 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; vinpocetine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP] 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:10618442 PMID:10814504 PMID:10872825 |
|
NCBI chr 1:16,994,072...17,312,828
Ensembl chr 1:15,182,704...15,492,900
|
|
G |
Pde8a |
phosphodiesterase 8A |
multiple interactions increases metabolic processing increases hydrolysis |
ISO |
Dipyridamole inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP] PDE8A protein results in increased hydrolysis of Cyclic AMP Dipyridamole inhibits the reaction [PDE8A protein results in increased hydrolysis of Cyclic AMP] |
CTD |
PMID:9671792 PMID:12681444 |
|
NCBI chr 1:144,575,203...144,698,216
Ensembl chr 1:135,166,237...135,288,024
|
|
G |
Pde8b |
phosphodiesterase 8B |
multiple interactions increases metabolic processing increases hydrolysis |
ISO |
9-(2-hydroxy-3-nonyl)adenine inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Sildenafil Citrate inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP] |
CTD |
PMID:9784418 PMID:12681444 |
|
NCBI chr 2:28,009,841...28,244,050
Ensembl chr 2:26,276,635...26,509,209
|
|
G |
Pde9a |
phosphodiesterase 9A |
increases hydrolysis |
ISO |
PDE9A protein results in increased hydrolysis of Cyclic AMP |
CTD |
PMID:9624146 |
|
NCBI chr20:9,471,136...9,564,286
Ensembl chr20:9,469,848...9,562,948
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions affects abundance |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; [PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP]; tubacin affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubastatin A affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; W 7 affects the reaction [PDK1 protein affects the abundance of Cyclic AMP] |
CTD |
PMID:28887310 |
|
NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
multiple interactions |
ISO |
PEBP1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] |
CTD |
PMID:26670611 |
|
NCBI chr12:44,946,307...44,967,890
Ensembl chr12:39,302,840...39,307,862
|
|
G |
Pfn2 |
profilin 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PFN2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 2:144,217,100...144,222,936
Ensembl chr 2:142,067,104...142,072,938
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]] |
CTD |
PMID:37552060 |
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pkia |
cAMP-dependent protein kinase inhibitor alpha |
multiple interactions |
ISO |
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein] |
CTD |
PMID:29669941 |
|
NCBI chr 2:96,306,181...96,380,959
Ensembl chr 2:94,398,869...94,414,282
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
increases expression multiple interactions |
EXP |
Cyclic AMP results in increased expression of PLA2G4A mRNA; Cyclic AMP results in increased expression of PLA2G4A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A protein] |
CTD |
PMID:22187434 |
|
NCBI chr13:64,427,921...64,572,352
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions increases abundance |
EXP ISO |
[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP] POMC protein modified form results in increased abundance of Cyclic AMP Quercetin analog inhibits the reaction [POMC protein modified form results in increased abundance of Cyclic AMP] |
CTD |
PMID:4306506 PMID:26586997 |
|
NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
ISO |
Cyclic AMP results in increased expression of POR mRNA |
CTD |
PMID:25576683 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
ISO EXP |
Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA] [Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein] Cyclic AMP results in increased expression of PPARGC1A mRNA |
CTD |
PMID:18602936 PMID:22117073 PMID:22676303 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp1r14b |
protein phosphatase 1, regulatory (inhibitor) subunit 14B |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PPP1R14B mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:213,594,416...213,596,527
Ensembl chr 1:204,163,299...204,167,319 Ensembl chr12:204,163,299...204,167,319
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
multiple interactions affects response to substance |
ISO |
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein]; [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] |
CTD |
PMID:29669941 |
|
NCBI chr 2:238,297,140...238,389,317
Ensembl chr 2:235,636,885...235,726,198
|
|
G |
Prkar1a |
protein kinase cAMP-dependent type I regulatory subunit alpha |
multiple interactions |
ISO |
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] |
CTD |
PMID:29669941 |
|
NCBI chr10:95,120,537...95,139,028
Ensembl chr10:94,620,039...94,639,041
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
multiple interactions |
EXP |
Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2A protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2A protein] |
CTD |
PMID:11907174 |
|
NCBI chr 8:118,271,608...118,337,332
Ensembl chr 8:109,395,833...109,455,628
|
|
G |
Prkar2b |
protein kinase cAMP-dependent type II regulatory subunit beta |
multiple interactions |
EXP |
Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2B protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2B protein] |
CTD |
PMID:11907174 |
|
NCBI chr 6:54,291,143...54,381,639
Ensembl chr 6:48,563,662...48,653,933
|
|
G |
Prl |
prolactin |
multiple interactions increases secretion |
EXP ISO |
[Atrazine results in increased abundance of Cyclic AMP] which results in increased secretion of PRL protein 2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA] Cyclic AMP results in increased secretion of PRL protein |
CTD |
PMID:20074812 PMID:23022511 PMID:31953017 PMID:32446389 PMID:32781018 |
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prok1 |
prokineticin 1 |
affects response to substance |
ISO |
PROK1 protein affects the susceptibility to Cyclic AMP |
CTD |
PMID:21546446 |
|
NCBI chr 2:197,538,747...197,547,550
Ensembl chr 2:194,853,991...194,859,250
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO |
[5-hydroxyindomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [Indomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [sulindac sulfide binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP |
CTD |
PMID:15563582 |
|
NCBI chr 1:217,010,183...217,015,044
Ensembl chr 1:207,587,917...207,589,213
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions |
ISO |
[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:23526216 |
|
NCBI chr15:20,694,765...20,708,475
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Ptger3 |
prostaglandin E receptor 3 |
multiple interactions |
ISO |
[Dinoprostone results in increased activity of PTGER3 protein] which results in decreased abundance of Cyclic AMP |
CTD |
PMID:10357836 |
|
NCBI chr 2:249,264,985...249,409,966
Ensembl chr 2:246,606,183...246,684,434
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
multiple interactions |
ISO |
[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:23526216 |
|
NCBI chr 2:56,061,699...56,074,594
Ensembl chr 2:54,335,424...54,346,670
|
|
G |
Ptgir |
prostaglandin I2 receptor |
multiple interactions |
ISO |
[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:11895442 |
|
NCBI chr 1:86,707,690...86,710,073
Ensembl chr 1:77,579,596...77,581,979
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Cyclic AMP] |
CTD |
PMID:21873648 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pth |
parathyroid hormone |
increases abundance |
EXP |
PTH protein results in increased abundance of Cyclic AMP |
CTD |
PMID:26851681 |
|
NCBI chr 1:176,942,901...176,946,034
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
increases abundance |
ISO |
PTHLH protein results in increased abundance of Cyclic AMP |
CTD |
PMID:10600786 |
|
NCBI chr 4:181,919,400...181,930,454
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Ptma |
prothymosin alpha |
increases abundance |
ISO |
PTMA protein results in increased abundance of Cyclic AMP |
CTD |
PMID:9147362 |
|
NCBI chr 9:94,624,194...94,628,276
Ensembl chr 9:87,176,230...87,180,333
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RAB3B mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:128,859,034...128,926,087
Ensembl chr 5:123,644,423...123,697,401
|
|
G |
Ralgdsl1 |
ral guanine nucleotide dissociation stimulator like 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RGL1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:67,184,402...67,454,019
Ensembl chr13:64,635,246...64,904,191
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
increases activity |
ISO |
Cyclic AMP results in increased activity of RAP1A protein |
CTD |
PMID:24701590 |
|
NCBI chr 2:195,896,967...195,974,851
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rap1b |
RAP1B, member of RAS oncogene family |
multiple interactions |
EXP ISO |
[Pentoxifylline results in increased abundance of Cyclic AMP] results in increased abundance of [RAP1B protein binds to Guanosine Triphosphate] |
CTD |
PMID:21693435 |
|
NCBI chr 7:55,308,922...55,342,217
Ensembl chr 7:53,423,130...53,456,370
|
|
G |
Rbfox3 |
RNA binding fox-1 homolog 3 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein |
CTD |
PMID:33713149 |
|
NCBI chr10:104,218,940...104,655,863
Ensembl chr10:103,720,636...104,156,935
|
|
G |
Rbm12 |
RNA binding motif protein 12 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RBM12 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:165,069,744...165,089,994
Ensembl chr 3:144,611,623...144,629,915
|
|
G |
Rmdn3 |
regulator of microtubule dynamics 3 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RMDN3 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 3:126,579,811...126,601,016
Ensembl chr 3:106,125,951...106,146,586
|
|
G |
S100b |
S100 calcium binding protein B |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein |
CTD |
PMID:33713149 |
|
NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Scn2a |
sodium voltage-gated channel alpha subunit 2 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 3:70,710,862...70,845,569
Ensembl chr 3:50,302,877...50,437,214
|
|
G |
Sct |
secretin |
multiple interactions increases abundance |
EXP |
Epinephrine inhibits the reaction [SCT protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:6312992 |
|
NCBI chr 1:205,812,435...205,813,246
Ensembl chr 1:196,382,856...196,383,658
|
|
G |
Sdc1 |
syndecan 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SDC1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:37,282,041...37,304,503
Ensembl chr 6:31,562,739...31,585,264
|
|
G |
Slc17a6 |
solute carrier family 17 member 6 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 1:110,348,447...110,388,499
Ensembl chr 1:101,212,489...101,252,542
|
|
G |
Slc17a7 |
solute carrier family 17 member 7 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein |
CTD |
PMID:33713149 |
|
NCBI chr 1:104,786,172...104,798,049
Ensembl chr 1:95,649,745...95,661,588
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
affects transport |
ISO |
SLC22A8 protein affects the transport of Cyclic AMP |
CTD |
PMID:11306713 |
|
NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
affects expression multiple interactions |
ISO EXP |
Cyclic AMP affects the expression of SLC2A5 mRNA [[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose; [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein [Fructose results in increased abundance of Cyclic AMP] which results in increased stability of SLC2A5 mRNA |
CTD |
PMID:8037665 PMID:8554516 PMID:12820898 |
|
NCBI chr 5:165,857,412...165,892,928
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
multiple interactions |
EXP |
Nitric Oxide inhibits the reaction [SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]]; SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates] |
CTD |
PMID:12612912 |
|
NCBI chr 4:11,628,860...11,646,961
Ensembl chr 4:10,736,425...10,752,965
|
|
G |
Smoc2 |
SPARC related modular calcium binding 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SMOC2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 1:63,935,627...64,064,952
Ensembl chr 1:55,262,530...55,391,693
|
|
G |
Snx33 |
sorting nexin 33 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SNX33 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:66,213,133...66,224,926
Ensembl chr 8:57,317,161...57,327,538
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein] |
CTD |
PMID:23782265 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA] |
CTD |
PMID:20685861 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
increases expression |
ISO |
Cyclic AMP results in increased expression of SRD5A1 mRNA |
CTD |
PMID:25576683 |
|
NCBI chr 1:35,514,914...35,548,898
Ensembl chr 1:33,686,391...33,720,461
|
|
G |
Sst |
somatostatin |
multiple interactions |
ISO |
[SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22056254 |
|
NCBI chr11:90,461,546...90,462,823
Ensembl chr11:76,956,896...76,958,173
|
|
G |
Sstr2 |
somatostatin receptor 2 |
multiple interactions |
ISO |
[64Cu-CB-TE2A-Y3-TATE co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22056254 |
|
NCBI chr10:99,163,353...99,170,519
Ensembl chr10:98,664,216...98,674,351
|
|
G |
St6gal2 |
ST6 beta-galactoside alpha-2,6-sialyltransferase 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ST6GAL2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 9:9,508,928...9,606,900
Ensembl chr 9:9,182,399...9,269,697
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression |
ISO |
[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein; Calcium inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; Diltiazem promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Isradipine promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]]; myricetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; Nifedipine promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR protein] Cyclic AMP results in increased expression of STAR mRNA; Cyclic AMP results in increased expression of STAR protein |
CTD |
PMID:19822634 PMID:20100736 PMID:25576683 PMID:28668616 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Taar1 |
trace-amine-associated receptor 1 |
multiple interactions |
ISO |
[Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP [3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-chloro-2-(imidazolin-2-yl)isoindoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-phenyl-1,2,3,4-tetrahydroisoquinoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [6-nitroquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Antazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [BE 2254 results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [cirazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Clonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [efaroxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Fenoldopam results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Guanabenz results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [harman results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Histamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Idazoxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Methoxydimethyltryptamines results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [moxonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [N-methylquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [O-methyltyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Quipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [rilmenidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tranylcypromine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tryptamines analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:19725810 |
|
NCBI chr 1:23,336,978...23,337,976
Ensembl chr 1:21,517,258...21,532,084
|
|
G |
Tas1r2 |
taste 1 receptor member 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAS1R2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 5:157,192,799...157,208,937
Ensembl chr 5:151,830,701...151,925,345
|
|
G |
Tax1bp1 |
Tax1 binding protein 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAX1BP1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 4:83,152,549...83,208,463
Ensembl chr 4:81,821,989...81,879,100
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
multiple interactions |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA |
CTD |
PMID:32781018 |
|
NCBI chr 2:169,567,656...169,585,586
Ensembl chr 2:167,269,579...167,287,511
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA |
CTD |
PMID:33713149 |
|
NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tex14 |
testis expressed 14, intercellular bridge forming factor |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TEX14 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:72,729,017...72,859,697
Ensembl chr10:72,231,801...72,355,805
|
|
G |
Tff1 |
trefoil factor 1 |
multiple interactions increases expression |
ISO |
CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter] |
CTD |
PMID:20360387 |
|
NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein |
CTD |
PMID:33713149 |
|
NCBI chr 6:111,435,170...111,457,646
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Tmsb15b2 |
thymosin beta 15B2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMSB15B2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr X:105,090,980...105,093,094
Ensembl chr X:100,298,514...100,300,886
|
|
G |
Tmtc4 |
transmembrane O-mannosyltransferase targeting cadherins 4 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMTC4 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr15:106,406,795...106,463,226
Ensembl chr15:100,000,152...100,056,543
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
Cyclic AMP results in decreased expression of TNF protein Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] [[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:8550079 PMID:21266552 PMID:23566200 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf12 |
TNF superfamily member 12 |
decreases expression |
ISO |
Cyclic AMP results in decreased expression of TNFSF12 mRNA |
CTD |
PMID:22117073 |
|
NCBI chr10:54,902,616...54,912,628
Ensembl chr10:54,403,870...54,413,213
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases expression multiple interactions |
EXP |
Cyclic AMP results in increased expression of TRPV4 mRNA; Cyclic AMP results in increased expression of TRPV4 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 protein] |
CTD |
PMID:22187434 |
|
NCBI chr12:47,599,161...47,638,143
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions increases abundance |
ISO |
[Cobalt binds to dipyrido(3,2-a-2',3'-c)phenazine binds to N-(2-hydroxybenzyl)glycine analog] inhibits the reaction [TSHB protein results in increased abundance of Cyclic AMP]; [TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:19766106 PMID:21072367 PMID:21123444 |
|
NCBI chr 2:192,913,171...192,918,054
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
multiple interactions increases abundance |
ISO |
[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:19766106 PMID:21123444 |
|
NCBI chr 6:116,072,321...116,206,009
Ensembl chr 6:110,341,581...110,474,538
|
|
G |
Ttc6 |
tetratricopeptide repeat domain 6 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TTC6 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:80,872,055...81,103,170
Ensembl chr 6:75,136,792...75,368,178
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
ISO |
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein |
CTD |
PMID:33713149 |
|
NCBI chr19:68,365,687...68,374,741
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Uba5 |
ubiquitin-like modifier activating enzyme 5 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of UBA5 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 8:113,544,037...113,559,711
Ensembl chr 8:104,665,046...104,680,894
|
|
G |
Vash1 |
vasohibin 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr 6:112,060,086...112,076,689
Ensembl chr 6:106,329,123...106,345,726
|
|
G |
Vash2 |
vasohibin 2 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH2 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr13:105,060,857...105,092,325
Ensembl chr13:102,529,719...102,560,391
|
|
G |
Vat1 |
vesicle amine transport 1 |
multiple interactions |
EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VAT1 mRNA] |
CTD |
PMID:19414516 |
|
NCBI chr10:86,889,793...86,897,411
Ensembl chr10:86,389,545...86,397,224
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Cyclic AMP affects the reaction [Norepinephrine results in increased expression of VEGFA mRNA] |
CTD |
PMID:10788502 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vip |
vasoactive intestinal peptide |
multiple interactions increases abundance |
ISO EXP |
[VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP alpha-hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Endrin inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP] VIP protein results in increased abundance of Cyclic AMP; VIP results in increased abundance of Cyclic AMP |
CTD |
PMID:1657658 PMID:2467674 PMID:7733904 PMID:20732086 |
|
NCBI chr 1:44,470,232...44,478,561
Ensembl chr 1:42,065,120...42,073,216
|
|
G |
Vipr2 |
vasoactive intestinal peptide receptor 2 |
multiple interactions |
ISO |
[ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP; [VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP |
CTD |
PMID:7733904 |
|
NCBI chr 6:143,139,672...143,213,609
Ensembl chr 6:137,001,511...137,070,597
|
|
G |
Wnt5a |
Wnt family member 5A |
multiple interactions |
ISO |
WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]; WNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] |
CTD |
PMID:20685861 |
|
NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,697,032...3,718,234
|
|
G |
Zfp36l2 |
zinc finger protein 36, C3H type-like 2 |
increases abundance |
ISO |
ZFP36L2 protein mutant form results in increased abundance of Cyclic AMP |
CTD |
PMID:24830504 |
|
NCBI chr 6:16,242,622...16,246,662
Ensembl chr 6:10,490,032...10,494,064
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases export increases transport multiple interactions |
ISO |
ABCC4 protein results in increased export of Cyclic GMP ABCC4 protein results in increased transport of Cyclic GMP daidzein inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Dipyridamole inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; hesperetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; naringenin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Probenecid inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; Quercetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; resveratrol inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Silymarin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP] |
CTD |
PMID:11856762 PMID:16156793 |
|
NCBI chr15:101,948,387...102,182,912
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Agt |
angiotensinogen |
multiple interactions increases abundance |
EXP |
AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; AGT protein modified form inhibits the reaction [Streptozocin results in decreased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]] AGT protein modified form results in increased abundance of Cyclic GMP |
CTD |
PMID:11696475 PMID:28299329 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
EXP |
[PD 123319 results in decreased activity of AGTR2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] |
CTD |
PMID:16982965 |
|
NCBI chr X:116,914,320...116,918,504
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
AKT1 protein inhibits the reaction [Carbon Tetrachloride results in decreased abundance of Cyclic GMP] |
CTD |
PMID:12891555 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
ALDH2 protein affects the reaction [Nitroglycerin results in decreased abundance of Cyclic GMP] |
CTD |
PMID:17585900 |
|
NCBI chr12:40,610,244...40,643,220
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Apoe |
apolipoprotein E |
decreases abundance |
ISO |
APOE gene mutant form results in decreased abundance of Cyclic GMP |
CTD |
PMID:11397713 |
|
NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions |
EXP |
[bradykinin, Leu(8)-des-Arg(9)- results in decreased activity of BDKRB1 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] |
CTD |
PMID:16982965 |
|
NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
EXP |
[icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP] |
CTD |
PMID:16982965 |
|
NCBI chr 6:130,237,055...130,267,205
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Cyclic GMP affects the reaction [Nitric Oxide results in decreased activity of CASP3 protein] |
CTD |
PMID:9388267 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP] |
CTD |
PMID:25490417 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
multiple interactions |
ISO |
CCT7 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP] |
CTD |
PMID:24213632 |
|
NCBI chr 4:119,546,730...119,563,973
Ensembl chr 4:117,989,232...118,006,580
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases abundance |
EXP |
Puromycin Aminonucleoside inhibits the reaction [EDN1 protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:12972712 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn3 |
endothelin 3 |
multiple interactions increases abundance |
EXP |
Puromycin Aminonucleoside promotes the reaction [EDN3 protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:12972712 |
|
NCBI chr 3:183,980,458...184,004,958
Ensembl chr 3:163,562,520...163,585,093
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [HPH1 gene mutant form results in decreased abundance of Cyclic GMP] |
CTD |
PMID:25041251 PMID:25490417 |
|
NCBI chr12:24,841,285...24,844,725
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
affects abundance increases abundance multiple interactions |
ISO |
GCH1 protein affects the abundance of Cyclic GMP GCH1 gene mutant form results in increased abundance of Cyclic GMP CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP] |
CTD |
PMID:21963838 PMID:25490417 |
|
NCBI chr15:22,884,006...22,917,412
Ensembl chr15:20,402,527...20,437,698
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
EXP |
[manganese chloride results in increased chemical synthesis of Cyclic GMP] which results in increased secretion of GNRH1 protein |
CTD |
PMID:17110411 PMID:17290048 |
|
NCBI chr15:46,147,878...46,152,086
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions increases abundance |
ISO |
[GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP; GUCY1A1 protein mutant form inhibits the reaction [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole results in increased abundance of Cyclic GMP]; GUCY1A1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP] GUCY1A1 gene mutant form results in increased abundance of Cyclic GMP |
CTD |
PMID:22171090 PMID:24213632 PMID:25373139 |
|
NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
[GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP |
CTD |
PMID:22171090 |
|
NCBI chr 2:169,646,897...169,697,060
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Hmox2 |
heme oxygenase 2 |
affects abundance |
ISO |
HMOX2 affects the abundance of Cyclic GMP |
CTD |
PMID:16181104 |
|
NCBI chr10:11,303,512...11,337,640
Ensembl chr10:10,797,055...10,831,148
|
|
G |
Il12rb2 |
interleukin 12 receptor subunit beta 2 |
increases expression |
ISO |
Cyclic GMP results in increased expression of IL12RB2 mRNA |
CTD |
PMID:12451176 |
|
NCBI chr 4:97,756,089...97,844,937
Ensembl chr 4:96,426,842...96,515,289
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance |
EXP ISO |
Halothane inhibits the reaction [IL1B protein results in increased abundance of Cyclic GMP] [lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP; nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP] |
CTD |
PMID:11506125 PMID:14762100 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein] Cyclic GMP results in decreased phosphorylation of MAP2K1 protein |
CTD |
PMID:18225537 |
|
NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
decreases phosphorylation multiple interactions |
ISO |
Cyclic GMP results in decreased phosphorylation of MAP2K2 protein Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein] |
CTD |
PMID:18225537 |
|
NCBI chr 7:9,241,449...9,264,216
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases activity |
ISO |
Cyclic GMP analog results in increased activity of MAPK8 protein |
CTD |
PMID:11051267 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
[testosterone enanthate results in increased expression of NOS2 mRNA] which results in increased abundance of Cyclic GMP |
CTD |
PMID:20463352 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases abundance |
ISO EXP |
NOS3 protein affects the reaction [Ramipril results in increased abundance of Cyclic GMP] NOS3 protein results in increased abundance of Cyclic GMP |
CTD |
PMID:11504159 PMID:16891913 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases abundance |
ISO EXP |
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]; Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein] NPPA protein results in increased abundance of Cyclic GMP AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; carvedilol promotes the reaction [NPPA protein results in increased abundance of Cyclic GMP]; Puromycin Aminonucleoside inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]] |
CTD |
PMID:9421401 PMID:11696475 PMID:12022755 PMID:12582005 PMID:12972712 PMID:18225537 More...
|
|
NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppc |
natriuretic peptide C |
increases chemical synthesis increases abundance multiple interactions |
EXP |
NPPC protein results in increased chemical synthesis of Cyclic GMP NPPC protein results in increased abundance of Cyclic GMP Ammonia inhibits the reaction [NPPC protein results in increased chemical synthesis of Cyclic GMP]; Fluoroacetates inhibits the reaction [NPPC protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:17629948 PMID:18222015 |
|
NCBI chr 9:94,767,986...94,772,186
Ensembl chr 9:87,320,051...87,324,251
|
|
G |
Pde10a |
phosphodiesterase 10A |
multiple interactions increases hydrolysis |
ISO |
Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP] |
CTD |
PMID:10373451 |
|
NCBI chr 1:54,313,343...54,765,668
Ensembl chr 1:51,770,132...52,216,563
|
|
G |
Pde11a |
phosphodiesterase 11A |
multiple interactions increases hydrolysis |
ISO |
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; Dipyridamole inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; zaprinast inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP] |
CTD |
PMID:10725373 |
|
NCBI chr 3:81,320,822...81,704,397
Ensembl chr 3:60,913,562...61,297,158
|
|
G |
Pde1a |
phosphodiesterase 1A |
multiple interactions |
EXP |
PDE1A protein inhibits the reaction [Nitroglycerin results in increased abundance of Cyclic GMP] |
CTD |
PMID:11696475 |
|
NCBI chr 3:85,152,053...85,432,289
Ensembl chr 3:64,747,269...65,024,874
|
|
G |
Pde5a |
phosphodiesterase 5A |
decreases abundance |
ISO |
PDE5A protein results in decreased abundance of Cyclic GMP |
CTD |
PMID:10422958 |
|
NCBI chr 2:213,542,822...213,687,638
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Pde9a |
phosphodiesterase 9A |
increases hydrolysis multiple interactions |
ISO |
PDE9A protein results in increased hydrolysis of Cyclic GMP zaprinast inhibits the reaction [PDE9A protein results in increased hydrolysis of Cyclic GMP] |
CTD |
PMID:9624146 |
|
NCBI chr20:9,471,136...9,564,286
Ensembl chr20:9,469,848...9,562,948
|
|
G |
Pomc |
proopiomelanocortin |
affects abundance |
EXP |
POMC protein affects the abundance of Cyclic GMP |
CTD |
PMID:11193135 |
|
NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ptpn12 |
protein tyrosine phosphatase, non-receptor type 12 |
increases activity |
EXP |
Cyclic GMP results in increased activity of PTPN12 protein |
CTD |
PMID:12714323 |
|
NCBI chr 4:14,913,071...14,985,084
Ensembl chr 4:14,021,052...14,092,927
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
STK11 protein promotes the reaction [Histamine results in increased abundance of Cyclic GMP] |
CTD |
PMID:21145922 |
|
NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases abundance |
EXP |
7-(2-(4-(4-nitrobenzene)piperazinyl)ethyl)-1,3-dimethylxanthine inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; KMUP 1 inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; zaprinast inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP] |
CTD |
PMID:16754782 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases abundance |
ISO |
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [VEGFA protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:18575783 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
VIM protein affects the susceptibility to [Acetylcholine co-treated with Cyclic GMP co-treated with Indomethacin] |
CTD |
PMID:11588525 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
[Xanthine co-treated with XDH protein] inhibits the reaction [Nitroprusside results in increased abundance of Cyclic GMP] |
CTD |
PMID:17339839 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Cdipt |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
multiple interactions |
ISO |
[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate |
CTD |
PMID:2579070 |
|
NCBI chr 1:191,013,632...191,017,943
Ensembl chr 1:181,583,141...181,587,408
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] |
CTD |
PMID:35101544 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Nat2 |
N-acetyltransferase 2 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr16:26,974,874...27,005,191
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone |
CTD |
PMID:20545351 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
P2ry1 |
purinergic receptor P2Y1 |
decreases activity |
ISO |
Phosphoadenosine Phosphosulfate results in decreased activity of P2RY1 protein |
CTD |
PMID:22273509 |
|
NCBI chr 2:147,391,661...147,397,870
Ensembl chr 2:145,241,849...145,248,457
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions increases sulfation |
ISO |
2,2',3,4,4',5',6-heptabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Halogenated Diphenyl Ethers analog inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; Pentachlorophenol inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tribromodiphenyl ether 28 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein] SULT1A1 protein results in increased sulfation of Phosphoadenosine Phosphosulfate |
CTD |
PMID:11425650 PMID:16601080 PMID:20545351 |
|
NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions |
ISO |
[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol] |
CTD |
PMID:15483193 |
|
NCBI chr 1:84,582,011...84,639,001
Ensembl chr 1:74,911,100...75,508,134
|
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
affects binding multiple interactions |
ISO |
7-methylguanosine 5'-diphosphate analog binds to EIF4E protein 7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine-5'-monophosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Guanosine analog inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Quinolones inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Sulfonamides inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein] |
CTD |
PMID:27592390 |
|
NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:227,066,673...227,098,683
|
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine triphosphate inhibits the reaction [RNA Caps binds to EIF4E protein] |
CTD |
PMID:27592390 |
|
NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions affects binding |
ISO |
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate] |
CTD |
PMID:25940091 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4 gamma 1 |
multiple interactions affects binding |
ISO |
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate] |
CTD |
PMID:25940091 |
|
NCBI chr11:93,726,322...93,746,387
Ensembl chr11:80,221,919...80,241,941
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression |
ISO |
Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]]; pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein] |
CTD |
PMID:16415093 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB11 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB1A mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCC2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCG2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of AKT1 protein |
CTD |
PMID:20610540 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression increases response to substance |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 protein BCL2L11 protein results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP |
CTD |
PMID:14996839 |
|
NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased activity of CASP3 protein |
CTD |
PMID:14996839 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cfl1 |
cofilin 1 |
decreases phosphorylation |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased phosphorylation of CFL1 protein |
CTD |
PMID:20610540 |
|
NCBI chr 1:212,227,124...212,230,656
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form |
CTD |
PMID:15163550 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions increases phosphorylation |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of and results in increased activity of CREB1 protein 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of CREB1 protein |
CTD |
PMID:14741741 PMID:20610540 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NFE2L2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]] |
CTD |
PMID:16415093 |
|
NCBI chr 1:104,178,483...104,183,863
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]] |
CTD |
PMID:16415093 |
|
NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I3 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[Acetylcysteine results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] which results in increased cleavage of PARP1 protein |
CTD |
PMID:38042493 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions decreases activity |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein] 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased activity of RHOA protein |
CTD |
PMID:20610540 |
|
NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rtkn |
rhotekin |
multiple interactions |
EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein] |
CTD |
PMID:20610540 |
|
NCBI chr 4:117,198,496...117,215,660
Ensembl chr 4:115,640,774...115,657,952
|
|
G |
Scnn1a |
sodium channel epithelial 1 subunit alpha |
multiple interactions |
EXP |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] |
CTD |
PMID:15161604 |
|
NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:158,122,962...158,146,181
|
|
G |
Scnn1b |
sodium channel epithelial 1 subunit beta |
multiple interactions |
EXP |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] |
CTD |
PMID:15161604 |
|
NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:176,430,103...176,484,451
|
|
G |
Scnn1g |
sodium channel epithelial 1 subunit gamma |
multiple interactions |
EXP |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] |
CTD |
PMID:15161604 |
|
NCBI chr 1:185,736,225...185,770,099
Ensembl chr 1:176,304,942...176,338,816
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLC10A1 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1A4 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:27160211 |
|
NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Snap25 |
synaptosome associated protein 25 |
multiple interactions affects splicing |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP affects the splicing of SNAP25 exon] |
CTD |
PMID:22684629 |
|
NCBI chr 3:144,494,579...144,576,449
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP promotes the reaction [Capsaicin results in increased activity of TRPV1] |
CTD |
PMID:12886029 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Vip |
vasoactive intestinal peptide |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of VIP mRNA |
CTD |
PMID:2156696 |
|
NCBI chr 1:44,470,232...44,478,561
Ensembl chr 1:42,065,120...42,073,216
|
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
increases expression |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 protein |
CTD |
PMID:16166323 |
|
NCBI chr10:55,559,060...55,567,535
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Arhgef17 |
Rho guanine nucleotide exchange factor 17 |
multiple interactions |
ISO |
2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein] |
CTD |
PMID:23195829 |
|
NCBI chr 1:164,642,690...164,702,241
Ensembl chr 1:155,233,168...155,290,498
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein 8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein] |
CTD |
PMID:20471953 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein 8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein] |
CTD |
PMID:20471953 |
|
NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:11799084 |
|
NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO |
8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of PPARG protein] |
CTD |
PMID:20471953 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
multiple interactions increases activity decreases expression |
ISO EXP |
2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein] [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of PRKG1 protein 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein alternative form |
CTD |
PMID:9366573 PMID:11799084 PMID:23195829 |
|
NCBI chr 1:237,818,950...239,052,184
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein] |
CTD |
PMID:23195829 |
|
NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Scnn1a |
sodium channel epithelial 1 subunit alpha |
multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] |
CTD |
PMID:19359370 |
|
NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:158,122,962...158,146,181
|
|
G |
Scnn1b |
sodium channel epithelial 1 subunit beta |
multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] |
CTD |
PMID:19359370 |
|
NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:176,430,103...176,484,451
|
|
G |
Scnn1g |
sodium channel epithelial 1 subunit gamma |
multiple interactions |
ISO |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D] |
CTD |
PMID:19359370 |
|
NCBI chr 1:185,736,225...185,770,099
Ensembl chr 1:176,304,942...176,338,816
|
|
G |
Srf |
serum response factor |
multiple interactions |
ISO |
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein |
CTD |
PMID:23195829 |
|
NCBI chr 9:21,924,050...21,933,338
Ensembl chr 9:14,426,472...14,435,733
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
increases phosphorylation decreases phosphorylation |
ISO EXP |
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased phosphorylation of VASP protein 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased phosphorylation of VASP protein |
CTD |
PMID:11799084 PMID:16166323 |
|
NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:78,910,011...78,925,061
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABCA1 protein |
CTD |
PMID:17478430 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA] |
CTD |
PMID:27743861 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCC1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA] |
CTD |
PMID:27743861 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcd2 |
ATP binding cassette subfamily D member 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCD2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:124,142,597...124,191,202
Ensembl chr 7:122,263,032...122,311,642
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] |
CTD |
PMID:30610963 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ablim1 |
actin-binding LIM protein 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABLIM1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:266,088,868...266,377,169
Ensembl chr 1:256,084,297...256,371,969
|
|
G |
Ablim2 |
actin binding LIM protein family, member 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABLIM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:79,090,046...79,214,986
Ensembl chr14:74,866,281...74,990,334
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACAT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACE2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:33,925,458...33,972,851
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acp3 |
acid phosphatase 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ACP3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:113,784,372...113,833,033
Ensembl chr 8:104,905,586...104,954,236
|
|
G |
Adamts6 |
ADAM metallopeptidase with thrombospondin type 1 motif, 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADAMTS6 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 2:37,155,260...37,367,077
Ensembl chr 2:35,421,510...35,633,298
|
|
G |
Adamts8 |
ADAM metallopeptidase with thrombospondin type 1 motif, 8 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADAMTS8 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:37,607,001...37,626,597
Ensembl chr 8:29,349,114...29,368,404
|
|
G |
Adcy7 |
adenylate cyclase 7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADCY7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:34,913,154...34,972,366
Ensembl chr19:18,740,875...18,776,311
|
|
G |
Adgrd1 |
adhesion G protein-coupled receptor D1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRD1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:33,124,981...33,239,778
Ensembl chr12:27,488,908...27,603,696
|
|
G |
Adgrf5 |
adhesion G protein-coupled receptor F5 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADGRF5 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 9:25,014,861...25,128,045
Ensembl chr 9:17,520,009...17,623,968
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:10,009,983...10,047,138
Ensembl chr19:10,003,975...10,041,108
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADGRG2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:38,106,067...38,231,286
Ensembl chr X:34,297,402...34,422,609
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADRA2A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Agr2 |
anterior gradient 2, protein disulphide isomerase family member |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AGR2 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 6:58,435,908...58,456,678
Ensembl chr 6:52,708,602...52,729,371
|
|
G |
Agt |
angiotensinogen |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGT mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGTR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AHR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AIFM1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:132,528,107...132,567,237
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akap7 |
A-kinase anchoring protein 7 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AKAP7 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 1:21,906,503...22,168,663
Ensembl chr 1:20,087,373...20,217,797
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKAP9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:31,011,475...31,147,338
Ensembl chr 4:30,056,738...30,192,606
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ANGPT1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 7:75,415,959...75,668,696
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angptl1 |
angiopoietin-like 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ANGPTL1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:71,463,913...71,531,810
Ensembl chr13:68,962,991...68,992,570
|
|
G |
Ankh |
ANKH inorganic pyrophosphate transport regulator |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ANKH mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:79,883,350...80,011,222
Ensembl chr 2:78,153,026...78,280,187
|
|
G |
Anxa8 |
annexin A8 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of ANXA8 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr16:9,403,267...9,418,317
Ensembl chr16:9,397,113...9,412,043
|
|
G |
Aopep |
aminopeptidase O |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AOPEP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:1,817,001...2,133,008
Ensembl chr17:1,811,980...2,127,331
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APAF1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apbb1ip |
amyloid beta precursor protein binding family B member 1 interacting protein |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of APBB1IP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:89,849,474...89,941,099
Ensembl chr17:84,982,243...85,033,010
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APC mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:26,138,382...26,196,021
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Apcdd1 |
APC down-regulated 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APCDD1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:58,655,696...58,686,359
Ensembl chr18:56,385,264...56,416,070
|
|
G |
Ar |
androgen receptor |
decreases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AR mRNA [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA] |
CTD |
PMID:18467523 PMID:22079614 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AREG mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr14:17,256,384...17,265,641
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARHGEF2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:176,358,909...176,416,178
Ensembl chr 2:174,062,976...174,118,355
|
|
G |
Arhgef4 |
Rho guanine nucleotide exchange factor 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARHGEF4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:44,357,716...44,500,959
Ensembl chr 9:36,861,835...37,005,075
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARID5B mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:20,305,693...20,489,689
Ensembl chr20:20,307,731...20,487,433
|
|
G |
Armcx3 |
armadillo repeat containing, X-linked 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:102,230,464...102,234,017
Ensembl chr X:97,936,999...97,942,098
|
|
G |
Armcx4 |
armadillo repeat containing, X-linked 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:102,153,743...102,164,173
Ensembl chr X:97,860,629...97,870,912
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ASNS mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atp4a |
ATPase H+/K+ transporting subunit alpha |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ATP4A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:95,089,122...95,102,277
Ensembl chr 1:85,961,708...85,974,844
|
|
G |
Avpi1 |
arginine vasopressin-induced 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AVPI1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:250,879,530...250,885,448
Ensembl chr 1:240,930,236...240,936,154
|
|
G |
B4galnt3 |
beta-1,4-N-acetyl-galactosaminyl transferase 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of B4GALNT3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:155,081,261...155,181,255
Ensembl chr 4:153,409,004...153,509,321
|
|
G |
Bank1 |
B-cell scaffold protein with ankyrin repeats 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BANK1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:227,203,998...227,474,008
Ensembl chr 2:224,530,475...224,800,405
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BAX [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BAX protein |
CTD |
PMID:11802967 PMID:16709600 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BCAT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:179,695,662...179,777,973
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BCL2 |
CTD |
PMID:11802967 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein |
CTD |
PMID:16709600 |
|
NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 6:130,237,055...130,267,205
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:22,098,191...22,113,145
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP6 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BMP6 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Brinp1 |
BMP/retinoic acid inducible neural specific 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BRINP1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 5:87,363,621...87,565,580
Ensembl chr 5:82,348,930...82,493,150
|
|
G |
Btbd9 |
BTB domain containing 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BTBD9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:8,287,813...8,645,437
Ensembl chr20:8,288,711...8,643,960
|
|
G |
Cables1 |
Cdk5 and Abl enzyme substrate 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABLES1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:3,349,681...3,455,956
Ensembl chr18:3,075,524...3,181,181
|
|
G |
Cabp7 |
calcium binding protein 7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABP7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:83,822,322...83,832,667
Ensembl chr14:79,598,827...79,609,240
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CADM1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:56,744,374...57,075,264
Ensembl chr 8:47,847,325...48,182,833
|
|
G |
Cadm2 |
cell adhesion molecule 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CADM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:17,994,856...18,971,895
Ensembl chr11:4,555,159...5,525,400
|
|
G |
Caln1 |
calneuron 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CALN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:31,447,964...31,939,847
Ensembl chr12:25,819,628...26,303,344
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CALR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:40,213,367...40,218,262
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Camk2n1 |
calcium/calmodulin-dependent protein kinase II inhibitor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAMK2N1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:155,958,116...155,959,897
Ensembl chr 5:150,673,507...150,676,600
|
|
G |
Capn15 |
calpain 15 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CAPN15 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:15,477,311...15,503,913
Ensembl chr10:14,972,800...14,999,508
|
|
G |
Capn2 |
calpain 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:96,681,902...96,732,625
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Capn6 |
calpain 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:112,177,467...112,202,178
Ensembl chr X:107,380,774...107,405,489
|
|
G |
Card14 |
caspase recruitment domain family, member 14 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARD14 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:105,064,941...105,100,132
Ensembl chr10:104,566,424...104,601,905
|
|
G |
Cars1 |
cysteinyl-tRNA synthetase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:208,183,092...208,225,425
Ensembl chr 1:198,753,691...198,795,941
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CASP3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CASP9 mRNA |
CTD |
PMID:22079614 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CAT mRNA |
CTD |
PMID:16709600 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr4 |
carbonyl reductase 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CBR4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:33,625,734...33,695,067
Ensembl chr16:28,617,224...28,645,712
|
|
G |
Ccdc170 |
coiled-coil domain containing 170 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC170 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:43,351,010...43,458,192
Ensembl chr 1:40,945,961...41,085,040
|
|
G |
Ccdc3 |
coiled-coil domain containing 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCDC3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:77,941,148...78,044,820
Ensembl chr17:73,035,045...73,135,337
|
|
G |
Ccdc80 |
coiled-coil domain containing 80 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC80 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:69,191,188...69,224,844
Ensembl chr11:55,685,872...55,719,137
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]]; [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CCL2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCL2 protein |
CTD |
PMID:11230753 PMID:16997883 PMID:20940016 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn3 |
cellular communication network factor 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:87,983,788...87,990,810
Ensembl chr 7:86,094,000...86,101,019
|
|
G |
Ccn6 |
cellular communication network factor 6 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:44,123,932...44,139,745
Ensembl chr20:42,569,309...42,585,126
|
|
G |
Ccna1 |
cyclin A1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCNA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:141,383,352...141,428,205
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCND2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cd244 |
CD244 molecule |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD244 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:86,583,727...86,606,902
Ensembl chr13:84,052,493...84,074,492
|
|
G |
Cd74 |
CD74 molecule |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD74 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:56,527,071...56,536,406
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cd9 |
CD9 molecule |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:159,942,553...159,975,463
Ensembl chr 4:158,256,328...158,289,222
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH1 protein |
CTD |
PMID:32028606 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh22 |
cadherin 22 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH22 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:174,264,869...174,389,940
Ensembl chr 3:153,845,787...153,970,588
|
|
G |
Cdh4 |
cadherin 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:186,902,763...187,381,020
Ensembl chr 3:166,525,099...167,003,371
|
|
G |
Cdh6 |
cadherin 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDH6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:63,801,630...63,952,309
Ensembl chr 2:62,079,137...62,225,228
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDK2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDKN1A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdon |
cell adhesion associated, oncogene regulated |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDON mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 8:42,032,921...42,119,451
Ensembl chr 8:33,806,183...33,859,033
|
|
G |
Cdx1 |
caudal type homeo box 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:56,742,970...56,761,299
Ensembl chr18:54,473,444...54,490,814
|
|
G |
Ceacam6 |
CEA cell adhesion molecule 6 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEACAM6 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 1:89,544,415...89,562,552
Ensembl chr 1:80,416,531...80,434,668
|
|
G |
Cebpg |
CCAAT/enhancer binding protein gamma |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CEBPG mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:96,820,981...96,829,736
Ensembl chr 1:87,684,019...87,694,569
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CFLAR protein alternative form |
CTD |
PMID:16709600 |
|
NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
increases expression |
EXP ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGA mRNA |
CTD |
PMID:8404651 PMID:21467749 PMID:22079614 |
|
NCBI chr 5:54,283,109...54,295,464
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Cgn |
cingulin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGN mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:184,997,425...185,024,785
Ensembl chr 2:182,308,714...182,334,645
|
|
G |
Chn1 |
chimerin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CHN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:78,917,329...79,084,040
Ensembl chr 3:58,510,536...58,676,490
|
|
G |
Chp1 |
calcineurin-like EF-hand protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CHP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:126,989,800...127,025,071
Ensembl chr 3:106,536,004...106,571,251
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:63,164,817...63,190,384
Ensembl chr18:60,894,874...60,920,481
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEC protein |
CTD |
PMID:21097823 |
|
NCBI chr 4:148,124,924...148,137,806
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Ckmt2 |
creatine kinase, mitochondrial 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CKMT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:24,815,008...24,845,511
Ensembl chr 2:23,079,918...23,110,430
|
|
G |
Cldn1 |
claudin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CLDN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:87,926,376...87,941,533
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn5 |
claudin 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLDN5 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr11:95,717,172...95,718,598
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Clgn |
calmegin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLGN mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr19:41,601,568...41,633,207
Ensembl chr19:24,696,875...24,728,758
|
|
G |
Clic3 |
chloride intracellular channel 3 |
multiple interactions increases expression |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CLIC3 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLIC3 mRNA |
CTD |
PMID:16997883 PMID:22079614 |
|
NCBI chr 3:28,670,176...28,672,166
Ensembl chr 3:8,272,097...8,274,018
|
|
G |
Cmklr1 |
chemerin chemokine-like receptor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CMKLR1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr12:48,634,929...48,687,833
Ensembl chr12:42,974,410...43,028,129
|
|
G |
Cnih3 |
cornichon family AMPA receptor auxiliary protein 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNIH3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:95,548,440...95,739,500
Ensembl chr13:93,099,784...93,208,121
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Col15a1 |
collagen type XV alpha 1 chain |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL15A1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 5:66,297,546...66,403,172
Ensembl chr 5:61,501,963...61,607,591
|
|
G |
Col4a4 |
collagen type IV alpha 4 chain |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of COL4A4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:91,281,324...91,323,577
Ensembl chr 9:83,755,515...83,875,876
|
|
G |
Col4a6 |
collagen type IV alpha 6 chain |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL4A6 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr X:109,554,945...109,905,987
Ensembl chr X:104,766,957...105,117,500
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of COL6A3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL7A1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 8:118,483,364...118,515,736
Ensembl chr 8:109,604,861...109,637,252
|
|
G |
Colec12 |
collectin sub-family member 12 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of COLEC12 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:1,005,787...1,193,455
Ensembl chr18:732,950...920,618
|
|
G |
Coro2a |
coronin 2A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CORO2A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:65,623,820...65,677,483
Ensembl chr 5:60,828,247...60,859,035
|
|
G |
Cpm |
carboxypeptidase M |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CPM mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:55,111,599...55,172,114
Ensembl chr 7:53,225,696...53,286,220
|
|
G |
Cpo |
carboxypeptidase O |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CPO mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:72,813,802...72,832,056
|
|
G |
Cradd |
CASP2 and RIPK1 domain containing adaptor with death domain |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CRADD mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:31,827,131...31,839,796
Ensembl chr 7:29,798,586...29,952,907
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of CREB1 protein |
CTD |
PMID:18467523 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]] |
CTD |
PMID:2153673 |
|
NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CRHBP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:28,427,139...28,439,446
Ensembl chr 2:26,692,403...26,704,710
|
|
G |
Cst6 |
cystatin E/M |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CST6 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 1:212,084,676...212,086,384
Ensembl chr 1:202,655,322...202,657,030
|
|
G |
Ctnna2 |
catenin alpha 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTNNA2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:110,852,265...112,001,351
Ensembl chr 4:109,293,978...110,443,522
|
|
G |
Cttnbp2 |
cortactin binding protein 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CTTNBP2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:47,766,867...47,930,598
Ensembl chr 4:46,800,981...46,964,631
|
|
G |
Cux2 |
cut-like homeobox 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CUX2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:40,168,402...40,368,303
Ensembl chr12:34,520,959...34,705,806
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CX3CL1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,227,340...10,236,833
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CXCL12 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CXCL12 mRNA |
CTD |
PMID:20711499 PMID:22079614 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cycs |
cytochrome c, somatic |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYCS mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
ISO EXP |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein] |
CTD |
PMID:20147733 PMID:21126571 PMID:21610156 PMID:21664964 PMID:21726595 PMID:22546480 PMID:24014645 PMID:24328340 PMID:24740604 PMID:34896276 More...
|
|
NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions increases expression |
ISO |
bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B1 mRNA]; Mitotane affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B1 mRNA] |
CTD |
PMID:22079614 PMID:22172629 PMID:22546480 PMID:34896276 |
|
NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B2 mRNA |
CTD |
PMID:22079614 PMID:34896276 |
|
NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
[4-nitro-3-phenylphenol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of CYP17A1 protein; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]]; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP17A1 mRNA; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein] |
CTD |
PMID:18336853 PMID:21610156 PMID:21726595 PMID:22079614 PMID:22546480 PMID:24014645 PMID:34896276 More...
|
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
EXP ISO |
[vinclozolin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA]; bisphenol A inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; formestane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Methoxychlor inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein] [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 protein |
CTD |
PMID:10746939 PMID:18815356 PMID:21126571 PMID:21610156 PMID:22120136 PMID:23583632 PMID:28859905 PMID:30951242 More...
|
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 protein |
CTD |
PMID:7588239 PMID:22079614 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP2E1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP2F1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:82,416,130...82,429,896
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP3A5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP51A1 mRNA [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA; [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein] |
CTD |
PMID:18467523 PMID:22079614 |
|
NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP8B1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Cyth1 |
cytohesin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYTH1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:103,901,376...103,984,496
Ensembl chr10:103,366,145...103,485,760
|
|
G |
Dach2 |
dachshund family transcription factor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DACH2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:82,644,374...83,210,181
Ensembl chr X:78,451,593...79,017,592
|
|
G |
Dact1 |
dishevelled-binding antagonist of beta-catenin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DACT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:95,526,645...95,538,625
Ensembl chr 6:89,790,644...89,817,906
|
|
G |
Dcaf12l1 |
DDB1 and CUL4 associated factor 12-like 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DCAF12L1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:128,572,969...128,576,588
Ensembl chr X:123,695,286...123,698,905
|
|
G |
Dcbld2 |
discoidin, CUB and LCCL domain containing 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DCBLD2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:55,594,691...55,649,113
Ensembl chr11:42,125,787...42,179,697
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DGAT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DGKB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:60,368,101...61,124,420
Ensembl chr 6:54,641,614...55,397,043
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DHCR24 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DHCR7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dhrs2 |
dehydrogenase/reductase 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DHRS2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:32,658,855...32,673,591
Ensembl chr15:28,688,940...28,703,644
|
|
G |
Dhrs3 |
dehydrogenase/reductase 3 |
multiple interactions |
ISO |
7-propyl spirolactone inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein; Aldosterone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:156,747,962...156,782,417
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions increases activity |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of and results in increased activity of DIO2 protein 8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein Acetylcysteine inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]]; Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]] |
CTD |
PMID:11425850 PMID:18420745 |
|
NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [[Hydrogen Peroxide co-treated with Sodium Selenite] promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein] |
CTD |
PMID:18420745 |
|
NCBI chr 6:135,107,072...135,108,933
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DKK1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dnah5 |
dynein, axonemal, heavy chain 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAH5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:80,668,182...80,985,918
Ensembl chr 2:78,937,800...79,254,890
|
|
G |
Dnajb3 |
DnaJ heat shock protein family (Hsp40) member B3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DNAJB3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:96,243,345...96,244,358
Ensembl chr 9:88,795,488...88,796,560
|
|
G |
Dnajb7 |
DnaJ heat shock protein family (Hsp40) member B7 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAJB7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:114,812,886...114,814,200
Ensembl chr 7:112,932,616...112,945,537
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNAJB9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DNER mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:85,586,987...85,902,637
|
|
G |
Dock11 |
dedicator of cytokinesis 11 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DOCK11 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:119,997,523...120,180,643
Ensembl chr X:115,131,909...115,314,854
|
|
G |
Dok5 |
docking protein 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DOK5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:179,934,419...180,071,334
Ensembl chr 3:159,515,893...159,652,810
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:17,184,853...17,187,646
|
|
G |
Dusp16 |
dual specificity phosphatase 16 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP16 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:169,278,118...169,361,508
Ensembl chr 4:167,548,155...167,629,980
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of DUSP4 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr16:64,079,893...64,101,396
Ensembl chr16:57,377,229...57,398,138
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of DUSP6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EBP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:16,971,372...16,977,782
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ECHS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]] |
CTD |
PMID:18467523 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGFR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EGR2 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Elp1 |
elongator acetyltransferase complex subunit 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ELP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:76,248,545...76,300,985
Ensembl chr 5:71,456,310...71,505,762
|
|
G |
Emp2 |
epithelial membrane protein 2 |
multiple interactions decreases expression |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of EMP2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EMP2 mRNA |
CTD |
PMID:16997883 PMID:22079614 |
|
NCBI chr10:5,866,869...5,901,533
Ensembl chr10:5,360,073...5,394,733
|
|
G |
Enox1 |
ecto-NOX disulfide-thiol exchanger 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ENOX1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr15:58,924,519...59,488,919
Ensembl chr15:52,515,178...53,079,749
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EP300 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epg5 |
ectopic P-granules 5 autophagy tethering factor |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EPG5 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr18:73,679,106...73,776,694
Ensembl chr18:71,404,010...71,501,502
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of EPHX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:95,246,079...95,275,852
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ERAP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:5,666,337...5,705,256
Ensembl chr 2:3,931,904...3,972,447
|
|
G |
Erf |
Ets2 repressor factor |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ERF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:89,957,760...89,966,213
Ensembl chr 1:80,829,935...80,838,388
|
|
G |
Esr2 |
estrogen receptor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ESR2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrra |
estrogen related receptor, alpha |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ESRRA mRNA |
CTD |
PMID:23166782 |
|
NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Esrrg |
estrogen-related receptor gamma |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ESRRG mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:101,699,043...102,316,877
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Etnppl |
ethanolamine-phosphate phospho-lyase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ETNPPL mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:221,847,210...221,868,827
Ensembl chr 2:219,172,978...219,192,212
|
|
G |
Etv1 |
ETS variant transcription factor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ETV1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 6:61,316,836...61,408,985
Ensembl chr 6:55,590,234...55,681,775
|
|
G |
Etv5 |
ETS variant transcription factor 5 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ETV5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:92,113,171...92,170,758
Ensembl chr11:78,608,710...78,666,215
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
decreases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 protein [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 mRNA; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 protein; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA] |
CTD |
PMID:21903722 |
|
NCBI chr 4:77,624,223...77,698,598
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
F2rl2 |
coagulation factor II (thrombin) receptor-like 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of F2RL2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:28,706,766...28,711,808
Ensembl chr 2:26,972,054...26,977,098
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FABP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fads1 |
fatty acid desaturase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FADS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:216,252,605...216,267,618
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FASLG protein |
CTD |
PMID:16709600 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FBLN1 mRNA |
CTD |
PMID:15774544 |
|
NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions |
ISO |
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDFT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:41,588,114...41,616,168
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdx1 |
ferredoxin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:61,164,839...61,183,645
Ensembl chr 8:52,268,536...52,287,414
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein] |
CTD |
PMID:24740604 |
|
NCBI chr10:101,006,845...101,015,582
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Fer1l6 |
fer-1-like family member 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FER1L6 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 7:91,951,174...92,106,617
Ensembl chr 7:90,061,924...90,215,214
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FGF10 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:52,533,939...52,610,980
Ensembl chr 2:50,800,992...50,876,866
|
|
G |
Fgf13 |
fibroblast growth factor 13 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FGF13 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:142,312,381...142,838,581
Ensembl chr X:137,276,511...137,800,391
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FGF9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:36,325,552...36,369,995
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FHL2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:52,881,091...52,954,540
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Flot1 |
flotillin 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FLOT1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr20:2,922,662...2,932,906
Ensembl chr20:2,917,137...2,927,978
|
|
G |
Flot2 |
flotillin 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FLOT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:63,424,084...63,445,811
Ensembl chr10:62,920,665...62,947,756
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein] |
CTD |
PMID:16709600 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA] |
CTD |
PMID:16709600 |
|
NCBI chr20:47,251,968...47,348,254
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Foxr1 |
forkhead box R1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FOXR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:53,657,388...53,669,424
Ensembl chr 8:44,760,948...44,768,880
|
|
G |
Fras1 |
Fraser extracellular matrix complex subunit 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FRAS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:13,095,370...13,506,895
Ensembl chr14:12,793,599...13,200,726
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB protein Tetrachlorodibenzodioxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB mRNA] |
CTD |
PMID:8404651 PMID:10746652 PMID:21467749 |
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fzd10 |
frizzled class receptor 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FZD10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:33,734,364...33,737,559
Ensembl chr12:28,098,371...28,101,566
|
|
G |
Fzd4 |
frizzled class receptor 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FZD4 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 1:152,692,507...152,701,372
Ensembl chr 1:143,280,065...143,285,724
|
|
G |
Fzd7 |
frizzled class receptor 7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of FZD7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:60,930,875...60,935,781
|
|
G |
Gabbr2 |
gamma-aminobutyric acid type B receptor subunit 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GABBR2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:65,743,073...66,083,695
Ensembl chr 5:60,947,526...61,288,104
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GABRA4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:36,944,747...37,021,652
Ensembl chr14:36,590,782...36,665,844
|
|
G |
Gabrg1 |
gamma-aminobutyric acid type A receptor subunit gamma 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GABRG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:37,750,292...37,821,651
Ensembl chr14:37,396,294...37,635,956
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A protein |
CTD |
PMID:16709600 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Galnt12 |
polypeptide N-acetylgalactosaminyltransferase 12 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GALNT12 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 5:66,180,171...66,208,931
Ensembl chr 5:61,384,571...61,413,354
|
|
G |
Galr1 |
galanin receptor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GALR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:78,046,803...78,062,359
Ensembl chr18:75,772,023...75,787,577
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GAP43 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr11:71,882,131...71,975,799
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gck |
glucokinase |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GCK mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:84,999,019...85,041,098
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gcsam |
germinal center-associated, signaling and motility |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GCSAM mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:68,658,350...68,669,598
Ensembl chr11:55,196,712...55,206,992
|
|
G |
Gdf10 |
growth differentiation factor 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GDF10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:9,243,434...9,256,788
Ensembl chr16:9,237,261...9,249,343
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GDF15 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GFAP mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA] |
CTD |
PMID:15994020 |
|
NCBI chr10:88,352,987...88,361,661
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gfpt2 |
glutamine-fructose-6-phosphate transaminase 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GFPT2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr10:34,616,146...34,662,420
Ensembl chr10:34,115,052...34,161,329
|
|
G |
Gimap8 |
GTPase, IMAP family member 8 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GIMAP8 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:78,931,003...78,942,491
Ensembl chr 4:77,600,186...77,611,590
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GJA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GJB2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:35,375,977...35,393,817
Ensembl chr15:31,260,357...31,278,177
|
|
G |
Gk |
glycerol kinase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GK mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:54,106,708...54,189,940
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Glipr1 |
GLI pathogenesis-related 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GLIPR1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 7:49,373,579...49,399,190
Ensembl chr 7:47,487,345...47,498,429
|
|
G |
Glrx |
glutaredoxin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GLRX mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:7,073,737...7,083,548
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI2 protein] |
CTD |
PMID:19252090 |
|
NCBI chr 8:117,167,045...117,187,652
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI3 protein] |
CTD |
PMID:19252090 |
|
NCBI chr 2:198,430,920...198,468,874
Ensembl chr 2:195,742,642...195,780,742
|
|
G |
Gng2 |
G protein subunit gamma 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GNG2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:4,365,222...4,466,060
Ensembl chr15:4,316,059...4,417,183
|
|
G |
Gpr22 |
G protein-coupled receptor 22 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GPR22 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:54,037,998...54,044,994
Ensembl chr 6:48,310,505...48,317,486
|
|
G |
Gpr37 |
G protein-coupled receptor 37 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GPR37 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:55,104,355...55,126,420
Ensembl chr 4:54,138,870...54,161,001
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GPX1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Grb10 |
growth factor receptor bound protein 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GRB10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:90,708,653...90,816,399
Ensembl chr14:86,495,054...86,602,806
|
|
G |
Grb14 |
growth factor receptor bound protein 14 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GRB14 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:69,976,331...70,091,921
Ensembl chr 3:49,568,210...49,683,889
|
|
G |
Grem2 |
gremlin 2, DAN family BMP antagonist |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GREM2 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr13:89,310,897...89,403,856
Ensembl chr13:86,778,500...86,871,615
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
multiple interactions |
ISO |
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Grin3a |
glutamate ionotropic receptor NMDA type subunit 3A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GRIN3A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:68,802,333...69,001,880
Ensembl chr 5:64,009,980...64,206,085
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GSTA2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of GSTM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:198,312,179...198,316,962
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GSTM4 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:198,356,114...198,373,487
Ensembl chr 2:195,680,004...195,685,323
|
|
G |
Has2 |
hyaluronan synthase 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HAS2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 7:90,002,929...90,028,933
Ensembl chr 7:88,113,326...88,128,933
|
|
G |
Hbg1 |
hemoglobin subunit gamma 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HBG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:167,683,760...167,685,315
Ensembl chr 1:158,271,873...158,273,425
|
|
G |
Hdac3 |
histone deacetylase 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HDAC3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:30,021,847...30,041,061
Ensembl chr18:29,770,636...29,793,856
|
|
G |
Hdac5 |
histone deacetylase 5 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HDAC5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:87,653,139...87,688,078
Ensembl chr10:87,152,978...87,188,235
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HEY2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:28,641,100...28,651,187
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hlf |
HLF transcription factor, PAR bZIP family member |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HLF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:75,651,320...75,708,979
Ensembl chr10:75,154,507...75,211,935
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMGA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:5,612,902...5,620,596
Ensembl chr20:5,611,694...5,618,752
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMGCS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA] |
CTD |
PMID:15179140 PMID:15994020 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4g |
hepatocyte nuclear factor 4, gamma |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HNF4G mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:99,792,942...99,943,811
Ensembl chr 2:97,887,432...98,036,592
|
|
G |
Hoxb9 |
homeo box B9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HOXB9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:81,733,857...81,737,363
Ensembl chr10:81,237,312...81,240,818
|
|
G |
Hpca |
hippocalcin |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HPCA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:146,739,978...146,750,961
Ensembl chr 5:141,455,613...141,463,841
|
|
G |
Hs3st1 |
heparan sulfate-glucosamine 3-sulfotransferase 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HS3ST1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:75,398,101...75,429,628
Ensembl chr14:71,185,682...71,223,248
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
multiple interactions |
ISO |
4'-cyanobiphenyl-4-sulfonic acid (6-aminopyridin-2-yl)amide inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of and results in increased activity of HSD11B1 protein; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of HSD11B1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA; Hydrocortisone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr13:107,277,526...107,327,462
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD11B2 mRNA [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B2 protein |
CTD |
PMID:22079614 PMID:23275455 |
|
NCBI chr19:50,307,569...50,312,812
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
multiple interactions increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [bisphenol A results in decreased expression of HSD17B1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B1 mRNA |
CTD |
PMID:18815356 PMID:21273127 |
|
NCBI chr10:86,510,011...86,512,211
Ensembl chr10:86,009,728...86,011,927
|
|
G |
Hsd17b14 |
hydroxysteroid (17-beta) dehydrogenase 14 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD17B14 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:105,165,695...105,176,045
Ensembl chr 1:96,029,284...96,039,883
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
multiple interactions increases expression |
ISO |
bisphenol A inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 mRNA] [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] affects the expression of HSD17B2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 protein |
CTD |
PMID:18815356 PMID:21273127 PMID:21610156 |
|
NCBI chr19:62,662,320...62,733,944
Ensembl chr19:45,753,574...45,825,202
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:1,032,958...1,064,283
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
multiple interactions |
ISO |
[4-nitro-3-cresol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD17B4 protein |
CTD |
PMID:18336853 |
|
NCBI chr18:45,515,427...45,604,467
Ensembl chr18:43,328,824...43,417,952
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:84,702,875...84,722,810
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions decreases expression increases expression |
ISO |
2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD3B1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 protein |
CTD |
PMID:18815356 PMID:21726595 PMID:22079614 |
|
NCBI chr 2:188,858,574...188,864,694
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B2 mRNA [4-nitro-3-cresol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of HSD3B2 protein; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B2 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B2 mRNA] |
CTD |
PMID:18336853 PMID:22079614 PMID:22546480 PMID:34896276 |
|
NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSPA1A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSPA5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSPA8 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSPH1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:10,427,368...10,446,602
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of ICAM1 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Icam2 |
intercellular adhesion molecule 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ICAM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:91,808,449...91,819,319
Ensembl chr10:91,308,538...91,315,293
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ID1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IDI1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:66,539,761...66,547,524
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ier3 |
immediate early response 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IER3 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGF1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf2bp2 |
insulin-like growth factor 2 mRNA binding protein 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGF2BP2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:92,378,908...92,478,893
Ensembl chr11:78,874,414...78,974,377
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions increases expression decreases expression increases secretion |
ISO |
1-Butanol inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; 4'-cyanobiphenyl-4-sulfonic acid (6-aminopyridin-2-yl)amide inhibits the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein; Dexamethasone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; Hydrocortisone promotes the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 protein 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IGFBP1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IGFBP1 protein 8-Bromo Cyclic Adenosine Monophosphate results in increased secretion of IGFBP1 protein |
CTD |
PMID:16709600 PMID:17065600 PMID:18815356 PMID:20147733 PMID:21273127 PMID:21903722 PMID:23275455 More...
|
|
NCBI chr14:86,261,277...86,266,344
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP5 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Ikzf1 |
IKAROS family zinc finger 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IKZF1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:90,468,696...90,556,522
Ensembl chr14:86,255,065...86,342,416
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL18 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL1A mRNA |
CTD |
PMID:11230753 PMID:22079614 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:11112151 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il27ra |
interleukin 27 receptor subunit alpha |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL27RA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:41,014,730...41,026,740
Ensembl chr19:24,109,972...24,121,938
|
|
G |
Il4 |
interleukin 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il4r |
interleukin 4 receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL4R mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 1:189,545,739...189,570,639
Ensembl chr 1:180,115,120...180,139,980
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of IL6 mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:16997883 PMID:21803157 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL7R mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:60,179,561...60,204,937
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Inhba |
inhibin subunit beta A |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of INHBA mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr17:53,787,159...53,810,942
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of INSIG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Insm2 |
INSM transcriptional repressor 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of INSM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:78,708,983...78,711,575
|
|
G |
Iqgap2 |
IQ motif containing GTPase activating protein 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IQGAP2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:28,629,558...28,904,649
Ensembl chr 2:26,894,825...27,170,279
|
|
G |
Irs1 |
insulin receptor substrate 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IRS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Ism1 |
isthmin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ISM1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 3:147,476,983...147,555,900
Ensembl chr 3:127,021,865...127,101,894
|
|
G |
Itga2 |
integrin subunit alpha 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ITGA2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itpkb |
inositol-trisphosphate 3-kinase B |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ITPKB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:94,601,072...94,696,180
Ensembl chr13:92,069,216...92,162,004
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of JAG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:144,859,453...144,894,883
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Jarid2 |
jumonji and AT-rich interaction domain containing 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of JARID2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr17:19,983,217...20,163,598
Ensembl chr17:19,777,266...19,955,690
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of and results in increased phosphorylation of JUN protein |
CTD |
PMID:28697429 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of JUND mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kcnc2 |
potassium voltage-gated channel subfamily C member 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KCNC2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:49,586,274...49,770,212
Ensembl chr 7:47,700,288...47,883,968
|
|
G |
Kcnd2 |
potassium voltage-gated channel subfamily D member 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KCND2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:49,776,246...50,277,728
|
|
G |
Kcne4 |
potassium voltage-gated channel subfamily E regulatory subunit 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KCNE4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:87,674,264...87,699,088
Ensembl chr 9:80,247,379...80,250,979
|
|
G |
Kcnh6 |
potassium voltage-gated channel subfamily H member 6 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KCNH6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:91,449,025...91,471,012
Ensembl chr10:90,949,846...90,970,701
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KCNQ1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:207,721,134...208,054,073
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
multiple interactions increases expression decreases expression |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of KCTD12 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KCTD12 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KCTD12 mRNA |
CTD |
PMID:16997883 PMID:20147733 PMID:22079614 |
|
NCBI chr15:86,214,786...86,220,725
Ensembl chr15:79,801,191...79,806,282
|
|
G |
Kif5c |
kinesin family member 5C |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KIF5C mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:54,441,266...54,591,630
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Kirrel3 |
kirre like nephrin family adhesion molecule 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KIRREL3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:41,123,692...41,663,528
Ensembl chr 8:32,862,776...33,405,676
|
|
G |
Klhl5 |
kelch-like family member 5 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KLHL5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:43,497,915...43,565,833
Ensembl chr14:43,144,257...43,184,238
|
|
G |
Klrc1 |
killer cell lectin like receptor C1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KLRC1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:164,828,163...164,838,446
Ensembl chr 4:163,147,189...163,152,425
|
|
G |
Klrc2 |
killer cell lectin like receptor C2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KLRC2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:164,808,722...164,819,865
Ensembl chr 4:163,122,704...163,133,843
|
|
G |
Klrc3 |
killer cell lectin like receptor C3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KLRC3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:164,791,102...164,798,758
Ensembl chr 4:163,106,024...163,112,336
|
|
G |
Krt34 |
keratin 34 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KRT34 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr10:85,470,391...85,474,501
Ensembl chr10:84,970,017...84,974,040
|
|
G |
Krtap1-1 |
keratin associated protein 1-1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KRTAP1-5 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr10:85,041,910...85,042,476
Ensembl chr10:84,545,580...84,546,354
|
|
G |
L3mbtl3 |
L3MBTL histone methyl-lysine binding protein 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of L3MBTL3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:20,807,679...20,908,609
Ensembl chr 1:18,990,618...19,089,263
|
|
G |
Lama3 |
laminin subunit alpha 3 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LAMA3 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr18:3,797,898...4,033,021
Ensembl chr18:3,523,133...3,751,353
|
|
G |
Lamb3 |
laminin subunit beta 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LAMB3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:107,362,514...107,404,081
Ensembl chr13:104,833,873...104,875,405
|
|
G |
Lamp3 |
lysosomal-associated membrane protein 3 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LAMP3 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr11:94,657,817...94,726,451
Ensembl chr11:81,193,649...81,221,784
|
|
G |
Lat2 |
linker for activation of T cells family, member 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LAT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:27,740,647...27,754,760
Ensembl chr12:22,104,219...22,118,288
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LDLR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LEF1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lep |
leptin |
multiple interactions decreases response to substance |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased chemical synthesis of Progesterone]; LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased chemical synthesis of Progesterone]]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; SB 203580 inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]] LEP protein results in decreased susceptibility to 8-Bromo Cyclic Adenosine Monophosphate |
CTD |
PMID:19849856 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased chemical synthesis of Progesterone]]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]] |
CTD |
PMID:19849856 |
|
NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lgals1 |
galectin 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LGALS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lgr4 |
leucine-rich repeat-containing G protein-coupled receptor 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LGR4 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 3:116,901,968...117,004,584
Ensembl chr 3:96,447,858...96,548,899
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases expression multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHB mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHB protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]]; Tetrachlorodibenzodioxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHB mRNA] |
CTD |
PMID:2153673 PMID:8404651 PMID:21467749 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
decreases expression increases expression multiple interactions |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LHCGR mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHCGR mRNA T-2 Toxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHCGR mRNA] Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHCGR mRNA] |
CTD |
PMID:22079614 PMID:23583632 PMID:30951242 |
|
NCBI chr 6:11,415,361...11,480,834
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of LIF mRNA [NR5A1 protein co-treated with LIF protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Tretinoin] results in increased abundance of Progesterone |
CTD |
PMID:16997883 PMID:21610156 |
|
NCBI chr14:83,354,602...83,364,053
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Limch1 |
LIM and calponin homology domains 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LIMCH1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr14:41,466,433...41,779,477
Ensembl chr14:41,114,803...41,425,191
|
|
G |
Lingo1 |
leucine rich repeat and Ig domain containing 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LINGO1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:65,907,275...66,089,485
Ensembl chr 8:57,010,007...57,196,544
|
|
G |
Lipc |
lipase C, hepatic type |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LIPC mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lmnb1 |
lamin B1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LMNB1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:52,373,939...52,413,284
Ensembl chr18:50,175,874...50,214,502
|
|
G |
Lmo3 |
LIM domain only 3 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LMO3 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 4:172,965,944...173,028,980
Ensembl chr 4:171,234,696...171,292,222
|
|
G |
Loxl1 |
lysyl oxidase-like 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of LOXL1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 8:67,587,636...67,612,224
Ensembl chr 8:58,692,593...58,716,356
|
|
G |
Lpcat1 |
lysophosphatidylcholine acyltransferase 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPCAT1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 1:31,594,621...31,644,946
Ensembl chr 1:29,766,071...29,816,401
|
|
G |
Lpl |
lipoprotein lipase |
increases expression decreases activity |
EXP ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LPL mRNA 8-Bromo Cyclic Adenosine Monophosphate results in decreased activity of LPL protein |
CTD |
PMID:9032464 PMID:9414485 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrrc17 |
leucine rich repeat containing 17 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LRRC17 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:14,393,632...14,424,048
Ensembl chr 4:13,501,436...13,531,845
|
|
G |
Lss |
lanosterol synthase |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of LSS mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:12,090,641...12,118,230
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Lum |
lumican |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LUM mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:34,245,323...34,252,510
Ensembl chr 7:32,358,614...32,365,793
|
|
G |
Lxn |
latexin |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LXN mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 2:154,037,604...154,043,473
Ensembl chr 2:151,727,102...151,733,460
|
|
G |
Lypd1 |
Ly6/Plaur domain containing 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LYPD1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr13:39,874,937...39,922,385
Ensembl chr13:37,326,464...37,368,493
|
|
G |
Lyve1 |
lymphatic vessel endothelial hyaluronan receptor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of XLKD1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:174,393,387...174,410,977
Ensembl chr 1:164,962,872...164,976,309
|
|
G |
Mageb10 |
MAGE family member B10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MAGEB10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:212,239,403...212,240,410
Ensembl chr 1:202,810,179...202,811,167
|
|
G |
Mamdc2 |
MAM domain containing 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MAMDC2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:230,290,482...230,443,014
Ensembl chr 1:220,863,976...221,016,354
|
|
G |
Man1a1 |
mannosidase, alpha, class 1A, member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MAN1A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:33,745,158...33,928,584
Ensembl chr20:33,202,517...33,385,824
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MAP3K8 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:58,078,175...58,098,455
Ensembl chr17:53,383,131...53,403,216
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased activity of MAPK1 protein]; [1-Methyl-3-isobutylxanthine co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased activity of MAPK1 protein [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein; azalanstat inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:8526880 PMID:12657697 PMID:18467523 PMID:19252090 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk10 |
mitogen activated protein kinase 10 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MAPK10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:6,802,247...7,094,103
Ensembl chr14:6,497,707...6,786,201
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases expression |
ISO EXP |
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased activity of MAPK3 protein]; [1-Methyl-3-isobutylxanthine co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased activity of MAPK3 protein [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein; azalanstat inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein] 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MAPK3 mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:8526880 PMID:12657697 PMID:18467523 PMID:19252090 PMID:22079614 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MAPT mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mc2r |
melanocortin 2 receptor |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MC2R mRNA [20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter] |
CTD |
PMID:21610156 PMID:22079614 |
|
NCBI chr18:64,279,878...64,291,775
Ensembl chr18:62,004,948...62,015,488
|
|
G |
Mcf2 |
MCF.2 cell line derived transforming sequence |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MCF2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:143,444,510...143,550,839
Ensembl chr X:138,409,256...138,514,446
|
|
G |
Mcf2l |
MCF.2 cell line derived transforming sequence-like |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MCF2L mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:83,209,277...83,355,683
Ensembl chr16:76,507,133...76,652,733
|
|
G |
Mdh1 |
malate dehydrogenase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MDH1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:99,831,934...99,847,227
Ensembl chr14:95,630,306...95,645,925
|
|
G |
Medag |
mesenteric estrogen-dependent adipogenesis |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MEDAG mRNA |
CTD |
PMID:20147733 |
|
NCBI chr12:10,649,526...10,670,913
Ensembl chr12:5,613,208...5,634,767
|
|
G |
Mertk |
MER proto-oncogene, tyrosine kinase |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MERTK mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:115,939,351...116,046,554
|
|
G |
Metrnl |
meteorin-like, glial cell differentiation regulator |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of METRNL mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:107,462,148...107,476,143
Ensembl chr10:106,963,880...106,977,869
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MGST1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mia2 |
MIA SH3 domain ER export factor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MIA2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:82,522,398...82,620,136
Ensembl chr 6:76,787,508...76,885,211
|
|
G |
Micb |
MHC class I polypeptide-related sequence B |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MICB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:87,623,826...87,641,075
Ensembl chr 1:78,495,779...78,512,827
|
|
G |
Mme |
membrane metallo-endopeptidase |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MME mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MMP10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:12,974,707...12,982,613
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mmp16 |
matrix metallopeptidase 16 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MMP16 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 5:36,109,265...36,353,252
Ensembl chr 5:31,312,280...31,548,388
|
|
G |
Mob4 |
MOB family member 4, phocein |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MOB4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:64,111,170...64,135,740
Ensembl chr 9:56,617,368...56,641,329
|
|
G |
Mocos |
molybdenum cofactor sulfurase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MOCOS mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:16,206,402...16,251,928
Ensembl chr18:15,931,654...15,977,187
|
|
G |
Moxd1 |
monooxygenase, DBH-like 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MOXD1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:22,894,543...22,984,599
Ensembl chr 1:21,075,122...21,161,779
|
|
G |
Mpp3 |
MAGUK p55 scaffold protein 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MPP3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:87,445,905...87,475,461
Ensembl chr10:86,945,714...86,974,737
|
|
G |
Mrap |
melanocortin 2 receptor accessory protein |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MRAP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:43,477,382...43,489,118
Ensembl chr11:29,992,034...30,003,024
|
|
G |
Mras |
muscle RAS oncogene homolog |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MRAS mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:108,823,374...108,886,104
Ensembl chr 8:99,944,036...99,996,408
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MSMO1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:29,747,113...29,764,360
Ensembl chr16:24,980,697...24,998,016
|
|
G |
Msrb3 |
methionine sulfoxide reductase B3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MSRB3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:58,188,827...58,311,459
Ensembl chr 7:56,303,308...56,425,496
|
|
G |
Mtmr4 |
myotubularin related protein 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MTMR4 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr10:72,890,665...72,913,598
Ensembl chr10:72,392,551...72,416,342
|
|
G |
Mtss1 |
MTSS I-BAR domain containing 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MTSS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:92,378,228...92,517,444
Ensembl chr 7:90,488,754...90,627,968
|
|
G |
Muc1 |
mucin 1, cell surface associated |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of MUC1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 2:176,933,312...176,938,497
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Mug2 |
murinoglobulin 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PZP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:156,836,140...156,908,972
Ensembl chr 4:155,164,011...155,236,475
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MVD mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:67,404,911...67,414,974
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Mvk |
mevalonate kinase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MVK mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:47,802,002...47,819,503
Ensembl chr12:42,141,384...42,158,882
|
|
G |
Myb |
MYB proto-oncogene, transcription factor |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MYB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:17,759,309...17,793,306
Ensembl chr 1:15,939,761...15,973,057
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MYC mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh7b |
myosin heavy chain 7B |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MYH7B mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:164,537,211...164,582,441
Ensembl chr 3:144,098,190...144,122,084
|
|
G |
Mylip |
myosin regulatory light chain interacting protein |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MYLIP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:19,492,826...19,514,490
Ensembl chr17:19,286,650...19,308,295
|
|
G |
Myof |
myoferlin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MYOF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:245,086,109...245,234,768
Ensembl chr 1:235,673,666...235,822,334
|
|
G |
Mypn |
myopalladin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MYPN mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:25,435,554...25,521,149
Ensembl chr20:25,436,843...25,522,443
|
|
G |
N4bp2l1 |
NEDD4 binding protein 2-like 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of N4BP2L1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:4,938,199...4,965,003
Ensembl chr12:102,573...127,257
|
|
G |
Nalf1 |
NALCN channel auxiliary factor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NALF1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:86,415,540...86,938,150
Ensembl chr16:79,713,724...80,235,120
|
|
G |
Nanos1 |
nanos C2HC-type zinc finger 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NANOS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:269,883,713...269,887,611
Ensembl chr 1:259,897,939...259,898,730
|
|
G |
Nap1l2 |
nucleosome assembly protein 1-like 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NAP1L2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:72,239,849...72,242,247
Ensembl chr X:68,173,987...68,176,666
|
|
G |
Nav3 |
neuron navigator 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NAV3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:46,938,577...47,726,839
Ensembl chr 7:45,054,296...45,840,698
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of NCF2 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr13:67,505,492...67,536,015
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nectin3 |
nectin cell adhesion molecule 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NECTIN3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:67,825,296...67,931,999
Ensembl chr11:54,364,487...54,462,519
|
|
G |
Nek6 |
NIMA-related kinase 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NEK6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:42,693,994...42,766,026
Ensembl chr 3:22,284,279...22,395,990
|
|
G |
Ngef |
neuronal guanine nucleotide exchange factor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NGEF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:95,594,823...95,692,381
Ensembl chr 9:88,146,956...88,244,914
|
|
G |
Ngf |
nerve growth factor |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NGF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Niban1 |
niban apoptosis regulator 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NIBAN1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:66,224,219...66,377,728
Ensembl chr13:63,674,171...63,827,729
|
|
G |
Nid2 |
nidogen 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NID2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr15:4,507,224...4,562,949
Ensembl chr15:4,458,084...4,513,843
|
|
G |
Nkx2-1 |
NK2 homeobox 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of NKX2-1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 6:79,731,677...79,735,952
Ensembl chr 6:73,996,601...73,999,791
|
|
G |
Nmu |
neuromedin U |
increases expression |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NMU mRNA |
CTD |
PMID:23423171 |
|
NCBI chr14:32,198,789...32,226,397
Ensembl chr14:31,844,728...31,872,192
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in increased expression of NOS2 mRNA] |
CTD |
PMID:15994020 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch3 |
notch receptor 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NOTCH3 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 7:11,783,550...11,834,585
Ensembl chr 7:11,133,706...11,184,025
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NR1D1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:84,224,599...84,231,812
Ensembl chr10:83,728,318...83,735,705
|
|
G |
Nr1d2 |
nuclear receptor subfamily 1, group D, member 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NR1D2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:9,955,034...9,981,329
Ensembl chr15:7,524,257...7,550,553
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NR1H2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:104,178,483...104,183,863
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 protein] |
CTD |
PMID:27743861 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR1I2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR1I3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of NR3C1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 mRNA; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of ZNF486 mRNA]; NR3C1 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of WNT4 mRNA] |
CTD |
PMID:23275455 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR3C2 mRNA [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of NR3C2 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA] |
CTD |
PMID:22079614 PMID:23275455 |
|
NCBI chr19:47,619,853...47,964,089
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR4A1 protein 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR4A1 mRNA |
CTD |
PMID:21726595 PMID:22079614 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR4A2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR4A3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:67,157,141...67,198,287
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
ISO |
[20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Progesterone; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] affects the expression of HSD17B2 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Estradiol; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Progesterone; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Testosterone; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11B1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP17A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP21A1 mRNA; [NR5A1 protein co-treated with LIF protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Tretinoin] results in increased abundance of Progesterone |
CTD |
PMID:21610156 |
|
NCBI chr 3:42,874,505...42,896,109
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Nrcam |
neuronal cell adhesion molecule |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NRCAM mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:67,129,723...67,425,510
Ensembl chr 6:61,329,863...61,702,992
|
|
G |
Nrp1 |
neuropilin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NRP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:73,256,557...73,411,705
Ensembl chr19:56,359,455...56,513,633
|
|
G |
Ntf4 |
neurotrophin 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of NTF5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:105,030,035...105,032,866
Ensembl chr 1:95,893,457...95,897,243
|
|
G |
Nxn |
nucleoredoxin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NXN mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:61,607,557...61,745,807
Ensembl chr10:61,110,020...61,248,251
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of OGT mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:70,811,317...70,856,123
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Omg |
oligodendrocyte-myelin glycoprotein |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of OMG mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:64,959,316...64,962,050
Ensembl chr10:64,461,350...64,464,084
|
|
G |
Osbp2 |
oxysterol binding protein 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of OSBP2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:82,808,693...82,970,386
Ensembl chr14:78,585,089...78,746,786
|
|
G |
Ostf1 |
osteoclast stimulating factor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of OSTF1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:225,428,661...225,475,851
Ensembl chr 1:216,002,044...216,049,221
|
|
G |
Oxgr1 |
oxoglutarate receptor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of OXGR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:103,551,338...103,573,611
Ensembl chr15:97,144,293...97,166,612
|
|
G |
P4ha3 |
prolyl 4-hydroxylase subunit alpha 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of P4HA3 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 1:164,040,852...164,075,922
Ensembl chr 1:154,628,736...154,663,775
|
|
G |
Pakap |
paralemmin A kinase anchor protein |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PALM2AKAP2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:76,976,906...77,443,656
Ensembl chr 5:72,181,718...72,648,524
|
|
G |
Palmd |
palmdelphin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PALMD mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 2:207,574,413...207,626,239
Ensembl chr 2:204,889,533...204,941,519
|
|
G |
Pappa |
pappalysin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PAPPA mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 5:83,513,358...83,751,364
Ensembl chr 5:78,498,300...78,730,666
|
|
G |
Papss2 |
3'-phosphoadenosine 5'-phosphosulfate synthase 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PAPSS2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:239,867,597...239,952,614
Ensembl chr 1:230,454,426...230,539,331
|
|
G |
Paqr5 |
progestin and adipoQ receptor family member 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PAQR5 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 8:71,327,397...71,409,201
Ensembl chr 8:62,431,867...62,513,688
|
|
G |
Patj |
PATJ, crumbs cell polarity complex component |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PATJ mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:118,177,557...118,480,301
Ensembl chr 5:113,062,118...113,364,807
|
|
G |
Pbx4 |
PBX homeobox 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PBX4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:19,588,998...19,624,016
Ensembl chr16:19,555,090...19,590,014
|
|
G |
Pcdh20 |
protocadherin 20 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PCDH20 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:70,834,042...70,840,298
Ensembl chr15:64,425,534...64,431,790
|
|
G |
Pcdhb5 |
protocadherin beta 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PCDHB4 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr18:29,302,466...29,305,048
Ensembl chr18:29,028,382...29,053,259
|
|
G |
Pcsk1 |
proprotein convertase subtilisin/kexin type 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PCSK1 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 2:6,130,045...6,176,974
Ensembl chr 2:4,395,543...4,442,434
|
|
G |
Pde1a |
phosphodiesterase 1A |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PDE1A mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 3:85,152,053...85,432,289
Ensembl chr 3:64,747,269...65,024,874
|
|
G |
Pde2a |
phosphodiesterase 2A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PDE2A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:165,235,623...165,327,466
Ensembl chr 1:155,813,180...155,915,434
|
|
G |
Pde3a |
phosphodiesterase 3A |
increases expression |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PDE3A mRNA |
CTD |
PMID:12466227 |
|
NCBI chr 4:175,904,276...176,170,531
Ensembl chr 4:174,172,868...174,438,274
|
|
G |
Pdgfd |
platelet derived growth factor D |
decreases expression increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PDGFD mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PDGFD mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 8:11,773,335...12,007,277
Ensembl chr 8:3,488,423...3,722,395
|
|
G |
Pdlim4 |
PDZ and LIM domain 4 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of PDLIM4 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr10:38,699,444...38,713,696
Ensembl chr10:38,198,689...38,212,938
|
|
G |
Pdzrn3 |
PDZ domain containing RING finger 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PDZRN3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:135,327,082...135,553,294
Ensembl chr 4:133,770,736...133,996,959
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PECAM1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr10:92,090,263...92,152,002
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Peg10 |
paternally expressed 10 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PEG10 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 4:33,809,026...33,822,224
Ensembl chr 4:32,848,493...32,852,621
|
|
G |
Pgm5 |
phosphoglucomutase 5 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PGM5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:231,752,052...231,939,812
Ensembl chr 1:222,325,643...222,513,437
|
|
G |
Pgr |
progesterone receptor |
multiple interactions decreases expression |
ISO |
[8-Bromo Cyclic Adenosine Monophosphate co-treated with Progesterone co-treated with Estradiol] affects the expression of and affects the phosphorylation of PGR protein 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PGR protein |
CTD |
PMID:23275455 |
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Phactr3 |
phosphatase and actin regulator 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PHACTR3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:185,582,134...185,801,404
Ensembl chr 3:165,205,255...165,423,153
|
|
G |
Phaf1 |
phagophore assembly factor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PHAF1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:50,011,350...50,050,880
Ensembl chr19:33,101,490...33,138,914
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PID1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 9:92,732,471...92,951,168
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Pik3r3 |
phosphoinositide-3-kinase regulatory subunit 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PIK3R3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:134,936,790...135,009,303
Ensembl chr 5:129,701,229...129,772,583
|
|
G |
Pitpnc1 |
phosphatidylinositol transfer protein, cytoplasmic 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PITPNC1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr10:92,663,260...92,928,616
Ensembl chr10:92,167,196...92,429,297
|
|
G |
Pla2r1 |
phospholipase A2 receptor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PLA2R1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:65,292,629...65,422,462
Ensembl chr 3:44,883,943...45,013,660
|
|
G |
Plat |
plasminogen activator, tissue type |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PLAT mRNA |
CTD |
PMID:20147733 |
|
NCBI chr16:75,943,061...76,022,037
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plcb1 |
phospholipase C beta 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PLCB1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Pld1 |
phospholipase D1 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of and results in increased activity of PLD1 protein; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA] |
CTD |
PMID:17065600 |
|
NCBI chr 2:112,777,820...112,975,857
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Pmepa1 |
prostate transmembrane protein, androgen induced 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PMEPA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:182,430,193...182,478,649
Ensembl chr 3:162,012,751...162,060,454
|
|
G |
Pon3 |
paraoxonase 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PON3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:34,323,546...34,350,244
Ensembl chr 4:33,349,168...33,383,855
|
|
G |
Pou3f1 |
POU class 3 homeobox 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of POU3F1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:142,195,090...142,198,070
Ensembl chr 5:136,910,391...136,913,371
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PPARA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PPARG mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in increased expression of PPARG mRNA] |
CTD |
PMID:15994020 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppfibp1 |
PPFIA binding protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PPFIBP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:181,538,249...181,682,079
Ensembl chr 4:179,808,794...179,951,428
|
|
G |
Ppm1h |
protein phosphatase, Mg2+/Mn2+ dependent, 1H |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PPM1H mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:60,224,087...60,484,947
Ensembl chr 7:58,338,661...58,599,547
|
|
G |
Ppp1r3c |
protein phosphatase 1, regulatory subunit 3C |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PPP1R3C mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 1:243,873,524...243,878,527
Ensembl chr 1:234,460,652...234,465,961
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
multiple interactions |
ISO |
[PRKACB protein mutant form results in increased susceptibility to 8-Bromo Cyclic Adenosine Monophosphate analog] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] |
CTD |
PMID:29669941 |
|
NCBI chr 2:238,297,140...238,389,317
Ensembl chr 2:235,636,885...235,726,198
|
|
G |
Prkar1a |
protein kinase cAMP-dependent type I regulatory subunit alpha |
multiple interactions |
ISO |
[PRKACB protein mutant form results in increased susceptibility to 8-Bromo Cyclic Adenosine Monophosphate analog] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] |
CTD |
PMID:29669941 |
|
NCBI chr10:95,120,537...95,139,028
Ensembl chr10:94,620,039...94,639,041
|
|
G |
Prkar2b |
protein kinase cAMP-dependent type II regulatory subunit beta |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRKAR2B mRNA [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of PRKAR2B protein |
CTD |
PMID:18467523 PMID:22079614 |
|
NCBI chr 6:54,291,143...54,381,639
Ensembl chr 6:48,563,662...48,653,933
|
|
G |
Prkca |
protein kinase C, alpha |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRKCA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:93,388,991...93,787,617
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prl |
prolactin |
multiple interactions increases expression decreases expression increases secretion |
ISO EXP |
1-Butanol inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA]; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Dexamethasone] results in increased expression of PRL mRNA; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA]; Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA]; Tobacco Smoke Pollution inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL protein 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PRL mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PRL protein 8-Bromo Cyclic Adenosine Monophosphate results in increased secretion of PRL protein |
CTD |
PMID:15774544 PMID:16709600 PMID:17065600 PMID:18815356 PMID:20147733 PMID:20955787 PMID:21273127 PMID:21467749 PMID:21903722 PMID:23275455 More...
|
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prmt7 |
protein arginine methyltransferase 7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PRMT7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:51,020,596...51,071,401
Ensembl chr19:34,110,747...34,162,577
|
|
G |
Prss23 |
serine protease 23 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PRSS23 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:152,815,301...152,835,005
Ensembl chr 1:143,401,396...143,422,091
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PSAT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:222,623,553...222,646,187
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PTGDR2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:217,010,183...217,015,044
Ensembl chr 1:207,587,917...207,589,213
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PTGS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [PTGS2 co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of VEGFA |
CTD |
PMID:11112151 PMID:12821125 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pth |
parathyroid hormone |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PTH mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:176,942,901...176,946,034
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PTHLH mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 4:181,919,400...181,930,454
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [HU 211 results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:12163181 |
|
NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ptp4a1 |
protein tyrosine phosphatase 4A1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PTP4A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:40,710,250...40,718,176
Ensembl chr 9:33,214,208...33,221,964
|
|
G |
Ptpre |
protein tyrosine phosphatase, receptor type, E |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PTPRE mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:199,774,195...199,924,646
Ensembl chr 1:190,344,401...190,489,534
|
|
G |
Ptprf |
protein tyrosine phosphatase, receptor type, F |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PTPRF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:137,027,376...137,109,405
Ensembl chr 5:131,742,754...131,810,023
|
|
G |
Ptprz1 |
protein tyrosine phosphatase, receptor type Z1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PTPRZ1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:52,363,006...52,560,905
Ensembl chr 4:51,397,601...51,595,218
|
|
G |
Pts |
6-pyruvoyl-tetrahydropterin synthase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PTS mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:59,767,234...59,774,265
Ensembl chr 8:50,870,841...50,877,869
|
|
G |
Pxylp1 |
2-phosphoxylose phosphatase 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PXYLP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:106,299,303...106,364,603
Ensembl chr 8:97,419,776...97,485,064
|
|
G |
Pygl |
glycogen phosphorylase L |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PYGL mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:94,433,558...94,476,219
Ensembl chr 6:88,697,593...88,740,310
|
|
G |
Rab25 |
RAB25, member RAS oncogene family |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RAB25 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:176,298,124...176,304,221
Ensembl chr 2:174,000,323...174,006,422
|
|
G |
Rab27b |
RAB27B, member RAS oncogene family |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RAB27B mRNA |
CTD |
PMID:20147733 |
|
NCBI chr18:65,870,230...66,069,597
Ensembl chr18:63,600,937...63,757,180
|
|
G |
Rabgap1 |
RAB GTPase activating protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RABGAP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:41,617,784...41,735,795
Ensembl chr 3:21,208,055...21,326,013
|
|
G |
Ran |
RAN, member RAS oncogene family |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RAN mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:33,311,155...33,314,339
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
increases activity |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased activity of RAP1A protein |
CTD |
PMID:10908723 |
|
NCBI chr 2:195,896,967...195,974,851
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rap1b |
RAP1B, member of RAS oncogene family |
increases activity |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in increased activity of RAP1B protein |
CTD |
PMID:10908723 |
|
NCBI chr 7:55,308,922...55,342,217
Ensembl chr 7:53,423,130...53,456,370
|
|
G |
Rarg |
retinoic acid receptor, gamma |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RARG mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:135,246,427...135,268,889
Ensembl chr 7:133,367,833...133,390,177
|
|
G |
Rarres2 |
retinoic acid receptor responder 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RARRES2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:78,853,450...78,856,652
Ensembl chr 4:77,522,535...77,525,556
|
|
G |
Rasd1 |
ras related dexamethasone induced 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RASD1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr10:45,265,975...45,275,279
Ensembl chr10:44,766,455...44,768,186
|
|
G |
Rasip1 |
Ras interacting protein 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RASIP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:105,233,599...105,246,028
Ensembl chr 1:96,091,074...96,109,562
|
|
G |
Rassf5 |
Ras association domain family member 5 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RASSF5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:45,189,768...45,255,277
Ensembl chr13:42,637,549...42,703,024
|
|
G |
Rassf6 |
Ras association domain family member 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RASSF6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:17,717,505...17,757,507
Ensembl chr14:17,442,789...17,473,330
|
|
G |
Rbms3 |
RNA binding motif, single stranded interacting protein 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RBMS3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:125,183,311...125,970,239
Ensembl chr 8:116,309,882...117,625,423
|
|
G |
Rbp1 |
retinol binding protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RBP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:107,904,589...107,926,109
Ensembl chr 8:99,025,206...99,046,743
|
|
G |
Reps2 |
RALBP1 associated Eps domain containing 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of REPS2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr X:35,681,260...35,954,103
Ensembl chr X:32,049,399...32,317,414
|
|
G |
Rfx6 |
regulatory factor X, 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RFX6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:31,562,490...31,615,967
Ensembl chr20:31,019,829...31,073,147
|
|
G |
Rgs16 |
regulator of G-protein signaling 16 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RGS16 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:68,421,480...68,443,312
Ensembl chr13:65,887,530...65,892,857
|
|
G |
Rhbg |
Rh family B glycoprotein |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RHBG mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:176,002,886...176,015,201
Ensembl chr 2:173,704,562...173,717,321
|
|
G |
Rhob |
ras homolog family member B |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RHOB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rhobtb1 |
Rho-related BTB domain containing 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RHOBTB1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:19,326,197...19,455,182
Ensembl chr20:19,327,155...19,403,012
|
|
G |
Rhou |
ras homolog family member U |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RHOU mRNA |
CTD |
PMID:22079614 |
|
NCBI chr19:68,538,960...68,548,733
Ensembl chr19:51,641,227...51,650,552
|
|
G |
Rilp |
Rab interacting lysosomal protein |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RILP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:60,853,316...60,857,096
Ensembl chr10:60,355,278...60,358,781
|
|
G |
Rin3 |
Ras and Rab interactor 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RIN3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:127,196,648...127,305,821
Ensembl chr 6:121,431,339...121,540,957
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RIPK3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:33,253,071...33,262,025
Ensembl chr15:29,283,145...29,292,121
|
|
G |
Ripor2 |
RHO family interacting cell polarization regulator 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RIPOR2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr17:40,751,771...40,975,611
Ensembl chr17:40,323,867...40,548,092
|
|
G |
Rnf144b |
ring finger protein 144B |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RNF144B mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:17,637,564...17,786,685
Ensembl chr17:17,432,786...17,562,760
|
|
G |
Robo2 |
roundabout guidance receptor 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ROBO2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:26,015,919...27,583,750
Ensembl chr11:12,528,951...13,041,536
|
|
G |
Ror1 |
receptor tyrosine kinase-like orphan receptor 1 |
multiple interactions decreases expression |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ROR1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ROR1 mRNA |
CTD |
PMID:16997883 PMID:22079614 |
|
NCBI chr 5:119,859,744...120,203,573
Ensembl chr 5:114,744,304...115,088,155
|
|
G |
Rora |
RAR-related orphan receptor A |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RORA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:78,182,710...78,915,730
Ensembl chr 8:69,301,733...70,025,931
|
|
G |
Rorb |
RAR-related orphan receptor B |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RORB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:225,790,216...225,970,973
Ensembl chr 1:216,363,629...216,544,390
|
|
G |
Rph3al |
rabphilin 3A-like (without C2 domains) |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RPH3AL mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:61,188,288...61,331,591
Ensembl chr10:60,690,031...60,801,883
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RRM2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Rspo1 |
R-spondin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RSPO1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:142,536,162...142,557,611
Ensembl chr 5:137,251,659...137,272,933
|
|
G |
Runx1t1 |
RUNX1 partner transcriptional co-repressor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RUNX1T1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:31,984,946...32,136,878
Ensembl chr 5:27,187,551...27,335,592
|
|
G |
Rxrb |
retinoid X receptor beta |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RXRB mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:4,818,707...4,824,968
Ensembl chr20:4,816,815...4,828,773
|
|
G |
Rxrg |
retinoid X receptor gamma |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of RXRG mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:82,276,330...82,318,097
Ensembl chr13:79,743,563...79,785,167
|
|
G |
Ryr3 |
ryanodine receptor 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of RYR3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:119,886,129...120,433,465
Ensembl chr 3:99,432,505...99,704,961
|
|
G |
Samd3 |
sterile alpha motif domain containing 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SAMD3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:20,920,129...20,967,595
Ensembl chr 1:19,103,036...19,148,192
|
|
G |
Sc5d |
sterol-C5-desaturase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SC5D mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:51,526,669...51,538,277
Ensembl chr 8:42,632,672...42,641,273
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SCARB1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:36,957,302...37,023,982
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scg2 |
secretogranin II |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SCG2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:88,251,531...88,257,208
Ensembl chr 9:80,803,075...80,821,097
|
|
G |
Scgb1c1 |
secretoglobin, family 1C, member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SCGB1C1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:205,352,216...205,354,656
Ensembl chr 1:195,923,803...195,925,022
|
|
G |
Scrg1 |
stimulator of chondrogenesis 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SCRG1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:37,770,739...37,799,010
Ensembl chr16:32,760,028...32,788,299
|
|
G |
Serpina11 |
serpin family A member 11 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SERPINA11 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:128,668,030...128,677,476
Ensembl chr 6:122,903,250...122,912,670
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of SERPINE1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Serpini1 |
serpin family I member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SERPINI1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:162,645,209...162,731,737
Ensembl chr 2:160,346,758...160,433,135
|
|
G |
Sesn3 |
sestrin 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SESN3 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 8:19,415,307...19,470,943
Ensembl chr 8:11,133,678...11,185,842
|
|
G |
Sf1 |
splicing factor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SF1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:213,090,256...213,112,688
Ensembl chr 1:203,670,018...203,684,330
|
|
G |
Sfrp1 |
secreted frizzled-related protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SFRP1 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr16:75,278,325...75,316,736
Ensembl chr16:68,575,763...68,614,286
|
|
G |
Sftpb |
surfactant protein B |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SFTPB mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:104,359,396...104,368,436
|
|
G |
Sftpc |
surfactant protein C |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SFTPC mRNA |
CTD |
PMID:16997883 |
|
NCBI chr15:52,006,274...52,009,324
Ensembl chr15:45,596,574...45,610,777
|
|
G |
Sgcd |
sarcoglycan, delta |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SGCD mRNA |
CTD |
PMID:20147733 |
|
NCBI chr10:31,847,713...32,829,554
Ensembl chr10:31,280,511...31,724,840
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SGK1 mRNA Estradiol inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SGK1 mRNA]; Genistein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SGK1 mRNA] |
CTD |
PMID:21056929 |
|
NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Sgms1 |
sphingomyelin synthase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SGMS1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:239,409,991...239,681,195
Ensembl chr 1:229,998,119...230,259,603
|
|
G |
Sh3bp5 |
SH3-domain binding protein 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SH3BP5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:6,589,877...6,676,524
Ensembl chr16:6,583,465...6,698,975
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SIRT1 protein |
CTD |
PMID:16709600 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt3 |
sirtuin 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SIRT3 mRNA |
CTD |
PMID:23166782 |
|
NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC16A6 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr10:94,923,888...94,946,990
Ensembl chr10:94,426,244...94,448,779
|
|
G |
Slc17a5 |
solute carrier family 17 member 5 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SLC17A5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:88,274,497...88,309,734
|
|
G |
Slc25a36 |
solute carrier family 25 member 36 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLC25A36 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 8:106,539,355...106,573,240
Ensembl chr 8:97,662,127...97,693,703
|
|
G |
Slc26a4 |
solute carrier family 26 member 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC26A4 protein |
CTD |
PMID:22811483 |
|
NCBI chr 6:53,835,102...53,873,968
Ensembl chr 6:48,107,588...48,145,703
|
|
G |
Slc26a7 |
solute carrier family 26 member 7 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC26A7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:32,681,653...32,819,110
Ensembl chr 5:27,887,042...28,021,658
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC27A2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:113,804,728...113,842,208
|
|
G |
Slc27a4 |
solute carrier family 27 member 4 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SLC27A4 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:33,472,903...33,485,824
Ensembl chr 3:13,075,022...13,087,943
|
|
G |
Slc2a12 |
solute carrier family 2 member 12 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC2A12 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 1:24,623,558...24,683,577
Ensembl chr 1:22,804,418...22,860,971
|
|
G |
Slc39a8 |
solute carrier family 39 member 8 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLC39A8 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 2:226,845,686...226,992,668
Ensembl chr 2:224,256,654...224,319,129
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SLC3A2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc51a |
solute carrier family 51 member A |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC51A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:81,804,141...81,818,539
Ensembl chr11:68,299,086...68,313,485
|
|
G |
Slc5a12 |
solute carrier family 5 member 12 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC5A12 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:117,633,885...117,683,966
Ensembl chr 3:97,179,326...97,228,405
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC5A7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:7,922,693...7,953,509
Ensembl chr 9:7,595,444...7,626,258
|
|
G |
Slc6a14 |
solute carrier family 6 member 14 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLC6A14 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr X:117,109,063...117,169,522
Ensembl chr X:112,314,691...112,375,096
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC6A9 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 5:136,660,022...136,694,173
Ensembl chr 5:131,374,542...131,408,728
|
|
G |
Slc7a1 |
solute carrier family 7 member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC7A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:11,664,488...11,740,030
Ensembl chr12:6,628,007...6,703,849
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slc9a1 |
solute carrier family 9 member A1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC9A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:150,859,412...150,913,525
Ensembl chr 5:145,576,334...145,629,624
|
|
G |
Slco4c1 |
solute carrier organic anion transporter family, member 4C1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLCO4C1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 9:104,624,802...104,676,462
Ensembl chr 9:97,178,861...97,229,715
|
|
G |
Smoc1 |
SPARC related modular calcium binding 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SMOC1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 6:106,432,592...106,593,956
Ensembl chr 6:100,701,346...100,862,699
|
|
G |
Smox |
spermine oxidase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SMOX mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 3:139,184,793...139,220,174
Ensembl chr 3:118,731,900...118,765,710 Ensembl chr X:118,731,900...118,765,710
|
|
G |
Snca |
synuclein alpha |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SNCA mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Soat1 |
sterol O-acyltransferase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SOAT1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:71,105,178...71,147,776
Ensembl chr13:68,552,317...68,597,494
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SOCS3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SOD1 mRNA |
CTD |
PMID:16709600 PMID:22079614 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 protein; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA] |
CTD |
PMID:16709600 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox5 |
SRY-box transcription factor 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SOX5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:178,512,272...179,467,686
Ensembl chr 4:176,785,892...177,736,852
|
|
G |
Spata9 |
spermatogenesis associated 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPATA9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:7,197,372...7,235,408
Ensembl chr 2:5,465,575...5,503,538
|
|
G |
Spink5 |
serine peptidase inhibitor, Kazal type 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPINK5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr18:36,515,347...36,584,038
Ensembl chr18:36,264,452...36,332,185
|
|
G |
Spock2 |
SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPOCK2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:28,580,262...28,607,198
Ensembl chr20:28,033,475...28,064,272
|
|
G |
Spon1 |
spondin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPON1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 1:177,363,526...177,662,689
Ensembl chr 1:167,928,972...168,228,226
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions decreases expression |
EXP ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; Dinitrochlorobenzene inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; KT 5823 inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]] 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SPP1 mRNA |
CTD |
PMID:20453393 PMID:22079614 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sprr1a |
small proline-rich protein 1A |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPRR1A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:180,750,709...180,752,625
Ensembl chr 2:178,055,096...178,057,063
|
|
G |
Sprr1b |
small proline-rich protein 1B |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPRR1B mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:180,704,457...180,706,355
Ensembl chr 2:178,009,130...178,009,567
|
|
G |
Sprr3 |
small proline-rich protein 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPRR3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:180,723,038...180,725,695
Ensembl chr 2:178,027,425...178,029,891
|
|
G |
Spry2 |
sprouty RTK signaling antagonist 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SPRY2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:89,106,809...89,111,926
Ensembl chr15:82,692,143...82,698,009
|
|
G |
Sqle |
squalene epoxidase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SQLE mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:92,758,175...92,773,049
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SRD5A1 mRNA |
CTD |
PMID:24014645 |
|
NCBI chr 1:35,514,914...35,548,898
Ensembl chr 1:33,686,391...33,720,461
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SREBF1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650
|
|
G |
St3gal1 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ST3GAL1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:100,734,300...100,802,443
Ensembl chr 7:98,845,270...98,913,236
|
|
G |
St3gal6 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 6 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ST3GAL6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr11:55,530,120...55,590,950
Ensembl chr11:42,077,621...42,121,776
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression multiple interactions |
EXP ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; SB 203580 inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; T-2 Toxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA] 2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; 8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [sodium arsenite results in increased expression of STAR mRNA]; 8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [sodium arsenite results in increased expression of STAR protein]; Anisomycin promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Dantrolene inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; Ryanodine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; SB 203580 promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; SB 203580 promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; sodium arsenite promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; sodium arsenite promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Valproic Acid inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Valproic Acid inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein] |
CTD |
PMID:15713539 PMID:16254025 PMID:18815356 PMID:19849856 PMID:20732403 PMID:21726595 PMID:22079614 PMID:22546480 PMID:23183170 PMID:24014645 PMID:24328340 PMID:24740604 PMID:28859905 PMID:30951242 PMID:34896276 More...
|
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stard3 |
StAR-related lipid transfer domain containing 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of STARD3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:83,853,622...83,876,162
Ensembl chr10:83,357,359...83,550,976
|
|
G |
Stc1 |
stanniocalcin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STC1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr15:50,709,439...50,720,093
Ensembl chr15:44,299,621...44,310,264
|
|
G |
Stc2 |
stanniocalcin 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of STC2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:16,755,508...16,765,275
Ensembl chr10:16,250,853...16,262,973
|
|
G |
Stk17b |
serine/threonine kinase 17b |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of STK17B mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:62,801,912...62,832,511
Ensembl chr 9:55,307,668...55,338,031
|
|
G |
Stra6 |
signaling receptor and transporter of retinol STRA6 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of STRA6 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:67,444,757...67,464,719
Ensembl chr 8:58,549,736...58,568,860
|
|
G |
Stx2 |
syntaxin 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STX2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:33,315,447...33,350,788
Ensembl chr12:27,689,819...27,714,751
|
|
G |
Stx3 |
syntaxin 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of STX3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:217,940,697...218,114,865
Ensembl chr 1:208,639,115...208,685,805
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SULT2A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:84,582,011...84,639,001
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Sult4a1 |
sulfotransferase family 4A, member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SULT4A1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:117,096,064...117,120,714
Ensembl chr 7:115,216,066...115,240,085
|
|
G |
Sv2c |
synaptic vesicle glycoprotein 2c |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SV2C mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:28,967,631...29,163,168
Ensembl chr 2:27,232,933...27,428,477
|
|
G |
Svil |
supervillin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SVIL mRNA |
CTD |
PMID:20147733 |
|
NCBI chr17:57,343,910...57,539,508
Ensembl chr17:52,648,502...52,793,404
|
|
G |
Syne1 |
spectrin repeat containing nuclear envelope protein 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SYNE1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:43,917,640...44,388,802
Ensembl chr 1:41,512,030...41,983,322
|
|
G |
Syt12 |
synaptotagmin 12 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SYT12 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:211,158,745...211,189,780
Ensembl chr 1:201,730,371...201,759,609
|
|
G |
Syt9 |
synaptotagmin 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SYT9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:170,687,666...170,868,146
Ensembl chr 1:161,275,734...161,455,007
|
|
G |
Tac1 |
tachykinin, precursor 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TAC1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tacc2 |
transforming, acidic coiled-coil containing protein 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TACC2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:194,546,428...194,758,152
Ensembl chr 1:185,116,111...185,327,881
|
|
G |
Tafa5 |
TAFA chemokine like family member 5 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TAFA5 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:120,493,447...120,714,720
Ensembl chr 7:118,613,889...118,834,353
|
|
G |
Tbc1d2 |
TBC1 domain family, member 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TBC1D2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 5:65,679,670...65,727,978
Ensembl chr 5:60,884,124...60,931,352
|
|
G |
Tcf21 |
transcription factor 21 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TCF21 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 1:24,520,499...24,523,358
Ensembl chr 1:22,701,353...22,704,202
|
|
G |
Tef |
TEF transcription factor, PAR bZIP family member |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TEF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:115,197,180...115,221,930
Ensembl chr 7:113,317,283...113,341,783
|
|
G |
Tent5a |
terminal nucleotidyltransferase 5A |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TENT5A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:95,102,349...95,109,100
Ensembl chr 8:86,225,357...86,229,045
|
|
G |
Tesk1 |
testis associated actin remodelling kinase 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TESK1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:62,487,763...62,493,492
Ensembl chr 5:57,691,969...57,697,698
|
|
G |
Testin |
testin gene |
decreases expression multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TESTIN mRNA lonidamine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TESTIN mRNA] |
CTD |
PMID:11090432 |
|
NCBI chr17:3,829,012...3,864,995
Ensembl chr17:3,846,899...3,859,385
|
|
G |
Tfpi2 |
tissue factor pathway inhibitor 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TFPI2 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr 4:32,936,462...32,941,385
Ensembl chr 4:31,982,178...31,986,600
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TGFB1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb1i1 |
transforming growth factor beta 1 induced transcript 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TGFB1I1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:192,258,992...192,265,903
Ensembl chr 1:182,828,544...182,837,080
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TGFB2 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr13:100,691,540...100,793,227
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TGFB3 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 6:111,435,170...111,457,646
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TGFBR2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]] |
CTD |
PMID:21726595 |
|
NCBI chr10:84,198,141...84,225,659
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TIPARP mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 2:152,063,769...152,090,414
Ensembl chr 2:149,753,682...149,780,327
|
|
G |
Tlcd3a |
TLC domain containing 3A |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TLCD3A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:61,556,193...61,563,529
Ensembl chr10:61,058,042...61,065,283
|
|
G |
Tmc5 |
transmembrane channel-like 5 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TMC5 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 1:182,349,102...182,433,679
Ensembl chr 1:172,914,457...172,999,474
|
|
G |
Tmod1 |
tropomodulin 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TMOD1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 5:65,112,062...65,189,563
Ensembl chr 5:60,338,512...60,393,956
|
|
G |
Tmx4 |
thioredoxin-related transmembrane protein 4 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TMX4 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 3:142,309,026...142,352,415
Ensembl chr 3:121,856,261...121,899,641
|
|
G |
Tnc |
tenascin C |
multiple interactions increases expression |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TNC mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNC mRNA |
CTD |
PMID:16997883 PMID:20147733 |
|
NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] |
CTD |
PMID:10495789 PMID:11230753 PMID:21803157 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
increases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNFAIP3 mRNA [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TNFAIP3 mRNA |
CTD |
PMID:16997883 PMID:22079614 |
|
NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNFRSF10A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr15:51,249,883...51,278,091
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfrsf12a |
TNF receptor superfamily member 12A |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNFRSF12A mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:13,211,670...13,213,666
Ensembl chr10:12,689,890...12,709,045
|
|
G |
Tnfrsf19 |
TNF receptor superfamily member 19 |
decreases expression increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TNFRSF19 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNFRSF19 mRNA |
CTD |
PMID:20147733 PMID:22079614 |
|
NCBI chr15:39,268,305...39,334,566
Ensembl chr15:35,092,206...35,180,795
|
|
G |
Tnfsf4 |
TNF superfamily member 4 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TNFSF4 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr13:76,256,654...76,280,133
Ensembl chr13:73,723,329...73,746,788
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNNT2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:49,819,123...49,837,125
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TP53; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TP53 protein |
CTD |
PMID:10642304 PMID:11802967 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tph2 |
tryptophan hydroxylase 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TPH2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:52,571,909...52,676,305
Ensembl chr 7:50,685,694...50,789,424
|
|
G |
Tpm1 |
tropomyosin 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TPM1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 8:76,516,654...76,543,661
Ensembl chr 8:67,635,479...67,662,802
|
|
G |
Tpmt |
thiopurine S-methyltransferase |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TPMT mRNA |
CTD |
PMID:22079614 |
|
NCBI chr17:17,850,308...17,868,976
Ensembl chr17:17,644,173...17,662,709
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TRIB3 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Trim2 |
tripartite motif-containing 2 |
multiple interactions increases expression |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TRIM2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TRIM2 mRNA |
CTD |
PMID:16997883 PMID:20147733 |
|
NCBI chr 2:171,798,654...171,950,193
Ensembl chr 2:169,500,634...169,652,927
|
|
G |
Trim24 |
tripartite motif-containing 24 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TRIM24 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 4:67,534,240...67,659,014
Ensembl chr 4:66,566,686...66,717,241
|
|
G |
Trip10 |
thyroid hormone receptor interactor 10 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of TRIP10 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 9:2,219,695...2,234,771
Ensembl chr 9:2,133,671...2,147,799
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TRPA1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:9,163,060...9,217,325
Ensembl chr 5:4,379,999...4,433,570
|
|
G |
Tshz2 |
teashirt zinc finger homeobox 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TSHZ2 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr 3:178,824,221...179,271,151
Ensembl chr 3:158,405,423...158,850,128
|
|
G |
Ttc9 |
tetratricopeptide repeat domain 9 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TTC9 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:107,064,527...107,099,361
Ensembl chr 6:101,333,141...101,368,110
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
EXP |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in decreased expression of TXN1 protein] |
CTD |
PMID:20453393 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of UGT2B17 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of UGT2B7 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:21,251,535...21,274,451
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Unc5b |
unc-5 netrin receptor B |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of UNC5B mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:29,240,639...29,307,270
Ensembl chr20:28,697,726...28,764,537
|
|
G |
Ushbp1 |
USH1 protein network component harmonin binding protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of USHBP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:18,091,311...18,101,927
Ensembl chr16:18,057,326...18,067,877
|
|
G |
Uts2 |
urotensin 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of UTS2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:166,725,471...166,739,063
Ensembl chr 5:161,450,846...161,456,237
|
|
G |
Uty |
ubiquitously transcribed tetratricopeptide repeat containing, Y-linked |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of UTY mRNA |
CTD |
PMID:22079614 |
|
NCBI chr Y:1,018,111...1,178,493
Ensembl chr Y:924,168...1,103,422
|
|
G |
Vdr |
vitamin D receptor |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of VDR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
ISO |
[PTGS2 co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of VEGFA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of VEGFA mRNA |
CTD |
PMID:10788502 PMID:12821125 PMID:20147733 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of VEGFC mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:44,445,293...44,560,887
Ensembl chr16:37,712,262...37,827,848
|
|
G |
Vgf |
VGF nerve growth factor inducible |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of VGF mRNA |
CTD |
PMID:22079614 |
|
NCBI chr12:25,274,004...25,281,803
Ensembl chr12:19,637,320...19,640,341
|
|
G |
Vgll3 |
vestigial-like family member 3 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of VGLL3 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr11:17,089,484...17,136,501
Ensembl chr11:3,643,069...3,689,140
|
|
G |
Vipr1 |
vasoactive intestinal peptide receptor 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of VIPR1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 8:130,181,219...130,217,098
Ensembl chr 8:121,310,248...121,339,585
|
|
G |
Vldlr |
very low density lipoprotein receptor |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of VLDLR mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:234,239,769...234,272,150
Ensembl chr 1:224,814,377...224,845,920
|
|
G |
Vmo1 |
vitelline membrane outer layer 1 homolog |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of VMO1 mRNA |
CTD |
PMID:20147733 |
|
NCBI chr10:55,726,572...55,733,432
Ensembl chr10:55,227,944...55,229,289
|
|
G |
Wdr17 |
WD repeat domain 17 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of WDR17 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr16:43,792,989...43,924,187
Ensembl chr16:37,059,895...37,191,122
|
|
G |
Whrn |
whirlin |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of WHRN mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:81,843,820...81,933,400
Ensembl chr 5:76,828,301...76,912,223
|
|
G |
Wif1 |
Wnt inhibitory factor 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of WIF1 mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 7:58,433,326...58,503,853
Ensembl chr 7:56,548,053...56,618,360
|
|
G |
Wnt4 |
Wnt family member 4 |
decreases expression multiple interactions |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of WNT4 mRNA [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of WNT4 mRNA; NR3C1 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of WNT4 mRNA] |
CTD |
PMID:22079614 PMID:23275455 |
|
NCBI chr 5:154,797,245...154,818,565
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Wnt5b |
Wnt family member 5B |
multiple interactions |
ISO |
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of WNT5B mRNA |
CTD |
PMID:16997883 |
|
NCBI chr 4:154,281,852...154,406,081
Ensembl chr 4:152,609,569...152,733,407
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of XBP1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr14:84,604,623...84,609,707
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Zbtb12 |
zinc finger and BTB domain containing 12 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ZBTB12 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr20:3,942,302...3,945,148
|
|
G |
Zbtb18 |
zinc finger and BTB domain containing 18 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ZBTB18 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr13:91,971,602...91,980,058
Ensembl chr13:89,439,420...89,448,862
|
|
G |
Zbtb32 |
zinc finger and BTB domain containing 32 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ZBTB32 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 1:94,969,374...94,978,553
Ensembl chr 1:85,841,931...85,844,236
|
|
G |
Zfp36l1 |
zinc finger protein 36, C3H type-like 1 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ZFP36L1 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:104,663,396...104,669,815
Ensembl chr 6:98,930,718...98,935,748
|
|
G |
Zfp36l2 |
zinc finger protein 36, C3H type-like 2 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ZFP36L2 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 6:16,242,622...16,246,662
Ensembl chr 6:10,490,032...10,494,064
|
|
G |
Zfp46 |
zinc finger protein 46 |
decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ZNF436 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr 5:153,802,887...153,813,388
Ensembl chr 5:148,520,855...148,529,459
|
|
G |
Znf454 |
zinc finger protein 454 |
increases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ZNF454 mRNA |
CTD |
PMID:22079614 |
|
NCBI chr10:35,684,741...35,701,281
Ensembl chr10:35,185,028...35,245,505
|
|
|
G |
Arhgef17 |
Rho guanine nucleotide exchange factor 17 |
multiple interactions |
ISO |
[8-bromocyclic GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein |
CTD |
PMID:23195829 |
|
NCBI chr 1:164,642,690...164,702,241
Ensembl chr 1:155,233,168...155,290,498
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]] |
CTD |
PMID:9388267 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
increases expression multiple interactions |
ISO |
8-bromocyclic GMP results in increased expression of COX4I1 protein tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of COX4I1 protein] |
CTD |
PMID:24041027 |
|
NCBI chr19:65,630,383...65,636,623
Ensembl chr19:48,721,199...48,727,921
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
increases expression |
ISO |
8-bromocyclic GMP results in increased expression of DUSP10 mRNA; 8-bromocyclic GMP results in increased expression of DUSP10 protein |
CTD |
PMID:29165873 |
|
NCBI chr13:98,145,317...98,183,304
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP ISO |
8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] 8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of EDN1 mRNA]; 8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of EDN1 protein] |
CTD |
PMID:16023617 PMID:29165873 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn3 |
endothelin 3 |
multiple interactions |
EXP |
8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] |
CTD |
PMID:16023617 |
|
NCBI chr 3:183,980,458...184,004,958
Ensembl chr 3:163,562,520...163,585,093
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]; 8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] |
CTD |
PMID:16023617 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of HIF1A mRNA]; 8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of HIF1A protein] |
CTD |
PMID:29165873 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
8-bromocyclic GMP results in increased expression of HMOX1 mRNA; 8-bromocyclic GMP results in increased expression of HMOX1 protein |
CTD |
PMID:24041027 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
8-bromocyclic GMP promotes the reaction [IL1B protein results in increased abundance of Nitrites]; Dipyridamole promotes the reaction [8-bromocyclic GMP promotes the reaction [IL1B protein results in increased abundance of Nitrites]] |
CTD |
PMID:8904084 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
increases expression multiple interactions |
ISO |
8-bromocyclic GMP results in increased expression of IL4 mRNA Cyclosporine inhibits the reaction [8-bromocyclic GMP results in increased expression of IL4 mRNA] |
CTD |
PMID:16533816 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
8-bromocyclic GMP results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:17828804 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
8-bromocyclic GMP results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:17828804 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases phosphorylation |
ISO |
8-bromocyclic GMP results in decreased phosphorylation of MYC protein |
CTD |
PMID:17828804 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ndufb8 |
NADH:ubiquinone oxidoreductase subunit B8 |
increases expression multiple interactions |
ISO |
8-bromocyclic GMP results in increased expression of NDUFB8 protein tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of NDUFB8 protein] |
CTD |
PMID:24041027 |
|
NCBI chr 1:253,357,878...253,362,936
Ensembl chr 1:243,408,619...243,413,817
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
affects localization |
ISO |
8-bromocyclic GMP affects the localization of NFATC1 protein |
CTD |
PMID:16533816 |
|
NCBI chr18:76,321,386...76,430,997
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
increases expression multiple interactions |
ISO |
8-bromocyclic GMP results in increased expression of NRF1 mRNA tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of NRF1 mRNA] |
CTD |
PMID:24041027 |
|
NCBI chr 4:59,632,366...59,738,166
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Pde5a |
phosphodiesterase 5A |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with 8-bromocyclic GMP] results in increased expression of PDE5A protein; [1-Methyl-3-isobutylxanthine co-treated with 8-bromocyclic GMP] results in increased expression of PDE5A protein modified form |
CTD |
PMID:20613715 |
|
NCBI chr 2:213,542,822...213,687,638
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO |
8-bromocyclic GMP results in increased expression of PPARGC1A mRNA tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:24041027 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
increases expression multiple interactions |
EXP ISO |
8-bromocyclic GMP results in increased expression of PRKG1 protein [8-bromocyclic GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein |
CTD |
PMID:12620371 PMID:23195829 |
|
NCBI chr 1:237,818,950...239,052,184
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Scnn1b |
sodium channel epithelial 1 subunit beta |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with 8-bromocyclic GMP] results in increased expression of SCNN1B protein |
CTD |
PMID:20613715 |
|
NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:176,430,103...176,484,451
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
EXP |
8-bromocyclic GMP results in increased expression of SOD2 mRNA; 8-bromocyclic GMP results in increased expression of SOD2 protein |
CTD |
PMID:14996425 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; Dinitrochlorobenzene inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]] |
CTD |
PMID:20453393 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Srf |
serum response factor |
multiple interactions |
ISO |
[8-bromocyclic GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein |
CTD |
PMID:23195829 |
|
NCBI chr 9:21,924,050...21,933,338
Ensembl chr 9:14,426,472...14,435,733
|
|
G |
Sst |
somatostatin |
decreases secretion |
EXP |
8-bromocyclic GMP results in decreased secretion of SST protein |
CTD |
PMID:17961553 |
|
NCBI chr11:90,461,546...90,462,823
Ensembl chr11:76,956,896...76,958,173
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression multiple interactions |
ISO |
8-bromocyclic GMP results in increased expression of TFAM mRNA tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of TFAM mRNA] |
CTD |
PMID:24041027 |
|
NCBI chr20:17,355,373...17,367,422
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]; 8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] |
CTD |
PMID:16023617 |
|
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]] |
CTD |
PMID:9388267 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
EXP |
8-bromocyclic GMP results in increased expression of TP53 protein |
CTD |
PMID:9888876 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions increases phosphorylation |
EXP ISO |
8-bromocyclic GMP inhibits the reaction [1-oleoyl-2-acetylglycerol results in increased activity of TRPC6 protein] 8-bromocyclic GMP results in increased phosphorylation of TRPC6 protein KT 5823 inhibits the reaction [8-bromocyclic GMP results in increased phosphorylation of TRPC6 protein] |
CTD |
PMID:20177073 |
|
NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
EXP |
8-bromocyclic GMP inhibits the reaction [Glucose results in decreased expression of TXN1 protein] |
CTD |
PMID:20453393 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
multiple interactions increases expression |
ISO |
tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of UQCRC1 protein] |
CTD |
PMID:24041027 |
|
NCBI chr 8:118,468,223...118,479,968
Ensembl chr 8:109,589,706...109,601,480
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression |
ISO |
8-bromocyclic GMP results in decreased expression of VCAM1 protein |
CTD |
PMID:17828804 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
8-bromocyclic GMP results in decreased expression of VEGFA protein |
CTD |
PMID:17828804 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
affects binding |
ISO |
acetoacetyl CoA binds to HSD17B2 protein |
CTD |
PMID:25526675 |
|
NCBI chr19:62,662,320...62,733,944
Ensembl chr19:45,753,574...45,825,202
|
|
|
G |
Acly |
ATP citrate lyase |
increases abundance affects abundance |
ISO |
ACLY protein results in increased abundance of Acetyl Coenzyme A ACLY protein affects the abundance of Acetyl Coenzyme A |
CTD |
PMID:28077572 PMID:36933457 |
|
NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,412,049...85,463,320
|
|
G |
App |
amyloid beta precursor protein |
affects localization increases secretion multiple interactions |
ISO |
APP protein affects the localization of Acetyl Coenzyme A Acetyl Coenzyme A results in increased secretion of APP protein modified form Acetyl Coenzyme A inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form] IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] |
CTD |
PMID:16122837 PMID:22906069 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Crat |
carnitine O-acetyltransferase |
decreases activity |
EXP |
Acetyl Coenzyme A deficiency results in decreased activity of CRAT protein |
CTD |
PMID:8075222 |
|
NCBI chr 3:34,073,504...34,087,099
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
decreases abundance multiple interactions |
ISO |
ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A] |
CTD |
PMID:25440059 |
|
NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,765,013...7,835,587
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Fluoxetine results in decreased expression of G6PC1 protein] which results in increased abundance of Acetyl Coenzyme A |
CTD |
PMID:33179799 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] |
CTD |
PMID:16122837 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects binding |
ISO |
Acetyl Coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Metrnl |
meteorin-like, glial cell differentiation regulator |
multiple interactions |
ISO |
METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Acetyl Coenzyme A] |
CTD |
PMID:30213948 |
|
NCBI chr10:107,462,148...107,476,143
Ensembl chr10:106,963,880...106,977,869
|
|
G |
Nat1 |
N-acetyltransferase 1 |
multiple interactions affects binding |
ISO |
[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]; Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein] Acetyl Coenzyme A binds to NAT1 protein |
CTD |
PMID:20545351 PMID:22835378 |
|
NCBI chr16:26,984,882...27,005,194
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nat2 |
N-acetyltransferase 2 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr16:26,974,874...27,005,191
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone |
CTD |
PMID:20545351 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
increases abundance |
ISO |
ECHS1 gene mutant form results in increased abundance of acryloyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Hibch |
3-hydroxyisobutyryl-CoA hydrolase |
increases abundance |
ISO |
HIBCH gene mutant form results in increased abundance of acryloyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 9:56,082,082...56,161,796
Ensembl chr 9:48,590,099...48,669,824
|
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
EXP |
Glutathione Disulfide affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]; Glutathione Disulfide affects the reaction [Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]]; Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein] |
CTD |
PMID:21130751 |
|
NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
multiple interactions |
ISO |
[2,2',4,4'-tetrabromodiphenyl ether metabolite co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; Estradiol inhibits the reaction [[tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein] |
CTD |
PMID:23959441 |
|
NCBI chr14:20,700,444...20,718,719
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
affects binding multiple interactions |
ISO |
adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]; Dehydroepiandrosterone inhibits the reaction [Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]] |
CTD |
PMID:24059442 |
|
NCBI chr 1:84,582,011...84,639,001
Ensembl chr 1:74,911,100...75,508,134
|
|
|
G |
Nudt11 |
nudix hydrolase 11 |
multiple interactions |
ISO |
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate |
CTD |
PMID:12121577 |
|
NCBI chr X:18,998,587...19,005,208
Ensembl chr X:16,326,598...16,333,145
|
|
|
G |
Cd80 |
Cd80 molecule |
increases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD80 protein |
CTD |
PMID:15944274 |
|
NCBI chr11:75,760,073...75,798,978
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD86 protein |
CTD |
PMID:15944274 |
|
NCBI chr11:77,647,565...77,706,178
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in decreased expression of IL10 protein |
CTD |
PMID:15944274 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL12B protein |
CTD |
PMID:15944274 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL1B protein |
CTD |
PMID:15944274 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
affects response to substance |
ISO |
P2RX7 protein affects the susceptibility to adenosine 5'-O-(3-thiotriphosphate) |
CTD |
PMID:12873706 |
|
NCBI chr12:39,550,531...39,594,984
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
adenosine 5'-O-(3-thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:19,790,499...19,797,873
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases activity multiple interactions |
EXP |
adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein Capsaicin promotes the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein]; capsazepine inhibits the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein] |
CTD |
PMID:11140687 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:57,851,428...57,876,513
|
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
ISO |
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 |
|
NCBI chr 4:177,262,848...177,386,837
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[4-dimethylaminocinnamaldehyde co-treated with Adenosine Monophosphate] binds to ALDH1A1 protein |
CTD |
PMID:10609638 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
increases abundance |
ISO |
ERCC6 gene mutant form results in increased abundance of Adenosine Monophosphate |
CTD |
PMID:25440059 |
|
NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,765,013...7,835,587
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Adenosine Monophosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] |
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 |
|
NCBI chr 1:105,727,473...105,731,167
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Nudt11 |
nudix hydrolase 11 |
multiple interactions |
ISO |
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate |
CTD |
PMID:12121577 |
|
NCBI chr X:18,998,587...19,005,208
Ensembl chr X:16,326,598...16,333,145
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Adenosine Monophosphate results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Adenosine Monophosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:108,169,980...108,269,822
|
|
G |
Tp73 |
tumor protein p73 |
affects abundance |
ISO |
TP73 protein affects the abundance of Adenosine Monophosphate |
CTD |
PMID:25554796 |
|
NCBI chr 5:169,903,801...169,988,075
Ensembl chr 5:164,621,377...164,681,128
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions affects binding |
ISO |
estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein mutant form]; estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein]; Vanadates promotes the reaction [Adenosine Diphosphate binds to ABCC1 protein] Adenosine Diphosphate binds to ABCC1 protein; Adenosine Diphosphate binds to ABCC1 protein mutant form |
CTD |
PMID:18336795 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Adenosine Diphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ak1 |
adenylate kinase 1 |
increases abundance |
ISO |
AK1 protein results in increased abundance of Adenosine Diphosphate |
CTD |
PMID:11390963 |
|
NCBI chr 3:36,310,113...36,320,760
Ensembl chr 3:15,912,485...15,923,041
|
|
G |
Alb |
albumin |
decreases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in decreased secretion of ALB protein Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of ALB protein] |
CTD |
PMID:17303692 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases abundance |
ISO |
PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Adenosine Diphosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases response to substance |
ISO |
AXL protein results in decreased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein] |
CTD |
PMID:16781456 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd40lg |
CD40 ligand |
increases expression multiple interactions |
ISO |
Adenosine Diphosphate results in increased expression of CD40LG protein clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein] |
CTD |
PMID:11297035 PMID:17043144 |
|
NCBI chr X:140,164,341...140,176,057
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and results in decreased activity of CFTR protein; P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein] |
CTD |
PMID:15684079 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Diphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein] |
CTD |
PMID:23184943 |
|
NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions |
ISO |
CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid] |
CTD |
PMID:16772608 PMID:18004210 PMID:18394438 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Dtymk |
deoxythymidylate kinase |
multiple interactions |
ISO |
DTYMK protein binds to [N1-(4-bis(pivaloyloxymethyl)phosphinylbuten-2-yl)thymine co-treated with Adenosine Diphosphate] |
CTD |
PMID:21128666 |
|
NCBI chr 9:101,762,899...101,771,733
Ensembl chr 9:94,315,552...94,324,870
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
Adenosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP1 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP1 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr10:17,184,853...17,187,646
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
multiple interactions |
ISO |
Adenosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP6 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP6 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Epha4 |
Eph receptor A4 |
increases phosphorylation multiple interactions |
ISO |
Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein Benzoic Acid analog inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein] |
CTD |
PMID:22273509 |
|
NCBI chr 9:86,263,982...86,406,744
Ensembl chr 9:78,815,460...78,958,139
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions decreases activity |
ISO |
Adenosine Diphosphate inhibits the reaction [ERN1 protein binds to ERN1 protein] Adenosine Diphosphate results in decreased activity of ERN1 protein |
CTD |
PMID:25164867 |
|
NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,330,654...91,421,029
|
|
G |
F2 |
coagulation factor II, thrombin |
increases abundance multiple interactions |
ISO |
F2 protein results in increased abundance of Adenosine Diphosphate Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]; resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate] |
CTD |
PMID:15342215 |
|
NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fga |
fibrinogen alpha chain |
multiple interactions increases secretion |
ISO |
Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGA protein] |
CTD |
PMID:17303692 |
|
NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fgb |
fibrinogen beta chain |
decreases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in decreased secretion of FGB protein Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of FGB protein] |
CTD |
PMID:17303692 |
|
NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Fgg |
fibrinogen gamma chain |
increases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in increased secretion of FGG protein Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGG protein] |
CTD |
PMID:17303692 |
|
NCBI chr 2:170,652,929...170,660,372
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gas6 |
growth arrest specific 6 |
increases response to substance |
ISO |
GAS6 protein results in increased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr16:82,747,676...82,778,090
Ensembl chr16:76,045,426...76,075,904
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; U 0126 inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]] |
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and affects the folding of HRAS protein |
CTD |
PMID:16388579 |
|
NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Adenosine Diphosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Adenosine Diphosphate results in increased expression of IL6 protein MRS 2211 inhibits the reaction [Adenosine Diphosphate results in increased expression of IL6 protein] |
CTD |
PMID:24849676 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
ISO |
ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Adenosine Diphosphate] |
CTD |
PMID:16214444 |
|
NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itga2b |
integrin subunit alpha 2b |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr10:87,908,697...87,926,225
Ensembl chr10:87,408,536...87,426,168
|
|
G |
Itgb1bp2 |
integrin subunit beta 1 binding protein 2 |
multiple interactions |
ISO |
Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr X:70,612,118...70,617,158
Ensembl chr X:66,572,537...66,577,174
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr10:90,009,927...90,067,787
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Adenosine Diphosphate results in increased phosphorylation of MAPK1 protein Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK1 protein]] |
CTD |
PMID:15034929 PMID:32941855 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Adenosine Diphosphate results in increased phosphorylation of MAPK3 protein Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:15034929 PMID:32941855 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:24466103 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24466103 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions increases abundance |
ISO |
PF-06840003 inhibits the reaction [MAPT protein mutant form results in increased abundance of Adenosine Diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mertk |
MER proto-oncogene, tyrosine kinase |
increases response to substance |
ISO |
MERTK protein results in increased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:115,939,351...116,046,554
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
NOS2 protein affects the susceptibility to [Phenylephrine co-treated with Adenosine Diphosphate] |
CTD |
PMID:11498454 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nt5e |
5' nucleotidase, ecto |
decreases activity |
ISO |
Adenosine Diphosphate analog results in decreased activity of NT5E protein |
CTD |
PMID:18404487 |
|
NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
P2ry12 |
purinergic receptor P2Y12 |
affects response to substance increases response to substance multiple interactions |
ISO EXP |
P2RY12 gene polymorphism affects the susceptibility to Adenosine Diphosphate; P2RY12 protein affects the susceptibility to Adenosine Diphosphate P2RY12 protein results in increased susceptibility to Adenosine Diphosphate Epinephrine inhibits the reaction [P2RY12 gene mutant form results in decreased susceptibility to Adenosine Diphosphate] P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein] |
CTD |
PMID:11196645 PMID:11413167 PMID:18404433 PMID:23849096 |
|
NCBI chr 2:145,631,487...145,673,194
Ensembl chr 2:143,481,430...143,523,361
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
increases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in increased secretion of PDGFB protein Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of PDGFB protein] |
CTD |
PMID:17303692 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pf4 |
platelet factor 4 |
increases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in increased secretion of PF4 protein silidianin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]; Silybin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]; silychristin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein] |
CTD |
PMID:19428933 PMID:29439388 |
|
NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Pfkm |
phosphofructokinase, muscle |
multiple interactions |
ISO |
Adenosine Diphosphate inhibits the reaction [resveratrol results in decreased activity of PFKM protein] |
CTD |
PMID:23454376 |
|
NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Pgp |
phosphoglycolate phosphatase |
decreases phosphorylation |
ISO |
PGP protein results in decreased phosphorylation of Adenosine Diphosphate |
CTD |
PMID:24338473 |
|
NCBI chr10:13,999,782...14,002,408
Ensembl chr10:13,494,291...13,497,858
|
|
G |
Ppbp |
pro-platelet basic protein |
increases secretion |
ISO |
Adenosine Diphosphate results in increased secretion of PPBP protein |
CTD |
PMID:19428933 |
|
NCBI chr14:17,586,495...17,587,299
Ensembl chr14:17,302,326...17,303,130
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and affects the folding of PPP5C protein |
CTD |
PMID:23184943 |
|
NCBI chr 1:86,818,297...86,842,505
Ensembl chr 1:77,690,208...77,714,456
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
increases glutathionylation multiple interactions |
EXP |
Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein] |
CTD |
PMID:16781456 |
|
NCBI chr 3:177,056,588...177,106,424
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; Heparin promotes the reaction [Adenosine Diphosphate affects the localization of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]]; P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; Quercetin inhibits the reaction [Adenosine Diphosphate results in increased expression of SELP protein] |
CTD |
PMID:9740346 PMID:18394438 PMID:18404433 PMID:23249183 |
|
NCBI chr13:79,009,379...79,044,994
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Sirt3 |
sirtuin 3 |
decreases abundance |
ISO |
SIRT3 protein results in decreased abundance of Adenosine Diphosphate |
CTD |
PMID:23166782 |
|
NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Taldo1 |
transaldolase 1 |
increases abundance |
ISO |
TALDO1 gene mutant form results in increased abundance of Adenosine Diphosphate |
CTD |
PMID:19436114 |
|
NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:196,493,589...196,503,974
|
|
G |
Thbs1 |
thrombospondin 1 |
increases secretion |
ISO |
Adenosine Diphosphate results in increased secretion of THBS1 protein |
CTD |
PMID:17303692 |
|
NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; U 0126 inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:108,169,980...108,269,822
|
|
G |
Tyro3 |
TYRO3 protein tyrosine kinase |
increases response to substance |
ISO |
TYRO3 protein results in increased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 3:127,231,468...127,254,806
Ensembl chr 3:106,777,635...106,797,142
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
increases phosphorylation multiple interactions |
ISO |
Adenosine Diphosphate results in increased phosphorylation of VASP protein N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of VASP protein] |
CTD |
PMID:25329809 |
|
NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:78,910,011...78,925,061
|
|
|
G |
Adprh |
ADP-ribosylarginine hydrolase |
increases hydrolysis |
ISO |
ADPRH protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite |
CTD |
PMID:21498885 |
|
NCBI chr11:75,805,347...75,811,686
Ensembl chr11:62,299,793...62,306,931
|
|
G |
Adprs |
ADP-ribosylserine hydrolase |
increases hydrolysis multiple interactions |
ISO |
ADPRS protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite Adenosine Diphosphate Ribose inhibits the reaction [ADPRS protein results in increased hydrolysis of O-Acetyl-ADP-Ribose] |
CTD |
PMID:21498885 |
|
NCBI chr 5:143,898,542...143,903,816
Ensembl chr 5:138,614,022...138,619,296
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
ISO |
NOS1 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased ribosylation of Adenosine Diphosphate Ribose] |
CTD |
PMID:10318960 |
|
NCBI chr12:44,276,011...44,456,371
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions increases activity |
EXP ISO |
Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]; Clotrimazole inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]; Flufenamic Acid inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]] Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein 2-aminoethoxydiphenyl borate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]]; Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Copper Sulfate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; ferrous chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; lead nitrate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Mercuric Chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Miconazole inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Selenium Oxides inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein] 4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; [Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein; Glutathione inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; Glutathione inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; TRPM2 protein promotes the reaction [Adenosine Diphosphate Ribose results in increased uptake of Calcium] |
CTD |
PMID:18204483 PMID:20878536 PMID:21900507 PMID:22750002 PMID:33309544 PMID:35395232 More...
|
|
NCBI chr20:10,703,190...10,752,795
Ensembl chr20:10,707,014...10,753,181
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of ABCB11 mRNA |
CTD |
PMID:27090119 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of ABCC2 mRNA |
CTD |
PMID:27090119 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
AICA ribonucleotide promotes the reaction [ABL1 protein mutant form binds to BECN1 protein]; AICA ribonucleotide promotes the reaction [ABL1 protein mutant form binds to XPO1 protein]; AICA ribonucleotide promotes the reaction [ABL1 protein mutant form binds to YWHAQ protein]; AICA ribonucleotide results in decreased expression of and affects the localization of ABL1 protein mutant form |
CTD |
PMID:33070465 |
|
NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation multiple interactions increases expression |
ISO EXP |
AICA ribonucleotide results in increased phosphorylation of ACACA protein AICA ribonucleotide inhibits the reaction [fipronil results in increased expression of and results in decreased phosphorylation of ACACA protein]; AICA ribonucleotide results in decreased expression of and results in increased phosphorylation of ACACA protein AICA ribonucleotide results in increased expression of ACACA protein modified form |
CTD |
PMID:15297373 PMID:16020477 PMID:16873680 PMID:20080969 PMID:25743752 PMID:27103584 More...
|
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
increases phosphorylation |
ISO |
AICA ribonucleotide results in increased phosphorylation of ACACB protein |
CTD |
PMID:16873680 |
|
NCBI chr12:48,026,394...48,138,214
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions increases expression |
EXP ISO |
AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of ACADM mRNA] AICA ribonucleotide results in increased expression of ACADM mRNA; AICA ribonucleotide results in increased expression of ACADM protein |
CTD |
PMID:19699196 PMID:25743752 |
|
NCBI chr 2:245,518,693...245,542,864
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:27688165 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression multiple interactions |
ISO EXP |
AICA ribonucleotide results in increased expression of ADIPOQ protein AICA ribonucleotide inhibits the reaction [Palmitic Acid results in decreased expression of ADIPOQ mRNA] |
CTD |
PMID:20980258 PMID:25108154 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form results in decreased oxidation of Fatty Acids]; AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein]; AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form results in increased susceptibility to Glucose deficiency]; PRKAA2 protein affects the reaction [AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form affects the susceptibility to Glucose deficiency]] AICAR increases phosphorylation of Akt1 protein in myotubes |
CTD RGD |
PMID:15806154 PMID:19574345 |
RGD:407574726 |
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
decreases expression |
ISO |
AICA ribonucleotide results in decreased expression of APP protein modified form |
CTD |
PMID:20080969 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in decreased expression of ARG1 mRNA] |
CTD |
PMID:25108154 |
|
NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [Ethanol results in decreased expression of ATG5 protein] |
CTD |
PMID:24582693 |
|
NCBI chr20:49,380,835...49,471,826
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Becn1 |
beclin 1 |
increases expression multiple interactions |
EXP ISO |
AICA ribonucleotide results in increased expression of BECN1 protein AICA ribonucleotide promotes the reaction [ABL1 protein mutant form binds to BECN1 protein]; AICA ribonucleotide promotes the reaction [XPO1 protein binds to BECN1 protein]; AICA ribonucleotide results in increased expression of and affects the localization of BECN1 protein AICA ribonucleotide promotes the reaction [4-nonylphenol results in increased expression of BECN1 protein] |
CTD |
PMID:28041982 PMID:33070465 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
EXP ISO |
AICA ribonucleotide results in increased activity of CASP3 protein AICA ribonucleotide inhibits the reaction [sunitinib results in increased cleavage of CASP3 protein] |
CTD |
PMID:16469385 PMID:21906609 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [sunitinib results in increased cleavage of CASP7 protein] |
CTD |
PMID:21906609 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
increases activity |
EXP |
AICA ribonucleotide results in increased activity of CASP9 protein |
CTD |
PMID:16469385 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions increases expression |
ISO |
AICA ribonucleotide promotes the reaction [FOXO1 protein results in increased expression of CAT mRNA] AICA ribonucleotide results in increased expression of CAT mRNA; AICA ribonucleotide results in increased expression of CAT protein |
CTD |
PMID:25065674 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression |
EXP ISO |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased expression of CCL2 mRNA] AICA ribonucleotide results in decreased expression of CCL2 mRNA AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]]; dorsomorphin inhibits the reaction [AICA ribonucleotide results in decreased expression of CCL2 mRNA] |
CTD |
PMID:24465016 PMID:25108154 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased expression of CCL3 mRNA] |
CTD |
PMID:21745629 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
AICA ribonucleotide inhibits the reaction [ELAVL1 protein binds to CCNA2 3' UTR] AICA ribonucleotide results in decreased expression of CCNA2 mRNA; AICA ribonucleotide results in decreased expression of CCNA2 protein |
CTD |
PMID:12730239 |
|
NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions decreases expression |
ISO |
AICA ribonucleotide inhibits the reaction [ELAVL1 protein binds to CCNB1 3' UTR] AICA ribonucleotide results in decreased expression of CCNB1 mRNA; AICA ribonucleotide results in decreased expression of CCNB1 protein |
CTD |
PMID:12730239 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
AICA ribonucleotide results in increased expression of and affects the localization of CD36 protein |
CTD |
PMID:28038998 |
|
NCBI chr 4:18,209,088...18,302,142
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression multiple interactions |
ISO |
AICA ribonucleotide results in decreased expression of CEBPA protein AICA ribonucleotide inhibits the reaction [fipronil results in increased expression of CEBPA protein] |
CTD |
PMID:27103584 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases phosphorylation |
ISO |
AICA ribonucleotide results in increased phosphorylation of CEBPB protein |
CTD |
PMID:28038998 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Colforsin results in increased activity of CFTR protein] |
CTD |
PMID:12519745 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein] |
CTD |
PMID:27688165 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression multiple interactions |
ISO |
AICA ribonucleotide results in increased expression of CPT1A mRNA; AICA ribonucleotide results in increased expression of CPT1A protein AICA ribonucleotide inhibits the reaction [TP53 gene mutant form results in increased expression of CPT1A protein] dorsomorphin inhibits the reaction [AICA ribonucleotide results in increased expression of CPT1A mRNA] |
CTD |
PMID:24465016 PMID:25743752 PMID:33070465 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of CPT1B mRNA]; AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of CPT1B protein] |
CTD |
PMID:19699196 |
|
NCBI chr 7:122,370,974...122,380,473
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
ISO |
[AICA ribonucleotide results in increased phosphorylation of HDAC5 protein] which results in increased expression of CTNNB1 mRNA; [AICA ribonucleotide results in increased phosphorylation of HDAC5 protein] which results in increased expression of CTNNB1 protein; AICA ribonucleotide inhibits the reaction [[HDAC5 protein binds to MEF2 protein] which binds to CTNNB1 promoter]; PRKAA2 protein affects the reaction [AICA ribonucleotide results in increased expression of CTNNB1 mRNA]; PRKAA2 protein affects the reaction [AICA ribonucleotide results in increased expression of CTNNB1 protein] AICA ribonucleotide results in increased expression of CTNNB1 mRNA; AICA ribonucleotide results in increased expression of CTNNB1 protein |
CTD |
PMID:21454484 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased expression of CYBA protein] |
CTD |
PMID:21195169 |
|
NCBI chr19:67,396,143...67,404,214
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased expression of CYBB protein] |
CTD |
PMID:21195169 |
|
NCBI chr X:16,030,596...16,065,065
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
EXP |
AICA ribonucleotide promotes the reaction [NR1I3 protein results in increased expression of CYP2B10 mRNA]; PRKAA2 protein promotes the reaction [AICA ribonucleotide promotes the reaction [NR1I3 protein results in increased expression of CYP2B10 mRNA]] |
CTD |
PMID:22815988 |
|
NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [EGFR protein results in increased import of Deoxyglucose] |
CTD |
PMID:19625624 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
decreases phosphorylation |
ISO |
AICA ribonucleotide results in decreased phosphorylation of EIF2S1 protein |
CTD |
PMID:22898769 |
|
NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein] AICA ribonucleotide results in decreased phosphorylation of EIF4EBP1 protein AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:15806154 PMID:21195169 PMID:28041982 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
multiple interactions decreases localization |
ISO |
AICA ribonucleotide inhibits the reaction [ELAVL1 protein binds to CCNA2 3' UTR]; AICA ribonucleotide inhibits the reaction [ELAVL1 protein binds to CCNB1 3' UTR] AICA ribonucleotide results in decreased localization of ELAVL1 protein |
CTD |
PMID:12730239 |
|
NCBI chr12:7,441,699...7,482,625
Ensembl chr12:2,645,061...2,684,784
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions increases expression increases phosphorylation increases activity |
ISO |
AICA ribonucleotide promotes the reaction [FOXO1 protein results in increased expression of CAT mRNA]; AICA ribonucleotide promotes the reaction [FOXO1 protein results in increased expression of SOD2 mRNA] AICA ribonucleotide results in increased expression of FOXO1 protein AICA ribonucleotide results in increased phosphorylation of FOXO1 protein AICA ribonucleotide results in increased activity of FOXO1 protein |
CTD |
PMID:25065674 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased phosphorylation of MAPK1 protein]; AICA ribonucleotide inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased phosphorylation of MAPK3 protein]; AICA ribonucleotide inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16020477 |
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of G6PC1 mRNA |
CTD |
PMID:19664596 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gck |
glucokinase |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of GCK mRNA; AICA ribonucleotide results in decreased expression of GCK protein |
CTD |
PMID:19438972 |
|
NCBI chr14:84,999,019...85,041,098
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gpr68 |
G protein-coupled receptor 68 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TNF protein promotes the reaction [Oxygen deficiency results in increased expression of GPR68 mRNA]]; AICA ribonucleotide inhibits the reaction [TNF protein results in increased expression of GPR68 mRNA] |
CTD |
PMID:28174749 |
|
NCBI chr 6:125,865,205...125,895,674
Ensembl chr 6:120,135,436...120,166,089
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
multiple interactions |
EXP |
GRB2 protein affects the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein] |
CTD |
PMID:11978788 |
|
NCBI chr10:101,380,354...101,448,138
Ensembl chr10:100,869,718...100,949,309
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
increases expression |
ISO |
AICA ribonucleotide results in increased expression of GSTK1 protein |
CTD |
PMID:20980258 |
|
NCBI chr 4:72,085,532...72,089,934
Ensembl chr 4:71,118,896...71,123,292
|
|
G |
Hdac5 |
histone deacetylase 5 |
multiple interactions increases phosphorylation |
ISO |
[AICA ribonucleotide results in increased phosphorylation of HDAC5 protein] which results in increased expression of CTNNB1 mRNA; [AICA ribonucleotide results in increased phosphorylation of HDAC5 protein] which results in increased expression of CTNNB1 protein; AICA ribonucleotide inhibits the reaction [[HDAC5 protein binds to MEF2 protein] which binds to CTNNB1 promoter] |
CTD |
PMID:21454484 |
|
NCBI chr10:87,653,139...87,688,078
Ensembl chr10:87,152,978...87,188,235
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
decreases expression |
ISO |
AICA ribonucleotide results in decreased expression of HNF4A mRNA |
CTD |
PMID:24428821 |
|
NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of HSD3B1 mRNA; AICA ribonucleotide results in decreased expression of HSD3B1 protein |
CTD |
PMID:16020477 |
|
NCBI chr 2:188,858,574...188,864,694
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased phosphorylation of MAPK1 protein]; AICA ribonucleotide inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased phosphorylation of MAPK3 protein]; AICA ribonucleotide inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16020477 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO |
AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; dorsomorphin inhibits the reaction [AICA ribonucleotide results in decreased expression of IL1B mRNA] |
CTD |
PMID:24465016 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
EXP ISO |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA] AICA ribonucleotide results in decreased expression of IL6 mRNA AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; dorsomorphin inhibits the reaction [AICA ribonucleotide results in decreased expression of IL6 mRNA] |
CTD |
PMID:24465016 PMID:25108154 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [INS1 protein results in increased phosphorylation of TBC1D1 protein]; AICA ribonucleotide inhibits the reaction [INS1 protein results in increased phosphorylation of TBC1D4 protein] |
CTD |
PMID:24343960 PMID:26627467 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Insr |
insulin receptor |
multiple interactions decreases activity decreases expression |
ISO |
5'-amino-5'-deoxyadenosine inhibits the reaction [AICA ribonucleotide results in decreased activity of INSR promoter]; 5'-amino-5'-deoxyadenosine inhibits the reaction [AICA ribonucleotide results in decreased expression of INSR mRNA]; 5'-amino-5'-deoxyadenosine inhibits the reaction [AICA ribonucleotide results in decreased expression of INSR protein]; Dipyridamole inhibits the reaction [AICA ribonucleotide results in decreased activity of INSR promoter]; Dipyridamole inhibits the reaction [AICA ribonucleotide results in decreased expression of INSR mRNA]; Dipyridamole inhibits the reaction [AICA ribonucleotide results in decreased expression of INSR protein] AICA ribonucleotide results in decreased expression of INSR mRNA; AICA ribonucleotide results in decreased expression of INSR protein |
CTD |
PMID:15694368 |
|
NCBI chr12:5,991,135...6,129,275
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
affects response to substance |
ISO |
KCNJ11 protein affects the susceptibility to AICA ribonucleotide |
CTD |
PMID:24498880 |
|
NCBI chr 1:105,727,473...105,731,167
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Klf15 |
KLF transcription factor 15 |
decreases expression |
ISO |
AICA ribonucleotide results in decreased expression of KLF15 mRNA |
CTD |
PMID:24428821 |
|
NCBI chr 4:124,522,652...124,535,613
Ensembl chr 4:122,965,807...122,978,374
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
increases activity |
EXP |
AICAR increases activity of Map3k7 protein in cardiac muscle cells |
RGD |
PMID:17085580 |
RGD:155791450 |
NCBI chr 5:51,149,524...51,212,012
Ensembl chr 5:46,357,931...46,415,597
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation decreases phosphorylation |
EXP ISO |
AICA ribonucleotide inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased phosphorylation of MAPK1 protein]; AICA ribonucleotide inhibits the reaction [IGF1 protein results in increased phosphorylation of MAPK1 protein] AICA ribonucleotide results in increased phosphorylation of MAPK1 protein AICA ribonucleotide results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:16020477 PMID:28038998 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation decreases phosphorylation |
EXP ISO |
AICA ribonucleotide inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased phosphorylation of MAPK3 protein]; AICA ribonucleotide inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]; MAPK3 protein affects the reaction [AICA ribonucleotide results in increased uptake of Deoxyglucose]; PTK2B protein affects the reaction [AICA ribonucleotide results in increased activity of MAPK3 protein] AICA ribonucleotide results in increased phosphorylation of MAPK3 protein AICA ribonucleotide results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:11978788 PMID:16020477 PMID:28038998 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Acetaminophen results in decreased expression of MFN1 protein]; AICA ribonucleotide inhibits the reaction [Diclofenac results in decreased expression of MFN1 protein] |
CTD |
PMID:27792760 |
|
NCBI chr 2:117,240,525...117,288,017
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Acetaminophen results in decreased expression of MFN2 protein]; AICA ribonucleotide inhibits the reaction [Diclofenac results in decreased expression of MFN2 protein] |
CTD |
PMID:27792760 |
|
NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased expression of MMP13 protein] |
CTD |
PMID:27688165 |
|
NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity |
ISO |
AICA ribonucleotide results in decreased activity of MMP2 protein |
CTD |
PMID:20590612 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity |
ISO |
AICA ribonucleotide results in decreased activity of MMP9 protein |
CTD |
PMID:20590612 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpst |
mercaptopyruvate sulfurtransferase |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of MPST mRNA |
CTD |
PMID:35577173 |
|
NCBI chr 7:111,836,079...111,843,651
Ensembl chr 7:109,955,675...109,963,141
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases activity decreases phosphorylation multiple interactions |
ISO EXP |
AICA ribonucleotide results in decreased activity of MTOR protein AICA ribonucleotide results in decreased phosphorylation of MTOR protein AICA ribonucleotide promotes the reaction [4-nonylphenol results in decreased phosphorylation of MTOR protein] AICA ribonucleotide promotes the reaction [Cadmium results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:19625624 PMID:21767558 PMID:27363783 PMID:28041982 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased expression of NCF1 protein] |
CTD |
PMID:21195169 |
|
NCBI chr12:28,121,816...28,131,080
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased expression of NCF2 protein] |
CTD |
PMID:21195169 |
|
NCBI chr13:67,505,492...67,536,015
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Ncf4 |
neutrophil cytosolic factor 4 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased expression of NCF4 protein] |
CTD |
PMID:21195169 |
|
NCBI chr 7:111,705,926...111,723,893
Ensembl chr 7:109,826,020...109,843,389
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein] |
CTD |
PMID:22025971 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA] AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]] |
CTD |
PMID:24465016 PMID:25108154 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Palmitic Acid inhibits the reaction [Acetylcholine results in increased phosphorylation of NOS3 protein]] |
CTD |
PMID:25108154 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases expression |
ISO |
AICA ribonucleotide results in decreased expression of NR0B2 mRNA |
CTD |
PMID:24428821 |
|
NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of NR1H4 mRNA; AICA ribonucleotide results in decreased expression of NR1H4 protein |
CTD |
PMID:27090119 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Phenobarbital results in increased localization of and results in increased activity of NR1I3 protein]; AICA ribonucleotide promotes the reaction [NR1I3 protein results in increased expression of CYP2B10 mRNA]; PRKAA2 protein promotes the reaction [AICA ribonucleotide promotes the reaction [NR1I3 protein results in increased expression of CYP2B10 mRNA]] |
CTD |
PMID:20686344 PMID:22815988 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions increases expression |
EXP |
dorsomorphin inhibits the reaction [AICA ribonucleotide results in increased expression of NRF1 mRNA] |
CTD |
PMID:20438809 |
|
NCBI chr 4:59,632,366...59,738,166
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Acetaminophen results in decreased expression of OPA1 protein]; AICA ribonucleotide inhibits the reaction [Diclofenac results in decreased expression of OPA1 protein] |
CTD |
PMID:27792760 |
|
NCBI chr11:84,612,943...84,690,025
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Pdx1 |
pancreatic and duodenal homeobox 1 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of PDX1 mRNA; AICA ribonucleotide results in decreased expression of PDX1 protein |
CTD |
PMID:19438972 |
|
NCBI chr12:12,793,957...12,799,156
Ensembl chr12:7,757,865...7,763,064
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of PPARA mRNA]; AICA ribonucleotide inhibits the reaction [Phenylephrine results in decreased expression of PPARA protein] |
CTD |
PMID:19699196 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP ISO |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in decreased expression of PPARG mRNA] AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased expression of PPARG protein] |
CTD |
PMID:25108154 PMID:27688165 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression decreases expression |
EXP ISO |
dorsomorphin inhibits the reaction [AICA ribonucleotide results in increased expression of PPARGC1A mRNA] AICA ribonucleotide results in decreased expression of PPARGC1A mRNA AICA ribonucleotide inhibits the reaction [Glucose results in decreased expression of PPARGC1A protein]; dorsomorphin promotes the reaction [AICA ribonucleotide results in decreased expression of PPARGC1A mRNA] AICA ribonucleotide inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of PPARGC1A protein] |
CTD |
PMID:20438809 PMID:23090186 PMID:24428821 PMID:25522270 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation multiple interactions increases expression increases activity |
EXP ISO |
AICA ribonucleotide results in increased phosphorylation of PRKAA1 protein AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of PRKAA1 protein]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of PRKAA1 protein]]; dorsomorphin inhibits the reaction [AICA ribonucleotide results in increased phosphorylation of PRKAA1 protein] AICA ribonucleotide promotes the reaction [Quercetin results in increased phosphorylation of and results in increased activity of PRKAA1 protein]; AICA ribonucleotide results in increased phosphorylation of and results in increased activity of PRKAA1 protein; PRKAA1 protein affects the reaction [AICA ribonucleotide results in increased expression of CYP4F2 mRNA]; Quercetin promotes the reaction [AICA ribonucleotide results in increased phosphorylation of and results in increased activity of PRKAA1 protein] AICA ribonucleotide results in increased expression of PRKAA1 protein modified form [AICA ribonucleotide results in increased phosphorylation of PRKAA1 protein] which results in decreased secretion of Progesterone; AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in decreased phosphorylation of PRKAA1 protein]; AICA ribonucleotide inhibits the reaction [Sodium Chloride, Dietary results in decreased phosphorylation of and results in decreased activity of PRKAA1 protein]; AICA ribonucleotide inhibits the reaction [Sodium Chloride, Dietary results in increased expression of PRKAA1 mRNA] AICA ribonucleotide results in increased activity of PRKAA1 protein |
CTD |
PMID:12519745 PMID:16020477 PMID:16873680 PMID:19293639 PMID:20349193 PMID:21195169 PMID:21205922 PMID:23266269 PMID:24465016 PMID:25743752 PMID:28298333 More...
|
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions increases phosphorylation |
ISO EXP |
AICA ribonucleotide results in increased phosphorylation of and results in increased activity of PRKAA2 protein; PRKAA2 protein affects the reaction [AICA ribonucleotide results in increased expression of CYP4F2 mRNA] PRKAA2 protein promotes the reaction [AICA ribonucleotide promotes the reaction [NR1I3 protein results in increased expression of CYP2B10 mRNA]] AICA ribonucleotide results in increased phosphorylation of PRKAA2 protein PRKAA2 protein affects the reaction [AICA ribonucleotide inhibits the reaction [AKT1 protein mutant form affects the susceptibility to Glucose deficiency]]; PRKAA2 protein affects the reaction [AICA ribonucleotide results in increased expression of CTNNB1 mRNA]; PRKAA2 protein affects the reaction [AICA ribonucleotide results in increased expression of CTNNB1 protein] |
CTD |
PMID:15806154 PMID:16873680 PMID:18482975 PMID:21205922 PMID:21454484 PMID:22815988 More...
|
|
NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Prkcz |
protein kinase C, zeta |
multiple interactions increases activity |
EXP |
1-Butanol inhibits the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein]; Genistein inhibits the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein]; GRB2 protein affects the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein]; PTK2B protein affects the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein] |
CTD |
PMID:11978788 |
|
NCBI chr 5:171,101,774...171,212,694
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Pten |
phosphatase and tensin homolog |
increases response to substance |
ISO |
PTEN protein results in increased susceptibility to AICA ribonucleotide |
CTD |
PMID:19625624 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:22025971 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
EXP |
AICA ribonucleotide results in increased phosphorylation of and results in increased activity of PTK2B protein; PTK2B protein affects the reaction [AICA ribonucleotide results in increased activity of MAPK3 protein]; PTK2B protein affects the reaction [AICA ribonucleotide results in increased activity of PRKCZ protein] |
CTD |
PMID:11978788 |
|
NCBI chr15:44,536,275...44,656,754
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased expression of RAC1 protein] |
CTD |
PMID:21195169 |
|
NCBI chr12:16,150,411...16,170,864
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
EXP |
RAF1 protein affects the reaction [AICA ribonucleotide results in increased uptake of Deoxyglucose] |
CTD |
PMID:11978788 |
|
NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
AICA ribonucleotide inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased activity of RELA protein] AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]] |
CTD |
PMID:22058332 PMID:25108154 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
AICA ribonucleotide results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:19625624 |
|
NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases phosphorylation increases phosphorylation |
EXP |
AICA ribonucleotide inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [AICA ribonucleotide results in increased phosphorylation of RPS6KB1 protein] AICA ribonucleotide results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:15342961 PMID:21195169 PMID:28041982 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases expression |
ISO EXP |
AICA ribonucleotide inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein]; AICA ribonucleotide inhibits the reaction [Streptozocin results in decreased activity of SIRT1 protein]; dorsomorphin inhibits the reaction [AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein]]; dorsomorphin inhibits the reaction [AICA ribonucleotide results in increased expression of SIRT1 protein] AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased expression of SIRT1 protein] [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide |
CTD |
PMID:22058332 PMID:23090186 PMID:24465016 PMID:25108154 PMID:27688165 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27090119 |
|
NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
decreases activity |
ISO |
AICA ribonucleotide results in decreased activity of SLC15A1 protein |
CTD |
PMID:22108913 |
|
NCBI chr15:104,944,461...104,991,316
Ensembl chr15:98,537,641...98,582,545
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of SLC2A2 mRNA; AICA ribonucleotide results in decreased expression of SLC2A2 protein |
CTD |
PMID:19438972 |
|
NCBI chr 2:113,537,884...113,568,422
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions increases localization |
EXP ISO |
1-Butanol inhibits the reaction [AICA ribonucleotide results in increased localization of SLC2A4 protein]; Genistein inhibits the reaction [AICA ribonucleotide results in increased localization of SLC2A4 protein]; U 0126 inhibits the reaction [AICA ribonucleotide results in increased localization of SLC2A4 protein]; wortmannin inhibits the reaction [AICA ribonucleotide results in increased localization of SLC2A4 protein] AICA ribonucleotide inhibits the reaction [Palmitates results in decreased expression of SLC2A4 mRNA] |
CTD |
PMID:11978788 PMID:21802492 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
decreases expression |
EXP |
AICA ribonucleotide results in decreased expression of SLCO1A2 mRNA |
CTD |
PMID:27090119 |
|
NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
AICA ribonucleotide promotes the reaction [FOXO1 protein results in increased expression of SOD2 mRNA] AICA ribonucleotide results in increased expression of SOD2 mRNA; AICA ribonucleotide results in increased expression of SOD2 protein |
CTD |
PMID:25065674 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO |
[AICA ribonucleotide co-treated with Sirolimus] results in increased expression of SQSTM1 protein; TP53 gene mutant form promotes the reaction [AICA ribonucleotide results in increased expression of SQSTM1 protein] |
CTD |
PMID:33070465 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased phosphorylation of STK11 protein] |
CTD |
PMID:27688165 |
|
NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tbc1d1 |
TBC1 domain family member 1 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [INS1 protein results in increased phosphorylation of TBC1D1 protein] |
CTD |
PMID:26627467 |
|
NCBI chr14:44,289,241...44,489,246
Ensembl chr14:43,935,636...44,136,499
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [INS1 protein results in increased phosphorylation of TBC1D4 protein] |
CTD |
PMID:24343960 PMID:26627467 |
|
NCBI chr15:84,670,756...84,848,876
Ensembl chr15:78,257,121...78,434,265
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased expression of MMP13 protein]; AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased expression of PPARG protein]; AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased expression of SIRT1 protein]; AICA ribonucleotide inhibits the reaction [TGFB1 protein results in decreased phosphorylation of STK11 protein]; AICA ribonucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; AICA ribonucleotide inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; AICA ribonucleotide inhibits the reaction [TGFB1 protein results in increased expression of TIMP1 protein] |
CTD |
PMID:27688165 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [TGFB1 protein results in increased expression of TIMP1 protein] |
CTD |
PMID:27688165 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] AICA ribonucleotide inhibits the reaction [TNF protein promotes the reaction [Oxygen deficiency results in increased expression of GPR68 mRNA]]; AICA ribonucleotide inhibits the reaction [TNF protein results in increased expression of GPR68 mRNA] AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased expression of TNF mRNA] |
CTD |
PMID:22025971 PMID:25108154 PMID:28174749 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [Lipopolysaccharides results in increased expression of TNFRSF1A protein] |
CTD |
PMID:22025971 |
|
NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases phosphorylation |
ISO |
[Resveratrol co-treated with AICA ribonucleotide] inhibits the reaction [Glucose results in increased expression of TP53 protein]; AICA ribonucleotide inhibits the reaction [TP53 gene mutant form results in increased expression of CPT1A protein]; AICA ribonucleotide promotes the reaction [TP53 gene mutant form results in increased phosphorylation of ULK1 protein]; TP53 gene mutant form promotes the reaction [AICA ribonucleotide results in increased expression of SQSTM1 protein]; TP53 gene mutant form promotes the reaction [AICA ribonucleotide results in increased phosphorylation of ULK1 protein] AICA ribonucleotide results in increased phosphorylation of TP53 protein |
CTD |
PMID:26188290 PMID:33070465 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased expression of TXNIP protein] |
CTD |
PMID:29031535 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
AICA ribonucleotide inhibits the reaction [Indican results in decreased expression of UCP2 mRNA] |
CTD |
PMID:25703824 |
|
NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
AICA ribonucleotide promotes the reaction [TP53 gene mutant form results in increased phosphorylation of ULK1 protein]; AICA ribonucleotide results in increased expression of and results in increased phosphorylation of ULK1 protein; TP53 gene mutant form promotes the reaction [AICA ribonucleotide results in increased phosphorylation of ULK1 protein] |
CTD |
PMID:33070465 |
|
NCBI chr12:51,511,492...51,537,746
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
AICA ribonucleotide inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased secretion of VEGFA protein] |
CTD |
PMID:30724446 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xpo1 |
exportin 1 |
multiple interactions |
ISO |
AICA ribonucleotide promotes the reaction [ABL1 protein mutant form binds to XPO1 protein]; AICA ribonucleotide promotes the reaction [XPO1 protein binds to BECN1 protein]; AICA ribonucleotide promotes the reaction [XPO1 protein binds to YWHAQ protein] |
CTD |
PMID:33070465 |
|
NCBI chr14:101,434,450...101,476,705
Ensembl chr14:97,233,270...97,275,498
|
|
G |
Ywhaq |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta |
multiple interactions |
ISO |
AICA ribonucleotide promotes the reaction [ABL1 protein mutant form binds to YWHAQ protein]; AICA ribonucleotide promotes the reaction [XPO1 protein binds to YWHAQ protein] |
CTD |
PMID:33070465 |
|
NCBI chr 6:46,664,358...46,694,875
Ensembl chr 6:40,935,949...40,966,273
|
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of CEBPA protein |
CTD |
PMID:19427183 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of DLK1 mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of FABP4 mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of FAS mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of glucosamine 6-phosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of LEP mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases expression |
ISO |
glucosamine 6-phosphate results in increased expression of LIPE mRNA |
CTD |
PMID:19427183 |
|
NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of LPL mRNA |
CTD |
PMID:19427183 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of PPARG protein |
CTD |
PMID:19427183 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of SREBF1 protein |
CTD |
PMID:19427183 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
glucosamine 6-phosphate results in decreased expression of TNF mRNA |
CTD |
PMID:19427183 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Galk1 |
galactokinase 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors binds to and results in decreased activity of GALK1 protein] which results in decreased abundance of galactose-1-phosphate; [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate |
CTD |
PMID:20696150 |
|
NCBI chr10:101,742,067...101,746,244
Ensembl chr10:101,235,994...101,247,337
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of glucose-1-phosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of glucose-1-phosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Adenylyl Imidodiphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects activity |
ISO |
Adenylyl Imidodiphosphate affects the activity of CFTR protein |
CTD |
PMID:15657297 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
affects binding |
ISO |
Adenylyl Imidodiphosphate binds to CSNK2A1 protein |
CTD |
PMID:34344863 |
|
NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:140,709,991...140,756,696
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
Adenylyl Imidodiphosphate inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:19,790,499...19,797,873
Ensembl chr15:17,360,304...17,367,679
|
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
multiple interactions |
ISO |
Adenosine Triphosphate affects the reaction [ABCA8 protein results in increased uptake of estradiol-17 beta-glucuronide] |
CTD |
PMID:12379217 |
|
NCBI chr10:95,416,984...95,490,647
Ensembl chr10:94,917,520...94,990,988
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO EXP |
Adenosine Triphosphate promotes the reaction [ABCB11 protein results in increased uptake of fexofenadine] |
CTD |
PMID:18245269 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions affects binding increases hydrolysis |
ISO EXP |
[Cobalt results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Magnesium results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Manganese results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; ABCB1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; aurapten promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate] Adenosine Triphosphate binds to ABCB1 protein [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:2900677 PMID:14978246 PMID:18829547 PMID:18955043 PMID:22233293 PMID:23685082 PMID:32497533 More...
|
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions affects activity increases hydrolysis affects binding |
ISO |
[Adenosine Triphosphate affects the activity of ABCC1 protein] which results in increased transport of Acetaminophen metabolite; ABCC1 protein binds to and results in increased degradation of Adenosine Triphosphate; ABCC1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; ABCC1 protein mutant form binds to and results in increased hydrolysis of Adenosine Triphosphate; Adenosine Triphosphate binds to and affects the folding of ABCC1 protein; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Bilirubin]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of estradiol-17 beta-glucuronide]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Leukotriene C4]; daidzein promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Resveratrol promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] Daunorubicin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Vanadates inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] Adenosine Triphosphate binds to ABCC1 protein |
CTD |
PMID:10856430 PMID:11278000 PMID:14978246 PMID:15245331 PMID:15355964 PMID:15459206 PMID:15737336 PMID:15838832 PMID:16156793 PMID:18336795 PMID:18955043 PMID:32472168 More...
|
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions affects activity affects metabolic processing |
EXP ISO |
Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased secretion of Fluo-3]; Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of temocaprilat] Adenosine Triphosphate affects the activity of ABCC2 protein [Adenosine Triphosphate affects the activity of ABCC2 protein] which results in increased transport of Acetaminophen metabolite; [Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide; Adenosine Triphosphate affects the reaction [ABCC2 protein results in increased transport of Mercury]; verlukast inhibits the reaction [[Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide] ABCC2 protein affects the metabolism of Adenosine Triphosphate Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of S-1,2-dichlorovinyl-N-acetylcysteine] |
CTD |
PMID:9067317 PMID:9794919 PMID:20060011 PMID:22027652 PMID:24039982 PMID:32003934 PMID:32472168 More...
|
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [ABCC3 protein affects the transport of fexofenadine] |
CTD |
PMID:18245269 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions affects activity increases hydrolysis |
ISO |
[Adenosine Triphosphate affects the activity of ABCC4 protein] which results in increased transport of Acetaminophen metabolite; ABCC4 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; daidzein promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]]; Resveratrol promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]] |
CTD |
PMID:14978246 PMID:16156793 PMID:32472168 |
|
NCBI chr15:101,948,387...102,182,912
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
affects binding |
ISO |
Adenosine Triphosphate binds to ABCC6 protein |
CTD |
PMID:11880368 |
|
NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
multiple interactions |
EXP |
Adenosine Triphosphate deficiency inhibits the reaction [Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein]] |
CTD |
PMID:19095654 |
|
NCBI chr 1:105,734,992...105,816,272
Ensembl chr 1:96,598,647...96,679,510
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
EXP ISO |
Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein] Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 PMID:28842488 |
|
NCBI chr 4:177,262,848...177,386,837
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases hydrolysis multiple interactions |
ISO |
ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate; Lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate]; Sulfasalazine inhibits the reaction [[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate] |
CTD |
PMID:18829547 PMID:32003934 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions increases chemical synthesis |
ISO |
[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] ABL1 protein mutant form results in increased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:19366808 PMID:33070465 |
|
NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
multiple interactions |
ISO |
[ACSL5 protein affects the susceptibility to Palmitic Acid] which affects the abundance of Adenosine Triphosphate |
CTD |
PMID:32347412 |
|
NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ACTA2 mRNA]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ACTA2 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein] |
CTD |
PMID:32721574 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
increases secretion |
EXP |
ADCYAP1 protein results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:18563302 |
|
NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions decreases expression |
EXP |
Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein]; CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein]; Cyclosporine inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A protein] |
CTD |
PMID:21464294 |
|
NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Adenosine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases activity multiple interactions |
ISO |
Adenosine Triphosphate results in decreased activity of AKT1 protein Alcohols inhibits the reaction [Adenosine Triphosphate results in decreased activity of AKT1 protein] |
CTD |
PMID:24300283 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
increases abundance |
ISO |
ALDH5A1 gene mutant form results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:29031482 |
|
NCBI chr17:40,560,373...40,586,711
Ensembl chr17:40,130,883...40,158,677
|
|
G |
Alk |
ALK receptor tyrosine kinase |
affects binding multiple interactions |
ISO |
ALK protein binds to Adenosine Triphosphate [ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib; ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate] |
CTD |
PMID:22072639 |
|
NCBI chr 6:28,631,431...29,351,321
Ensembl chr 6:22,880,625...23,598,034
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases response to substance multiple interactions |
ISO |
ALPL gene mutant form results in increased susceptibility to Adenosine Triphosphate ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] |
CTD |
PMID:27466191 |
|
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions |
EXP |
[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein; arsenite affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Cadmium affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; chromium hexavalent ion affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Lead affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein] |
CTD |
PMID:20655937 |
|
NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases secretion |
ISO |
Adenosine Triphosphate inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form]; Adenosine Triphosphate inhibits the reaction [Rotenone results in decreased secretion of APP protein modified form]; Rotenone inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:22906069 PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
EXP |
Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein] |
CTD |
PMID:21464294 |
|
NCBI chr10:55,645,539...55,653,485
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Asic1 |
acid sensing ion channel subunit 1 |
multiple interactions |
EXP |
[Acids binds to and affects the activity of ASIC1 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr 7:132,677,158...132,707,379
Ensembl chr 7:130,799,917...130,828,541
|
|
G |
Asic2 |
acid sensing ion channel subunit 2 |
multiple interactions |
EXP |
[Acids binds to and affects the activity of ASIC2 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr10:66,368,308...67,438,237
Ensembl chr10:65,870,594...66,940,424
|
|
G |
Asic3 |
acid sensing ion channel subunit 3 |
multiple interactions |
EXP |
[Acids binds to and affects the activity of ASIC3 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr 4:11,652,946...11,657,415
Ensembl chr 4:10,760,597...10,764,643
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7A protein |
CTD |
PMID:20964302 |
|
NCBI chr X:75,159,635...75,267,094
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions increases phosphorylation |
ISO |
[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7B protein Adenosine Triphosphate results in increased phosphorylation of ATP7B protein |
CTD |
PMID:19405516 PMID:20964302 |
|
NCBI chr16:76,654,725...76,726,092
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
increases hydrolysis |
EXP |
ATP8B1 protein results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:11584374 |
|
NCBI chr18:60,286,605...60,427,862
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Avp |
arginine vasopressin |
multiple interactions increases secretion |
EXP |
Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of AVP protein]; bisindolylmaleimide I inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; Dactinomycin inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of AVP protein] |
CTD |
PMID:11102496 |
|
NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Adenosine Triphosphate binds to P2RY11 protein] which results in decreased expression of BCL2 protein |
CTD |
PMID:21503959 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
multiple interactions |
ISO |
[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] |
CTD |
PMID:19366808 |
|
NCBI chr20:13,468,732...13,596,333
Ensembl chr20:13,471,668...13,597,016
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases abundance |
ISO |
BIRC5 protein results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:32497533 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Cabin1 |
calcineurin binding protein 1 |
multiple interactions |
EXP |
CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein] |
CTD |
PMID:21464294 |
|
NCBI chr20:12,892,750...13,014,801
Ensembl chr20:12,893,358...13,015,357
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases secretion multiple interactions |
EXP |
Adenosine Triphosphate results in increased secretion of CALCA protein Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]; Flurbiprofen inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]]; Suramin inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]] |
CTD |
PMID:12044622 |
|
NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Casp1 |
caspase 1 |
increases activity multiple interactions |
EXP ISO |
Adenosine Triphosphate results in increased activity of CASP1 mRNA; Adenosine Triphosphate results in increased activity of CASP1 protein [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein] [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein; Acetylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; fraxinellone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of CASP1 protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Niclosamide co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CASP1 protein; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of CASP1 protein modified form]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA] |
CTD |
PMID:18604214 PMID:19130485 PMID:21832250 PMID:23430110 PMID:24149798 PMID:25288807 PMID:25448682 PMID:26431797 PMID:26586371 PMID:29378952 PMID:32721574 PMID:33524445 PMID:33929904 PMID:34212273 PMID:34217685 PMID:34405489 PMID:35131329 PMID:35962723 PMID:36002070 PMID:36088791 PMID:36577999 PMID:36847822 PMID:37001609 PMID:38135199 PMID:38401882 More...
|
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO |
Adenosine Triphosphate results in increased expression of CASP3 Adenosine Triphosphate inhibits the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3] |
CTD |
PMID:19448140 PMID:24732427 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein] Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein] |
CTD |
PMID:24149798 PMID:25288807 |
|
NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Cat |
catalase |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of CAT mRNA |
CTD |
PMID:22129738 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion multiple interactions |
ISO |
Adenosine Triphosphate results in increased secretion of CCL3 protein azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CCL3 protein] |
CTD |
PMID:26522449 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides]]; [Phosphatidylinositol 4,5-Diphosphate co-treated with Adenosine Triphosphate] results in increased activity of CFTR protein; Adenosine Triphosphate affects the reaction [Curcumin results in increased activity of CFTR protein mutant form]; Adenosine Triphosphate binds to and results in increased activity of CFTR protein; Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides] |
CTD |
PMID:14710196 PMID:15623556 PMID:17178710 PMID:20675434 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein] Adenosine Triphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein] |
CTD |
PMID:23184943 |
|
NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of COL1A1 mRNA]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of COL1A1 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein] |
CTD |
PMID:32721574 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:14975680 |
|
NCBI chr11:96,072,371...96,091,956
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate; Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:21816645 |
|
NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Crkl |
CRK like proto-oncogene, adaptor protein |
multiple interactions |
ISO |
[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; [BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] |
CTD |
PMID:19366808 |
|
NCBI chr11:97,033,033...97,067,457
Ensembl chr11:83,526,530...83,563,238
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[CSF2 protein affects the susceptibility to stearic acid] which affects the abundance of Adenosine Triphosphate |
CTD |
PMID:32347412 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
multiple interactions affects binding |
ISO |
silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]] |
CTD |
PMID:21174434 |
|
NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:140,709,991...140,756,696
|
|
G |
Csnk2b |
casein kinase 2 beta |
multiple interactions affects binding |
ISO |
silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]] |
CTD |
PMID:21174434 |
|
NCBI chr20:3,704,833...3,709,999
Ensembl chr20:3,698,733...3,707,133
|
|
G |
Cstb |
cystatin B |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein] |
CTD |
PMID:25288807 |
|
NCBI chr20:10,245,157...10,247,199
Ensembl chr20:10,245,462...10,247,526
|
|
G |
Ctsb |
cathepsin B |
increases activity multiple interactions |
ISO |
Adenosine Triphosphate results in increased activity of CTSB protein azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of CTSB protein] |
CTD |
PMID:26522449 |
|
NCBI chr15:41,565,607...41,586,479
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases secretion multiple interactions |
ISO |
Adenosine Triphosphate results in increased secretion of CXCL2 protein azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CXCL2 protein] |
CTD |
PMID:26522449 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Dmd |
dystrophin |
increases secretion multiple interactions |
ISO |
DMD gene mutant form results in increased secretion of Adenosine Triphosphate Nifedipine inhibits the reaction [DMD gene mutant form results in increased secretion of Adenosine Triphosphate] |
CTD |
PMID:24349043 |
|
NCBI chr X:51,070,098...53,437,845
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP1 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr10:17,184,853...17,187,646
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP6 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP6 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of EGFR protein] |
CTD |
PMID:26104857 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions increases expression |
EXP |
Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA] |
CTD |
PMID:10723097 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [Toluene 2,4-Diisocyanate results in increased expression of ENPP2 protein] |
CTD |
PMID:26072274 |
|
NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Enpp7 |
ectonucleotide pyrophosphatase/phosphodiesterase 7 |
decreases activity |
ISO |
Adenosine Triphosphate results in decreased activity of ENPP7 protein |
CTD |
PMID:12885774 |
|
NCBI chr10:104,740,763...104,745,760
Ensembl chr10:104,242,223...104,246,589
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
decreases abundance multiple interactions |
ISO |
ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:25440059 |
|
NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,765,013...7,835,587
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions increases transport increases abundance increases secretion |
ISO |
2,4,3',5'-tetramethoxystilbene inhibits the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; [RWJ-56110 co-treated with 2,4,3',5'-tetramethoxystilbene] inhibits the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; calmidazolium affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Fendiline affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate]; Resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate] F2 protein results in increased transport of Adenosine Triphosphate STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate] |
CTD |
PMID:2030746 PMID:15342215 PMID:30696774 PMID:35288162 |
|
NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions decreases abundance |
ISO |
FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; Protein Kinase Inhibitors inhibits the reaction [FASN protein results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:26670611 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors results in decreased activity of FBP1 protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:31974165 |
|
NCBI chr17:2,212,941...2,235,749
Ensembl chr17:2,208,031...2,230,071
|
|
G |
Fbxo3 |
F-box protein 3 |
multiple interactions |
EXP |
FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein] |
CTD |
PMID:35962723 |
|
NCBI chr 3:110,872,185...110,904,479
Ensembl chr 3:90,417,297...90,449,557
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
EXP ISO |
Adenosine Triphosphate results in increased expression of FOS mRNA ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] [Phenylephrine co-treated with Adenosine Triphosphate] results in increased expression of FOS mRNA; Glucose affects the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] |
CTD |
PMID:10723097 PMID:19463813 PMID:27466191 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
increases expression multiple interactions |
ISO |
Adenosine Triphosphate results in increased expression of FSCN1 mRNA Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of FSCN1 mRNA] |
CTD |
PMID:29733962 |
|
NCBI chr12:16,710,601...16,723,734
Ensembl chr12:11,597,048...11,610,211
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions increases secretion |
ISO EXP |
oxophenylarsine inhibits the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; Phosphatidylinositol 4,5-Diphosphate affects the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein] NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]] |
CTD |
PMID:12471042 |
|
NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases export |
ISO |
GJA1 protein mutant form results in increased export of Adenosine Triphosphate; GJA1 protein results in increased export of Adenosine Triphosphate |
CTD |
PMID:17687502 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO EXP |
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein] [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of GSDMD protein; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of GSDMD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein] |
CTD |
PMID:33851234 PMID:34212273 PMID:34217685 PMID:35962723 PMID:36577999 PMID:37001609 More...
|
|
NCBI chr 7:109,423,209...109,427,771
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
[GSTP1 protein co-treated with Glutathione] inhibits the reaction [[Adenosine Triphosphate results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-amino-1-methyl-6-phenolimidazo(4,5-b)pyridine-DNA adduct]; [GSTP1 protein co-treated with Glutathione] inhibits the reaction [Adenosine Triphosphate results in increased activity of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] |
CTD |
PMID:11196146 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; U 0126 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]] |
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
multiple interactions affects binding |
ISO |
[Curcumin binds to 4-bis(2-chloroethyl)aminobenzaldehyde] inhibits the reaction [HCK protein binds to Adenosine Triphosphate] |
CTD |
PMID:33617879 |
|
NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:141,571,587...141,614,693
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [protoporphyrin IX results in decreased activity of HIF1A protein] |
CTD |
PMID:23624237 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk1 |
hexokinase 1 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein] |
CTD |
PMID:37001609 |
|
NCBI chr20:30,773,222...30,874,814
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hk2 |
hexokinase 2 |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of HK2 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of HK2 protein |
CTD |
PMID:36577999 |
|
NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmgb1 |
high mobility group box 1 |
affects chemical synthesis multiple interactions |
ISO |
HMGB1 protein affects the chemical synthesis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein; Adenosine Triphosphate promotes the reaction [fullerene C60 results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [graphene oxide results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [Nanotubes, Carbon results in increased secretion of HMGB1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein] |
CTD |
PMID:21641551 PMID:31504961 PMID:34405489 |
|
NCBI chr12:11,009,236...11,015,941
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein]] |
CTD |
PMID:34217685 PMID:38135199 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein] |
CTD |
PMID:24149798 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
affects chemical synthesis |
ISO |
HSPB1 protein affects the chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:21641551 |
|
NCBI chr12:26,430,640...26,432,301
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions increases expression |
EXP |
bisindolylmaleimide I inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; chelerythrine inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; Neomycin inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; resveratrol inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; tricyclodecane-9-yl-xanthogenate inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein] |
CTD |
PMID:16178011 |
|
NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [Fructose results in increased expression of ICAM1 protein] |
CTD |
PMID:18508964 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone] |
CTD |
PMID:14623498 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein] |
CTD |
PMID:17707769 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il18 |
interleukin 18 |
multiple interactions increases secretion |
ISO EXP |
[Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL18 protein; [Disulfiram co-treated with Adenosine Triphosphate] inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein] Adenosine Triphosphate results in increased secretion of IL18 protein 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA] |
CTD |
PMID:17404311 PMID:24149798 PMID:26431797 PMID:27311643 PMID:29378952 PMID:31993881 PMID:33579316 PMID:33851234 PMID:34212273 PMID:34405489 PMID:35962723 PMID:36088791 PMID:36577999 PMID:36847822 More...
|
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein]]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein] |
CTD |
PMID:26068648 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion decreases abundance |
EXP ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein; Enzyme Inhibitors inhibits the reaction [IL1B protein results in decreased abundance of Adenosine Triphosphate]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]] Adenosine Triphosphate results in increased secretion of IL1B protein (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; [[Air Pollutants results in increased abundance of Particulate Matter] results in increased susceptibility to [Dietary Fats co-treated with Lipopolysaccharides co-treated with Adenosine Triphosphate]] which results in increased secretion of IL1B protein; [[Air Pollutants results in increased abundance of Particulate Matter] results in increased susceptibility to [Lipopolysaccharides co-treated with Adenosine Triphosphate]] which results in increased secretion of IL1B protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of and affects the cleavage of IL1B protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; Okadaic Acid inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA]; zinc chloride inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]] 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; [Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein; [Disulfiram co-treated with Adenosine Triphosphate] inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein; Apigenin inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; flavone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; L 709049 inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; MitoTEMPO inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]]; tyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA] |
CTD |
PMID:10365824 PMID:14623498 PMID:17404311 PMID:18604214 PMID:19130485 PMID:22221676 PMID:23430110 PMID:24149798 PMID:24158569 PMID:24685903 PMID:26068648 PMID:26086368 PMID:26431797 PMID:26586371 PMID:26819091 PMID:26968431 PMID:27311643 PMID:29378952 PMID:29960001 PMID:31993881 PMID:32721574 PMID:33050067 PMID:33524445 PMID:33579316 PMID:33851234 PMID:33929904 PMID:34212273 PMID:34217685 PMID:34405489 PMID:35962723 PMID:36002070 PMID:36088791 PMID:36577999 PMID:36847822 PMID:37001609 PMID:37062408 PMID:37544346 PMID:38135199 PMID:38401882 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein]; NF157 compound inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein] Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; resveratrol inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]] [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL6 mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein]; MRS 2211 inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein] |
CTD |
PMID:17707769 PMID:24793913 PMID:24849676 PMID:25348860 PMID:26104857 PMID:26522449 PMID:33851234 PMID:37001609 PMID:37544346 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions increases secretion |
ISO EXP |
Adenosine Triphosphate inhibits the reaction [Glucose results in increased secretion of INS1 protein] Adenosine Triphosphate results in increased secretion of INS1 protein [[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein] |
CTD |
PMID:10535451 PMID:10780946 PMID:16366736 PMID:22221676 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[ammonium ferrous sulfate results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; [chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; INS protein inhibits the reaction [Acetaminophen results in decreased abundance of Adenosine Triphosphate]; Mannose inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate]; Phloretin inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate] |
CTD |
PMID:17965850 PMID:26739624 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irf2 |
interferon regulatory factor 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IRF2 mRNA; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IRF2 mRNA] |
CTD |
PMID:34212273 |
|
NCBI chr16:52,171,855...52,283,620
Ensembl chr16:45,439,225...45,550,024
|
|
G |
Itgb1bp2 |
integrin subunit beta 1 binding protein 2 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]] Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr X:70,612,118...70,617,158
Ensembl chr X:66,572,537...66,577,174
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein] |
CTD |
PMID:24149798 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnd2 |
potassium voltage-gated channel subfamily D member 2 |
multiple interactions increases abundance |
ISO |
[[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased abundance of Adenosine Triphosphate; [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate KCND2 protein results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:34418280 |
|
NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:49,776,246...50,277,728
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Adenosine Triphosphate deficiency results in decreased activity of KCNH2 protein |
CTD |
PMID:12531891 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions decreases response to substance |
ISO |
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] KCNJ11 protein mutant form results in decreased susceptibility to Adenosine Triphosphate |
CTD |
PMID:11390963 PMID:28842488 |
|
NCBI chr 1:105,727,473...105,731,167
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Kcnj15 |
potassium inwardly-rectifying channel, subfamily J, member 15 |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of KCNJ15 protein |
CTD |
PMID:15328350 |
|
NCBI chr11:48,046,953...48,091,285
Ensembl chr11:34,577,363...34,621,952
|
|
G |
Kcnj8 |
potassium inwardly-rectifying channel, subfamily J, member 8 |
multiple interactions decreases response to substance |
EXP |
Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein] KCNJ8 protein mutant form results in decreased susceptibility to Adenosine Triphosphate |
CTD |
PMID:28842488 |
|
NCBI chr 4:177,240,692...177,246,548
Ensembl chr 4:175,508,912...175,515,603
|
|
G |
Khk |
ketohexokinase |
multiple interactions |
ISO |
KHK protein promotes the reaction [Fructose results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:19158351 |
|
NCBI chr 6:31,165,246...31,175,779
Ensembl chr 6:25,445,300...25,455,717
|
|
G |
Kif5a |
kinesin family member 5A |
multiple interactions increases hydrolysis |
ISO |
Adenosine Triphosphate inhibits the reaction [zinc chloride results in decreased activity of KIF5A protein]; Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]; Egtazic Acid inhibits the reaction [Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]] |
CTD |
PMID:24239783 PMID:28122263 |
|
NCBI chr 7:64,937,210...64,974,339
Ensembl chr 7:63,049,424...63,092,858
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
[[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] which results in decreased secretion of LEP protein |
CTD |
PMID:10780946 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of LIPE protein |
CTD |
PMID:7155675 |
|
NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lpl |
lipoprotein lipase |
affects response to substance |
ISO |
LPL protein affects the susceptibility to Adenosine Triphosphate |
CTD |
PMID:11786490 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
affects binding |
ISO |
Adenosine Triphosphate binds to MAP2K1 protein |
CTD |
PMID:17693661 |
|
NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation increases activity |
ISO EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK1 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK1 protein]]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12513686 PMID:15034929 PMID:21503959 PMID:24300283 PMID:26104857 PMID:26522449 PMID:30502331 PMID:32941855 PMID:34405489 More...
|
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation increases activity |
ISO EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK3 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK3 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK3 protein]]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12513686 PMID:15034929 PMID:21503959 PMID:24300283 PMID:26104857 PMID:26522449 PMID:30502331 PMID:32941855 PMID:34405489 More...
|
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions decreases abundance |
EXP ISO |
[annonacin results in decreased abundance of Adenosine Triphosphate] which affects the localization of MAPT protein MAPT protein mutant form results in decreased abundance of Adenosine Triphosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:17634376 PMID:39172838 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Metrnl |
meteorin-like, glial cell differentiation regulator |
multiple interactions |
ISO |
METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:30213948 |
|
NCBI chr10:107,462,148...107,476,143
Ensembl chr10:106,963,880...106,977,869
|
|
G |
Mfn2 |
mitofusin 2 |
decreases response to substance multiple interactions increases chemical synthesis |
ISO EXP |
MFN2 results in decreased susceptibility to Adenosine Triphosphate deficiency MFN2 protein inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate] MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate] MFN2 protein results in increased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:22292091 PMID:24898700 PMID:25416777 |
|
NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mir219a1 |
microRNA 219a-1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of MIR219A1 mRNA; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein] |
CTD |
PMID:35962723 |
|
NCBI chr20:4,831,580...4,831,689
Ensembl chr20:4,829,687...4,829,796
|
|
G |
Mir23b |
microRNA 23b |
multiple interactions decreases abundance |
ISO |
[[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate MIR23B mRNA results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:34418280 |
|
NCBI chr17:1,819,386...1,819,482
Ensembl chr17:1,813,667...1,813,763
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP2 mRNA; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP2 mRNA] |
CTD |
PMID:36847822 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases activity increases secretion |
EXP ISO |
1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; SB 3CT compound inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; wortmannin inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP9 mRNA; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP9 mRNA] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of MMP9 protein] Adenosine Triphosphate results in increased secretion of MMP9 protein |
CTD |
PMID:20195827 PMID:26522449 PMID:36847822 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mt-atp6 |
mitochondrially encoded ATP synthase membrane subunit 6 |
affects abundance |
EXP |
ATP6 protein affects the abundance of Adenosine Triphosphate |
CTD |
PMID:18273840 |
|
NCBI chr MT:7,919...8,599
Ensembl chr MT:7,919...8,599
|
|
G |
Mt-co3 |
mitochondrially encoded cytochrome c oxidase III |
increases abundance |
ISO |
COX3 protein results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:17428446 |
|
NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
increases hydrolysis |
ISO |
MVD protein results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:9392419 |
|
NCBI chr19:67,404,911...67,414,974
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Mvk |
mevalonate kinase |
increases hydrolysis multiple interactions |
ISO |
MVK protein results in increased hydrolysis of Adenosine Triphosphate 3,3-dimethylallyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; dolichol monophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; Farnesol inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; farnesyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranyl diphosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranylgeranyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; isopentenyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate] |
CTD |
PMID:9392419 |
|
NCBI chr12:47,802,002...47,819,503
Ensembl chr12:42,141,384...42,158,882
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of MYD88 protein; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of MYD88 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein] |
CTD |
PMID:34405489 PMID:37544346 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases abundance |
ISO |
MYH7 gene mutant form results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:29741611 |
|
NCBI chr15:32,416,525...32,439,851
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Nadsyn1 |
NAD synthetase 1 |
multiple interactions |
ISO |
[Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased activity of NADSYN1 protein; [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD |
CTD |
PMID:12547821 |
|
NCBI chr 1:208,410,914...208,439,242
Ensembl chr 1:198,981,604...199,009,869
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
multiple interactions increases response to substance |
EXP |
NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]] NCS1 protein results in increased susceptibility to Adenosine Triphosphate |
CTD |
PMID:12471042 |
|
NCBI chr 3:34,920,949...34,966,554
Ensembl chr 3:14,523,220...14,568,829
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
affects localization multiple interactions |
EXP ISO |
Adenosine Triphosphate affects the localization of NFATC1 protein azetidine analog inhibits the reaction [Adenosine Triphosphate affects the localization of NFATC1 protein] |
CTD |
PMID:21464294 PMID:26522449 |
|
NCBI chr18:76,321,386...76,430,997
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfatc3 |
nuclear factor of activated T-cells 3 |
affects localization |
EXP |
Adenosine Triphosphate affects the localization of NFATC3 protein |
CTD |
PMID:21464294 |
|
NCBI chr19:50,870,464...50,944,992
Ensembl chr19:33,960,852...34,035,150
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein]] |
CTD |
PMID:34217685 PMID:38135199 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP ISO |
Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]] [Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein] |
CTD |
PMID:21464294 PMID:24149798 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
[NGF protein co-treated with Adenosine Triphosphate] results in increased uptake of Calcium |
CTD |
PMID:1374475 |
|
NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nlrp1a |
NLR family, pyrin domain containing 1A |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with resveratrol] results in increased expression of NLRP1 mRNA |
CTD |
PMID:24149798 |
|
NCBI chr10:56,277,134...56,332,229
Ensembl chr10:55,778,560...55,825,180
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of NLRP3 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein] 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased activity of NLRP3 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with Resveratrol] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; Acetylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein] |
CTD |
PMID:18604214 PMID:23430110 PMID:24149798 PMID:26086368 PMID:26586371 PMID:29378952 PMID:32721574 PMID:33524445 PMID:34217685 PMID:34405489 PMID:35131329 PMID:35962723 PMID:36088791 PMID:36847822 PMID:37001609 PMID:37544346 PMID:38135199 PMID:38401882 More...
|
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nolc1 |
nucleolar and coiled-body phosphoprotein 1 |
multiple interactions |
ISO |
Adenosine Triphosphate affects the reaction [Doxorubicin binds to NOLC1 protein] |
CTD |
PMID:17129415 |
|
NCBI chr 1:254,870,195...254,881,070
Ensembl chr 1:244,921,377...244,932,088
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NOS2 protein; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NOS2 protein] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein] [Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased abundance of Nitric Oxide] |
CTD |
PMID:21464294 PMID:26522449 PMID:36847822 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
Adenosine Triphosphate affects the reaction [Alcohols affects the phosphorylation of NOS3 protein]; Adenosine Triphosphate inhibits the reaction [Alcohols results in decreased expression of NOS3 protein] |
CTD |
PMID:24300283 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Npy |
neuropeptide Y |
affects response to substance |
ISO |
NPY protein affects the susceptibility to Adenosine Triphosphate |
CTD |
PMID:15003356 |
|
NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
increases expression |
EXP |
Adenosine Triphosphate results in increased expression of NR4A1 mRNA |
CTD |
PMID:10723097 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Oas1a |
2'-5' oligoadenylate synthetase 1A |
multiple interactions |
ISO |
[OAS1 protein results in increased metabolism of Adenosine Triphosphate] which results in increased chemical synthesis of 2',5'-oligoadenylate |
CTD |
PMID:15732009 |
|
NCBI chr12:41,330,423...41,341,130
Ensembl chr12:35,669,801...35,680,517
|
|
G |
Oxt |
oxytocin/neurophysin I prepropeptide |
multiple interactions increases secretion |
EXP |
Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of OXT protein] |
CTD |
PMID:11102496 |
|
NCBI chr 3:138,235,754...138,236,594
Ensembl chr 3:117,782,650...117,783,490
|
|
G |
P2rx1 |
purinergic receptor P2X 1 |
multiple interactions affects binding |
EXP |
geldanamycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; herbimycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; monorden promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1] ATP binds to P2rx1 protein |
CTD RGD |
PMID:11930156 PMID:12237343 |
RGD:727431 |
NCBI chr10:58,117,107...58,132,167
Ensembl chr10:57,618,586...57,633,623
|
|
G |
P2rx2 |
purinergic receptor P2X 2 |
multiple interactions affects activity increases activity affects response to substance |
EXP ISO |
1-amino-4-(3-(4,6-dichloro(1,3,5)triazine-2-ylamino)phenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Acetylcysteine inhibits the reaction [Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Cadmium Chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cobaltous chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Copper promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cupric chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Dithiothreitol inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercuric Chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; methyl methanethiosulfonate inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; methyl methanethiosulfonate inhibits the reaction [Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; myxothiazol promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; nickel chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; palladium chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; zinc chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein] ATP affects activity of rat P2x2 receptor in transfected glial cells P2RX2 protein affects the susceptibility to Adenosine Triphosphate |
CTD RGD |
PMID:15081800 PMID:16190872 PMID:19793987 PMID:21207957 PMID:16388598 |
RGD:1642662 |
NCBI chr12:51,999,107...52,002,627
Ensembl chr12:46,339,549...46,342,891
|
|
G |
P2rx3 |
purinergic receptor P2X 3 |
multiple interactions increases activity affects activity |
EXP |
Eugenol inhibits the reaction [P2RX3 protein affects the activity of Adenosine Triphosphate] Adenosine Triphosphate results in increased activity of P2RX3 protein |
CTD |
PMID:19967073 PMID:27481062 |
|
NCBI chr 3:90,487,506...90,531,315
Ensembl chr 3:70,080,851...70,125,178
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
multiple interactions increases activity |
EXP ISO |
[Cadmium co-treated with Zinc] promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [Mercury co-treated with Copper] inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cadmium promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cobalt promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]]; Mercury inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro(3,2-e)-1,4-diazepin-2-one inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [ginsenoside M1 co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 mRNA; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 protein; ginsenoside M1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Ivermectin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:10737610 PMID:15629187 PMID:19793987 PMID:21638035 PMID:24149798 PMID:27481062 PMID:30545933 More...
|
|
NCBI chr12:39,505,438...39,523,349
Ensembl chr12:33,844,396...33,862,253
|
|
G |
P2rx5 |
purinergic receptor P2X 5 |
affects transport |
EXP |
ATP affects transport ion flux of P2rx5 receptor |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:58,276,329...58,291,108
Ensembl chr10:57,777,819...57,789,423
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions increases response to substance increases expression decreases response to substance increases activity |
ISO EXP |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein; Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein; AZ 11645373 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; calmidazolium inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; KN 62 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased transport of Barium]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein]; ZINC58368839 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein] P2RX7 protein results in increased susceptibility to Adenosine Triphosphate Adenosine Triphosphate results in increased expression of P2RX7 protein P2RX7 gene mutant form results in decreased susceptibility to Adenosine Triphosphate 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein] |
CTD |
PMID:11003599 PMID:17728465 PMID:19023039 PMID:21638035 PMID:23565201 PMID:24101734 PMID:24149798 PMID:26522449 PMID:27466191 PMID:27481062 PMID:30545933 PMID:31263019 PMID:31504961 More...
|
|
NCBI chr12:39,550,531...39,594,984
Ensembl chr12:33,879,745...33,934,619
|
|
G |
P2ry1 |
purinergic receptor P2Y1 |
multiple interactions affects activity |
ISO EXP |
[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium] [N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate binds to and results in decreased activity of P2RY1 protein] inhibits the reaction [Adenosine Triphosphate results in increased uptake of Calcium] Adenosine Triphosphate affects the activity of P2RY1 protein |
CTD |
PMID:12694404 PMID:15243297 PMID:16973929 PMID:22129738 |
|
NCBI chr 2:147,391,661...147,397,870
Ensembl chr 2:145,241,849...145,248,457
|
|
G |
P2ry13 |
purinergic receptor P2Y13 |
multiple interactions |
ISO |
MRS 2211 inhibits the reaction [P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide] |
CTD |
PMID:22129738 |
|
NCBI chr 2:145,620,321...145,624,730
Ensembl chr 2:143,470,425...143,473,434
|
|
G |
P2ry2 |
purinergic receptor P2Y2 |
multiple interactions affects activity increases activity |
ISO EXP |
[Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Calcium [Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased uptake of Calcium Adenosine Triphosphate affects the activity of P2RY2 protein |
CTD |
PMID:11527950 PMID:15243297 PMID:17003265 |
|
NCBI chr 1:164,764,119...164,779,578
Ensembl chr 1:155,351,165...155,367,632
|
|
G |
P2ry4 |
pyrimidinergic receptor P2Y4 |
multiple interactions |
ISO |
[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium] |
CTD |
PMID:12694404 |
|
NCBI chr X:69,722,604...69,757,726
Ensembl chr X:65,683,232...65,721,748
|
|
G |
P2ry6 |
pyrimidinergic receptor P2Y6 |
multiple interactions |
ISO |
N,N''-1,4-butanediylbis(N'-(3-isothiocyanatophenyl))thiourea inhibits the reaction [P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide] |
CTD |
PMID:22129738 |
|
NCBI chr 1:164,707,188...164,742,689
Ensembl chr 1:155,295,111...155,330,808
|
|
G |
Panx1 |
Pannexin 1 |
decreases activity multiple interactions increases export |
ISO |
Adenosine Triphosphate results in decreased activity of PANX1 protein Carbenoxolone inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate]; Probenecid inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate] |
CTD |
PMID:19023039 PMID:19213873 |
|
NCBI chr 8:20,128,783...20,171,200
Ensembl chr 8:11,850,730...11,889,774
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases expression |
ISO |
PARP1 mutant form inhibits the reaction [Cadmium results in decreased abundance of Adenosine Triphosphate] PARP1 protein affects the reaction [pyrithione zinc results in decreased abundance of Adenosine Triphosphate]; PARP1 protein affects the reaction [Zinc results in decreased abundance of Adenosine Triphosphate] Adenosine Triphosphate results in increased expression of PARP1 protein |
CTD |
PMID:17728843 PMID:19809895 PMID:21767558 PMID:22253048 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions affects response to substance |
ISO |
[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium; Adenosine Triphosphate promotes the reaction [PDK1 protein affects the abundance of Calcium]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium] |
CTD |
PMID:28887310 |
|
NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pfkm |
phosphofructokinase, muscle |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [resveratrol results in decreased activity of PFKM protein] |
CTD |
PMID:23454376 |
|
NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Pgp |
phosphoglycolate phosphatase |
decreases phosphorylation |
ISO |
PGP protein results in decreased phosphorylation of Adenosine Triphosphate |
CTD |
PMID:24338473 |
|
NCBI chr10:13,999,782...14,002,408
Ensembl chr10:13,494,291...13,497,858
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions affects binding |
ISO |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [Adenosine Triphosphate binds to PIK3CA protein]; Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]] |
CTD |
PMID:17550345 PMID:18754654 |
|
NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]] |
CTD |
PMID:17550345 |
|
NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of PLA2G4A protein |
CTD |
PMID:10535451 |
|
NCBI chr13:64,427,921...64,572,352
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Plau |
plasminogen activator, urokinase |
increases secretion |
ISO |
Adenosine Triphosphate results in increased secretion of PLAU protein |
CTD |
PMID:20177776 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plpp3 |
phospholipid phosphatase 3 |
decreases chemical synthesis |
ISO |
PLPP3 gene mutant form results in decreased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:28982073 |
|
NCBI chr 5:125,156,000...125,231,119
Ensembl chr 5:119,927,085...120,002,205
|
|
G |
Pml |
PML nuclear body scaffold |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PML protein; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased abundance of Reactive Oxygen Species]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein] |
CTD |
PMID:23430110 |
|
NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Pmvk |
phosphomevalonate kinase |
increases hydrolysis |
ISO |
PMVK protein results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:9392419 |
|
NCBI chr 2:177,174,344...177,184,076
Ensembl chr 2:174,876,657...174,886,364
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Fenofibrate results in increased activity of PPARA protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:19593819 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions decreases abundance |
ISO |
FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]] PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate; PPARG protein results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:26670611 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PPARGC1A protein; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PPARGC1A protein] |
CTD |
PMID:38135199 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
multiple interactions |
ISO |
Adenosine Triphosphate binds to and affects the folding of PPP5C protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein] |
CTD |
PMID:23184943 |
|
NCBI chr 1:86,818,297...86,842,505
Ensembl chr 1:77,690,208...77,714,456
|
|
G |
Prdx2 |
peroxiredoxin 2 |
increases expression |
EXP |
Adenosine Triphosphate results in increased expression of PRDX2 protein modified form |
CTD |
PMID:16178011 |
|
NCBI chr19:40,085,788...40,091,083
Ensembl chr19:23,180,930...23,186,194
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to Metformin] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Dihydroxyacetone co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:31974165 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions |
ISO |
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to Metformin] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Dihydroxyacetone co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:31974165 |
|
NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
[[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin |
CTD |
PMID:16087181 |
|
NCBI chr10:93,388,991...93,787,617
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein] |
CTD |
PMID:24149798 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO EXP |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to PYCARD protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to PYCARD protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PYCARD gene mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of G(M3) Ganglioside]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein] |
CTD |
PMID:18604214 PMID:23430110 PMID:24149798 PMID:24475307 PMID:29378952 PMID:32721574 PMID:34405489 PMID:35962723 PMID:36577999 PMID:38135199 PMID:38401882 More...
|
|
NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Ralbp1 |
ralA binding protein 1 |
multiple interactions |
ISO |
[[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin; Adenosine Triphosphate promotes the reaction [RALBP1 protein affects the transport of Leukotriene C4] |
CTD |
PMID:15386349 PMID:16087181 |
|
NCBI chr 9:112,903,289...112,940,093
Ensembl chr 9:105,456,425...105,492,707
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased phosphorylation of RELA protein; [mitochondrial uncoupler BAM15 co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased phosphorylation of RELA protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein] [Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; Resveratrol promotes the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein]; S-Nitrosoglutathione promotes the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein] |
CTD |
PMID:21464294 PMID:24149798 PMID:33524445 PMID:34217685 PMID:34405489 PMID:37544346 More...
|
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhof |
ras homolog family member F, filopodia associated |
multiple interactions increases expression |
ISO |
Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of RHOF mRNA] |
CTD |
PMID:29733962 |
|
NCBI chr12:39,082,413...39,107,528
Ensembl chr12:33,431,280...33,446,703
|
|
G |
S100a10 |
S100 calcium binding protein A10 |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of S100A10 mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:179,220,887...179,229,661
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of S100A11 mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 2:181,875,132...181,880,542
Ensembl chr 2:179,191,715...179,197,044
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
multiple interactions increases expression |
ISO |
Adenosine Triphosphate results in increased expression of and results in increased secretion of S100A4 protein; Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of S100A4 protein] Adenosine Triphosphate results in increased expression of S100A4 mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:176,091,804...176,093,254
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of S100A6 mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 2:178,398,189...178,399,763
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
Sell |
selectin L |
multiple interactions |
ISO |
P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein] |
CTD |
PMID:11003599 |
|
NCBI chr13:78,950,100...78,969,604
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Sftpa1 |
surfactant protein A1 |
multiple interactions |
ISO |
[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]] |
CTD |
PMID:15065867 |
|
NCBI chr16:17,042,264...17,045,770
Ensembl chr16:17,008,180...17,011,685
|
|
G |
Sftpb |
surfactant protein B |
increases secretion multiple interactions |
ISO EXP |
Adenosine Triphosphate results in increased secretion of SFTPB protein Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPB protein] |
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:104,359,396...104,368,436
|
|
G |
Sftpc |
surfactant protein C |
increases secretion multiple interactions |
EXP ISO |
Adenosine Triphosphate results in increased secretion of SFTPC protein Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPC protein] |
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr15:52,006,274...52,009,324
Ensembl chr15:45,596,574...45,610,777
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP ISO |
[SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein]; SIRT1 protein promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate] [STK11 protein co-treated with Adenosine Triphosphate] results in increased activity of and results in increased phosphorylation of SIRT1 protein |
CTD |
PMID:16366736 PMID:34216621 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions |
ISO |
SIRT3 protein inhibits the reaction [Metformin results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:23166782 |
|
NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc25a14 |
solute carrier family 25 member 14 |
decreases chemical synthesis |
ISO |
SLC25A14 protein results in decreased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:20600837 |
|
NCBI chr X:132,685,518...132,723,705
Ensembl chr X:127,807,449...127,845,823
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
decreases stability |
ISO |
Adenosine Triphosphate results in decreased stability of SLC2A1 protein |
CTD |
PMID:11420438 |
|
NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases abundance |
ISO |
SLC2A4 protein results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:34904774 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc46a1 |
solute carrier family 46 member 1 |
multiple interactions |
ISO |
[SLC46A1 protein results in increased susceptibility to N-((5-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo(2,3-d)pyrimidin-6-yl)propyl)thiophen-2-yl)carbonyl)glutamic acid] which results in decreased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:21879757 |
|
NCBI chr10:63,859,551...63,865,987
Ensembl chr10:63,361,486...63,368,848
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [TSHB protein results in increased expression of SLC5A5 protein] |
CTD |
PMID:16439463 |
|
NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Snca |
synuclein alpha |
multiple interactions decreases abundance |
ISO |
GW8510 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate]; SB 216763 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:24989254 |
|
NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression |
EXP ISO |
Adenosine Triphosphate results in increased expression of SOD1 protein |
CTD |
PMID:16178011 PMID:22129738 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
affects chemical synthesis decreases abundance multiple interactions |
ISO |
SOD2 protein affects the chemical synthesis of Adenosine Triphosphate SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate MK-886 promotes the reaction [SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:20638473 PMID:25362851 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Srr |
serine racemase |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [Edetic Acid inhibits the reaction [SRR protein results in increased abundance of D-Aspartic Acid]]; Adenosine Triphosphate promotes the reaction [SRR protein results in increased abundance of D-Aspartic Acid] |
CTD |
PMID:27387750 |
|
NCBI chr10:60,267,936...60,285,094
Ensembl chr10:59,769,571...59,787,011
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
[STK11 protein co-treated with Adenosine Triphosphate] results in increased activity of and results in increased phosphorylation of SIRT1 protein |
CTD |
PMID:34216621 |
|
NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Stxbp2 |
syntaxin binding protein 2 |
multiple interactions |
ISO |
STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate] |
CTD |
PMID:30696774 |
|
NCBI chr12:6,487,265...6,498,351
Ensembl chr12:1,689,410...1,700,458
|
|
G |
Sugt1 |
SGT1 homolog, MIS12 kinetochore complex assembly cochaperone |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr15:61,400,478...61,441,303
Ensembl chr15:54,990,672...55,069,150
|
|
G |
Syn2 |
synapsin II |
multiple interactions |
ISO |
SYN2 mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of Calcium] |
CTD |
PMID:18701217 |
|
NCBI chr 4:149,858,919...150,016,845
Ensembl chr 4:148,186,270...148,344,192
|
|
G |
Tac1 |
tachykinin, precursor 1 |
increases secretion multiple interactions |
EXP |
Adenosine Triphosphate results in increased secretion of TAC1 protein Iloprost promotes the reaction [Adenosine Triphosphate results in increased secretion of TAC1 protein] |
CTD |
PMID:16039053 |
|
NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Taldo1 |
transaldolase 1 |
increases abundance |
ISO |
TALDO1 gene mutant form results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:19436114 |
|
NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:196,493,589...196,503,974
|
|
G |
Tas2r145 |
taste receptor, type 2, member 145 |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of TAS2R131 protein |
CTD |
PMID:29347925 |
|
NCBI chr 4:167,869,406...167,870,356
Ensembl chr 4:166,138,007...166,138,957
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Dimethyl Sulfoxide co-treated with TGFB1 protein] results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:35366062 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timm17a |
translocase of inner mitochondrial membrane 17A |
multiple interactions decreases expression |
ISO |
1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in decreased expression of TIMM17A protein] |
CTD |
PMID:24315374 |
|
NCBI chr13:49,282,918...49,296,363
Ensembl chr13:46,730,660...46,742,655
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases secretion multiple interactions |
ISO |
Adenosine Triphosphate results in decreased secretion of TIMP1 protein azetidine analog inhibits the reaction [Adenosine Triphosphate results in decreased secretion of TIMP1 protein] |
CTD |
PMID:26522449 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TLR4 protein; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TLR4 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein] |
CTD |
PMID:34405489 PMID:37544346 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases chemical synthesis |
ISO EXP |
[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TNF mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Chlorides]; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Potassium]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased secretion of TNF protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TNF mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA] Adenosine Triphosphate inhibits the reaction [Sunitinib results in increased expression of TNF protein]; TNF protein promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate] TNF protein results in decreased chemical synthesis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein; [Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein]; MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Rosiglitazone inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Vitamin K 3 promotes the reaction [[Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate] |
CTD |
PMID:8817062 PMID:10783394 PMID:14623498 PMID:17707769 PMID:23430110 PMID:24898700 PMID:26522449 PMID:29378952 PMID:32131635 PMID:33050067 PMID:33524445 PMID:33851234 PMID:36577999 PMID:37001609 PMID:37544346 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
increases abundance |
ISO |
TNFSF11 protein results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:26287518 |
|
NCBI chr15:60,083,008...60,114,479
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions increases hydrolysis |
ISO |
Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; copper-thiosemicarbazone complex analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Dithiothreitol inhibits the reaction [Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]]; Emodin inhibits the reaction [TOP2A results in increased hydrolysis of Adenosine Triphosphate]; Etoposide metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Thiosemicarbazones analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate] TOP2A protein results in increased hydrolysis of Adenosine Triphosphate; TOP2A results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:20855424 PMID:26982206 PMID:27533850 PMID:29272108 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Top2b |
DNA topoisomerase II beta |
increases hydrolysis multiple interactions |
ISO |
TOP2B protein results in increased hydrolysis of Adenosine Triphosphate cannabidiol hydroxyquinone inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate]; Cannabidiol metabolite inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate] |
CTD |
PMID:29272108 |
|
NCBI chr15:11,482,089...11,542,464
Ensembl chr15:9,051,341...9,112,085
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases abundance |
ISO |
TP53 protein inhibits the reaction [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] TP53 gene mutant form results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:21042727 PMID:33070465 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; U 0126 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:108,169,980...108,269,822
|
|
G |
Trpc3 |
transient receptor potential cation channel, subfamily C, member 3 |
multiple interactions increases activity |
ISO |
ethyl-1-(4-(2*3*3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate inhibits the reaction [Adenosine Triphosphate results in increased activity of TRPC3 protein] |
CTD |
PMID:19289841 |
|
NCBI chr 2:121,409,436...121,487,095
Ensembl chr 2:119,481,400...119,558,855
|
|
G |
Trpc5 |
transient receptor potential cation channel, subfamily C, member 5 |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of TRPC5 protein |
CTD |
PMID:19289841 |
|
NCBI chr X:112,742,828...113,027,638
Ensembl chr X:107,939,131...108,230,991
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of TRPC6 protein |
CTD |
PMID:19289841 |
|
NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Trpc7 |
transient receptor potential cation channel, subfamily C, member 7 |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of TRPC7 protein |
CTD |
PMID:19289841 |
|
NCBI chr17:7,707,954...7,839,064
Ensembl chr17:7,709,583...7,833,435
|
|
G |
Trpm4 |
transient receptor potential cation channel, subfamily M, member 4 |
decreases activity |
ISO EXP |
Adenosine Triphosphate results in decreased activity of TRPM4 protein |
CTD |
PMID:16966582 PMID:17188667 |
|
NCBI chr 1:104,918,462...104,949,453
Ensembl chr 1:95,782,000...95,812,532
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
[Capsaicin binds to and affects the activity of TRPV1 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [TSHB protein results in increased expression of SLC5A5 protein] |
CTD |
PMID:16439463 |
|
NCBI chr 2:192,913,171...192,918,054
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of TXN protein |
CTD |
PMID:22129738 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnip |
thioredoxin interacting protein |
increases activity |
EXP |
Adenosine Triphosphate results in increased activity of TXNIP mRNA |
CTD |
PMID:21832250 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions decreases abundance |
EXP ISO |
Adenosine Triphosphate inhibits the reaction [UCP1 protein results in increased transport of Protons] UCP1 results in decreased abundance of Adenosine Triphosphate UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]] |
CTD |
PMID:12734183 PMID:26670611 |
|
NCBI chr19:41,713,350...41,721,421
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO EXP |
Adenosine Triphosphate inhibits the reaction [UCP2 protein results in increased transport of Protons] [SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:12734183 PMID:16366736 |
|
NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ucp3 |
uncoupling protein 3 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [UCP3 protein results in increased transport of Protons] |
CTD |
PMID:12734183 |
|
NCBI chr 1:164,227,910...164,240,893
Ensembl chr 1:154,815,777...154,828,762
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
VDAC1 mutant form inhibits the reaction [chromium hexavalent ion results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:22858589 |
|
NCBI chr10:37,029,377...37,060,542
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
multiple interactions increases abundance decreases abundance |
ISO |
Acetylcysteine inhibits the reaction [XRCC1 gene mutant form results in decreased abundance of Adenosine Triphosphate]; Acetylcysteine promotes the reaction [XRCC1 protein results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:30998386 |
|
NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:80,141,207...80,168,701
|
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
multiple interactions |
ISO |
cylindrospermopsin results in increased expression of [ALDOA protein binds to fructose-1,6-diphosphate] |
CTD |
PMID:27494769 |
|
NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions decreases abundance |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate] APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
fructose-1,6-diphosphate results in increased expression of BAX protein |
CTD |
PMID:33078453 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
EXP |
[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr16:74,133,259...74,145,328
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:22227475 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:22227475 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions decreases abundance |
ISO |
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate] PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases degradation |
ISO |
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] fructose-1,6-diphosphate results in decreased degradation of NOS2 mRNA |
CTD |
PMID:22227475 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
fructose-1,6-diphosphate results in increased expression of TP53 protein |
CTD |
PMID:33078453 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
decreases activity |
ISO |
fructose 2,6-diphosphate results in decreased activity of FBP1 protein |
CTD |
PMID:31974165 |
|
NCBI chr17:2,212,941...2,235,749
Ensembl chr17:2,208,031...2,230,071
|
|
G |
Pfkfb1 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 |
decreases abundance |
ISO |
PFKFB1 gene mutant form results in decreased abundance of fructose 2,6-diphosphate |
CTD |
PMID:31974165 |
|
NCBI chr X:22,936,038...22,989,691
Ensembl chr X:19,508,546...19,562,182
|
|
G |
Pfkm |
phosphofructokinase, muscle |
multiple interactions |
ISO |
fructose 2,6-diphosphate inhibits the reaction [resveratrol results in decreased activity of PFKM protein] |
CTD |
PMID:23454376 |
|
NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:129,221,653...129,259,192
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA] |
CTD |
PMID:20083572 PMID:23227865 PMID:23362264 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein] |
CTD |
PMID:16452108 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases activity affects localization increases expression |
EXP ISO |
Bucladesine inhibits the reaction [estradiol-17 beta-glucuronide affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein] Bucladesine results in increased activity of ABCC2 protein Bucladesine results in increased expression of ABCC2 mRNA; Bucladesine results in increased expression of ABCC2 protein Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine results in increased activity of and affects the localization of ABCC2 protein; Dactinomycin inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; verlukast inhibits the reaction [Bucladesine results in increased activity of ABCC2 protein] |
CTD |
PMID:12029626 PMID:26049102 PMID:29052767 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Ache |
acetylcholinesterase |
increases activity increases expression |
EXP |
Bucladesine results in increased activity of ACHE protein; Bucladesine results in increased activity of ACHE protein alternative form Bucladesine results in increased expression of ACHE mRNA |
CTD |
PMID:18514641 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:38,418,565...38,427,384
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adm |
adrenomedullin |
decreases expression |
ISO |
Bucladesine results in decreased expression of ADM mRNA |
CTD |
PMID:19253104 |
|
NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein]; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]; Losartan inhibits the reaction [AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]] |
CTD |
PMID:36682589 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects localization increases activity multiple interactions |
ISO |
Bucladesine affects the localization of AHR protein Bucladesine results in increased activity of AHR protein Bucladesine affects the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:15972329 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ahrr |
aryl-hydrocarbon receptor repressor |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AHRR mRNA] |
CTD |
PMID:21979172 |
|
NCBI chr 1:30,822,219...30,917,251
Ensembl chr 1:28,993,634...29,088,673
|
|
G |
Ak5 |
adenylate kinase 5 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of AK5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:244,057,240...244,241,372
Ensembl chr 2:241,397,297...241,581,458
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA |
CTD |
PMID:22859313 |
|
NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Antxr1 |
ANTXR cell adhesion molecule 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ANTXR1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:121,148,102...121,335,549
Ensembl chr 4:119,590,771...119,778,232
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ANXA2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; Probucol inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; T0901317 promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol] |
CTD |
PMID:20083572 PMID:23227865 |
|
NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Ar |
androgen receptor |
multiple interactions |
EXP |
[Quercetin co-treated with Bucladesine] results in increased expression of AR mRNA |
CTD |
PMID:23200735 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ARHGEF2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:176,358,909...176,416,178
Ensembl chr 2:174,062,976...174,118,355
|
|
G |
Atf1 |
activating transcription factor 1 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]] |
CTD |
PMID:12164941 |
|
NCBI chr 7:133,240,774...133,283,488
Ensembl chr 7:131,362,450...131,404,670
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions increases phosphorylation increases expression |
ISO |
Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ATF2 protein modified form] Bucladesine results in increased phosphorylation of ATF2 protein |
CTD |
PMID:26049102 |
|
NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atp11a |
ATPase phospholipid transporting 11A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP11A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:83,359,884...83,469,807
Ensembl chr16:76,657,752...76,767,640
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ATP2B1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:33,735,871...33,843,295
|
|
G |
Atp6v0c |
ATPase H+ transporting V0 subunit C |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP6V0C mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:13,700,764...13,707,147
Ensembl chr10:13,196,204...13,201,500
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] |
CTD |
PMID:16822680 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BCAT1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:179,695,662...179,777,973
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCKDK mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:191,945,809...191,950,480
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] Bucladesine results in decreased expression of BCL2 protein |
CTD |
PMID:10697531 PMID:16822680 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l13 |
Bcl2-like 13 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCL2L13 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:155,728,284...155,785,058
Ensembl chr 4:154,056,127...154,108,985
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
ISO |
1-bromopropane inhibits the reaction [Bucladesine results in increased expression of BDNF mRNA]; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:19189864 PMID:29698629 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein-like |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BET1L mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:205,361,041...205,365,036
Ensembl chr 1:195,931,411...195,935,040
|
|
G |
Bicd1 |
BICD cargo adaptor 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BICD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:184,208,891...184,362,840
Ensembl chr 4:182,479,071...182,627,434
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA] |
CTD |
PMID:20522807 |
|
NCBI chr15:22,098,191...22,113,145
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bsnd |
barttin CLCNK type accessory subunit beta |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BSND mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:126,480,590...126,489,389
Ensembl chr 5:121,251,774...121,260,571
|
|
G |
C1r |
complement C1r |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of C1R mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:159,099,013...159,109,770
Ensembl chr 4:157,412,692...157,423,484
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CALM1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:125,217,191...125,227,855
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Calr |
calreticulin |
increases stability |
ISO |
Bucladesine results in increased stability of CALR protein |
CTD |
PMID:9473613 |
|
NCBI chr19:40,213,367...40,218,262
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Capn2 |
calpain 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAPN2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:96,681,902...96,732,625
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein]; Bucladesine promotes the reaction [Hydroxyurea results in increased activity of CASP3 protein] |
CTD |
PMID:10697531 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cast |
calpastatin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CAST mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:5,707,633...5,817,213
Ensembl chr 2:3,973,112...4,082,659
|
|
G |
Cav2 |
caveolin 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAV2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:46,582,681...46,590,058
Ensembl chr 4:45,616,712...45,624,244
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein] |
CTD |
PMID:12538206 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CCN2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CCNB1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CCNB1 protein |
CTD |
PMID:22534328 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
EXP ISO |
Bucladesine results in increased expression of CCND1 protein [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] affects the expression of CCND1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 protein |
CTD |
PMID:16718685 PMID:21693435 PMID:22534328 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
EXP |
Bucladesine results in increased expression of CCND3 protein |
CTD |
PMID:16718685 |
|
NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Cd69 |
Cd69 molecule |
decreases expression |
ISO |
Bucladesine results in decreased expression of CD69 protein |
CTD |
PMID:25433234 |
|
NCBI chr 4:164,411,485...164,419,403
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein] |
CTD |
PMID:12538815 |
|
NCBI chr11:75,760,073...75,798,978
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cdc42bpa |
CDC42 binding protein kinase alpha |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CDC42BPA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:94,215,359...94,435,681
Ensembl chr13:91,684,007...91,903,732
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
EXP ISO |
Bucladesine results in increased expression of CDKN1A protein [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CDKN1A protein GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein] |
CTD |
PMID:16718685 PMID:20823114 PMID:22534328 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP |
Bucladesine results in increased expression of CDKN1B protein |
CTD |
PMID:16718685 PMID:21693435 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of CEBPB protein Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of CEBPB protein] |
CTD |
PMID:19282384 PMID:19698295 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CEBPZ mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:21,872,071...21,889,755
Ensembl chr 6:16,119,872...16,137,600
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions increases expression |
ISO EXP |
[Bucladesine co-treated with Tretinoin] results in increased activity of CHAT protein; [Tretinoin co-treated with Bucladesine] results in increased activity of CHAT protein Bucladesine results in increased expression of CHAT protein Nicotine promotes the reaction [Bucladesine results in increased expression of CHAT protein] |
CTD |
PMID:16724269 PMID:20361958 PMID:29665406 |
|
NCBI chr16:7,663,665...7,723,416
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Cldn5 |
claudin 5 |
increases expression |
ISO |
Bucladesine results in increased expression of CLDN5 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr11:95,717,172...95,718,598
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Cngb1 |
cyclic nucleotide gated channel subunit beta 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CNGB1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:9,732,646...9,798,864
Ensembl chr19:9,726,595...9,791,173
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:11576339 PMID:16430859 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] |
CTD |
PMID:11576339 |
|
NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:12,021,182...12,048,932
Ensembl chr20:12,021,767...12,057,564
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of COX6A2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:192,218,970...192,221,188
Ensembl chr 1:182,788,528...182,789,274
|
|
G |
Cplx1 |
complexin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CPLX1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:1,329,073...1,360,781
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation multiple interactions |
ISO |
Bucladesine results in increased phosphorylation of CREB1 protein [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]] [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:12164941 PMID:18787026 PMID:19282384 PMID:36565944 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]] [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]] |
CTD |
PMID:19282384 PMID:20685861 PMID:36565944 |
|
NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CREM mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:58,932,011...59,001,160
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
EXP |
Bucladesine inhibits the reaction [arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:8769853 |
|
NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
Bucladesine promotes the reaction [Tretinoin results in increased expression of CSF1R mRNA] |
CTD |
PMID:8445950 |
|
NCBI chr18:56,834,152...56,860,804
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
multiple interactions affects localization |
ISO |
Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein]; Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein] Bucladesine affects the localization of CTBP1 protein |
CTD |
PMID:18184656 |
|
NCBI chr14:81,679,956...81,707,331
Ensembl chr14:77,455,696...77,482,821
|
|
G |
Ctbp2 |
C-terminal binding protein 2 |
affects localization multiple interactions |
ISO |
Bucladesine affects the localization of CTBP2 protein Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein] |
CTD |
PMID:18184656 |
|
NCBI chr 1:197,208,536...197,348,802
Ensembl chr 1:187,782,682...187,920,222
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases phosphorylation |
EXP |
Bucladesine results in increased phosphorylation of CTNNB1 protein |
CTD |
PMID:26964897 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctps2 |
CTP synthase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CTPS2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:35,277,658...35,418,505
Ensembl chr X:31,645,873...31,786,733
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Bucladesine results in decreased expression of CXCL12 mRNA |
CTD |
PMID:20711499 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cyb5d1 |
cytochrome b5 domain containing 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CYB5D1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:54,612,230...54,616,375
Ensembl chr10:54,113,438...54,117,911
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression multiple interactions |
EXP ISO |
Bucladesine results in increased expression of CYP11A1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA] [Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA] |
CTD |
PMID:21693180 PMID:21979172 PMID:23200735 PMID:35987080 |
|
NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of CYP11B1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP11B1 mRNA] |
CTD |
PMID:35987080 |
|
NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
fluorene-9-bisphenol affects the reaction [Bucladesine results in increased expression of CYP11B2 mRNA] |
CTD |
PMID:35987080 |
|
NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression increases expression multiple interactions |
EXP ISO |
Bucladesine results in decreased expression of CYP17A1 mRNA Bucladesine results in increased expression of CYP17A1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP17A1 mRNA] [Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:21458522 PMID:21693180 PMID:23200735 PMID:35987080 |
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of CYP19A1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:35987080 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP ISO |
Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:1849469 PMID:16901605 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:1849469 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
Bucladesine results in increased expression of CYP1B1 mRNA |
CTD |
PMID:11559018 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Bucladesine promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol] |
CTD |
PMID:8531136 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein] |
CTD |
PMID:20823114 |
|
NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddx27 |
DEAD-box helicase 27 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DDX27 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:176,163,220...176,182,418
Ensembl chr 3:155,744,150...155,763,372
|
|
G |
Des |
desmin |
multiple interactions |
EXP ISO |
[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of DES mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA |
CTD |
PMID:19089455 PMID:20823114 |
|
NCBI chr 9:84,299,626...84,307,344
Ensembl chr 9:76,850,982...76,858,699
|
|
G |
Dhx9 |
DExH-box helicase 9 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DHX9 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:68,152,813...68,189,580
Ensembl chr13:65,602,323...65,639,069
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DIO2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dtymk |
deoxythymidylate kinase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DTYMK mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:101,762,899...101,771,733
Ensembl chr 9:94,315,552...94,324,870
|
|
G |
Eda |
ectodysplasin-A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EDA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:69,118,577...69,520,274
Ensembl chr X:65,078,673...65,480,172
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EEF1A1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:88,221,839...88,225,688
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EFEMP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:106,811,769...106,890,961
Ensembl chr14:102,610,908...102,690,018
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EGR2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Epb41l4a |
erythrocyte membrane protein band 4.1 like 4A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPB41L4A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:25,680,169...25,890,998
Ensembl chr18:25,406,057...25,615,149
|
|
G |
Epha3 |
Eph receptor A3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPHA3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:14,585,041...14,920,721
Ensembl chr11:1,140,985...1,473,900
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression multiple interactions |
EXP |
Bucladesine results in increased expression of ESR1 mRNA [Quercetin co-treated with Bucladesine] results in increased expression of ESR1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of ESR1 mRNA] |
CTD |
PMID:21693180 PMID:23200735 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EYA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:9,646,599...9,884,609
Ensembl chr 5:4,955,543...5,101,483
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
multiple interactions |
ISO |
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]] |
CTD |
PMID:36565944 |
|
NCBI chr 4:77,624,223...77,698,598
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FADS2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression multiple interactions |
EXP |
Bucladesine results in increased expression of FAS mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of FAS mRNA] |
CTD |
PMID:12414803 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fbxo11 |
F-box protein 11 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXO11 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:12,240,348...12,316,223
Ensembl chr 6:6,486,015...6,562,662
|
|
G |
Fbxw5 |
F-box and WD repeat domain containing 5 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXW5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:28,720,670...28,725,237
Ensembl chr 3:8,322,543...8,327,092
|
|
G |
Fcer2 |
Fc epsilon receptor II |
decreases expression |
ISO |
Bucladesine results in decreased expression of FCER2 protein |
CTD |
PMID:1328389 |
|
NCBI chr12:6,540,697...6,552,364
Ensembl chr12:1,742,815...1,754,476
|
|
G |
Fgd1 |
FYVE, RhoGEF and PH domain containing 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FGD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:23,466,791...23,509,773
Ensembl chr X:20,023,746...20,066,566
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions |
ISO |
FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; FGF9 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone] |
CTD |
PMID:22798350 |
|
NCBI chr15:36,325,552...36,369,995
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Filip1l |
filamin A interacting protein 1-like |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FILIP1L mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:56,403,467...56,646,422
Ensembl chr11:42,940,467...43,177,415
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
[bisphenol A co-treated with Bucladesine] results in increased methylation of FKBP5 intron; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 protein; [Bucladesine co-treated with Dexamethasone] results in increased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 protein; [fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron; bisphenol A promotes the reaction [[fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron]; Dexamethasone inhibits the reaction [[Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA]; Estradiol inhibits the reaction [[Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA] |
CTD |
PMID:26427651 |
|
NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
affects expression multiple interactions increases expression |
ISO |
Bucladesine affects the expression of FOS protein Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein] Bucladesine results in increased expression of FOS mRNA; Bucladesine results in increased expression of FOS protein |
CTD |
PMID:7798212 PMID:9187264 PMID:19282384 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein] |
CTD |
PMID:20823114 PMID:36682589 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fscn2 |
fascin actin-bundling protein 2, retinal |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FSCN2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:106,121,038...106,139,683
Ensembl chr10:105,634,783...105,641,322
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions increases expression |
ISO |
IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC1 mRNA]; STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]] Bucladesine results in increased expression of G6PC1 mRNA; Bucladesine results in increased expression of G6PC1 protein |
CTD |
PMID:22859313 PMID:26064446 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gars1 |
glycyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GARS1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:85,484,939...85,542,876
Ensembl chr 4:84,171,596...84,212,609
|
|
G |
Gbe1 |
1,4-alpha-glucan branching enzyme 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GBE1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:22,181,194...22,446,640
Ensembl chr11:8,734,820...9,000,210
|
|
G |
Gbp2 |
guanylate binding protein 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GBP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GCNT2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:24,002,592...24,107,339
Ensembl chr17:23,796,859...23,901,611
|
|
G |
Gdf3 |
growth differentiation factor 3 |
affects expression multiple interactions |
ISO |
Bucladesine affects the expression of GDF3 mRNA; Bucladesine affects the expression of GDF3 protein bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 protein]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 protein] |
CTD |
PMID:31400064 |
|
NCBI chr 4:157,503,547...157,507,923
Ensembl chr 4:155,830,909...155,835,937
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
ISO |
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]] |
CTD |
PMID:36565944 |
|
NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GIPC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:41,380,125...41,392,078
Ensembl chr19:24,453,123...24,486,997
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases expression |
EXP |
GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein]; Tolbutamide promotes the reaction [Bucladesine results in increased expression of GJA1 protein] |
CTD |
PMID:11741589 PMID:16718685 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gpd1 |
glycerol-3-phosphate dehydrogenase 1 |
multiple interactions |
ISO |
Bucladesine promotes the reaction [Bezafibrate results in increased expression of GPD1 mRNA] |
CTD |
PMID:1976021 |
|
NCBI chr 7:132,722,982...132,730,373
Ensembl chr 7:130,844,138...130,851,529
|
|
G |
Gpkow |
G patch domain and KOW motifs |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GPKOW mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:17,463,521...17,478,298
Ensembl chr X:14,791,610...14,806,384
|
|
G |
Gpnmb |
glycoprotein nmb |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GPNMB mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:79,341,128...79,362,366
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions increases expression |
ISO |
KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA1 mRNA] |
CTD |
PMID:26049102 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of GSTA2 mRNA KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA2 mRNA] |
CTD |
PMID:26049102 |
|
NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of GSTA4 mRNA KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA4 mRNA] |
CTD |
PMID:26049102 |
|
NCBI chr 8:87,947,247...87,964,490
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Bucladesine results in increased expression of HIF1A mRNA |
CTD |
PMID:18591213 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions increases expression |
ISO |
[tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] inhibits the reaction [Bucladesine results in increased expression of HMGCR mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of HMGCR mRNA] |
CTD |
PMID:35987080 PMID:38603619 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hoxa1 |
homeobox A1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA] |
CTD |
PMID:20823114 |
|
NCBI chr 4:82,586,505...82,589,209
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
decreases expression multiple interactions |
ISO |
Bucladesine results in decreased expression of HSD17B1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in decreased expression of HSD17B1 mRNA] |
CTD |
PMID:35987080 |
|
NCBI chr10:86,510,011...86,512,211
Ensembl chr10:86,009,728...86,011,927
|
|
G |
Hsd17b12 |
hydroxysteroid (17-beta) dehydrogenase 12 |
increases expression |
EXP |
Bucladesine results in increased expression of HSD17B12 mRNA |
CTD |
PMID:21458522 |
|
NCBI chr 3:100,445,393...100,568,898
Ensembl chr 3:79,990,056...80,113,617
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression |
EXP |
Bucladesine results in increased expression of HSD3B1 mRNA |
CTD |
PMID:21458522 |
|
NCBI chr 2:188,858,574...188,864,694
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of HSD3B2 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of HSD3B2 mRNA] |
CTD |
PMID:35987080 |
|
NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression increases phosphorylation |
EXP ISO |
Bucladesine results in increased expression of HSP27 protein Bucladesine results in increased phosphorylation of HSPB1 protein |
CTD |
PMID:7541446 PMID:10559386 |
|
NCBI chr12:26,430,640...26,432,301
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of HTR1A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Iapp |
islet amyloid polypeptide |
increases expression |
EXP |
Bucladesine results in increased expression of IAPP mRNA |
CTD |
PMID:9142872 |
|
NCBI chr 4:176,968,097...176,975,363
Ensembl chr 4:175,237,115...175,242,920
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] |
CTD |
PMID:12538815 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of ID1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ID1 mRNA] |
CTD |
PMID:20522807 |
|
NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Ifrd2 |
interferon-related developmental regulator 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IFRD2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:117,139,612...117,144,834
Ensembl chr 8:108,260,969...108,266,194
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]; FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone] |
CTD |
PMID:22798350 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of IGFBP1 [Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein] |
CTD |
PMID:12093828 PMID:20823114 PMID:30328349 |
|
NCBI chr14:86,261,277...86,266,344
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:86,270,208...86,277,944
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:84,491,471...84,503,487
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Ighe |
immunoglobulin heavy constant epsilon |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]] |
CTD |
PMID:12230500 |
|
|
|
G |
Il10 |
interleukin 10 |
decreases expression multiple interactions |
ISO |
Bucladesine results in decreased expression of IL10 Bucladesine promotes the reaction [Zymosan results in increased expression of IL10 protein] |
CTD |
PMID:11301049 PMID:19273625 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IL12B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
decreases expression decreases secretion |
ISO |
Bucladesine results in decreased expression of IL13 mRNA Bucladesine results in decreased secretion of IL13 protein |
CTD |
PMID:16083514 |
|
NCBI chr10:38,290,926...38,293,483
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]; Dipyridamole promotes the reaction [Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]] |
CTD |
PMID:8904084 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of IL23A mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of IL23A mRNA |
CTD |
PMID:19273625 PMID:20823114 |
|
NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:721,809...723,923
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression |
ISO |
Bucladesine results in decreased expression of IL2RA protein |
CTD |
PMID:1709825 PMID:25433234 |
|
NCBI chr17:71,759,802...71,808,475
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL4 protein] |
CTD |
PMID:11886533 PMID:12230500 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL5 protein] |
CTD |
PMID:11886533 |
|
NCBI chr10:38,375,132...38,378,003
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Bucladesine co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:20388727 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
decreases expression multiple interactions |
EXP |
Bucladesine results in decreased expression of INHA mRNA [Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA; Atrazine inhibits the reaction [Bucladesine results in decreased expression of INHA mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA] |
CTD |
PMID:21693180 PMID:23200735 |
|
NCBI chr 9:84,443,109...84,446,010
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Insl3 |
insulin-like 3 |
multiple interactions increases expression |
EXP |
[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of INSL3 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA] |
CTD |
PMID:21458522 PMID:21693180 PMID:23200735 |
|
NCBI chr16:18,432,668...18,434,539
Ensembl chr16:18,384,829...18,400,560
|
|
G |
Ints7 |
integrator complex subunit 7 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of INTS7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:105,686,208...105,739,609
Ensembl chr13:103,155,090...103,208,592
|
|
G |
Irf9 |
interferon regulatory factor 9 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IRF9 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr15:33,065,422...33,071,881
Ensembl chr15:29,095,789...29,101,236
|
|
G |
Isg20l2 |
interferon stimulated exonuclease gene 20-like 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ISG20L2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:175,694,638...175,704,125
Ensembl chr 2:173,396,780...173,406,614
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITGB1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:73,602,277...73,650,271
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itih5 |
inter-alpha-trypsin inhibitor heavy chain 5 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITIH5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:73,161,886...73,261,930
Ensembl chr17:68,252,128...68,352,207
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of JUN mRNA; Bucladesine results in increased expression of JUN protein Bucladesine results in increased expression of JUN protein; Bucladesine results in increased expression of JUN protein modified form Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein modified form]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein] [Bucladesine co-treated with ciglitazone] results in increased expression of and results in increased phosphorylation of JUN protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of JUN mRNA]; Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein; ciglitazone promotes the reaction [Bucladesine results in increased expression of JUN mRNA]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein] |
CTD |
PMID:9187264 PMID:18755854 PMID:19282384 PMID:19698295 PMID:26049102 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kat2a |
lysine acetyltransferase 2A |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein] |
CTD |
PMID:18184656 |
|
NCBI chr10:86,132,535...86,140,877
Ensembl chr10:85,632,216...85,640,166
|
|
G |
Kcnc4 |
potassium voltage-gated channel subfamily C member 4 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KCNC4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:197,747,095...197,788,467
Ensembl chr 2:195,071,769...195,099,233
|
|
G |
Kng1 |
kininogen 1 |
increases activity |
EXP |
Bucladesine results in increased activity of KNG1 |
CTD |
PMID:1334751 |
|
NCBI chr11:91,317,354...91,340,148
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Krt8 |
keratin 8 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA] |
CTD |
PMID:20823114 |
|
NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Lamb2 |
laminin subunit beta 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LAMB2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:118,056,899...118,069,090
Ensembl chr 8:109,178,409...109,190,549
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LDHA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
Bucladesine results in decreased expression of LEP mRNA |
CTD |
PMID:9002984 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lgals3 |
galectin 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of LGALS3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr15:23,099,795...23,111,731
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
decreases expression multiple interactions |
EXP |
Bucladesine results in decreased expression of LHCGR mRNA [Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA] |
CTD |
PMID:21693180 PMID:23200735 |
|
NCBI chr 6:11,415,361...11,480,834
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Lipe |
lipase E, hormone sensitive type |
affects localization increases activity increases expression multiple interactions |
EXP ISO |
Bucladesine affects the localization of LIPE protein Bucladesine results in increased activity of LIPE protein Bucladesine results in increased expression of LIPE mRNA [Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein; CAY 10499 inhibits the reaction [Bucladesine results in increased activity of and results in increased phosphorylation of LIPE protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of LIPE mRNA]; NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]; NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] |
CTD |
PMID:11160373 PMID:23362264 |
|
NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
LOC120095955 |
mucin-12-like |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MUC12 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:25,127,100...25,137,925
|
|
G |
Lpar3 |
lysophosphatidic acid receptor 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LPAR3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:237,785,371...237,854,199
Ensembl chr 2:235,149,065...235,193,357
|
|
G |
Ltbp1 |
latent transforming growth factor beta binding protein 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LTBP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:25,781,625...26,177,346
Ensembl chr 6:20,029,629...20,425,349
|
|
G |
Ltc4s |
leukotriene C4 synthase |
decreases secretion |
ISO |
Bucladesine results in decreased secretion of LTC4S protein |
CTD |
PMID:16083514 |
|
NCBI chr10:35,060,002...35,066,466
Ensembl chr10:34,560,360...34,562,651
|
|
G |
Map1a |
microtubule-associated protein 1A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MAP1A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:128,716,907...128,736,638
Ensembl chr 3:108,263,151...108,282,899
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Map4k4 |
mitogen-activated protein kinase kinase kinase kinase 4 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MAP4K4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:49,696,573...49,822,353
Ensembl chr 9:42,200,278...42,326,698
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein Bucladesine results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK1 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein]] |
CTD |
PMID:8526880 PMID:19282384 PMID:22875961 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein Bucladesine results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK3 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein]] |
CTD |
PMID:8526880 PMID:19282384 PMID:22875961 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgat4b |
alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MGAT4B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:35,049,421...35,060,307
Ensembl chr10:34,549,433...34,559,229
|
|
G |
Mir125a |
microRNA 125a |
decreases expression |
EXP ISO |
Bucladesine results in decreased expression of MIR125A mRNA |
CTD |
PMID:23045399 |
|
NCBI chr 1:67,350,675...67,350,759
Ensembl chr 1:58,677,626...58,677,710
|
|
G |
Mir145 |
microRNA 145 |
decreases expression |
EXP ISO |
Bucladesine results in decreased expression of MIR145 mRNA |
CTD |
PMID:23045399 |
|
NCBI chr18:57,369,983...57,370,070
Ensembl chr18:55,099,640...55,099,727
|
|
G |
Mir27b |
microRNA 27b |
multiple interactions |
ISO |
[Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MIR27B mRNA |
CTD |
PMID:30328349 |
|
NCBI chr17:1,819,147...1,819,243
Ensembl chr17:1,813,426...1,813,529
|
|
G |
Mir455 |
microRNA 455 |
decreases expression |
EXP ISO |
Bucladesine results in decreased expression of MIR455 mRNA |
CTD |
PMID:23045399 |
|
NCBI chr 5:81,704,834...81,704,911
Ensembl chr 5:76,689,313...76,689,390
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
Bucladesine results in decreased expression of MKI67 protein |
CTD |
PMID:16718685 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MMP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:117,368,833...117,380,350
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTR mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:62,911,705...62,996,544
Ensembl chr17:58,220,071...58,304,822
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Bucladesine results in decreased expression of MYC mRNA; Bucladesine results in decreased expression of MYC protein |
CTD |
PMID:7798212 PMID:9187264 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh9 |
myosin, heavy chain 9 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYH9 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:111,224,291...111,304,963
Ensembl chr 7:109,343,706...109,424,457
|
|
G |
Myl12a |
myosin light chain 12A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:118,338,592...118,346,277
Ensembl chr 9:110,873,959...110,916,580
|
|
G |
Myl12b |
myosin light chain 12B |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:118,320,479...118,334,810
|
|
G |
Mylk |
myosin light chain kinase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:79,288,243...79,535,450
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Myof |
myoferlin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYOF mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:245,086,109...245,234,768
Ensembl chr 1:235,673,666...235,822,334
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NCF1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:28,121,816...28,131,080
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ndst1 |
N-deacetylase and N-sulfotransferase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NDST1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:56,407,308...56,470,007
Ensembl chr18:54,140,779...54,178,191
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA |
CTD |
PMID:29698629 |
|
NCBI chr15:46,477,330...46,481,203
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nefm |
neurofilament medium chain |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:29698629 |
|
NCBI chr15:46,535,857...46,541,161
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Neurog1 |
neurogenin 1 |
multiple interactions affects expression |
ISO |
bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 protein] Bucladesine affects the expression of NEUROG1 mRNA; Bucladesine affects the expression of NEUROG1 protein |
CTD |
PMID:31400064 |
|
NCBI chr17:8,368,096...8,369,615
Ensembl chr17:8,362,821...8,364,571
|
|
G |
Nexn |
nexilin (F actin binding protein) |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NEXN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:243,846,736...243,878,268
Ensembl chr 2:241,186,790...241,218,342
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases response to substance |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of CYP2A5 mRNA]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC1 mRNA] |
CTD |
PMID:22859313 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA |
CTD |
PMID:29698629 |
|
NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nom1 |
nucleolar protein with MIF4G domain 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NOM1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:6,562,931...6,586,093
Ensembl chr 4:5,892,909...5,909,709
|
|
G |
Nphp1 |
nephrocystin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NPHP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:135,413,927...135,469,505
Ensembl chr 3:114,960,650...115,016,234
|
|
G |
Nptxr |
neuronal pentraxin receptor |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NPTXR mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:113,217,046...113,235,122
Ensembl chr 7:111,336,664...111,354,802
|
|
G |
Npy |
neuropeptide Y |
increases expression |
EXP |
Bucladesine results in increased expression of NPY mRNA |
CTD |
PMID:19912776 |
|
NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression multiple interactions |
ISO |
Bucladesine results in decreased expression of NR0B1 mRNA; Bucladesine results in decreased expression of NR0B1 protein Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 protein]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]] |
CTD |
PMID:18787026 PMID:19282384 |
|
NCBI chr X:54,707,658...54,711,786
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] |
CTD |
PMID:23362264 |
|
NCBI chr 1:104,178,483...104,183,863
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] |
CTD |
PMID:23362264 |
|
NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NR2F1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:9,776,179...9,785,924
Ensembl chr 2:8,040,377...8,050,123
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions increases expression |
ISO |
NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of NR4A1 protein] [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]] |
CTD |
PMID:18787026 PMID:19282384 PMID:36565944 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions increases expression |
ISO |
Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of NR5A1 mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of NR5A1 protein] Bucladesine results in increased expression of NR5A1 mRNA; Bucladesine results in increased expression of NR5A1 protein NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA] |
CTD |
PMID:18184656 PMID:18787026 PMID:35987080 |
|
NCBI chr 3:42,874,505...42,896,109
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NRIP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:28,382,835...28,466,483
Ensembl chr11:14,895,553...14,981,761
|
|
G |
Nt5e |
5' nucleotidase, ecto |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NT5E mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Ntf3 |
neurotrophin 3 |
increases expression |
EXP |
Bucladesine results in increased expression of NTF3 protein |
CTD |
PMID:19854260 |
|
NCBI chr 4:160,601,161...160,670,623
Ensembl chr 4:158,914,957...158,984,596
|
|
G |
Nts |
neurotensin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NTS mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:39,451,484...39,460,888
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Nup155 |
nucleoporin 155 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NUP155 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:58,927,171...58,980,162
Ensembl chr 2:57,201,272...57,254,148
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions decreases activity |
ISO |
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [Bucladesine results in decreased activity of ODC1 protein] |
CTD |
PMID:6284819 |
|
NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Ogfrl1 |
opioid growth factor receptor-like 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OGFRL1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:33,320,501...33,338,742
Ensembl chr 9:25,828,869...25,842,352
|
|
G |
Or8b8 |
olfactory receptor family 8 subfamily B member 8 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OR8B8 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:45,882,321...45,883,253
Ensembl chr 8:37,693,499...37,694,547
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of P4HB mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:106,335,300...106,346,911
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Paep |
progestagen associated endometrial protein |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PAEP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:28,929,252...28,932,592
Ensembl chr 3:8,531,138...8,534,430
|
|
G |
Pakap |
paralemmin A kinase anchor protein |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PALM2AKAP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:76,976,906...77,443,656
Ensembl chr 5:72,181,718...72,648,524
|
|
G |
Pax6 |
paired box 6 |
multiple interactions affects expression |
ISO |
bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 protein]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 protein] Bucladesine affects the expression of PAX6 mRNA; Bucladesine affects the expression of PAX6 protein |
CTD |
PMID:31400064 |
|
NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:92,135,637...92,157,014
|
|
G |
Pcdh18 |
protocadherin 18 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDH18 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:135,982,929...135,996,917
Ensembl chr 2:133,832,001...133,845,883
|
|
G |
Pcdhb5 |
protocadherin beta 5 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDHB4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:29,302,466...29,305,048
Ensembl chr18:29,028,382...29,053,259
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions increases expression |
ISO EXP |
Metformin inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA] Lithium Chloride inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA] |
CTD |
PMID:1371108 PMID:24428821 |
|
NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
decreases expression |
ISO |
Bucladesine results in decreased expression of PDGFA mRNA |
CTD |
PMID:1650039 |
|
NCBI chr12:20,759,366...20,780,337
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PDK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pf4 |
platelet factor 4 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PF4 mRNA [Bucladesine co-treated with Tetrachlorodibenzodioxin] results in increased expression of PF4 mRNA |
CTD |
PMID:21979172 |
|
NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Pgrmc2 |
progesterone receptor membrane component 2 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PGRMC2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:125,996,190...126,012,090
Ensembl chr 2:124,068,260...124,084,155
|
|
G |
Pitpnc1 |
phosphatidylinositol transfer protein, cytoplasmic 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PITPNC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:92,663,260...92,928,616
Ensembl chr10:92,167,196...92,429,297
|
|
G |
Pkd2l1 |
polycystin 2 like 1, transient receptor potential cation channel |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PKD2L1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:252,982,096...253,019,235
Ensembl chr 1:243,032,913...243,070,031
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLAT mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:75,943,061...76,022,037
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plekhg3 |
pleckstrin homology and RhoGEF domain containing G3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLEKHG3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:100,998,965...101,042,120
Ensembl chr 6:95,266,058...95,310,359
|
|
G |
Plin1 |
perilipin 1 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PLIN1 mRNA LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA] |
CTD |
PMID:23362264 |
|
NCBI chr 1:143,073,612...143,086,199
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Pls3 |
plastin 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PLS3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:116,401,247...116,495,898
Ensembl chr X:111,589,254...111,683,891
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
multiple interactions increases activity |
ISO |
Ascorbic Acid inhibits the reaction [Bucladesine results in increased activity of PMP22 promoter] |
CTD |
PMID:15034573 |
|
NCBI chr10:48,294,932...48,324,941
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PNPLA6 mRNA Bucladesine results in increased expression of and results in increased activity of PNPLA6 protein; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein] |
CTD |
PMID:20380879 |
|
NCBI chr12:6,372,284...6,401,632
Ensembl chr12:1,560,363...1,603,734
|
|
G |
Pomc |
proopiomelanocortin |
increases expression |
ISO |
Bucladesine results in increased expression of POMC mRNA; Bucladesine results in increased expression of POMC protein modified form |
CTD |
PMID:1325994 |
|
NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
affects expression multiple interactions |
ISO |
Bucladesine affects the expression of POU5F1 mRNA; Bucladesine affects the expression of POU5F1 protein bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 protein] |
CTD |
PMID:31400064 |
|
NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PPARG protein [ciglitazone co-treated with Bucladesine] affects the expression of PPARG mRNA; [ciglitazone co-treated with Bucladesine] results in increased expression of PPARG protein |
CTD |
PMID:19698295 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO |
Bucladesine results in increased expression of PPARGC1A mRNA; Bucladesine results in increased expression of PPARGC1A protein IL22 protein inhibits the reaction [Bucladesine results in increased expression of PPARGC1A protein]; Metformin inhibits the reaction [Bucladesine results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:24428821 PMID:26064446 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppia |
peptidylprolyl isomerase A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PPIA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:85,491,223...85,496,884
Ensembl chr14:81,275,091...81,299,601
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
increases expression |
EXP |
Bucladesine results in increased expression of PRIMA1 mRNA |
CTD |
PMID:18514641 |
|
NCBI chr 6:128,094,686...128,155,592
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions increases activity |
EXP |
KT 5720 inhibits the reaction [Bucladesine results in increased activity of PRKACA protein] |
CTD |
PMID:31300867 |
|
NCBI chr19:41,059,843...41,083,189
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
[Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL protein; [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]; Losartan inhibits the reaction [AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]] |
CTD |
PMID:20823114 PMID:30328349 PMID:36682589 |
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prss12 |
serine protease 12 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PRSS12 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:214,308,695...214,368,679
Ensembl chr 2:211,624,134...211,684,126
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 protein]]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:11095985 PMID:12164941 PMID:24003391 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk7 |
protein tyrosine kinase 7 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTK7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:21,849,756...21,916,077
Ensembl chr 9:14,351,202...14,418,494
|
|
G |
Ptpa |
protein phosphatase 2 phosphatase activator |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTPA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:34,087,637...34,118,100
Ensembl chr 3:13,689,741...13,722,549
|
|
G |
Rab1b |
RAB1B, member RAS oncogene family |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB1B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:211,835,133...211,843,408
Ensembl chr 1:202,405,759...202,413,868 Ensembl chr X:202,405,759...202,413,868
|
|
G |
Rab31 |
RAB31, member RAS oncogene family |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB31 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:112,693,596...112,828,104
Ensembl chr 9:105,246,709...105,381,253
|
|
G |
Ran |
RAN, member RAS oncogene family |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RAN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:33,311,155...33,314,339
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases activity decreases phosphorylation multiple interactions |
ISO EXP |
Bucladesine results in decreased activity of RB1 protein Bucladesine results in decreased phosphorylation of RB1 protein Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein] |
CTD |
PMID:10697531 PMID:16718685 |
|
NCBI chr15:54,780,858...54,911,989
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Ren |
renin |
increases secretion increases expression |
ISO |
Bucladesine results in increased secretion of REN protein Bucladesine results in increased expression of REN mRNA |
CTD |
PMID:9256163 |
|
NCBI chr13:47,348,312...47,359,539
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Ret |
ret proto-oncogene |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RET mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:151,326,431...151,368,176
|
|
G |
Rgs10 |
regulator of G-protein signaling 10 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RGS10 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:192,376,772...192,422,640
Ensembl chr 1:182,946,336...182,987,697
|
|
G |
Rhobtb3 |
Rho-related BTB domain containing 3 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RHOBTB3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:7,094,972...7,201,507
Ensembl chr 2:5,363,388...5,419,041
|
|
G |
Rin1 |
Ras and Rab interactor 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RIN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:211,785,107...211,789,755
Ensembl chr 1:202,355,890...202,362,729
|
|
G |
Rpn1 |
ribophorin I |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:122,100,976...122,122,382
Ensembl chr 4:120,543,667...120,565,069
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPS6KB1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rpsa |
ribosomal protein SA |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RPSA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:128,728,761...128,732,736
Ensembl chr 8:119,851,225...119,855,247
|
|
G |
S100a14 |
S100 calcium binding protein A14 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of S100A14 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:178,305,976...178,308,004
Ensembl chr 2:176,008,395...176,010,423
|
|
G |
Saraf |
store-operated calcium entry-associated regulatory factor |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SARAF mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:64,720,404...64,738,653
Ensembl chr16:58,017,231...58,035,545
|
|
G |
Scamp4 |
secretory carrier membrane protein 4 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SCAMP4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:9,752,193...9,764,614
Ensembl chr 7:9,101,489...9,113,967
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions increases expression |
ISO EXP |
LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA] |
CTD |
PMID:23045399 PMID:23362264 |
|
NCBI chr12:36,957,302...37,023,982
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Sdcbp |
syndecan binding protein |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SDCBP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:24,245,279...24,314,712
Ensembl chr 5:19,489,961...19,527,572
|
|
G |
Selenot |
selenoprotein T |
multiple interactions increases expression |
EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA]; nickel chloride inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA] |
CTD |
PMID:18198219 |
|
NCBI chr 2:144,954,324...144,971,375
Ensembl chr 2:142,804,405...142,821,427
|
|
G |
Sema3a |
semaphorin 3A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SEMA3A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:22,239,418...22,709,907
Ensembl chr 4:21,287,982...21,494,432
|
|
G |
Septin11 |
septin 11 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SEPTIN11 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:15,119,760...15,275,222
Ensembl chr14:14,844,580...14,990,853
|
|
G |
Sfn |
stratifin |
multiple interactions |
ISO |
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of SFN mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein |
CTD |
PMID:22534328 |
|
NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Sik3 |
SIK family kinase 3 |
multiple interactions increases phosphorylation |
ISO |
yakuchinone-A inhibits the reaction [Bucladesine results in increased phosphorylation of SIK3 protein] |
CTD |
PMID:38164184 |
|
NCBI chr 8:55,208,969...55,419,138
Ensembl chr 8:46,311,989...46,522,444
|
|
G |
Slc18a3 |
solute carrier family 18 member A3 |
increases expression multiple interactions |
EXP |
Bucladesine results in increased expression of SLC18A3 protein Nicotine promotes the reaction [Bucladesine results in increased expression of SLC18A3 protein] |
CTD |
PMID:20361958 |
|
NCBI chr16:7,719,953...7,722,814
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
[Progesterone co-treated with Bucladesine] results in increased expression of SLC2A1 protein |
CTD |
PMID:18948400 |
|
NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions |
ISO |
Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA] |
CTD |
PMID:12820898 |
|
NCBI chr 5:165,857,412...165,892,928
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Smad6 |
SMAD family member 6 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA] |
CTD |
PMID:20522807 |
|
NCBI chr 8:73,345,457...73,414,985
Ensembl chr 8:64,450,114...64,519,763
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression increases activity |
ISO |
Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of SOD2 mRNA]; protein kinase inhibitor peptide inhibits the reaction [Bucladesine results in increased activity of SOD2 protein] |
CTD |
PMID:12093828 PMID:20685861 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox1 |
SRY-box transcription factor 1 |
multiple interactions affects expression |
ISO |
bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 protein] Bucladesine affects the expression of SOX1 mRNA; Bucladesine affects the expression of SOX1 protein |
CTD |
PMID:31400064 |
|
NCBI chr16:83,837,689...83,841,703
Ensembl chr16:77,137,584...77,138,762
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions increases expression |
ISO |
Organophosphates inhibits the reaction [Bucladesine results in increased expression of SREBF2 mRNA] |
CTD |
PMID:38603619 |
|
NCBI chr 7:115,542,774...115,600,945
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Srsf7 |
serine and arginine rich splicing factor 7 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SRSF7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:20,564,035...20,571,205
Ensembl chr 6:14,811,808...14,818,965
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression decreases expression |
ISO EXP |
27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [[T0901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] which results in increased abundance of Progesterone; [Bucladesine co-treated with ciglitazone] results in increased expression of STAR mRNA; [Bucladesine co-treated with ciglitazone] results in increased phosphorylation of STAR protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone; [Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; [T0901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR protein]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [T0901317 results in increased expression of STAR mRNA]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [LG 100268 results in increased expression of STAR mRNA]]; Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA; Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein; CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR protein]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; lead acetate inhibits the reaction [Bucladesine results in increased expression of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Tetradecanoylphorbol Acetate promotes the reaction [[Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] [IMOL S-140 co-treated with triphenyl phosphate co-treated with tris(chloroethyl)phosphate co-treated with diphenylcresyl phosphate co-treated with tert-butylphenyl diphenyl phosphate co-treated with tri-xylenyl phosphate] inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; [tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Organophosphates inhibits the reaction [Bucladesine results in increased expression of STAR mRNA] Bucladesine results in increased expression of STAR mRNA; Bucladesine results in increased expression of STAR protein Bucladesine results in decreased expression of STAR mRNA [Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA] |
CTD |
PMID:10964798 PMID:10993823 PMID:11213355 PMID:18755854 PMID:18787026 PMID:19253104 PMID:19282384 PMID:19698295 PMID:20083572 PMID:21047949 PMID:21693180 PMID:21979172 PMID:23200735 PMID:23362264 PMID:35987080 PMID:38603619 More...
|
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]] |
CTD |
PMID:26064446 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stk38 |
serine/threonine kinase 38 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of STK38 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:7,035,923...7,070,657
Ensembl chr20:7,034,242...7,068,198
|
|
G |
Sulf1 |
sulfatase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SULF1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:11,145,950...11,308,622
Ensembl chr 5:6,362,911...6,525,584
|
|
G |
Tagln |
transgelin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TAGLN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:55,121,647...55,127,121
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tcea1 |
transcription elongation factor A1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TCEA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:19,414,351...19,466,629
Ensembl chr 5:14,631,454...14,668,745 Ensembl chr15:14,631,454...14,668,745
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TERT mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Testin |
testin gene |
decreases expression multiple interactions |
EXP |
Bucladesine results in decreased expression of TESTIN mRNA Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA]; lonidamine inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA] |
CTD |
PMID:11090432 |
|
NCBI chr17:3,829,012...3,864,995
Ensembl chr17:3,846,899...3,859,385
|
|
G |
Tfrc |
transferrin receptor |
decreases expression |
ISO |
Bucladesine results in decreased expression of TFRC protein |
CTD |
PMID:2989362 |
|
NCBI chr11:81,668,478...81,690,318
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfa |
transforming growth factor alpha |
decreases expression |
EXP |
Bucladesine results in decreased expression of TGFA mRNA |
CTD |
PMID:11843059 |
|
NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] |
CTD |
PMID:11576339 PMID:16430859 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
[O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein; [phenylsaligenin cyclic phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein |
CTD |
PMID:32749514 |
|
NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
EXP |
Bucladesine results in increased expression of TH mRNA |
CTD |
PMID:19912776 |
|
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
EXP |
Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of TJP1 protein] |
CTD |
PMID:16716901 |
|
NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnc |
tenascin C |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TNC mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Bucladesine inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Bucladesine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] Bucladesine inhibits the reaction [Zymosan results in increased expression of TNF protein] |
CTD |
PMID:11301049 PMID:12509806 PMID:12538815 PMID:15081246 PMID:20388727 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of TP53 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of TP53 protein |
CTD |
PMID:22534328 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TPI1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:159,301,558...159,305,088
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Tpsg1 |
tryptase gamma 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TPSG1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:14,889,838...14,895,605
Ensembl chr10:14,386,352...14,390,258
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TXN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Ube2d2b |
ubiquitin-conjugating enzyme E2D 2B |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of UBE2D4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:2,060,926...2,062,400
Ensembl chr14:1,916,845...1,917,416
|
|
G |
Ucp1 |
uncoupling protein 1 |
increases expression multiple interactions |
EXP |
Bucladesine results in increased expression of UCP1 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of UCP1 mRNA] |
CTD |
PMID:12414803 |
|
NCBI chr19:41,713,350...41,721,421
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ugcg |
UDP-glucose ceramide glucosyltransferase |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of UGCG mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:78,828,006...78,860,725
Ensembl chr 5:74,032,978...74,065,393
|
|
G |
Usp12 |
ubiquitin specific peptidase 12 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of USP12 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:13,423,625...13,477,547
Ensembl chr12:8,309,750...8,363,656
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
Bucladesine results in increased expression of VEGFA mRNA |
CTD |
PMID:18591213 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
[Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein |
CTD |
PMID:20823114 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vps39 |
VPS39 subunit of HOPS complex |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VPS39 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:127,721,076...127,758,658
Ensembl chr 3:107,267,310...107,304,975
|
|
G |
Wnt5a |
Wnt family member 5A |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WNT5A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,697,032...3,718,234
|
|
G |
Wwtr1 |
WW domain containing transcription regulator 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WWTR1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:143,801,181...143,916,941
Ensembl chr 2:141,648,108...141,766,968
|
|
G |
Zbtb45 |
zinc finger and BTB domain containing 45 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZBTB45 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:82,707,633...82,712,926
Ensembl chr 1:73,635,448...73,639,556
|
|
G |
Zscan10 |
zinc finger and SCAN domain containing 10 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN10 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:13,140,929...13,150,897
Ensembl chr10:12,636,302...12,646,275
|
|
G |
Zscan20 |
zinc finger and SCAN domain containing 20 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN20 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:146,214,023...146,240,678
Ensembl chr 5:140,930,689...140,956,336
|
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects binding |
ISO |
butyryl-coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,562,288...6,667,064
|
|
|
G |
Tdrd7 |
tudor domain containing 7 |
increases expression |
ISO |
bis(3',5')-cyclic diguanylic acid results in increased expression of TDRD7 mRNA |
CTD |
PMID:32273341 |
|
NCBI chr 5:65,034,317...65,108,165
Ensembl chr 5:60,238,678...60,312,544
|
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
cangrelor results in decreased expression of and results in decreased activity of F3 protein; Indomethacin promotes the reaction [cangrelor results in decreased expression of and results in decreased activity of F3 protein] |
CTD |
PMID:20200314 |
|
NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Uridine Diphosphate results in increased activity of GPR17 protein] |
CTD |
PMID:18974869 |
|
NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Itga2b |
integrin subunit alpha 2b |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr10:87,908,697...87,926,225
Ensembl chr10:87,408,536...87,426,168
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr10:90,009,927...90,067,787
Ensembl chr10:89,509,989...89,564,679
|
|
G |
P2ry12 |
purinergic receptor P2Y12 |
multiple interactions affects response to substance decreases activity |
ISO |
[cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased abundance of phosphatidylinositol 3,4,5-triphosphate; [cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein P2RY12 gene polymorphism affects the susceptibility to cangrelor cangrelor results in decreased activity of P2RY12 protein |
CTD |
PMID:12606772 PMID:20126830 PMID:22273509 |
|
NCBI chr 2:145,631,487...145,673,194
Ensembl chr 2:143,481,430...143,523,361
|
|
G |
Pf4 |
platelet factor 4 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased secretion of PF4 protein] |
CTD |
PMID:22273509 |
|
NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Selp |
selectin P |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]] |
CTD |
PMID:18404433 |
|
NCBI chr13:79,009,379...79,044,994
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Syk |
spleen associated tyrosine kinase |
multiple interactions |
ISO |
[cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein |
CTD |
PMID:12606772 |
|
NCBI chr17:12,756,493...12,830,927
Ensembl chr17:12,604,619...12,661,410
|
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
Cytidine Diphosphate Choline results in decreased expression of CASP3 protein |
CTD |
PMID:12443983 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
EXP |
Cytidine Diphosphate Choline results in decreased expression of ICAM1 mRNA |
CTD |
PMID:16193989 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
multiple interactions |
ISO |
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18164358 |
|
NCBI chr 2:112,003,677...112,064,274
Ensembl chr 2:110,074,957...110,135,588
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases expression |
ISO |
Cytidine Diphosphate Choline results in decreased expression of PARP1 protein modified form |
CTD |
PMID:12443983 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression multiple interactions |
EXP |
Cytidine Diphosphate Choline results in increased expression of SIRT1 protein Cytidine Diphosphate Choline results in increased expression of and results in increased activity of SIRT1 protein |
CTD |
PMID:23600725 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
|
G |
Pon1 |
paraoxonase 1 |
decreases activity |
ISO |
clindamycin phosphate results in decreased activity of PON1 protein |
CTD |
PMID:16880604 |
|
NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:33,294,722...33,321,360
|
|
|
G |
Cmas |
cytidine monophosphate N-acetylneuraminic acid synthetase |
affects abundance |
ISO |
CMAS protein affects the abundance of Cytidine Monophosphate N-Acetylneuraminic Acid |
CTD |
PMID:27380425 |
|
NCBI chr 4:177,449,801...177,468,117
Ensembl chr 4:175,718,808...175,737,125
|
|
|
G |
Acot8 |
acyl-CoA thioesterase 8 |
affects hydrolysis |
ISO |
ACOT8 protein affects the hydrolysis of Coenzyme A analog |
CTD |
PMID:16141203 |
|
NCBI chr 3:173,950,530...173,962,188
Ensembl chr 3:153,531,193...153,542,851
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects binding |
ISO |
Coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,562,288...6,667,064
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Cytidine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
App |
amyloid beta precursor protein |
increases secretion |
ISO |
Cytidine Triphosphate results in increased secretion of APP protein modified form |
CTD |
PMID:22906069 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
P2rx1 |
purinergic receptor P2X 1 |
affects binding |
EXP |
CTP binds to P2rx1 protein |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:58,117,107...58,132,167
Ensembl chr10:57,618,586...57,633,623
|
|
G |
P2rx5 |
purinergic receptor P2X 5 |
affects transport |
EXP |
CTP affects transport ion flux of P2rx5 receptor |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:58,276,329...58,291,108
Ensembl chr10:57,777,819...57,789,423
|
|
|
G |
Cd38 |
CD38 molecule |
decreases abundance |
ISO |
CD38 gene mutant form results in decreased abundance of Cyclic ADP-Ribose |
CTD |
PMID:23343681 |
|
NCBI chr14:71,384,532...71,424,794
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Homer1 |
homer scaffold protein 1 |
multiple interactions |
EXP |
HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]] |
CTD |
PMID:12887973 |
|
NCBI chr 2:26,279,012...26,388,279
Ensembl chr 2:24,543,093...24,644,785
|
|
G |
Ryr2 |
ryanodine receptor 2 |
multiple interactions |
EXP |
HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]] |
CTD |
PMID:12887973 |
|
NCBI chr17:63,081,527...63,667,141
Ensembl chr17:58,389,925...58,975,142
|
|
|
G |
Cdipt |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
multiple interactions |
ISO |
[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate |
CTD |
PMID:2579070 |
|
NCBI chr 1:191,013,632...191,017,943
Ensembl chr 1:181,583,141...181,587,408
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of erythrose 4-phosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
multiple interactions |
ISO |
cylindrospermopsin results in increased expression of [ALDOA protein binds to fructose-1,6-diphosphate] |
CTD |
PMID:27494769 |
|
NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions decreases abundance |
ISO |
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
fructose-1,6-diphosphate results in increased expression of BAX protein |
CTD |
PMID:33078453 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
EXP |
[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr16:74,133,259...74,145,328
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:22227475 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:22227475 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions decreases abundance |
ISO |
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate] MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases degradation |
ISO |
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] fructose-1,6-diphosphate results in decreased degradation of NOS2 mRNA |
CTD |
PMID:22227475 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
fructose-1,6-diphosphate results in increased expression of TP53 protein |
CTD |
PMID:33078453 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Galk1 |
galactokinase 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors binds to and results in decreased activity of GALK1 protein] which results in decreased abundance of galactose-1-phosphate; [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate |
CTD |
PMID:20696150 |
|
NCBI chr10:101,742,067...101,746,244
Ensembl chr10:101,235,994...101,247,337
|
|
|
G |
App |
amyloid beta precursor protein |
decreases abundance multiple interactions |
ISO |
APP protein mutant form results in decreased abundance of Glucose-6-Phosphate PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Glucose-6-Phosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate] |
CTD |
PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors results in decreased activity of FBP1 protein] which results in decreased abundance of Glucose-6-Phosphate |
CTD |
PMID:31974165 |
|
NCBI chr17:2,212,941...2,235,749
Ensembl chr17:2,208,031...2,230,071
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Fluoxetine results in decreased expression of G6PC1 protein] which results in increased abundance of Glucose-6-Phosphate |
CTD |
PMID:33179799 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pc2 |
glucose-6-phosphatase catalytic subunit 2 |
increases hydrolysis |
ISO |
G6PC2 protein results in increased hydrolysis of Glucose-6-Phosphate |
CTD |
PMID:14722102 |
|
NCBI chr 3:53,999,821...54,005,539
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
multiple interactions |
ISO |
GPD2 protein inhibits the reaction [Dihydroxyacetone results in increased abundance of Glucose-6-Phosphate]; GPD2 protein inhibits the reaction [Glucose results in increased abundance of Glucose-6-Phosphate]; GPD2 protein inhibits the reaction [Glycerol results in increased abundance of Glucose-6-Phosphate] |
CTD |
PMID:31974165 |
|
NCBI chr 3:62,209,432...62,346,590
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate] |
CTD |
PMID:39172838 |
|
NCBI chr16:74,133,259...74,145,328
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions decreases abundance |
ISO |
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Glucose-6-Phosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Glucose-6-Phosphate] MAPT protein mutant form results in decreased abundance of Glucose-6-Phosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Glucose-6-Phosphate] |
CTD |
PMID:39172838 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA |
CTD |
PMID:20505214 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Pfkfb1 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 |
increases abundance multiple interactions |
ISO |
PFKFB1 gene mutant form results in increased abundance of Glucose-6-Phosphate PFKFB1 gene mutant form inhibits the reaction [Metformin results in decreased abundance of Glucose-6-Phosphate metabolite] |
CTD |
PMID:31974165 |
|
NCBI chr X:22,936,038...22,989,691
Ensembl chr X:19,508,546...19,562,182
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to Metformin] which results in increased abundance of Glucose-6-Phosphate |
CTD |
PMID:31974165 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions |
ISO |
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to Metformin] which results in increased abundance of Glucose-6-Phosphate |
CTD |
PMID:31974165 |
|
NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate] |
CTD |
PMID:39172838 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:103,323,120...103,371,650
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
mannose-6-phosphate affects the reaction [GUSB protein affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]] |
CTD |
PMID:26438400 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
ISO |
mannose-6-phosphate affects the reaction [GUSB protein affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]] |
CTD |
PMID:26438400 |
|
NCBI chr12:32,337,281...32,350,838
Ensembl chr12:26,697,951...26,726,905
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
mannose-6-phosphate affects the reaction [GUSB protein affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]] |
CTD |
PMID:26438400 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
ISO |
mannose-6-phosphate affects the reaction [GUSB protein affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]] |
CTD |
PMID:26438400 |
|
NCBI chr12:32,337,281...32,350,838
Ensembl chr12:26,697,951...26,726,905
|
|
|
G |
Taldo1 |
transaldolase 1 |
increases abundance |
ISO |
TALDO1 gene mutant form results in increased abundance of ribose-5-phosphate |
CTD |
PMID:19436114 |
|
NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:196,493,589...196,503,974
|
|
|
G |
Taldo1 |
transaldolase 1 |
increases abundance |
ISO |
TALDO1 gene mutant form results in increased abundance of xylulose-5-phosphate |
CTD |
PMID:19436114 |
|
NCBI chr 1:205,923,196...205,933,526
Ensembl chr 1:196,493,589...196,503,974
|
|
|
G |
Dck |
deoxycytidine kinase |
increases metabolic processing affects activity |
ISO |
DCK protein results in increased metabolism of 2'-deoxycytidine 5'-triphosphate 2'-deoxycytidine 5'-triphosphate affects the activity of DCK protein |
CTD |
PMID:9586059 |
|
NCBI chr14:19,589,298...19,610,326
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Polk |
DNA polymerase kappa |
multiple interactions affects binding |
ISO |
2'-deoxycytidine 5'-triphosphate promotes the reaction [N(2)-furfuryl-deoxyguanosine results in increased stability of POLK protein]; N-(2'-deoxyguanosin-8-yl)-3-aminobenzanthrone inhibits the reaction [POLK protein binds to 2'-deoxycytidine 5'-triphosphate] |
CTD |
PMID:28823149 PMID:31286773 |
|
NCBI chr 2:29,556,831...29,616,960
Ensembl chr 2:27,822,679...27,882,313
|
|
|
G |
Hsdl2 |
hydroxysteroid dehydrogenase like 2 |
multiple interactions |
ISO |
[decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:74,443,872...74,479,839
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
multiple interactions |
ISO |
[decanoyl-coenzyme A co-treated with NADP] binds to PECR protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:73,897,880...73,926,511
|
|
|
G |
Samhd1 |
SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 |
decreases abundance |
ISO |
SAMHD1 protein results in decreased abundance of deoxyguanosine triphosphate |
CTD |
PMID:26342080 |
|
NCBI chr 3:166,179,742...166,214,448
Ensembl chr 3:145,761,558...145,794,386
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of Dihydroxyacetone Phosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Dihydroxyacetone Phosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
affects metabolic processing |
EXP |
TPI1 protein affects the metabolism of Dihydroxyacetone Phosphate |
CTD |
PMID:14762718 |
|
NCBI chr 4:159,301,558...159,305,088
Ensembl chr 4:157,615,386...157,619,541
|
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
thymidine 5'-diphosphate binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:740,929...818,310
Ensembl chr 9:653,659...756,334
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Thymidine Monophosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Tyms |
thymidylate synthetase |
multiple interactions |
ISO |
[Fluorouracil results in decreased activity of TYMS protein] which results in decreased abundance of Thymidine Monophosphate |
CTD |
PMID:29258758 |
|
NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:113,313,452...113,329,536
|
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
increases export |
ISO |
ABCC5 protein results in increased export of 2'-deoxyuridylic acid |
CTD |
PMID:15897250 |
|
NCBI chr11:93,975,579...94,071,659
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Tyms |
thymidylate synthetase |
multiple interactions |
ISO |
[Fluorouracil results in decreased activity of TYMS protein] which results in increased abundance of 2'-deoxyuridylic acid |
CTD |
PMID:29258758 |
|
NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:113,313,452...113,329,536
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Flavin Mononucleotide] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Rfk |
riboflavin kinase |
increases abundance |
ISO |
RFK protein results in increased abundance of Flavin Mononucleotide |
CTD |
PMID:21308351 |
|
NCBI chr 1:224,226,632...224,234,185
Ensembl chr 1:214,799,825...214,807,438 Ensembl chr X:214,799,825...214,807,438
|
|
G |
Slc52a3 |
solute carrier family 52 member 3 |
multiple interactions |
EXP |
Flavin Mononucleotide inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin] |
CTD |
PMID:19122205 |
|
NCBI chr 3:160,959,233...160,976,170
Ensembl chr 3:140,509,473...140,514,096
|
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions decreases abundance |
ISO |
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-6-phosphate] |
CTD |
PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
|
G |
Fut8 |
fucosyltransferase 8 |
multiple interactions decreases activity |
ISO |
Guanosine Diphosphate inhibits the reaction [Mersalyl results in decreased activity of FUT8 protein]; Guanosine Diphosphate inhibits the reaction [p-Chloromercuribenzoic Acid results in decreased activity of FUT8 protein]; Guanosine Diphosphate inhibits the reaction [Phenylglyoxal results in decreased activity of FUT8 protein] Guanosine Diphosphate results in decreased activity of FUT8 protein |
CTD |
PMID:12770769 |
|
NCBI chr 6:101,682,354...101,909,784
Ensembl chr 6:95,949,991...96,176,677
|
|
G |
Gmds |
GDP-mannose 4, 6-dehydratase |
affects binding |
ISO |
Guanosine Diphosphate binds to GMDS protein |
CTD |
PMID:25526675 |
|
NCBI chr17:32,304,029...32,830,708
Ensembl chr17:32,095,386...32,621,961
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Guanosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] |
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
[Enzyme Inhibitors binds to and results in decreased activity of SOS1 protein] promotes the reaction [HRAS protein binds to Guanosine Diphosphate]; Enzyme Inhibitors inhibits the reaction [SOS1 protein binds to [HRAS protein binds to Guanosine Diphosphate]] |
CTD |
PMID:25825487 |
|
NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
EXP |
Guanosine Diphosphate affects the reaction [Serotonin inhibits the reaction [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide binds to HTR1A protein]] |
CTD |
PMID:21126535 |
|
NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions affects binding |
ISO |
KRAS protein mutant form inhibits the reaction [SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein]]; SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein] Guanosine Diphosphate binds to KRAS protein; Guanosine Diphosphate binds to KRAS protein mutant form |
CTD |
PMID:28154176 |
|
NCBI chr 4:179,916,255...179,949,613
|
|
G |
Pgp |
phosphoglycolate phosphatase |
decreases phosphorylation |
ISO |
PGP protein results in decreased phosphorylation of Guanosine Diphosphate |
CTD |
PMID:24338473 |
|
NCBI chr10:13,999,782...14,002,408
Ensembl chr10:13,494,291...13,497,858
|
|
G |
Rab3a |
RAB3A, member RAS oncogene family |
affects binding multiple interactions |
EXP |
Guanosine Diphosphate binds to RAB3A protein [alpha-latrotoxin promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]; [black widow spider venom promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein] |
CTD |
PMID:7929154 |
|
NCBI chr16:18,718,164...18,722,273
Ensembl chr16:18,684,188...18,688,336
|
|
G |
Sos1 |
SOS Ras/Rac guanine nucleotide exchange factor 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors binds to and results in decreased activity of SOS1 protein] promotes the reaction [HRAS protein binds to Guanosine Diphosphate]; Enzyme Inhibitors inhibits the reaction [SOS1 protein binds to [HRAS protein binds to Guanosine Diphosphate]]; KRAS protein mutant form inhibits the reaction [SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein]]; SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein] |
CTD |
PMID:25825487 PMID:28154176 |
|
NCBI chr 6:20,286,117...20,363,350
Ensembl chr 6:14,533,360...14,611,107
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Guanosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:108,169,980...108,269,822
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of guanosine diphosphate glucose] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
multiple interactions |
ISO |
guanosine 5'-O-(2-thiodiphosphate) inhibits the reaction [Serotonin results in increased expression of ACAT1 protein] |
CTD |
PMID:16157345 |
|
NCBI chr 8:62,876,003...62,905,080
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
decreases activity |
ISO |
guanosine 5'-O-(2-thiodiphosphate) results in decreased activity of TRPC6 protein |
CTD |
PMID:11179201 |
|
NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:5,758,935...5,828,092
|
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
affects hydrolysis |
ISO |
ACOT4 protein affects the hydrolysis of glutaryl-coenzyme A |
CTD |
PMID:16141203 |
|
NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:103,668,753...103,673,917
|
|
G |
Acot8 |
acyl-CoA thioesterase 8 |
affects hydrolysis |
ISO |
ACOT8 protein affects the hydrolysis of glutaryl-coenzyme A |
CTD |
PMID:16141203 |
|
NCBI chr 3:173,950,530...173,962,188
Ensembl chr 3:153,531,193...153,542,851
|
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions decreases abundance |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glyceraldehyde 3-Phosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glyceraldehyde 3-Phosphate] APP protein mutant form results in decreased abundance of Glyceraldehyde 3-Phosphate PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Glyceraldehyde 3-Phosphate] |
CTD |
PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors results in decreased activity of FBP1 protein] which results in decreased abundance of Glyceraldehyde 3-Phosphate metabolite |
CTD |
PMID:31974165 |
|
NCBI chr17:2,212,941...2,235,749
Ensembl chr17:2,208,031...2,230,071
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions decreases abundance |
ISO |
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Glyceraldehyde 3-Phosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Glyceraldehyde 3-Phosphate] MAPT protein mutant form results in decreased abundance of Glyceraldehyde 3-Phosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Glyceraldehyde 3-Phosphate] |
CTD |
PMID:39172838 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Pfkfb1 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 |
multiple interactions decreases chemical synthesis |
ISO |
PFKFB1 gene mutant form inhibits the reaction [Metformin results in increased abundance of Glyceraldehyde 3-Phosphate metabolite] PFKFB1 gene mutant form results in decreased chemical synthesis of Glyceraldehyde 3-Phosphate metabolite |
CTD |
PMID:31974165 |
|
NCBI chr X:22,936,038...22,989,691
Ensembl chr X:19,508,546...19,562,182
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glyceraldehyde 3-Phosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glyceraldehyde 3-Phosphate] |
CTD |
PMID:39172838 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:103,323,120...103,371,650
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases hydrolysis |
ISO |
ABCB1 protein results in increased hydrolysis of Guanosine Triphosphate |
CTD |
PMID:2900677 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Guanosine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
App |
amyloid beta precursor protein |
increases secretion |
ISO |
Guanosine Triphosphate results in increased secretion of APP protein modified form |
CTD |
PMID:22906069 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Cdc42 |
cell division cycle 42 |
multiple interactions |
ISO EXP |
Resveratrol promotes the reaction [CDC42 protein binds to Guanosine Triphosphate]; Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to CDC42 protein]; Zoledronic Acid results in increased expression of [CDC42 protein binds to Guanosine Triphosphate] Ethanol results in decreased expression of [CDC42 protein binds to Guanosine Triphosphate] Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to CDC42 protein]; Zoledronic Acid results in increased abundance of [Guanosine Triphosphate binds to CDC42 protein] |
CTD |
PMID:15217905 PMID:16734383 PMID:20829428 PMID:28871336 |
|
NCBI chr 5:154,838,478...154,876,629
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Crh |
corticotropin releasing hormone |
decreases activity |
EXP |
Guanosine Triphosphate results in decreased activity of CRH protein |
CTD |
PMID:2153673 |
|
NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
CSF1 protein results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; Risedronic Acid promotes the reaction [CSF1 protein results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]] |
CTD |
PMID:16734383 |
|
NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Fut8 |
fucosyltransferase 8 |
decreases activity |
ISO |
Guanosine Triphosphate results in decreased activity of FUT8 protein |
CTD |
PMID:12770769 |
|
NCBI chr 6:101,682,354...101,909,784
Ensembl chr 6:95,949,991...96,176,677
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
ISO |
[dicyanocobinamide results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]] which results in increased metabolism of Guanosine Triphosphate |
CTD |
PMID:22171090 |
|
NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
[dicyanocobinamide results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]] which results in increased metabolism of Guanosine Triphosphate |
CTD |
PMID:22171090 |
|
NCBI chr 2:169,646,897...169,697,060
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Gypa |
glycophorin A |
increases expression |
ISO |
Guanosine Triphosphate results in increased expression of GYPA protein |
CTD |
PMID:17002868 |
|
NCBI chr19:44,354,669...44,370,304
Ensembl chr19:27,450,308...27,465,822
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Guanosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] |
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
[Enzyme Inhibitors binds to and results in decreased activity of SOS1 protein] inhibits the reaction [HRAS protein binds to Guanosine Triphosphate] |
CTD |
PMID:25825487 |
|
NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO |
Guanosine Triphosphate analog affects the reaction [Histamine inhibits the reaction [Pyrilamine binds to HRH1 protein]] |
CTD |
PMID:2419744 |
|
NCBI chr 4:149,120,511...149,204,267
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions affects binding |
ISO EXP |
6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-pyridazin-3-one inhibits the reaction [alpha-methylhistamine promotes the reaction [Guanosine Triphosphate binds to HRH3 protein]]; alpha-methylhistamine promotes the reaction [Guanosine Triphosphate binds to HRH3 protein] |
CTD |
PMID:21634396 |
|
NCBI chr 3:187,569,174...187,575,263
Ensembl chr 3:167,191,558...167,196,642
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
EXP |
Guanosine Triphosphate affects the reaction [Serotonin binds to HTR1A protein]; Guanosine Triphosphate affects the reaction [Serotonin inhibits the reaction [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide binds to HTR1A protein]]; Manganese inhibits the reaction [Guanosine Triphosphate affects the reaction [Serotonin binds to HTR1A protein]] |
CTD |
PMID:21126535 |
|
NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
affects binding multiple interactions increases hydrolysis |
ISO |
Guanosine Triphosphate binds to KRAS protein; Guanosine Triphosphate binds to KRAS protein mutant form KRAS protein mutant form inhibits the reaction [RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate]]; RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate] KRAS protein mutant form results in increased hydrolysis of Guanosine Triphosphate; KRAS protein results in increased hydrolysis of Guanosine Triphosphate |
CTD |
PMID:28154176 |
|
NCBI chr 4:179,916,255...179,949,613
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
affects binding multiple interactions |
ISO |
LRRK2 protein binds to Guanosine Triphosphate sodium arsenite inhibits the reaction [LRRK2 protein binds to Guanosine Triphosphate] |
CTD |
PMID:24942733 |
|
NCBI chr 7:124,706,246...124,867,234
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Mtnr1b |
melatonin receptor 1B |
multiple interactions |
ISO |
Guanosine Triphosphate inhibits the reaction [Carbaryl inhibits the reaction [Melatonin binds to MTNR1B protein]]; Guanosine Triphosphate inhibits the reaction [Carbofuran inhibits the reaction [Melatonin binds to MTNR1B protein]] |
CTD |
PMID:28027439 |
|
NCBI chr 8:20,919,593...20,934,109
Ensembl chr 8:12,638,219...12,652,737
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
affects binding multiple interactions |
EXP |
Guanosine Triphosphate binds to OPRM1 protein Dronabinol promotes the reaction [Guanosine Triphosphate binds to OPRM1 protein] |
CTD |
PMID:16823391 |
|
NCBI chr 1:45,565,371...45,818,722
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
P2rx5 |
purinergic receptor P2X 5 |
affects transport |
EXP |
GTP affects transport ion flux of P2rx5 receptor |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:58,276,329...58,291,108
Ensembl chr10:57,777,819...57,789,423
|
|
G |
P2ry4 |
pyrimidinergic receptor P2Y4 |
multiple interactions |
EXP |
Guanosine Triphosphate binds to and results in increased activity of P2RY4 protein |
CTD |
PMID:15654852 |
|
NCBI chr X:69,722,604...69,757,726
Ensembl chr X:65,683,232...65,721,748
|
|
G |
Panx1 |
Pannexin 1 |
decreases activity |
ISO |
Guanosine Triphosphate results in decreased activity of PANX1 protein |
CTD |
PMID:19023039 |
|
NCBI chr 8:20,128,783...20,171,200
Ensembl chr 8:11,850,730...11,889,774
|
|
G |
Pgp |
phosphoglycolate phosphatase |
decreases phosphorylation |
ISO |
PGP protein results in decreased phosphorylation of Guanosine Triphosphate |
CTD |
PMID:24338473 |
|
NCBI chr10:13,999,782...14,002,408
Ensembl chr10:13,494,291...13,497,858
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
ISO |
[Guanosine Triphosphate co-treated with Lithium] results in decreased activity of POMC protein modified form; [Guanosine Triphosphate co-treated with Potassium] results in decreased activity of POMC protein modified form; [Guanosine Triphosphate co-treated with Sodium Chloride] results in decreased activity of POMC protein modified form |
CTD |
PMID:2550106 |
|
NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Rab3a |
RAB3A, member RAS oncogene family |
affects binding increases cleavage multiple interactions |
EXP |
[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein; Guanosine Triphosphate binds to RAB3A protein; RAB3A protein binds to Guanosine Triphosphate; SNCA protein binds to [RAB3A protein binds to Guanosine Triphosphate] RAB3A protein results in increased cleavage of Guanosine Triphosphate [alpha-latrotoxin promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]; [black widow spider venom promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]; manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]; manganese chloride promotes the reaction [SNCA protein binds to [RAB3A protein binds to Guanosine Triphosphate]]; manganese chloride results in increased expression of [RAB3A protein binds to Guanosine Triphosphate]; SNCA protein promotes the reaction [manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]] |
CTD |
PMID:7929154 PMID:29289693 |
|
NCBI chr16:18,718,164...18,722,273
Ensembl chr16:18,684,188...18,688,336
|
|
G |
Rabgap1 |
RAB GTPase activating protein 1 |
multiple interactions affects binding |
EXP |
manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]; SNCA protein promotes the reaction [manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]] |
CTD |
PMID:29289693 |
|
NCBI chr 3:41,617,784...41,735,795
Ensembl chr 3:21,208,055...21,326,013
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
ISO EXP |
Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; Zoledronic Acid results in increased expression of [RAC1 protein binds to Guanosine Triphosphate] Ethanol results in decreased expression of [RAC1 protein binds to Guanosine Triphosphate] CSF1 protein results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; GGTI 298 results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; mevastatin results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; Risedronic Acid promotes the reaction [CSF1 protein results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]]; Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; Zoledronic Acid results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein] |
CTD |
PMID:16734383 PMID:20829428 PMID:28871336 |
|
NCBI chr12:16,150,411...16,170,864
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rap1b |
RAP1B, member of RAS oncogene family |
multiple interactions |
ISO EXP |
[Pentoxifylline results in increased abundance of Cyclic AMP] results in increased abundance of [RAP1B protein binds to Guanosine Triphosphate] |
CTD |
PMID:21693435 |
|
NCBI chr 7:55,308,922...55,342,217
Ensembl chr 7:53,423,130...53,456,370
|
|
G |
Rasa1 |
RAS p21 protein activator 1 |
multiple interactions |
ISO |
KRAS protein mutant form inhibits the reaction [RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate]]; RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate] |
CTD |
PMID:28154176 |
|
NCBI chr 2:17,593,136...17,676,707
Ensembl chr 2:15,857,980...15,940,854
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions affects binding |
ISO EXP |
Dronabinol inhibits the reaction [Guanosine Triphosphate binds to and results in increased activity of RHOA protein]; Guanosine Triphosphate binds to and results in increased activity of RHOA protein; Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to RHOA protein]; Zoledronic Acid results in increased abundance of [Guanosine Triphosphate binds to RHOA protein] 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one promotes the reaction [Guanosine Triphosphate binds to RHOA protein] Asbestos, Crocidolite inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]; Cadmium Chloride promotes the reaction [RHOA protein binds to Guanosine Triphosphate]; Dronabinol inhibits the reaction [Guanosine Triphosphate binds to and results in increased activity of RHOA protein]; Guanosine Triphosphate binds to and results in increased activity of RHOA protein; Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to RHOA protein]; tempol inhibits the reaction [Asbestos, Crocidolite inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]]; tempol inhibits the reaction [Vitamin K 3 inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]]; Vitamin K 3 inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]; Zoledronic Acid results in increased expression of [RHOA protein binds to Guanosine Triphosphate] |
CTD |
PMID:16734383 PMID:21257924 PMID:25268128 PMID:26220685 PMID:28871336 PMID:29307655 More...
|
|
NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Snca |
synuclein alpha |
multiple interactions affects binding |
EXP |
manganese chloride promotes the reaction [SNCA protein binds to [RAB3A protein binds to Guanosine Triphosphate]]; SNCA protein promotes the reaction [manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]] |
CTD |
PMID:29289693 |
|
NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sos1 |
SOS Ras/Rac guanine nucleotide exchange factor 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors binds to and results in decreased activity of SOS1 protein] inhibits the reaction [HRAS protein binds to Guanosine Triphosphate] |
CTD |
PMID:25825487 |
|
NCBI chr 6:20,286,117...20,363,350
Ensembl chr 6:14,533,360...14,611,107
|
|
G |
Tgm2 |
transglutaminase 2 |
affects binding |
ISO |
Guanosine Triphosphate binds to TGM2 protein |
CTD |
PMID:15556610 |
|
NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Guanosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:108,169,980...108,269,822
|
|
|
G |
Adora2a |
adenosine A2a receptor |
multiple interactions |
ISO |
ADORA2A protein affects the reaction [[Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein] which results in increased activity of Guanosine 5'-O-(3-Thiotriphosphate)] |
CTD |
PMID:14756803 |
|
NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions affects binding |
ISO |
(1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone metabolite promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; 5F-CUMYL-PICA promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; AM 6527 promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; delta(9)-tetrahydrocannabinolic acid promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]]; delta(9)-tetrahydrocannabinolic acid promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; Dronabinol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; XLR-11 metabolite promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; XLR-11 promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)] |
CTD |
PMID:28087785 PMID:29549157 PMID:32510591 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects binding |
ISO |
(1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone metabolite promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; 4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; 5F-CUMYL-PICA promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; afimoxifene inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; AM 281 inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; AM 6527 promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; cannabinoid CB2 receptor agonist ABK5 promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; Dronabinol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; iodopravadoline inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; ridaifen-B inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; Tamoxifen inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; XLR-11 metabolite promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; XLR-11 promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)] |
CTD |
PMID:27936172 PMID:28087785 PMID:29549157 PMID:29906493 PMID:30951717 PMID:32510591 More...
|
|
NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Gna13 |
G protein subunit alpha 13 |
affects binding multiple interactions |
ISO |
Guanosine 5'-O-(3-Thiotriphosphate) binds to GNA13 protein [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of GPR55 protein] affects the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to GNA13 protein] |
CTD |
PMID:17876302 |
|
NCBI chr10:94,837,271...94,870,290
Ensembl chr10:94,337,725...94,370,774
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
affects binding |
ISO |
GNAI1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate) |
CTD |
PMID:29748632 |
|
NCBI chr 4:17,706,061...17,790,176
Ensembl chr 4:16,814,001...16,896,417
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
affects binding |
ISO |
GNAI3 protein binds to Guanosine 5'-O-(3-Thiotriphosphate) |
CTD |
PMID:29748632 |
|
NCBI chr 2:198,430,920...198,468,874
Ensembl chr 2:195,742,642...195,780,742
|
|
G |
Gnao1 |
G protein subunit alpha o1 |
affects binding |
ISO |
GNAO1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate) |
CTD |
PMID:29748632 |
|
NCBI chr19:11,040,788...11,198,437
Ensembl chr19:11,035,956...11,192,493
|
|
G |
Gnas |
GNAS complex locus |
affects binding |
ISO |
GNAS protein binds to Guanosine 5'-O-(3-Thiotriphosphate) |
CTD |
PMID:29748632 |
|
NCBI chr 3:183,489,648...183,554,570
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gnaz |
G protein subunit alpha z |
affects binding |
ISO |
GNAZ protein binds to Guanosine 5'-O-(3-Thiotriphosphate) |
CTD |
PMID:29748632 |
|
NCBI chr20:13,642,853...13,693,616
Ensembl chr20:13,644,640...13,669,907
|
|
G |
Gpr55 |
G protein-coupled receptor 55 |
multiple interactions |
ISO |
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of GPR55 protein] affects the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to GNA13 protein] |
CTD |
PMID:17876302 |
|
NCBI chr 9:94,037,748...94,081,426
Ensembl chr 9:86,590,885...86,640,613
|
|
G |
Hrh4 |
histamine receptor H4 |
affects binding multiple interactions |
ISO |
Guanosine 5'-O-(3-Thiotriphosphate) binds to HRH4 protein Histamine promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to HRH4 protein] |
CTD |
PMID:11181941 |
|
NCBI chr18:4,440,977...4,457,132
Ensembl chr18:4,166,270...4,246,345
|
|
G |
Myl9 |
myosin light chain 9 |
multiple interactions |
EXP |
[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein]; Y 27632 inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:29660437 |
|
NCBI chr 3:165,742,020...165,748,409
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
[7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which affects the localization of Guanosine 5'-O-(3-Thiotriphosphate); [chlornaltrexamine binds to and results in decreased activity of OPRM1 protein] which affects the localization of Guanosine 5'-O-(3-Thiotriphosphate); [clocinnamox binds to and results in decreased activity of OPRM1 protein] which affects the localization of Guanosine 5'-O-(3-Thiotriphosphate) [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein] which results in increased activity of Guanosine 5'-O-(3-Thiotriphosphate); ADORA2A protein affects the reaction [[Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein] which results in increased activity of Guanosine 5'-O-(3-Thiotriphosphate)] |
CTD |
PMID:11413242 PMID:14756803 |
|
NCBI chr 1:45,565,371...45,818,722
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
Plcb1 |
phospholipase C beta 1 |
multiple interactions increases activity |
EXP |
[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein; Caffeine inhibits the reaction [[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein]; Caffeine inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of PLCB1 protein]; Theophylline inhibits the reaction [[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein]; Theophylline inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of PLCB1 protein] |
CTD |
PMID:15998294 |
|
NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Plcg2 |
phospholipase C, gamma 2 |
multiple interactions |
ISO |
[[RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein] which results in increased chemical synthesis of Inositol Phosphates; [Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]; [Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein results in increased chemical synthesis of Inositol Phosphates]; [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein; PLCG2 protein mutant form results in decreased susceptibility to [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] |
CTD |
PMID:25903139 PMID:27542411 |
|
NCBI chr19:62,456,196...62,592,684
Ensembl chr19:45,547,416...45,683,930
|
|
G |
Plek |
pleckstrin |
increases phosphorylation multiple interactions |
ISO |
Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein dioleoylphosphatidic acid analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein]; Oleic Acid promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein]; phosphatidylethanol analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein] |
CTD |
PMID:8928743 |
|
NCBI chr14:95,598,650...95,631,326
Ensembl chr14:91,397,019...91,454,131
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions increases phosphorylation |
EXP |
Guanosine 5'-O-(3-Thiotriphosphate) inhibits the reaction [15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid results in increased phosphorylation of PPP1R12A protein] Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PPP1R12A protein |
CTD |
PMID:29660437 |
|
NCBI chr 7:45,368,922...45,480,158
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
Guanosine 5'-O-(3-Thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:19,790,499...19,797,873
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
ISO |
Methohexital inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of RAC1 protein]; Pentobarbital inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of RAC1 protein]; Secobarbital inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of RAC1 protein]; Thiamylal inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of RAC1 protein] |
CTD |
PMID:15263067 |
|
NCBI chr12:16,150,411...16,170,864
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rac2 |
Rac family small GTPase 2 |
multiple interactions |
ISO |
[[RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein] which results in increased chemical synthesis of Inositol Phosphates; [Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]; [Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein results in increased chemical synthesis of Inositol Phosphates]; [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein; PLCG2 protein mutant form results in decreased susceptibility to [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] |
CTD |
PMID:25903139 PMID:27542411 |
|
NCBI chr 7:111,981,825...112,009,201
Ensembl chr 7:110,116,260...110,128,720
|
|
G |
Rhoa |
ras homolog family member A |
affects localization multiple interactions |
EXP |
Guanosine 5'-O-(3-Thiotriphosphate) affects the localization of RHOA protein [Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein]; Sevoflurane inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) affects the localization of RHOA protein] |
CTD |
PMID:12960549 PMID:29660437 |
|
NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rock2 |
Rho-associated coiled-coil containing protein kinase 2 |
affects localization multiple interactions |
EXP |
Guanosine 5'-O-(3-Thiotriphosphate) affects the localization of ROCK2 protein sevoflurane inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) affects the localization of ROCK2 protein] |
CTD |
PMID:12960549 |
|
NCBI chr 6:45,407,823...45,502,773
Ensembl chr 6:39,679,082...39,774,031
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
increases activity |
ISO |
Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of TRPC6 protein |
CTD |
PMID:11179201 |
|
NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:5,758,935...5,828,092
|
|
|
G |
Fut8 |
fucosyltransferase 8 |
decreases activity |
ISO |
Guanosine Monophosphate results in decreased activity of FUT8 protein |
CTD |
PMID:12770769 |
|
NCBI chr 6:101,682,354...101,909,784
Ensembl chr 6:95,949,991...96,176,677
|
|
G |
Gmds |
GDP-mannose 4, 6-dehydratase |
affects binding |
ISO |
Guanosine Monophosphate binds to GMDS protein |
CTD |
PMID:25526675 |
|
NCBI chr17:32,304,029...32,830,708
Ensembl chr17:32,095,386...32,621,961
|
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
multiple interactions |
ISO |
[hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:73,897,880...73,926,511
|
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Inosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] |
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Inosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:108,169,980...108,269,822
|
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases abundance |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate] APP protein mutant form results in increased abundance of Inosine Monophosphate PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Inosine Monophosphate] |
CTD |
PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[Inosine Monophosphate co-treated with potassium oxonate] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; SCH 442416 inhibits the reaction [Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]] |
CTD |
PMID:20868668 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Impdh2 |
inosine monophosphate dehydrogenase 2 |
affects binding multiple interactions |
ISO |
Inosine Monophosphate binds to IMPDH2 protein berberrubine inhibits the reaction [Inosine Monophosphate binds to IMPDH2 protein] |
CTD |
PMID:37871880 |
|
NCBI chr 8:118,135,204...118,139,892
Ensembl chr 8:109,256,728...109,261,359
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions affects abundance |
ISO |
PF-06840003 affects the reaction [MAPT protein mutant form affects the abundance of Inosine Monophosphate] |
CTD |
PMID:39172838 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[potassium oxonate co-treated with Inosine Monophosphate] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]; Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]; SCH 442416 inhibits the reaction [Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]] |
CTD |
PMID:20868668 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate] |
CTD |
PMID:39172838 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
[Inosine Monophosphate co-treated with potassium oxonate] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; SCH 442416 inhibits the reaction [Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]] |
CTD |
PMID:20868668 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp73 |
tumor protein p73 |
affects abundance |
ISO |
TP73 protein affects the abundance of Inosine Monophosphate |
CTD |
PMID:25554796 |
|
NCBI chr 5:169,903,801...169,988,075
Ensembl chr 5:164,621,377...164,681,128
|
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects binding |
ISO |
isobutyryl-coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,562,288...6,667,064
|
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
multiple interactions |
ISO |
cylindrospermopsin results in increased expression of [ALDOA protein binds to fructose-1,6-diphosphate] |
CTD |
PMID:27494769 |
|
NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
App |
amyloid beta precursor protein |
decreases abundance multiple interactions |
ISO |
APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
fructose-1,6-diphosphate results in increased expression of BAX protein |
CTD |
PMID:33078453 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
EXP |
[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr16:74,133,259...74,145,328
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:22227475 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:22227475 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions decreases abundance |
ISO |
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate] MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases degradation |
ISO |
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] fructose-1,6-diphosphate results in decreased degradation of NOS2 mRNA |
CTD |
PMID:22227475 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate] |
CTD |
PMID:39172838 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
fructose-1,6-diphosphate results in increased expression of TP53 protein |
CTD |
PMID:33078453 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
lauroyl-coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Hsdl2 |
hydroxysteroid dehydrogenase like 2 |
multiple interactions |
ISO |
[lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:74,443,872...74,479,839
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
multiple interactions |
ISO |
[lauroyl-coenzyme A co-treated with NADP] binds to PECR protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:81,347,170...81,375,809
Ensembl chr 9:73,897,880...73,926,511
|
|
|
G |
Mlycd |
malonyl-CoA decarboxylase |
multiple interactions |
ISO |
PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] |
CTD |
PMID:14641110 |
|
NCBI chr19:64,356,582...64,372,447
Ensembl chr19:47,447,970...47,463,793
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] |
CTD |
PMID:14641110 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
increases abundance |
ISO |
ECHS1 gene mutant form results in increased abundance of methacrylyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Hibch |
3-hydroxyisobutyryl-CoA hydrolase |
increases abundance |
ISO |
HIBCH gene mutant form results in increased abundance of methacrylyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 9:56,082,082...56,161,796
Ensembl chr 9:48,590,099...48,669,824
|
|
|
G |
Dbi |
diazepam binding inhibitor |
affects binding |
ISO |
S-tetradecanoyl-coenzyme A binds to DBI protein |
CTD |
PMID:17044054 |
|
NCBI chr13:33,794,231...33,802,632
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
S-tetradecanoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
S-tetradecanoyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA] |
CTD |
PMID:18467523 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of CREB1 protein |
CTD |
PMID:18467523 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions increases expression decreases response to substance |
EXP |
CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased activity of HIF1A protein]; CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of IRS2 mRNA]; CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of NR4A2 mRNA]; CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of PPARGC1A mRNA]; CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of VEGFA protein] monobutyryl cyclic AMP results in increased expression of CREM mRNA CREM protein results in decreased susceptibility to monobutyryl cyclic AMP |
CTD |
PMID:25381014 |
|
NCBI chr17:58,932,011...59,001,160
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
multiple interactions |
ISO |
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA; [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 mRNA]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP51 protein] |
CTD |
PMID:18467523 |
|
NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]] |
CTD |
PMID:18467523 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased activity of HIF1A protein]; monobutyryl cyclic AMP results in increased expression of and affects the localization of and results in increased activity of HIF1A protein |
CTD |
PMID:25381014 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Irs2 |
insulin receptor substrate 2 |
increases expression multiple interactions |
EXP |
monobutyryl cyclic AMP results in increased expression of IRS2 mRNA CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of IRS2 mRNA] |
CTD |
PMID:25381014 |
|
NCBI chr16:85,190,310...85,214,543
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein; azalanstat inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:18467523 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein; azalanstat inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:18467523 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
increases expression multiple interactions |
EXP |
monobutyryl cyclic AMP results in increased expression of NR4A2 mRNA CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of NR4A2 mRNA] |
CTD |
PMID:25381014 |
|
NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
EXP |
monobutyryl cyclic AMP results in increased expression of PPARGC1A mRNA CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:25381014 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkar2b |
protein kinase cAMP-dependent type II regulatory subunit beta |
multiple interactions |
ISO |
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of PRKAR2B protein |
CTD |
PMID:18467523 |
|
NCBI chr 6:54,291,143...54,381,639
Ensembl chr 6:48,563,662...48,653,933
|
|
G |
Rps6 |
ribosomal protein S6 |
increases expression |
EXP |
monobutyryl cyclic AMP results in increased expression of RPS6 protein modified form |
CTD |
PMID:25381014 |
|
NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
EXP |
monobutyryl cyclic AMP results in increased expression of VEGFA protein CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of VEGFA protein] |
CTD |
PMID:25381014 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of ACADM mRNA] |
CTD |
PMID:23834033 |
|
NCBI chr 2:245,518,693...245,542,864
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
EXP |
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of ACP5 protein] |
CTD |
PMID:30292833 |
|
NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:34752167 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in decreased expression of ALDOA protein] |
CTD |
PMID:38159578 |
|
NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Axin1 |
axin 1 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in increased expression of AXIN1 protein] |
CTD |
PMID:32005247 |
|
NCBI chr10:15,667,894...15,720,092
Ensembl chr10:15,163,684...15,215,615
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
EXP ISO |
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in decreased activity of BGLAP protein]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in decreased expression of BGLAP protein] |
CTD |
PMID:30292833 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO EXP |
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of CASP1 protein modified form] |
CTD |
PMID:30292833 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[Nicotinamide Mononucleotide co-treated with Zearalenone] results in decreased expression of CAT protein |
CTD |
PMID:38159578 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CCND1 protein]; Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased expression of CCND1 protein] |
CTD |
PMID:32005247 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of CD36 mRNA] |
CTD |
PMID:38159578 |
|
NCBI chr 4:18,209,088...18,302,142
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of CD38 mRNA] |
CTD |
PMID:38159578 |
|
NCBI chr14:71,384,532...71,424,794
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]]; Dicumarol inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]]; Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein] |
CTD |
PMID:37640247 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein]]; Dicumarol inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein]]; Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein] |
CTD |
PMID:37640247 |
|
NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:34752167 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of CPT1A mRNA] |
CTD |
PMID:38159578 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CTNNB1 protein]; Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased expression of CTNNB1 protein] |
CTD |
PMID:32005247 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of DGAT1 mRNA] |
CTD |
PMID:38159578 |
|
NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of DGAT2 mRNA] |
CTD |
PMID:38159578 |
|
NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Elovl3 |
ELOVL fatty acid elongase 3 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of ELOVL3 mRNA] |
CTD |
PMID:38159578 |
|
NCBI chr 1:254,938,731...254,942,559
Ensembl chr 1:244,997,287...245,001,115
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
decreases abundance |
ISO |
ERCC6 gene mutant form results in decreased abundance of Nicotinamide Mononucleotide |
CTD |
PMID:25440059 |
|
NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of FASN mRNA] |
CTD |
PMID:38159578 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Foxo4 |
forkhead box O4 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of FOXO4 mRNA] |
CTD |
PMID:36336710 |
|
NCBI chr X:70,425,218...70,432,120
Ensembl chr X:66,385,558...66,392,115
|
|
G |
Galnt1 |
polypeptide N-acetylgalactosaminyltransferase 1 |
increases expression |
ISO |
Nicotinamide Mononucleotide results in increased expression of GALNT1 mRNA |
CTD |
PMID:29935245 |
|
NCBI chr18:15,763,697...15,843,598
Ensembl chr18:15,489,020...15,568,245
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
[resveratrol co-treated with Nicotinamide Mononucleotide] inhibits the reaction [RETN protein results in increased activity of GLB1 protein] |
CTD |
PMID:23827175 |
|
NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein] |
CTD |
PMID:34752167 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of H2AX protein] |
CTD |
PMID:36756972 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO EXP |
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of IL18 protein]; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of IL18 mRNA] |
CTD |
PMID:30292833 PMID:38159578 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of IL1B protein]; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of IL1B mRNA] |
CTD |
PMID:30292833 PMID:38159578 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of LPIN1 protein] |
CTD |
PMID:38159578 |
|
NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:38159578 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:38159578 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mir34a |
microRNA 34a |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of ACADM mRNA]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARA mRNA]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARD mRNA] |
CTD |
PMID:23834033 |
|
NCBI chr 5:165,815,952...165,816,053
Ensembl chr 5:160,533,002...160,533,103
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
affects binding multiple interactions |
EXP ISO |
NAMPT protein binds to Nicotinamide Mononucleotide Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CCND1 protein]; Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CTNNB1 protein] Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]] |
CTD |
PMID:16901503 PMID:23834033 PMID:32005247 |
|
NCBI chr 6:55,152,756...55,189,547
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 protein] Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 protein] |
CTD |
PMID:30292833 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nnt |
nicotinamide nucleotide transhydrogenase |
multiple interactions |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein]]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of FOXO4 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of PPARGC1A mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of SHANK2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein] |
CTD |
PMID:36336710 |
|
NCBI chr 2:53,144,157...53,237,857
Ensembl chr 2:51,411,413...51,504,823
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
Nicotinamide Mononucleotide results in increased expression of NQO1 protein 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide results in increased expression of NQO1 protein] |
CTD |
PMID:37640247 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
affects abundance multiple interactions |
ISO |
PARP1 protein affects the abundance of Nicotinamide Mononucleotide [Nicotinamide Mononucleotide co-treated with Cisplatin] results in decreased expression of PARP1 protein; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PARP1 mRNA] |
CTD |
PMID:19426698 PMID:34089817 PMID:38159578 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in decreased expression of PGK1 protein] |
CTD |
PMID:38159578 |
|
NCBI chr X:75,336,988...75,352,962
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PNPLA2 protein] |
CTD |
PMID:38159578 |
|
NCBI chr 1:205,982,279...205,987,361
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARA mRNA] |
CTD |
PMID:23834033 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARD mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PPARD mRNA] |
CTD |
PMID:23834033 PMID:38159578 |
|
NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PPARG mRNA] |
CTD |
PMID:38159578 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:36336710 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
EXP |
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of PYCARD protein] |
CTD |
PMID:30292833 |
|
NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Retn |
resistin |
multiple interactions |
ISO |
[resveratrol co-treated with Nicotinamide Mononucleotide] inhibits the reaction [RETN protein results in increased activity of GLB1 protein] |
CTD |
PMID:23827175 |
|
NCBI chr12:6,508,653...6,511,115
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of SCD1 mRNA] |
CTD |
PMID:38159578 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Shank2 |
SH3 and multiple ankyrin repeat domains 2 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of SHANK2 mRNA] |
CTD |
PMID:36336710 |
|
NCBI chr 1:208,575,144...209,020,300
Ensembl chr 1:199,169,429...199,589,394
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression multiple interactions |
EXP ISO |
Nicotinamide Mononucleotide results in increased expression of SIRT1 mRNA Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of SIRT1 mRNA] Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in decreased expression of SIRT1 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in decreased expression of SIRT1 protein] |
CTD |
PMID:32087266 PMID:38159578 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc12a8 |
solute carrier family 12, member 8 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in decreased expression of SLC12A8 mRNA] |
CTD |
PMID:38159578 |
|
NCBI chr11:80,622,000...80,771,674
Ensembl chr11:67,116,877...67,266,834
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:46,533,580...46,590,128
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:46,490,262...46,532,954
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in decreased expression of SOD1 protein] |
CTD |
PMID:38159578 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
[Nicotinamide Mononucleotide co-treated with Zearalenone] results in decreased expression of SOD2 mRNA |
CTD |
PMID:38159578 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein]]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein] |
CTD |
PMID:36336710 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:34752167 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of TNF mRNA] |
CTD |
PMID:38159578 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions |
ISO EXP |
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP protein] Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP protein] |
CTD |
PMID:30292833 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP ISO |
Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in increased expression of UCP2 protein] Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of UCP2 mRNA] |
CTD |
PMID:32087266 PMID:38159578 |
|
NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:154,839,209...154,845,611
|
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
oleoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
oleoyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
oleoyl-coenzyme A binds to and results in increased activity of PPARG protein |
CTD |
PMID:11139385 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
increases metabolic processing multiple interactions |
ISO |
ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A [ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide; benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Dehydroepiandrosterone promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Tetrachlorodibenzodioxin promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide] |
CTD |
PMID:10497882 |
|
NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis |
EXP |
CES1 protein results in increased hydrolysis of Palmitoyl Coenzyme A |
CTD |
PMID:8611161 |
|
NCBI chr19:30,046,494...30,085,039
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP |
valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Palmitoyl Coenzyme A] |
CTD |
PMID:19854160 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
DGAT1 protein results in increased metabolism of [Palmitoyl Coenzyme A co-treated with Vitamin A] |
CTD |
PMID:16214399 |
|
NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
Palmitoyl Coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
decreases expression |
ISO |
Palmitoyl Coenzyme A results in decreased expression of HNF4A mRNA; Palmitoyl Coenzyme A results in decreased expression of HNF4A protein |
CTD |
PMID:17992261 |
|
NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Palmitoyl Coenzyme A binds to and results in increased activity of PPARA protein Acetylglucosamine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Fenofibrate promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gamma-Aminobutyric Acid inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]; Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolazoline inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolmetin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] |
CTD |
PMID:11139385 PMID:18812576 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
Palmitoyl Coenzyme A binds to and results in increased activity of PPARG protein |
CTD |
PMID:11139385 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Shbg |
sex hormone binding globulin |
decreases expression |
ISO |
Palmitoyl Coenzyme A results in decreased expression of SHBG mRNA; Palmitoyl Coenzyme A results in decreased expression of SHBG protein |
CTD |
PMID:17992261 |
|
NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,332,941...54,351,057
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [AGT protein results in increased expression of EDNRA protein] |
CTD |
PMID:15007106 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein] |
CTD |
PMID:15177934 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ece1 |
endothelin converting enzyme 1 |
multiple interactions decreases activity |
EXP |
EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]]; phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]; phosphoramidon inhibits the reaction [Indomethacin results in increased expression of ECE1 protein] phosphoramidon decreases activity of recombinant Ece1 protein in COS cells |
CTD RGD |
PMID:11145282 PMID:16280098 PMID:8034569 |
RGD:728596 |
NCBI chr 5:155,361,031...155,462,723
Ensembl chr 5:150,077,644...150,179,371
|
|
G |
Edn1 |
endothelin 1 |
decreases expression multiple interactions |
EXP |
phosphoramidon results in decreased expression of EDN1 protein EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]]; EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased expression of EDN1 protein]]; phosphoramidon inhibits the reaction [Indomethacin results in increased expression of EDN1 protein] |
CTD |
PMID:11145282 PMID:16280098 PMID:16391412 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [AGT protein results in increased expression of EDNRA protein]; phosphoramidon inhibits the reaction [Phenylephrine results in increased expression of EDNRA protein] |
CTD |
PMID:15007106 |
|
NCBI chr19:47,137,360...47,207,961
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
EXP |
phosphoramidon results in increased expression of EDNRB protein |
CTD |
PMID:15007106 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] |
CTD |
PMID:15177934 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [Morphine results in decreased expression of ICAM1 protein alternative form] |
CTD |
PMID:10070497 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Kel |
Kell metallo-endopeptidase (Kell blood group) |
multiple interactions |
ISO |
KEL protein alternative form binds to and affects the metabolism of phosphoramidon |
CTD |
PMID:15769748 |
|
NCBI chr 4:70,568,241...70,585,666
Ensembl chr 4:70,568,243...70,585,631
|
|
G |
Lep |
leptin |
decreases expression |
EXP |
phosphoramidon results in decreased expression of LEP protein |
CTD |
PMID:16391412 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:15177934 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15177934 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mme |
membrane metallo-endopeptidase |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [Morphine results in increased activity of MME protein] |
CTD |
PMID:10070497 |
|
NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Nts |
neurotensin |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15177934 |
|
NCBI chr 7:39,451,484...39,460,888
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Sell |
selectin L |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [Morphine results in decreased expression of SELL protein alternative form] |
CTD |
PMID:10070497 |
|
NCBI chr13:78,950,100...78,969,604
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
[TAC1 protein co-treated with phosphoramidon] results in increased uptake of Oxygen |
CTD |
PMID:9808699 |
|
NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:35,679,704...35,687,178
|
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
multiple interactions increases expression |
EXP |
Minocycline inhibits the reaction [Poly C results in increased expression of GRIA1 mRNA] |
CTD |
PMID:19660546 |
|
NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
increases expression multiple interactions |
EXP |
Poly C results in increased expression of GRIN2A mRNA Minocycline inhibits the reaction [Poly C results in increased expression of GRIN2A mRNA] |
CTD |
PMID:19660546 |
|
NCBI chr10:6,136,458...6,560,003
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2c |
glutamate ionotropic receptor NMDA type subunit 2C |
multiple interactions increases expression |
EXP |
Minocycline inhibits the reaction [Poly C results in increased expression of GRIN2C mRNA] |
CTD |
PMID:19660546 |
|
NCBI chr10:100,987,410...101,006,064
Ensembl chr10:100,488,431...100,506,427
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP |
Poly C results in increased expression of IL1B protein |
CTD |
PMID:19660546 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
Poly G inhibits the reaction [Particulate Matter results in increased expression of ACTA2 mRNA]; Poly G inhibits the reaction [Particulate Matter results in increased expression of ACTA2 protein]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein] |
CTD |
PMID:30391304 PMID:31028789 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP |
Poly G inhibits the reaction [Silicon Dioxide results in increased expression of ATF6 protein] |
CTD |
PMID:31028789 |
|
NCBI chr13:85,460,312...85,639,959
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
EXP |
[Poly G co-treated with Silicon Dioxide] results in decreased expression of BNIP3 mRNA |
CTD |
PMID:38523403 |
|
NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
multiple interactions |
EXP |
Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of BNIP3L mRNA] |
CTD |
PMID:38523403 |
|
NCBI chr15:45,350,081...45,373,213
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
EXP |
Poly G inhibits the reaction [Silicon Dioxide results in increased expression of CASP12 protein] |
CTD |
PMID:31028789 |
|
NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
Poly G inhibits the reaction [Particulate Matter results in decreased expression of CDH1 mRNA]; Poly G inhibits the reaction [Particulate Matter results in decreased expression of CDH1 protein]; Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein] |
CTD |
PMID:30391304 PMID:31028789 PMID:38523403 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
Poly G inhibits the reaction [Particulate Matter results in increased expression of COL1A1 mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of COL1A1 mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of COL1A1 protein] |
CTD |
PMID:30391304 PMID:31028789 PMID:38523403 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
EXP |
Poly G inhibits the reaction [Particulate Matter results in increased expression of COL3A1 mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein] |
CTD |
PMID:30391304 PMID:31028789 PMID:38523403 |
|
NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
Poly G inhibits the reaction [Silicon Dioxide results in increased expression of DDIT3 protein] |
CTD |
PMID:31028789 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions |
EXP |
[Poly G co-treated with Silicon Dioxide] results in increased expression of DNM1L protein |
CTD |
PMID:38523403 |
|
NCBI chr11:98,084,049...98,135,663
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
Poly G inhibits the reaction [Silicon Dioxide results in increased expression of ERN1 protein] |
CTD |
PMID:31028789 |
|
NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Poly G inhibits the reaction [Silicon Dioxide results in increased expression of HSPA5 protein] |
CTD |
PMID:31028789 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Marco |
macrophage receptor with collagenous structure |
multiple interactions |
ISO EXP |
Poly G inhibits the reaction [MARCO protein binds to and results in increased uptake of Polystyrenes] Poly G inhibits the reaction [Particulate Matter results in increased expression of MARCO protein]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of MARCO protein] |
CTD |
PMID:17361018 PMID:30391304 PMID:31028789 PMID:38523403 |
|
NCBI chr13:34,169,011...34,210,340
Ensembl chr13:31,616,278...31,648,521
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
EXP |
Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of MFN2 protein] |
CTD |
PMID:38523403 |
|
NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
EXP |
Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of COX1 protein] |
CTD |
PMID:38523403 |
|
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-nd1 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 |
multiple interactions |
EXP |
Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of ND1 protein] |
CTD |
PMID:38523403 |
|
NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of PPARGC1A mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of PPARGC1A protein] |
CTD |
PMID:38523403 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
EXP |
[Poly G co-treated with Silicon Dioxide] results in decreased expression of PRKN mRNA |
CTD |
PMID:38523403 |
|
NCBI chr 1:51,236,410...52,430,242
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Sdha |
succinate dehydrogenase complex flavoprotein subunit A |
multiple interactions |
EXP |
Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of SDHA protein] |
CTD |
PMID:38523403 |
|
NCBI chr 1:30,764,553...30,789,523
Ensembl chr 1:28,940,164...28,961,535
|
|
G |
Tfam |
transcription factor A, mitochondrial |
multiple interactions |
EXP |
[Poly G co-treated with Silicon Dioxide] results in increased expression of TFAM protein |
CTD |
PMID:38523403 |
|
NCBI chr20:17,355,373...17,367,422
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
Poly G inhibits the reaction [Particulate Matter results in increased expression of VIM mRNA]; Poly G inhibits the reaction [Particulate Matter results in increased expression of VIM protein]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of VIM mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein] |
CTD |
PMID:30391304 PMID:31028789 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of ABAT mRNA |
CTD |
PMID:35688559 |
|
NCBI chr10:7,503,351...7,599,474
Ensembl chr10:6,999,819...7,092,835
|
|
G |
Abhd2 |
abhydrolase domain containing 2, acylglycerol lipase |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ABHD2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:142,626,748...142,707,892
Ensembl chr 1:133,217,375...133,299,061
|
|
G |
Ablim1 |
actin-binding LIM protein 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ABLIM1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:266,088,868...266,377,169
Ensembl chr 1:256,084,297...256,371,969
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of ACADS mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:47,154,259...47,163,580
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ADAM10 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:80,226,862...80,358,728
Ensembl chr 8:71,345,837...71,477,889
|
|
G |
Adar |
adenosine deaminase, RNA-specific |
affects localization |
ISO |
Poly I-C affects the localization of ADAR protein |
CTD |
PMID:22240577 |
|
NCBI chr 2:177,436,076...177,475,969
Ensembl chr 2:175,138,403...175,178,282
|
|
G |
Ahcyl1 |
adenosylhomocysteinase-like 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of AHCYL1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:197,982,335...198,016,770
Ensembl chr 2:195,294,153...195,345,815
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of AHR mRNA; Poly I-C results in increased expression of AHR protein AHR protein affects the reaction [[Poly I-C co-treated with Tetrachlorodibenzodioxin] results in increased expression of IL22 mRNA] |
CTD |
PMID:27783115 PMID:35295139 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akap5 |
A-kinase anchoring protein 5 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of AKAP5 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:100,787,169...100,796,712
Ensembl chr 6:95,051,537...95,061,578
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of AMIGO2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 7:130,270,639...130,273,735
Ensembl chr 7:128,390,412...128,394,695
|
|
G |
Apobr |
apolipoprotein B receptor |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of APOBR mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:190,599,595...190,603,782
Ensembl chr 1:181,168,916...181,173,528
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of APP mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
increases degradation multiple interactions |
ISO |
Poly I-C results in increased degradation of APPL1 protein APPL1 protein inhibits the reaction [Poly I-C results in increased expression of IL1B protein]; APPL1 protein inhibits the reaction [Poly I-C results in increased expression of TNF protein]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IKBKE protein]; APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased degradation of APPL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; trametinib inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; U 0126 inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr16:2,125,234...2,173,457
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
affects methylation |
EXP |
Poly I-C affects the methylation of ARC promoter |
CTD |
PMID:32843831 |
|
NCBI chr 7:108,444,959...108,448,413
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Arfgef3 |
ARFGEF family member 3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ARFGEF3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:15,058,574...15,223,742
Ensembl chr 1:13,244,830...13,404,084
|
|
G |
Arg2 |
arginase 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of ARG2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:103,669,001...103,694,375
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgap11a |
Rho GTPase activating protein 11A |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of ARHGAP11A mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:121,045,187...121,071,985
Ensembl chr 3:100,590,865...100,607,559
|
|
G |
Arhgap44 |
Rho GTPase activating protein 44 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ARHGAP44 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:50,154,724...50,322,027
Ensembl chr10:49,655,584...49,824,297
|
|
G |
Arhgap9 |
Rho GTPase activating protein 9 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of ARHGAP9 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:65,034,023...65,042,336
Ensembl chr 7:63,148,900...63,157,524
|
|
G |
Arhgef12 |
Rho guanine nucleotide exchange factor 12 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ARHGEF12 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:52,247,047...52,373,158
Ensembl chr 8:43,353,799...43,476,366
|
|
G |
Arhgef7 |
Rho guanine nucleotide exchange factor 7 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ARHGEF7 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:84,373,123...84,484,759
Ensembl chr16:77,671,023...77,782,697
|
|
G |
Arsb |
arylsulfatase B |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ARSB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:26,736,395...26,895,682
Ensembl chr 2:25,002,346...25,162,671
|
|
G |
Art3 |
ADP-ribosyltransferase 3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of ART3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:15,921,540...16,003,764
Ensembl chr14:15,637,237...15,665,407
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Poly I-C results in increased expression of ATF3 mRNA |
CTD |
PMID:27783115 |
|
NCBI chr13:105,274,103...105,331,653
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp2b2 |
ATPase plasma membrane Ca2+ transporting 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ATP2B2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 4:148,450,207...148,763,653
Ensembl chr 4:146,896,332...147,140,665
|
|
G |
Atp6v0a2 |
ATPase H+ transporting V0 subunit a2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of ATP6V0A2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr12:37,608,211...37,640,860
Ensembl chr12:31,822,733...32,007,069
|
|
G |
Atxn3 |
ataxin 3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ATXN3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:126,837,107...126,872,919
Ensembl chr 6:121,074,448...121,107,902
|
|
G |
B3gnt7 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of B3GNT7 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 9:94,404,197...94,408,148
Ensembl chr 9:86,956,220...86,960,170
|
|
G |
B4galt5 |
beta-1,4-galactosyltransferase 5 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of B4GALT5 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 3:176,437,073...176,453,001
Ensembl chr 3:156,018,053...156,070,074
|
|
G |
Baalc |
BAALC binder of MAP3K1 and KLF4 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of BAALC mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 7:71,803,640...71,877,608
Ensembl chr 7:69,918,998...69,992,288
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Poly I-C results in increased expression of BAX protein |
CTD |
PMID:21418039 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Poly I-C results in decreased expression of BCL2 protein |
CTD |
PMID:21418039 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of BCL2A1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:98,596,806...98,604,890
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions affects methylation |
ISO EXP |
[Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of BDNF mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of BDNF mRNA] Poly I-C affects the methylation of BDNF promoter |
CTD |
PMID:24889602 PMID:32843831 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bid |
BH3 interacting domain death agonist |
decreases expression |
ISO |
Poly I-C results in decreased expression of BID protein |
CTD |
PMID:21418039 |
|
NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
Poly I-C promotes the reaction [arsenic trioxide results in decreased expression of BIRC5 protein] |
CTD |
PMID:21418039 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Birc6 |
baculoviral IAP repeat-containing 6 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of BIRC6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:26,474,843...26,668,275
Ensembl chr 6:20,722,922...20,916,434
|
|
G |
Blmh |
bleomycin hydrolase |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of BLMH mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:62,270,170...62,313,349
Ensembl chr10:61,758,478...61,815,212
|
|
G |
Bltp1 |
bridge-like lipid transfer protein family member 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of BLTP1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:121,636,181...121,852,802
Ensembl chr 2:119,708,209...119,924,695
|
|
G |
Bola2-ps4 |
bolA family member 2, pseudogene 4 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of BOLA2-PS4 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:173,691,781...173,692,136
|
|
G |
Brms1l |
BRMS1 like transcriptional repressor |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of BRMS1L mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:79,001,803...79,035,735
Ensembl chr 6:73,266,691...73,300,631
|
|
G |
Brox |
BRO1 domain and CAAX motif containing |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of BROX mRNA |
CTD |
PMID:26923065 |
|
NCBI chr13:97,451,736...97,471,598
Ensembl chr13:94,920,112...94,940,227
|
|
G |
C10h16orf90 |
similar to human chromosome 16 open reading frame 90 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of C10H16ORF90 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:12,125,235...12,138,441
Ensembl chr10:11,618,348...11,629,910
|
|
G |
C1qtnf7 |
C1q and TNF related 7 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of C1QTNF7 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:71,680,415...71,792,931
Ensembl chr14:67,468,014...67,580,410
|
|
G |
Cage1 |
cancer antigen 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of CAGE1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:26,995,671...27,033,740
Ensembl chr17:26,790,033...26,828,204
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of CA3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Acetylcysteine inhibits the reaction [arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP3 protein]]; Acetylcysteine inhibits the reaction [Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]]; arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP3 protein]; Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein] |
CTD |
PMID:21418039 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP8 protein]; Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP8 protein] |
CTD |
PMID:21418039 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
Acetylcysteine inhibits the reaction [arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP9 protein]]; Acetylcysteine inhibits the reaction [Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]]; arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP9 protein]; Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein] |
CTD |
PMID:21418039 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases expression |
EXP |
Poly I-C results in decreased expression of CAT mRNA |
CTD |
PMID:23939143 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of CAV1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cbx1 |
chromobox 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of CBX1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:82,266,746...82,286,431
Ensembl chr10:81,770,342...81,791,096
|
|
G |
Cbx6 |
chromobox 6 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of CBX6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:113,253,364...113,263,413
Ensembl chr 7:111,372,980...111,383,091
|
|
G |
Ccl1 |
C-C motif chemokine ligand 1 |
increases expression |
ISO |
Poly I-C results in increased expression of CCL1 mRNA |
CTD |
PMID:27783115 |
|
NCBI chr10:67,625,962...67,628,740
Ensembl chr10:67,128,331...67,131,159
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions increases secretion |
ISO |
methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL11 protein] |
CTD |
PMID:24056979 |
|
NCBI chr10:67,525,975...67,530,576
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases secretion increases expression |
ISO EXP |
methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL2 protein] Poly I-C results in increased expression of CCL2 mRNA |
CTD |
PMID:23939143 PMID:24056979 PMID:34740670 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased secretion of CCL20 protein |
CTD |
PMID:35688559 |
|
NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
Ethanol inhibits the reaction [Poly I-C results in increased expression of CCL3 protein] [TL8-506 co-treated with Poly I-C] results in increased expression of CCL3 mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of CCL3 protein |
CTD |
PMID:19500611 PMID:35688559 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions increases expression increases secretion |
ISO |
Ethanol inhibits the reaction [Poly I-C results in increased expression of CCL4 protein]; methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL4 protein] 6-formylindolo(3,2-b)carbazole inhibits the reaction [Poly I-C results in increased expression of CCL4 mRNA]; [TL8-506 co-treated with Poly I-C] results in increased expression of CCL4 mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of CCL4 protein; Tetrachlorodibenzodioxin inhibits the reaction [Poly I-C results in increased expression of CCL4 mRNA] |
CTD |
PMID:19500611 PMID:24056979 PMID:27783115 PMID:35688559 |
|
NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions increases expression increases secretion |
ISO |
APPL1 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL5 protein]; trametinib promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA] Poly I-C results in increased expression of CCL5; Poly I-C results in increased expression of CCL5 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; [Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA; [TL8-506 co-treated with Poly I-C] results in increased expression of CCL5 mRNA; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Particulate Matter inhibits the reaction [Poly I-C results in increased expression of CCL5]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of CCL5] |
CTD |
PMID:23688403 PMID:24056979 PMID:24709138 PMID:25780039 PMID:35688559 |
|
NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of CCR7 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr10:84,594,399...84,604,514
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Cd200 |
Cd200 molecule |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of CD200 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr11:68,916,200...68,943,570
Ensembl chr11:55,410,196...55,501,648
|
|
G |
Cd40 |
CD40 molecule |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of CD40 protein [Poly I-C co-treated with IFNG protein] results in increased secretion of CD40 protein; [TL8-506 co-treated with Poly I-C] results in increased expression of CD40 mRNA |
CTD |
PMID:15246609 PMID:16224278 PMID:35688559 |
|
NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of CD44 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd80 |
Cd80 molecule |
increases expression |
ISO |
Poly I-C results in increased expression of CD80 protein |
CTD |
PMID:15246609 |
|
NCBI chr11:75,760,073...75,798,978
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd83 |
CD83 molecule |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of CD83 protein CEP-11004 inhibits the reaction [Poly I-C results in increased expression of CD83 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased expression of CD83 protein] |
CTD |
PMID:17698565 |
|
NCBI chr17:21,093,281...21,113,223
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions increases expression |
ISO |
[Poly I-C co-treated with IFNG protein] results in increased secretion of CD86 protein; CEP-11004 inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; Particulate Matter analog inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; Vehicle Emissions analog inhibits the reaction [Poly I-C results in increased expression of CD86 protein] |
CTD |
PMID:15246609 PMID:16224278 PMID:16890772 PMID:17698565 |
|
NCBI chr11:77,647,565...77,706,178
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdc42 |
cell division cycle 42 |
multiple interactions |
ISO |
[Poly I-C co-treated with Atorvastatin] results in decreased expression of CDC42 mRNA |
CTD |
PMID:34696514 |
|
NCBI chr 5:154,838,478...154,876,629
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdc42ep3 |
CDC42 effector protein 3 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of CDC42EP3 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 6:21,463,081...21,483,553
Ensembl chr 6:15,708,730...15,732,721
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of CDH1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of CDK6 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdx2 |
caudal type homeo box 2 |
multiple interactions |
ISO |
[Poly I-C co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of CDX2 mRNA; [Poly I-C co-treated with Tetrachlorodibenzodioxin] results in increased expression of CDX2 mRNA |
CTD |
PMID:27783115 |
|
NCBI chr12:12,762,769...12,769,246
Ensembl chr12:7,726,798...7,733,142
|
|
G |
Celf1 |
CUGBP, Elav-like family member 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of CELF1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:97,380,407...97,455,253
Ensembl chr 3:76,924,613...76,999,426
|
|
G |
Cfap263 |
cilia and flagella associated protein 263 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of CCDC113 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr19:9,503,062...9,522,957
Ensembl chr19:9,496,886...9,516,923
|
|
G |
Cfp |
complement factor properdin |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of CFP mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:3,715,551...3,721,113
Ensembl chr X:1,161,979...1,167,573
|
|
G |
Chsy1 |
chondroitin sulfate synthase 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of CHSY1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:129,100,088...129,161,167
Ensembl chr 1:119,686,350...119,750,601
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
inotodiol inhibits the reaction [Poly I-C results in increased expression of and results in increased phosphorylation of CHUK protein]; Poly I-C results in increased expression of and results in increased phosphorylation of CHUK protein |
CTD |
PMID:37886743 |
|
NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cibar2 |
CBY1 interacting BAR domain containing 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of CIBAR2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr19:65,126,231...65,138,015
Ensembl chr19:48,215,486...48,229,404
|
|
G |
Ckb |
creatine kinase B |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of CKB mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Clcc1 |
chloride channel CLIC-like 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of CLCC1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:198,984,455...199,015,015
Ensembl chr 2:196,296,393...196,326,913
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of CLCF1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:210,937,763...210,947,064
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Clec14a |
C-type lectin domain containing 14A |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of CLEC14A mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:81,616,414...81,619,556
Ensembl chr 6:75,881,473...75,884,612
|
|
G |
Clip3 |
CAP-GLY domain containing linker protein 3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of CLIP3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:94,674,492...94,690,643
Ensembl chr 1:85,547,206...85,563,184
|
|
G |
Cnnm1 |
cyclin and CBS domain divalent metal cation transport mediator 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of CNNM1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:252,245,377...252,304,205
Ensembl chr 1:242,296,422...242,353,513
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein]]; Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein] |
CTD |
PMID:31202911 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
increases expression |
EXP |
Poly I-C results in increased expression of CNR2 mRNA |
CTD |
PMID:27317300 |
|
NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Cntn1 |
contactin 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of CNTN1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:125,142,638...125,440,397
Ensembl chr 7:123,372,792...123,558,541
|
|
G |
Crabp1 |
cellular retinoic acid binding protein 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of CRABP1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:64,047,431...64,055,469
Ensembl chr 8:55,151,285...55,159,360
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions increases secretion increases expression |
ISO |
Ethanol inhibits the reaction [Poly I-C results in increased expression of CSF2 protein] Poly I-C results in increased secretion of CSF2 protein [TL8-506 co-treated with Poly I-C] results in increased expression of CSF2 mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of CSF2 protein; Smoke inhibits the reaction [Poly I-C results in increased secretion of CSF2 protein] |
CTD |
PMID:19500611 PMID:35688559 PMID:35817128 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csrp2 |
cysteine and glycine-rich protein 2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of CSRP2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 7:48,235,415...48,254,049
Ensembl chr 7:46,348,686...46,367,745
|
|
G |
Cttnbp2 |
cortactin binding protein 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of CTTNBP2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 4:47,766,867...47,930,598
Ensembl chr 4:46,800,981...46,964,631
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression multiple interactions |
EXP ISO |
Poly I-C results in increased expression of CXCL1 mRNA [TL8-506 co-treated with Poly I-C] results in increased secretion of CXCL1 protein |
CTD |
PMID:23939143 PMID:35688559 |
|
NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions increases secretion increases expression |
ISO EXP |
APPL1 protein promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; chrysin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; eriodictyol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Quercetin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA] Poly I-C results in increased secretion of CXCL10 protein cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA] Poly I-C results in increased expression of CXCL10 mRNA; Poly I-C results in increased expression of CXCL10 protein [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; [Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein; bafilomycin A1 inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased secretion of CXCL10 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Dronabinol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Dronabinol inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Particulate Matter inhibits the reaction [[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein]; Phosphorothioate Oligonucleotides inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Smoke inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Smoke inhibits the reaction [Poly I-C results in increased secretion of CXCL10 protein]; Vehicle Emissions inhibits the reaction [[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein] |
CTD |
PMID:19426678 PMID:25780039 PMID:26682054 PMID:28003376 PMID:28572013 PMID:28655636 PMID:28726298 PMID:32244040 PMID:34740670 PMID:35817128 PMID:36958387 More...
|
|
NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
EXP |
Poly I-C results in increased expression of CXCL2 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
Ethanol inhibits the reaction [Poly I-C results in increased expression of CXCL1 protein] [TL8-506 co-treated with Poly I-C] results in increased secretion of CXCL1 protein |
CTD |
PMID:19500611 PMID:35688559 |
|
NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions increases secretion increases expression |
ISO |
Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL9 mRNA]; methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CXCL9 protein] |
CTD |
PMID:19426678 PMID:24056979 |
|
NCBI chr14:16,007,166...16,012,077
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cyfip2 |
cytoplasmic FMR1 interacting protein 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of CYFIP2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:31,122,653...31,242,440
Ensembl chr10:30,621,318...30,741,113
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Poly I-C promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:27783115 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases expression |
EXP |
Poly I-C results in decreased expression of CYP2C11 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases expression |
EXP |
Poly I-C results in decreased expression of CYP2C6 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c7 |
cytochrome P450, family 2, subfamily c, polypeptide 7 |
decreases expression |
EXP |
Poly I-C results in decreased expression of CYP2C7 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr 1:247,966,295...248,022,393
Ensembl chr 1:237,332,659...237,388,709
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
decreases expression |
EXP |
Poly I-C results in decreased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr12:14,369,950...14,398,803
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyria |
CYFIP related Rac1 interactor A |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of CYRIA mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:40,774,165...40,883,005
Ensembl chr 6:35,045,208...35,150,668
|
|
G |
Cysrt1 |
cysteine rich tail 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of CYSRT1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:28,452,359...28,456,006
Ensembl chr 3:8,053,482...8,059,721
|
|
G |
Dab1 |
DAB adaptor protein 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of DAB1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:123,621,510...124,742,585
Ensembl chr 5:119,140,533...119,510,552
|
|
G |
Dck |
deoxycytidine kinase |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of DCK mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:19,589,298...19,610,326
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Dcun1d3 |
defective in cullin neddylation 1 domain containing 3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of DCUN1D3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:183,674,364...183,717,002
Ensembl chr 1:66,494,848...66,496,343 Ensembl chr 1:66,494,848...66,496,343
|
|
G |
Dcun1d4 |
defective in cullin neddylation 1 domain containing 4 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of DCUN1D4 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:35,006,792...35,087,285
Ensembl chr14:34,652,723...34,733,207
|
|
G |
Ddx21 |
DExD-box helicase 21 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of DDX21 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr20:31,077,044...31,097,238
Ensembl chr20:30,534,319...30,554,543
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of DDX3X mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:12,152,346...12,165,983
Ensembl chr X:9,479,532...9,493,168
|
|
G |
Ddx60 |
DEXD/H-box helicase 60 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of DDX60 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr16:33,087,940...33,208,843
Ensembl chr16:28,076,999...28,179,526
|
|
G |
Defb5 |
defensin beta 5 |
increases secretion |
ISO |
Poly I-C results in increased secretion of DEFB4 protein |
CTD |
PMID:17669408 |
|
NCBI chr16:77,315,424...77,317,828
Ensembl chr16:70,613,146...70,615,467
|
|
G |
Dhx58 |
DEXH-box helicase 58 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of DHX58 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr10:86,120,677...86,132,095
Ensembl chr10:85,620,357...85,631,525
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of DLG1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:82,416,853...82,607,797
Ensembl chr11:68,911,883...69,102,689
|
|
G |
Dnm2 |
dynamin 2 |
multiple interactions |
ISO |
DNM2 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:25780039 |
|
NCBI chr 8:28,254,344...28,336,297
Ensembl chr 8:19,978,400...20,060,157
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in increased expression of DNMT1 mRNA; [Arsenicals co-treated with Poly I-C] results in increased expression of DNMT1 mRNA |
CTD |
PMID:34303791 |
|
NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
ISO |
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in increased expression of DNMT3A mRNA; [Arsenicals co-treated with Poly I-C] results in increased expression of DNMT3A mRNA |
CTD |
PMID:34303791 |
|
NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Ebi3 |
Epstein-Barr virus induced 3 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of EBI3 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 9:861,441...874,731
Ensembl chr 9:783,617...787,544
|
|
G |
Eea1 |
early endosome antigen 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of EEA1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:32,441,281...32,608,808
Ensembl chr 7:30,554,552...30,718,487
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions affects methylation |
ISO EXP |
[Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of EGR1 mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR1 mRNA] Poly I-C affects the methylation of EGR1 promoter |
CTD |
PMID:24889602 PMID:32843831 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
increases expression increases phosphorylation increases response to substance |
ISO |
Poly I-C results in increased expression of EIF2AK2 mRNA Poly I-C results in increased phosphorylation of EIF2AK2 protein EIF2AK2 results in increased susceptibility to Poly I-C |
CTD |
PMID:10944112 PMID:17669408 PMID:22240577 PMID:22558189 |
|
NCBI chr 6:21,941,147...21,977,115
Ensembl chr 6:16,188,979...16,224,971
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
ISO |
Poly I-C results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:22240577 |
|
NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Epb41l5 |
erythrocyte membrane protein band 4.1 like 5 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of EPB41L5 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr13:33,221,705...33,321,400
Ensembl chr13:30,669,764...30,768,360
|
|
G |
Epc2l1 |
enhancer of polycomb homolog 2 (Drosophila)-like 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of EPC2L1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:91,059,649...91,062,367
Ensembl chr 1:81,932,016...81,934,442
|
|
G |
Ext1 |
exostosin glycosyltransferase 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of EXT1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 7:86,265,651...86,544,488
Ensembl chr 7:84,375,784...84,655,357
|
|
G |
F11r |
F11 receptor |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; CpG ODN 2006 inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; RTKI cpd inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; SB 203580 inhibits the reaction [Poly I-C results in decreased expression of F11R protein] |
CTD |
PMID:20932985 |
|
NCBI chr13:86,406,229...86,429,819
Ensembl chr13:83,873,797...83,897,402
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO |
Poly I-C results in increased expression of FABP4 mRNA |
CTD |
PMID:15705927 |
|
NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fam107a |
family with sequence similarity 107, member A |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of FAM107A mRNA |
CTD |
PMID:26923065 |
|
NCBI chr15:19,038,726...19,060,644
Ensembl chr15:16,607,205...16,630,396
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of FLT1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr12:12,333,050...12,504,750
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions decreases expression |
ISO |
Suramin inhibits the reaction [Poly I-C results in decreased expression of FMR1 protein] |
CTD |
PMID:23516405 |
|
NCBI chr X:152,284,857...152,322,686
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of FOSL1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxp1 |
forkhead box P1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of FOXP1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 4:133,117,346...133,808,647
Ensembl chr 4:131,564,756...132,112,258
|
|
G |
Fsd1l |
fibronectin type III and SPRY domain containing 1-like |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of FSD1L mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 5:73,052,565...73,130,292
Ensembl chr 5:68,258,932...68,334,928
|
|
G |
Fxyd3 |
FXYD domain-containing ion transport regulator 3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of FXYD3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:95,432,918...95,440,129
|
|
G |
Fxyd6 |
FXYD domain-containing ion transport regulator 6 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of FXYD6 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 8:54,575,578...54,602,715
Ensembl chr 8:45,678,885...45,705,958
|
|
G |
Fyttd1 |
forty-two-three domain containing 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of FYTTD1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:81,383,040...81,412,604
Ensembl chr11:67,877,967...67,907,511
|
|
G |
G0s2 |
G0/G1switch 2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of G0S2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr13:107,335,036...107,335,948
Ensembl chr13:104,806,156...104,807,451
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
affects localization |
ISO |
Poly I-C affects the localization of G3BP1 protein |
CTD |
PMID:22240577 |
|
NCBI chr10:40,087,533...40,120,931
Ensembl chr10:39,586,864...39,620,268
|
|
G |
G3bp2 |
G3BP stress granule assembly factor 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of G3BP2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:16,216,684...16,304,828
Ensembl chr14:15,987,417...16,020,548
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of GABRA1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:27,096,731...27,152,563
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of GABRB2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:27,438,127...27,657,680
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of GABRG2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:26,876,926...26,965,523
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
decreases expression multiple interactions |
EXP |
Poly I-C results in decreased expression of GAD1 protein Cannabidiol inhibits the reaction [Poly I-C results in decreased expression of GAD1 protein] |
CTD |
PMID:31202911 |
|
NCBI chr 3:75,777,260...75,818,099
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Galnt12 |
polypeptide N-acetylgalactosaminyltransferase 12 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of GALNT12 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 5:66,180,171...66,208,931
Ensembl chr 5:61,384,571...61,413,354
|
|
G |
Galnt3 |
polypeptide N-acetylgalactosaminyltransferase 3 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of GALNT3 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 3:71,150,559...71,187,321
Ensembl chr 3:50,742,512...50,766,268
|
|
G |
Gdap1 |
ganglioside-induced differentiation-associated-protein 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of GDAP1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:6,715,935...6,735,013
Ensembl chr 5:1,932,613...2,030,061
|
|
G |
Gdi1 |
GDP dissociation inhibitor 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of GDI1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:157,238,900...157,245,562
Ensembl chr X:152,087,444...152,094,272
|
|
G |
Get3 |
guided entry of tail-anchored proteins factor 3, ATPase |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of GET3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr19:40,034,675...40,043,064
Ensembl chr19:23,130,109...23,138,193
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
EXP |
Poly I-C results in increased expression of GFAP mRNA |
CTD |
PMID:27317300 |
|
NCBI chr10:88,352,987...88,361,661
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gh1 |
growth hormone 1 |
decreases expression |
ISO |
Poly I-C results in decreased expression of GH protein |
CTD |
PMID:21195166 |
|
NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Glce |
glucuronic acid epimerase |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of GLCE mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:71,441,607...71,507,639
Ensembl chr 8:62,546,107...62,612,040
|
|
G |
Glrb |
glycine receptor, beta |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of GLRB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:168,432,736...168,505,614
Ensembl chr 2:166,134,626...166,207,489
|
|
G |
Glyr1 |
glyoxylate reductase 1 homolog |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of GLYR1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:11,038,577...11,074,093
Ensembl chr10:10,532,154...10,567,637
|
|
G |
Gmfb |
glia maturation factor, beta |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of GMFB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr15:22,549,705...22,560,125
Ensembl chr15:20,067,263...20,080,331
|
|
G |
Gmppb |
GDP-mannose pyrophosphorylase B |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of GMPPB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:117,616,029...117,622,866
Ensembl chr 8:108,693,060...108,767,286
|
|
G |
Gns |
glucosamine (N-acetyl)-6-sulfatase |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of GNS mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 7:58,774,625...58,808,650
Ensembl chr 7:56,889,232...56,923,151
|
|
G |
Gpatch2l |
G patch domain containing 2-like |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of GPATCH2L mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:111,614,344...111,666,603
Ensembl chr 6:105,883,460...105,934,888
|
|
G |
Gpbp1 |
GC-rich promoter binding protein 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of GPBP1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:44,756,861...44,824,281
Ensembl chr 2:43,023,504...43,090,907
|
|
G |
Grwd1 |
glutamate-rich WD repeat containing 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of GRWD1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:105,437,708...105,443,410
Ensembl chr 1:96,301,261...96,307,201
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases expression |
EXP |
Poly I-C results in decreased expression of GSR mRNA |
CTD |
PMID:23939143 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gtpbp4 |
GTP binding protein 4 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of GTPBP4 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr17:65,997,472...66,019,530
Ensembl chr17:61,308,014...61,418,009
|
|
G |
Gzmb |
granzyme B |
multiple interactions increases expression |
ISO |
Particulate Matter inhibits the reaction [Poly I-C results in increased expression of GZMB mRNA]; Particulate Matter inhibits the reaction [Poly I-C results in increased expression of GZMB protein]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of GZMB mRNA]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of GZMB protein] Poly I-C results in increased expression of GZMB mRNA; Poly I-C results in increased expression of GZMB protein |
CTD |
PMID:23618096 |
|
NCBI chr15:34,459,007...34,462,469
Ensembl chr15:30,173,603...30,346,814
|
|
G |
Haus6 |
HAUS augmin like complex subunit 6 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of HAUS6 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 5:106,162,526...106,201,503
Ensembl chr 5:101,119,300...101,153,124
|
|
G |
Herc6 |
HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of HERC6 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 4:88,854,612...88,897,043
Ensembl chr 4:87,524,493...87,581,744
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of HEY2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:28,641,100...28,651,187
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
Indoprofen inhibits the reaction [Poly I-C results in increased secretion of and affects the localization of HMGB1 protein]; Poly I-C results in increased secretion of and affects the localization of HMGB1 protein |
CTD |
PMID:34755645 |
|
NCBI chr12:11,009,236...11,015,941
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP |
Diclofenac promotes the reaction [Poly I-C results in increased expression of HMOX1 mRNA] |
CTD |
PMID:23939143 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
EXP |
Poly I-C results in increased expression of HSP90AA1 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
increases expression |
EXP |
Poly I-C results in increased expression of HSPA1A mRNA |
CTD |
PMID:23939143 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
EXP |
Poly I-C results in increased expression of HSPA8 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
increases expression |
ISO |
Poly I-C results in increased expression of HTR2A mRNA |
CTD |
PMID:24889602 |
|
NCBI chr15:56,360,647...56,428,703
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Hycc1 |
hyccin PI4KA lipid kinase complex subunit 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of FAM126A mRNA; [TL8-506 co-treated with Poly I-C] results in increased expression of HYCC1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 4:12,024,692...12,131,504
Ensembl chr 4:11,132,385...11,239,113
|
|
G |
Ibtk |
inhibitor of Bruton tyrosine kinase |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of IBTK mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:95,505,630...95,579,435
Ensembl chr 8:86,625,597...86,698,260
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of IDO1 mRNA poly(I:C) co-treated with tryptophan or alone increases activity and expression of IDO1 protein in Langerhans cell-like dendritic cells |
CTD RGD |
PMID:27783115 PMID:26198597 |
RGD:11528429 |
NCBI chr16:74,133,259...74,145,328
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Ido2 |
indoleamine 2,3-dioxygenase 2 |
increases expression |
ISO |
Poly I-C results in increased expression of IDO2 mRNA |
CTD |
PMID:27783115 |
|
NCBI chr16:74,161,761...74,200,651
Ensembl chr16:67,459,190...67,496,324
|
|
G |
Ifi44 |
interferon-induced protein 44 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of IFI44 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 2:243,286,050...243,303,869
Ensembl chr 2:240,626,066...240,643,844
|
|
G |
Ifih1 |
interferon induced with helicase C domain 1 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of IFIH1 mRNA IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIH1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IFIH1 mRNA] |
CTD |
PMID:30341573 PMID:31154625 |
|
NCBI chr 3:67,635,924...67,683,968
Ensembl chr 3:47,227,364...47,275,456
|
|
G |
Ifit2 |
interferon-induced protein with tetratricopeptide repeats 2 |
multiple interactions increases expression |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of IFIT2 mRNA; Acetylcysteine inhibits the reaction [Dieldrin inhibits the reaction [Poly I-C results in increased expression of IFIT2 mRNA]]; Dieldrin inhibits the reaction [Poly I-C results in increased expression of IFIT2 mRNA] |
CTD |
PMID:34051100 PMID:35688559 |
|
NCBI chr 1:241,515,735...241,521,799
Ensembl chr 1:232,102,570...232,108,635
|
|
G |
Ifitm1 |
interferon induced transmembrane protein 1 |
increases expression |
ISO |
Poly I-C results in increased expression of IFITM1 mRNA |
CTD |
PMID:22240577 |
|
NCBI chr 1:205,496,757...205,498,796
Ensembl chr 1:196,067,963...196,069,169
|
|
G |
Ifna1 |
interferon, alpha 1 |
increases expression |
EXP |
Poly I-C results in increased expression of IFNA1 mRNA |
CTD |
PMID:28726298 |
|
NCBI chr 5:108,143,240...108,143,809
Ensembl chr 5:103,097,356...103,097,925
|
|
G |
Ifnb1 |
interferon beta 1 |
increases expression increases secretion multiple interactions |
ISO EXP |
Poly I-C results in increased expression of IFNB1 mRNA; Poly I-C results in increased expression of IFNB1 protein Poly I-C results in increased secretion of IFNB1 protein MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] apilimod inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; BX795 inhibits the reaction [Poly I-C results in increased expression of IFNB1 protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Progesterone inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Resveratrol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Sodium Selenite inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA] [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; [TL8-506 co-treated with Poly I-C] results in increased expression of IFNB1 mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of IFNB1 protein; [Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of IFNB1 mRNA; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Dronabinol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; IRF7 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; IRF7 protein mutant form affects the reaction [Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]]; IRF7 protein mutant form inhibits the reaction [Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Smoke inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Wortmannin inhibits the reaction [[Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of IFNB1 mRNA] |
CTD |
PMID:16116226 PMID:16399790 PMID:17669408 PMID:18279804 PMID:18323514 PMID:18779317 PMID:19426678 PMID:21418039 PMID:22546503 PMID:22558189 PMID:24423102 PMID:24600036 PMID:25780039 PMID:28572013 PMID:28726298 PMID:30726814 PMID:31154625 PMID:32244040 PMID:35688559 PMID:35817128 PMID:36958387 More...
|
|
NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases secretion increases expression |
ISO EXP |
[Poly I-C co-treated with IFNG protein] results in increased secretion of CD40 protein; [Poly I-C co-treated with IFNG protein] results in increased secretion of CD86 protein; Smoke inhibits the reaction [Poly I-C results in increased expression of IFNG mRNA] Poly I-C results in increased secretion of IFNG protein Ethanol inhibits the reaction [Poly I-C results in increased expression of IFNG protein] Poly I-C results in increased expression of IFNG mRNA; Poly I-C results in increased expression of IFNG protein |
CTD |
PMID:9328138 PMID:16224278 PMID:17321468 PMID:19500611 PMID:23618096 PMID:23939143 PMID:28572013 PMID:30836164 More...
|
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifnl1 |
interferon, lambda 1 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of IFNL1 mRNA Smoke inhibits the reaction [Poly I-C results in increased expression of IFNL1 mRNA] |
CTD |
PMID:35817128 |
|
NCBI chr 1:92,926,184...92,927,830
Ensembl chr 1:83,798,703...83,800,235
|
|
G |
Ifnlr1 |
interferon, lambda receptor 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of IFNLR1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 5:153,203,597...153,225,911
Ensembl chr 5:147,919,908...147,942,332
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions decreases expression |
ISO |
IL6 protein affects the reaction [Poly I-C results in decreased expression of IGF1 protein] Poly I-C results in decreased expression of IGF1 mRNA; Poly I-C results in decreased expression of IGF1 protein |
CTD |
PMID:1705203 PMID:21195166 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf2r |
insulin-like growth factor 2 receptor |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of IGF2R mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:50,526,878...50,615,265
Ensembl chr 1:47,979,109...48,067,501
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions decreases expression |
ISO |
IL6 protein affects the reaction [Poly I-C results in decreased expression of IGFBP3 protein] |
CTD |
PMID:21195166 |
|
NCBI chr14:86,270,208...86,277,944
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igsf3 |
immunoglobulin superfamily, member 3 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of IGSF3 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 2:191,499,972...191,588,249
Ensembl chr 2:188,811,380...188,899,645
|
|
G |
Igsf6 |
immunoglobulin superfamily, member 6 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of IGSF6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:185,041,462...185,051,956
Ensembl chr 1:175,610,167...175,620,722
|
|
G |
Ikbke |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
multiple interactions increases phosphorylation |
ISO |
APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IKBKE protein] |
CTD |
PMID:25780039 |
|
NCBI chr13:45,264,404...45,290,737
Ensembl chr13:42,712,159...42,737,143
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression increases secretion |
ISO EXP |
[TL8-506 co-treated with Poly I-C] results in increased secretion of IL10 protein; CEP-11004 inhibits the reaction [Poly I-C results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of IL10 protein] Poly I-C results in increased expression of IL10 mRNA Poly I-C results in increased expression of IL10 mRNA; Poly I-C results in increased expression of IL10 protein Citrinin inhibits the reaction [Poly I-C results in increased expression of IL10 mRNA]; Citrinin inhibits the reaction [Poly I-C results in increased expression of IL10 protein] |
CTD |
PMID:16224278 PMID:17698565 PMID:22771370 PMID:23618096 PMID:23939143 PMID:30836164 PMID:35688559 More...
|
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12a |
interleukin 12A |
multiple interactions increases expression |
ISO |
6-formylindolo(3,2-b)carbazole inhibits the reaction [Poly I-C results in increased expression of IL12A mRNA]; [CL 075 co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; [resiquimod co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; [TL8-506 co-treated with Poly I-C] results in increased expression of IL12A mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; indole-3-carbinol inhibits the reaction [Poly I-C results in increased expression of IL12A mRNA]; Poly I-C promotes the reaction [TL8-506 results in increased secretion of [IL12A protein binds to IL12B protein]]; Tetrachlorodibenzodioxin inhibits the reaction [Poly I-C results in increased expression of IL12A mRNA] |
CTD |
PMID:27783115 PMID:35688559 |
|
NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases expression |
ISO |
[[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of IL12B protein; [CL 075 co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; [resiquimod co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; [TL8-506 co-treated with Poly I-C] results in increased expression of IL12B mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; Particulate Matter analog inhibits the reaction [Poly I-C results in increased expression of IL12B protein]; Poly I-C promotes the reaction [TL8-506 results in increased secretion of [IL12A protein binds to IL12B protein]]; Vehicle Emissions analog inhibits the reaction [Poly I-C results in increased expression of IL12B protein] Poly I-C results in increased expression of IL12B mRNA; Poly I-C results in increased expression of IL12B protein Ethanol inhibits the reaction [Poly I-C results in increased expression of IL12B protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL12B mRNA] |
CTD |
PMID:16890772 PMID:19426678 PMID:19500611 PMID:23266719 PMID:35688559 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased secretion of IL13 protein |
CTD |
PMID:35688559 |
|
NCBI chr10:38,290,926...38,293,483
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il17a |
interleukin 17A |
increases expression |
ISO |
Poly I-C results in increased expression of IL17A protein |
CTD |
PMID:30836164 |
|
NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of IL1A mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of IL1A protein |
CTD |
PMID:35688559 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion increases expression |
ISO EXP |
APPL1 protein inhibits the reaction [Poly I-C results in increased expression of IL1B protein]; Citrinin inhibits the reaction [Poly I-C results in increased expression of IL1B mRNA]; Ethanol inhibits the reaction [Poly I-C results in increased expression of IL1B protein]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA] Poly I-C results in increased secretion of IL1B protein 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of IL1B protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of IL1B protein]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Poly I-C results in increased expression of IL1B mRNA]; [TL8-506 co-treated with Poly I-C] results in increased expression of IL1B mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of IL1B protein; Estradiol promotes the reaction [Poly I-C results in increased expression of IL1B protein]; inotodiol inhibits the reaction [Poly I-C results in increased expression of IL1B mRNA]; inotodiol inhibits the reaction [Poly I-C results in increased secretion of IL1B protein]; Tetrachlorodibenzodioxin promotes the reaction [Poly I-C results in increased expression of IL1B mRNA] Poly I-C results in increased expression of IL1B mRNA; Poly I-C results in increased expression of IL1B protein |
CTD |
PMID:16687389 PMID:17321468 PMID:19500611 PMID:22771370 PMID:23618096 PMID:23939143 PMID:25780039 PMID:27783115 PMID:28316773 PMID:30017638 PMID:35688559 PMID:37886743 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of IL1R1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of IL1RN mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il2 |
interleukin 2 |
increases expression increases secretion |
ISO |
Poly I-C results in increased expression of IL2 mRNA Poly I-C results in increased secretion of IL2 protein |
CTD |
PMID:9328138 PMID:23618096 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il21 |
interleukin 21 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased secretion of IL21 protein |
CTD |
PMID:35688559 |
|
NCBI chr 2:122,045,240...122,055,142
Ensembl chr 2:120,119,444...120,126,996
|
|
G |
Il22 |
interleukin 22 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased secretion of IL22 protein |
CTD |
PMID:35688559 |
|
NCBI chr 7:55,687,061...55,691,526
Ensembl chr 7:53,801,206...53,806,186
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of IL23A mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of IL23A protein |
CTD |
PMID:35688559 |
|
NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:721,809...723,923
|
|
G |
Il27 |
interleukin 27 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of IL27 mRNA [TL8-506 co-treated with Poly I-C] results in increased secretion of IL27 protein Luteolin inhibits the reaction [Poly I-C results in increased expression of IL27 mRNA] |
CTD |
PMID:19426678 PMID:35688559 |
|
NCBI chr 1:190,603,684...190,609,292
Ensembl chr 1:181,173,372...181,178,582
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of IL2RA mRNA |
CTD |
PMID:35688559 |
|
NCBI chr17:71,759,802...71,808,475
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased secretion of IL3 protein |
CTD |
PMID:35688559 |
|
NCBI chr10:38,906,460...38,908,810
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il33 |
interleukin 33 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of IL33 protein N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Poly I-C results in increased expression of IL33 protein] 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of IL33 protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of IL33 protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of IL33 protein] |
CTD |
PMID:25747661 PMID:30017638 |
|
NCBI chr 1:237,115,478...237,149,897
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il4 |
interleukin 4 |
multiple interactions increases expression increases secretion increases response to substance |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of IL4 protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2; [Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2; [Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein; [Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein; [Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprost; [Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone; [Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2; [TL8-506 co-treated with Poly I-C] results in increased secretion of IL4 protein; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; amorolfine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; butenafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Estradiol promotes the reaction [Poly I-C results in increased expression of IL4 protein]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Itraconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Ketoconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; luliconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Particulate Matter inhibits the reaction [Poly I-C results in increased secretion of IL4 protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Terbinafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased secretion of IL4 protein] IL4 protein results in increased susceptibility to Poly I-C |
CTD |
PMID:23618096 PMID:23688403 PMID:30017638 PMID:30836164 PMID:34740670 PMID:35688559 More...
|
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion increases expression |
ISO EXP |
[TL8-506 co-treated with Poly I-C] results in increased expression of IL6 mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of IL6 protein; [Vehicle Emissions analog co-treated with Poly I-C] results in increased secretion of IL6 protein; CEP-11004 inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; inotodiol inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; inotodiol inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; Particulate Matter promotes the reaction [Poly I-C results in increased expression of IL6]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; Smoke inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]; TRAF6 mutant form inhibits the reaction [Vehicle Emissions analog promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]]; Vehicle Emissions analog promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]; Vehicle Emissions promotes the reaction [Poly I-C results in increased expression of IL6] Poly I-C results in increased expression of IL6 mRNA; Poly I-C results in increased expression of IL6 protein Ethanol inhibits the reaction [Poly I-C results in increased expression of IL6 protein]; IL6 protein affects the reaction [Poly I-C results in decreased expression of IGF1 protein]; IL6 protein affects the reaction [Poly I-C results in decreased expression of IGFBP3 protein]; IL6 protein affects the reaction [Poly I-C results in increased expression of PRL2B1 mRNA]; IL6 protein affects the reaction [Poly I-C results in increased phosphorylation of and results in increased activity of STAT3 protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA] Poly I-C results in increased expression of IL6; Poly I-C results in increased expression of IL6 mRNA |
CTD |
PMID:9328138 PMID:16399790 PMID:16687389 PMID:17698565 PMID:18323514 PMID:19426678 PMID:19500611 PMID:21195166 PMID:23939143 PMID:24709138 PMID:26160521 PMID:28316773 PMID:30341573 PMID:30726814 PMID:30836164 PMID:35688559 PMID:35817128 PMID:36958387 PMID:37886743 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of INSIG1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Irf3 |
interferon regulatory factor 3 |
increases phosphorylation affects localization multiple interactions |
ISO |
Poly I-C results in increased phosphorylation of IRF3 protein Poly I-C affects the localization of IRF3 protein APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; BX795 inhibits the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; chrysin inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA]; DNM2 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; eriodictyol inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA]; Quercetin inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA]; Sodium Selenite inhibits the reaction [Poly I-C results in increased activity of IRF3 protein] [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C affects the localization of IRF3 protein]; [Vehicle Emissions analog co-treated with Poly I-C] affects the localization of IRF3 protein; Cannabidiol inhibits the reaction [Poly I-C affects the localization of IRF3 protein]; Dronabinol inhibits the reaction [Poly I-C results in increased localization of IRF3 protein]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:16399790 PMID:18279804 PMID:18779317 PMID:19426678 PMID:25780039 PMID:32244040 PMID:36958387 More...
|
|
NCBI chr 1:104,616,608...104,621,402
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Irf7 |
interferon regulatory factor 7 |
multiple interactions increases expression |
ISO EXP |
IRF7 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; IRF7 protein mutant form affects the reaction [Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]]; IRF7 protein mutant form inhibits the reaction [Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIH1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIT1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IRF9 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of ISG15 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of OAS1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of RIGI mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT2 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA] cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA] |
CTD |
PMID:22240577 PMID:28726298 PMID:31154625 |
|
NCBI chr 1:205,796,956...205,800,543
Ensembl chr 1:196,367,361...196,370,832
|
|
G |
Irf9 |
interferon regulatory factor 9 |
multiple interactions increases expression |
ISO |
IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IRF9 mRNA] |
CTD |
PMID:22240577 PMID:31154625 |
|
NCBI chr15:33,065,422...33,071,881
Ensembl chr15:29,095,789...29,101,236
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of ISG15 mRNA IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of ISG15 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of ISG15 mRNA] |
CTD |
PMID:31154625 PMID:36958387 |
|
NCBI chr 5:172,066,369...172,067,656
Ensembl chr 5:166,784,148...166,785,435
|
|
G |
Isg20 |
interferon stimulated exonuclease gene 20 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of ISG20 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:142,234,729...142,246,403
Ensembl chr 1:132,815,123...132,837,027
|
|
G |
Itga1 |
integrin subunit alpha 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of ITGA1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 2:48,379,181...48,545,336
Ensembl chr 2:46,653,193...46,812,238
|
|
G |
Itgam |
integrin subunit alpha M |
increases expression |
EXP |
Poly I-C results in increased expression of ITGAM mRNA; Poly I-C results in increased expression of ITGAM protein |
CTD |
PMID:27317300 |
|
NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb8 |
integrin subunit beta 8 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of ITGB8 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 6:146,267,982...146,351,245
Ensembl chr 6:140,127,203...140,208,476
|
|
G |
Jcad |
junctional cadherin 5 associated |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of JCAD mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:57,784,634...57,826,213
Ensembl chr17:53,089,382...53,130,967
|
|
G |
Kcna2 |
potassium voltage-gated channel subfamily A member 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of KCNA2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:197,392,746...197,406,606
Ensembl chr 2:194,704,639...194,718,400
|
|
G |
Kcnip4 |
potassium voltage-gated channel interacting protein 4 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of KCNIP4 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:65,593,297...66,743,994
Ensembl chr14:61,381,076...62,530,144
|
|
G |
Kcnq5 |
potassium voltage-gated channel subfamily Q member 5 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of KCNQ5 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:31,326,595...31,892,399
Ensembl chr 9:23,833,087...24,394,704
|
|
G |
Kif3b |
kinesin family member 3B |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of KIF3B mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 3:162,218,621...162,258,191
Ensembl chr 3:141,758,466...141,797,963
|
|
G |
Kif5b |
kinesin family member 5B |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of KIF5B mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:56,185,386...56,222,990
Ensembl chr17:51,489,944...51,527,508
|
|
G |
Kif5c |
kinesin family member 5C |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of KIF5C mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:54,441,266...54,591,630
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Klf4 |
KLF transcription factor 4 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of KLF4 protein Poly I-C promotes the reaction [MSI1 protein results in increased expression of KLF4 protein] |
CTD |
PMID:29486283 |
|
NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klrk1 |
killer cell lectin like receptor K1 |
increases expression |
ISO |
Poly I-C results in increased expression of KLRK1 mRNA; Poly I-C results in increased expression of KLRK1 protein |
CTD |
PMID:16472598 |
|
NCBI chr 4:164,767,377...164,778,453
Ensembl chr 4:163,081,927...163,092,459
|
|
G |
Kmo |
kynurenine 3-monooxygenase |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of KMO mRNA |
CTD |
PMID:35688559 |
|
NCBI chr13:90,089,340...90,121,108
Ensembl chr13:87,557,286...87,588,881
|
|
G |
Kpna3 |
karyopherin subunit alpha 3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of KPNA3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr15:39,712,375...39,786,127
Ensembl chr15:35,536,316...35,610,419
|
|
G |
Kpna7 |
karyopherin subunit alpha 7 |
multiple interactions increases expression |
ISO |
Atorvastatin inhibits the reaction [Poly I-C results in increased expression of KPNA7 mRNA]; Ivermectin inhibits the reaction [Poly I-C results in increased expression of KPNA7 mRNA] |
CTD |
PMID:34696514 |
|
NCBI chr12:14,690,124...14,728,478
Ensembl chr12:9,576,378...9,612,833
|
|
G |
Lamc1 |
laminin subunit gamma 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of LAMC1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr13:67,924,872...68,051,986
Ensembl chr13:65,374,372...65,501,492
|
|
G |
Lims2 |
LIM zinc finger domain containing 2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of LIMS2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr18:23,828,164...23,866,363
Ensembl chr18:23,553,937...23,592,137
|
|
G |
Lsm14b |
LSM family member 14B |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of LSM14B mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:187,503,251...187,514,041
Ensembl chr 3:167,125,628...167,136,432
|
|
G |
Lta |
lymphotoxin alpha |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of LTA mRNA |
CTD |
PMID:35688559 |
|
NCBI chr20:3,622,291...3,625,852
Ensembl chr20:3,618,853...3,620,859
|
|
G |
Macc1 |
MET transcriptional regulator MACC1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of MACC1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 6:146,495,544...146,574,254
Ensembl chr 6:140,352,755...140,430,255
|
|
G |
Macroh2a2 |
macroH2A.2 histone |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of MACROH2A2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr20:30,220,975...30,270,652
Ensembl chr20:29,678,222...29,727,891
|
|
G |
Mal2 |
mal, T-cell differentiation protein 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of MAL2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:87,790,239...87,823,219
Ensembl chr 7:85,900,453...85,933,429
|
|
G |
Map3k11 |
mitogen-activated protein kinase kinase kinase 11 |
increases phosphorylation |
ISO |
Poly I-C results in increased phosphorylation of MAP3K11 protein |
CTD |
PMID:17698565 |
|
NCBI chr 1:212,404,685...212,417,986
Ensembl chr 1:202,975,353...202,988,652
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of MAP3K8 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr17:58,078,175...58,098,455
Ensembl chr17:53,383,131...53,403,216
|
|
G |
Map4k5 |
mitogen-activated protein kinase kinase kinase kinase 5 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of MAP4K5 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 6:94,020,079...94,112,943
Ensembl chr 6:88,284,094...88,376,799
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation increases phosphorylation multiple interactions |
ISO |
Poly I-C results in decreased phosphorylation of MAPK1 protein Poly I-C results in increased phosphorylation of MAPK1 protein Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:23516405 PMID:25780039 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation increases phosphorylation multiple interactions |
ISO |
Poly I-C results in decreased phosphorylation of MAPK3 protein Poly I-C results in increased phosphorylation of MAPK3 protein Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23516405 PMID:25780039 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk4 |
mitogen-activated protein kinase 4 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of MAPK4 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr18:69,788,058...69,937,524
Ensembl chr18:67,512,807...67,661,842
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
inotodiol inhibits the reaction [Poly I-C results in increased expression of and results in increased phosphorylation of MAPK8 protein]; Poly I-C results in increased expression of and results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:37886743 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of MAPK9 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapre1 |
microtubule-associated protein, RP/EB family, member 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of MAPRE1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:162,679,020...162,707,167
Ensembl chr 3:142,212,955...142,246,983
|
|
G |
Marchf7 |
membrane associated ring-CH-type finger 7 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of MARCHF7 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:65,090,640...65,128,768
Ensembl chr 3:44,681,632...44,720,168
|
|
G |
Mblac2 |
metallo-beta-lactamase domain containing 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of MBLAC2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:13,721,752...13,764,558
Ensembl chr 2:11,986,027...12,030,950
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
EXP ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of MBP mRNA [TL8-506 co-treated with Poly I-C] results in increased expression of MBP mRNA |
CTD |
PMID:26923065 PMID:35688559 |
|
NCBI chr18:78,130,652...78,241,174
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of MEF2C mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:15,708,732...15,871,639
Ensembl chr 2:13,993,438...14,132,880
|
|
G |
Mfhas1 |
multifunctional ROCO family signaling regulator 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of MFHAS1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr16:63,248,833...63,336,441
Ensembl chr16:56,546,207...56,633,743
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of MGLL mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 4:122,749,436...122,851,440
Ensembl chr 4:121,192,195...121,294,179
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of MGST1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Micos13 |
mitochondrial contact site and cristae organizing system subunit 13 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of MICOS13 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:1,526,978...1,528,996
Ensembl chr 9:1,439,058...1,442,076
|
|
G |
Micu3 |
mitochondrial calcium uptake family, member 3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of MICU3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:58,624,702...58,714,302
Ensembl chr16:51,925,225...52,010,613
|
|
G |
Mir148b |
microRNA 148b |
multiple interactions |
ISO |
[Arsenicals co-treated with Poly I-C] results in decreased expression of MIR148B mRNA |
CTD |
PMID:34303791 |
|
NCBI chr 7:136,299,870...136,299,966
Ensembl chr 7:134,421,398...134,421,494
|
|
G |
Mir152 |
microRNA 152 |
multiple interactions |
ISO |
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of MIR152 mRNA; [Arsenicals co-treated with Poly I-C] results in decreased expression of MIR152 mRNA |
CTD |
PMID:34303791 |
|
NCBI chr10:82,329,383...82,329,467
Ensembl chr10:81,832,936...81,833,020
|
|
G |
Mir155 |
microRNA 155 |
multiple interactions increases expression |
ISO |
MIR155 mRNA inhibits the reaction [Progesterone inhibits the reaction [Poly I-C results in increased expression of MIR155 mRNA]]; Progesterone inhibits the reaction [Poly I-C results in increased expression of MIR155 mRNA] |
CTD |
PMID:22546503 |
|
NCBI chr11:37,261,114...37,261,178
Ensembl chr11:23,774,654...23,774,718
|
|
G |
Mir26a |
microRNA 26a |
multiple interactions |
EXP |
MIR26A mRNA inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF protein] |
CTD |
PMID:24423102 |
|
NCBI chr 8:127,633,048...127,633,137
Ensembl chr 8:118,755,289...118,755,378
|
|
G |
Mrps15 |
mitochondrial ribosomal protein S15 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of MRPS15 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:143,606,141...143,616,734
Ensembl chr 5:138,321,593...138,332,205
|
|
G |
Msi1 |
musashi RNA-binding protein 1 |
multiple interactions |
ISO |
Poly I-C promotes the reaction [MSI1 protein results in increased expression of KLF4 protein]; Poly I-C promotes the reaction [MSI1 protein results in increased expression of MYC protein]; Poly I-C promotes the reaction [MSI1 protein results in increased expression of POU5F1 protein]; Poly I-C promotes the reaction [MSI1 protein results in increased expression of SOX2 protein] |
CTD |
PMID:29486283 |
|
NCBI chr12:46,815,225...46,911,852
Ensembl chr12:41,158,599...41,191,076
|
|
G |
Mtpn |
myotrophin |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of MTPN mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 4:65,126,390...65,153,803
Ensembl chr 4:64,157,641...64,186,724
|
|
G |
Mtrex |
Mtr4 exosome RNA helicase |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of MTREX mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:46,233,528...46,293,827
Ensembl chr 2:44,461,444...44,560,627
|
|
G |
Mx1 |
MX dynamin like GTPase 1 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of MX1 mRNA Acetylcysteine inhibits the reaction [Dieldrin inhibits the reaction [Poly I-C results in increased expression of MX1 mRNA]]; Dieldrin inhibits the reaction [Poly I-C results in increased expression of MX1 mRNA] |
CTD |
PMID:17669408 PMID:22558189 PMID:34051100 |
|
NCBI chr11:50,269,056...50,294,699
Ensembl chr11:36,799,660...36,823,507
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression |
ISO |
Poly I-C promotes the reaction [MSI1 protein results in increased expression of MYC protein] Poly I-C results in increased expression of MYC protein |
CTD |
PMID:29486283 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of MYD88 mRNA cinnamaldehyde inhibits the reaction [Poly I-C results in increased expression of MYD88 mRNA] |
CTD |
PMID:18306459 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Naa60 |
N(alpha)-acetyltransferase 60, NatF catalytic subunit |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of NAA60 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:12,129,026...12,149,053
Ensembl chr10:11,587,916...11,642,755
|
|
G |
Nans |
N-acetylneuraminate synthase |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of NANS mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 5:65,575,970...65,593,164
Ensembl chr 5:60,780,392...60,814,950
|
|
G |
Napb |
NSF attachment protein beta |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of NAPB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:156,585,394...156,632,418
Ensembl chr 3:136,133,428...136,179,345
|
|
G |
Napepld |
N-acyl phosphatidylethanolamine phospholipase D |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of NAPEPLD mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 4:14,251,591...14,291,010
Ensembl chr 4:13,361,006...13,398,748
|
|
G |
Nbea |
neurobeachin |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of NBEA mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:141,930,147...142,489,172
Ensembl chr 2:139,780,021...140,340,584
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of NCF2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr13:67,505,492...67,536,015
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Ndst3 |
N-deacetylase and N-sulfotransferase 3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of NDST3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:214,386,804...214,552,739
Ensembl chr 2:211,704,898...211,854,584
|
|
G |
Necab1 |
N-terminal EF-hand calcium binding protein 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of NECAB1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:33,155,078...33,375,707
Ensembl chr 5:28,357,859...28,578,642 Ensembl chr 5:28,357,859...28,578,642
|
|
G |
Nedd4l |
NEDD4 like E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of NEDD4L mRNA |
CTD |
PMID:35688559 |
|
NCBI chr18:60,663,918...60,996,824
Ensembl chr18:58,393,509...58,723,137
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of NFKB1 mRNA [Ivermectin co-treated with Atorvastatin] inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]; Atorvastatin inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]; Ivermectin inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA] |
CTD |
PMID:34696514 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases phosphorylation multiple interactions |
ISO |
Poly I-C results in increased phosphorylation of NFKBIA protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; [Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:18779317 PMID:20932985 PMID:23688403 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbiz |
NFKB inhibitor zeta |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of NFKBIZ mRNA |
CTD |
PMID:35688559 |
|
NCBI chr11:58,251,720...58,279,767
Ensembl chr11:44,782,676...44,810,723
|
|
G |
Nhp2 |
NHP2 ribonucleoprotein |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of NHP2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr10:36,378,020...36,381,362
Ensembl chr10:35,877,054...35,882,545
|
|
G |
Nipa1 |
NIPA magnesium transporter 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of NIPA1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:115,608,221...116,010,503
Ensembl chr 1:106,834,000...106,874,790
|
|
G |
Nlgn3 |
neuroligin 3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of NLGN3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:70,469,251...70,497,380
Ensembl chr X:66,429,458...66,451,876
|
|
G |
Nmu |
neuromedin U |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of NMU mRNA |
CTD |
PMID:26923065 |
|
NCBI chr14:32,198,789...32,226,397
Ensembl chr14:31,844,728...31,872,192
|
|
G |
Nop58 |
NOP58 ribonucleoprotein |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of NOP58 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 9:68,614,992...68,638,911
Ensembl chr 9:61,120,929...61,144,810
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
pitavastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of NOS2 protein]; Sodium Selenite inhibits the reaction [Poly I-C results in increased expression of NOS2 protein] Diclofenac promotes the reaction [Poly I-C results in increased expression of NOS2 mRNA] Poly I-C results in increased expression of NOS2 mRNA; Poly I-C results in increased expression of NOS2 protein |
CTD |
PMID:17321468 PMID:18279804 PMID:18323514 PMID:21195166 PMID:23939143 PMID:30726814 More...
|
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nrsn1 |
neurensin 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of NRSN1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:40,234,302...40,252,614
Ensembl chr17:39,806,238...39,823,813
|
|
G |
Nuf2 |
NUF2 component of NDC80 kinetochore complex |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of NUF2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr13:84,226,448...84,290,957
Ensembl chr13:81,693,598...81,722,766
|
|
G |
Oas1a |
2'-5' oligoadenylate synthetase 1A |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of OAS1 mRNA [[Poly I-C co-treated with Interferon-alpha] results in increased activity of OAS1 protein] which results in increased abundance of 2',5'-oligoadenylate; [Poly I-C co-treated with Interferon-alpha] results in increased activity of OAS1 protein; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of OAS1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of OAS1 mRNA] |
CTD |
PMID:17669408 PMID:22240577 PMID:26055709 PMID:31154625 |
|
NCBI chr12:41,330,423...41,341,130
Ensembl chr12:35,669,801...35,680,517
|
|
G |
Oas2 |
2'-5' oligoadenylate synthetase 2 |
increases expression |
ISO |
Poly I-C results in increased expression of OAS2 mRNA |
CTD |
PMID:22240577 PMID:22558189 |
|
NCBI chr12:41,464,568...41,492,036
Ensembl chr12:35,806,759...35,829,371
|
|
G |
Oasl |
2'-5'-oligoadenylate synthetase-like |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of OASL mRNA |
CTD |
PMID:35688559 |
|
NCBI chr12:47,343,551...47,356,509
Ensembl chr12:41,682,900...41,695,641
|
|
G |
Or4e1 |
olfactory receptor family 4 subfamily E member 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of OR4E1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr15:27,673,536...27,684,988
Ensembl chr15:25,196,602...25,211,463
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
decreases expression multiple interactions |
ISO |
Poly I-C results in decreased expression of P2RX7 protein Suramin inhibits the reaction [Poly I-C results in decreased expression of P2RX7 protein] |
CTD |
PMID:23516405 |
|
NCBI chr12:39,550,531...39,594,984
Ensembl chr12:33,879,745...33,934,619
|
|
G |
P2ry2 |
purinergic receptor P2Y2 |
decreases expression multiple interactions |
ISO |
Poly I-C results in decreased expression of P2RY2 protein Suramin inhibits the reaction [Poly I-C results in decreased expression of P2RY2 protein] |
CTD |
PMID:23516405 |
|
NCBI chr 1:164,764,119...164,779,578
Ensembl chr 1:155,351,165...155,367,632
|
|
G |
Pak2 |
p21 (RAC1) activated kinase 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of PAK2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:82,212,896...82,273,803
Ensembl chr11:68,707,969...68,768,816
|
|
G |
Pard6g |
par-6 family cell polarity regulator gamma |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of PARD6G mRNA |
CTD |
PMID:26923065 |
|
NCBI chr18:75,772,992...75,840,041
Ensembl chr18:73,498,021...73,565,029
|
|
G |
Pcmtd1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of PCMTD1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:17,071,629...17,143,803
Ensembl chr 5:12,284,711...12,354,899
|
|
G |
Pdap1 |
PDGFA associated protein 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of PDAP1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:14,584,414...14,594,641
Ensembl chr12:9,470,574...9,535,374
|
|
G |
Pdcd6ip |
programmed cell death 6 interacting protein |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of PDCD6IP mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:122,469,223...122,524,993
Ensembl chr 8:113,590,998...113,646,773
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of PDGFB mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdha1l1 |
pyruvate dehydrogenase (lipoamide) alpha 1-like 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of PDHA1L1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:89,213,172...89,216,067
Ensembl chr16:82,511,511...82,514,372
|
|
G |
Peli1 |
pellino E3 ubiquitin protein ligase 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of PELI1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr14:99,455,970...99,510,474
Ensembl chr14:95,254,589...95,308,285 Ensembl chr 1:95,254,589...95,308,285
|
|
G |
Pgam1-ps11 |
phosphoglycerate mutase 1, pseudogene 11 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of PGAM1-PS11 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:51,948,181...51,979,610
|
|
G |
Phactr1 |
phosphatase and actin regulator 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of PHACTR1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:21,769,006...22,246,227
Ensembl chr17:21,562,721...22,039,831
|
|
G |
Phf7 |
PHD finger protein 7 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of PHF7 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:6,439,968...6,452,671
Ensembl chr16:6,433,537...6,446,911
|
|
G |
Pim1 |
Pim-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of PIM1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,554,921...7,559,174
|
|
G |
Pkib |
cAMP-dependent protein kinase inhibitor beta |
multiple interactions decreases expression |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of PKIB mRNA Poly I-C results in decreased expression of PKIB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr20:37,511,564...37,608,607
Ensembl chr20:36,905,340...37,062,187
|
|
G |
Plagl2 |
PLAG1 like zinc finger 2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of PLAGL2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 3:162,155,554...162,168,748
Ensembl chr 3:141,695,322...141,708,503
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of PLAUR mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Plcb1 |
phospholipase C beta 1 |
increases expression |
ISO |
Poly I-C results in increased expression of PLCB1 mRNA |
CTD |
PMID:24889602 |
|
NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Plcxd2 |
phosphatidylinositol-specific phospholipase C, X domain containing 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of PLCXD2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:68,263,626...68,315,962
Ensembl chr11:54,789,477...54,853,344
|
|
G |
Plekha8 |
pleckstrin homology domain containing A8 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of PLEKHA8 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 4:85,053,765...85,104,376
Ensembl chr 4:83,723,561...83,774,081
|
|
G |
Plppr4 |
phospholipid phosphatase related 4 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of PLPPR4 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:208,056,206...208,097,191
Ensembl chr 2:205,371,322...205,412,302
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of PMAIP1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr18:62,255,970...62,262,384
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pmvk |
phosphomevalonate kinase |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of PMVK mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:177,174,344...177,184,076
Ensembl chr 2:174,876,657...174,886,364
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
multiple interactions increases expression |
ISO |
Poly I-C promotes the reaction [MSI1 protein results in increased expression of POU5F1 protein] Poly I-C results in increased expression of POU5F1 protein |
CTD |
PMID:29486283 |
|
NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Prf1 |
perforin 1 |
multiple interactions increases expression |
ISO |
Particulate Matter inhibits the reaction [Poly I-C results in increased expression of PRF1 protein]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of PRF1 protein] Poly I-C results in increased expression of PRF1 mRNA; Poly I-C results in increased expression of PRF1 protein |
CTD |
PMID:23618096 |
|
NCBI chr20:29,789,040...29,794,550
Ensembl chr20:29,246,202...29,251,701
|
|
G |
Prkci |
protein kinase C, iota |
multiple interactions |
EXP ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of PRKCI mRNA [TL8-506 co-treated with Poly I-C] results in increased expression of PRKCI mRNA |
CTD |
PMID:26923065 PMID:35688559 |
|
NCBI chr 2:114,250,398...114,310,784
Ensembl chr 2:112,321,929...112,382,352
|
|
G |
Prodh2 |
proline dehydrogenase 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of PRODH2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:94,881,000...94,894,609
Ensembl chr 1:85,753,644...85,767,162
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of PTGS2 protein [Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of PTGS2 mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of PTGS2 mRNA]; resveratrol inhibits the reaction [Poly I-C results in increased expression of PTGS2 protein]; Sodium Selenite inhibits the reaction [Poly I-C results in increased expression of PTGS2 protein] |
CTD |
PMID:16116226 PMID:18279804 PMID:24889602 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pvalb |
parvalbumin |
multiple interactions |
EXP |
[Poly I-C co-treated with Cannabidiol] results in increased expression of PVALB protein |
CTD |
PMID:31326506 |
|
NCBI chr 7:111,653,820...111,668,469
Ensembl chr 7:109,772,593...109,784,561
|
|
G |
Rab29 |
RAB29, member RAS oncogene family |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of RAB29 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr13:45,859,930...45,865,468
Ensembl chr13:43,307,775...43,313,417
|
|
G |
Rab3ip |
RAB3A interacting protein |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of RAB3IP mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 7:54,417,418...54,461,253
Ensembl chr 7:52,532,401...52,561,043
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
EXP ISO |
[Poly I-C co-treated with HU 211] results in decreased expression of RAC1 mRNA [Poly I-C co-treated with Atorvastatin] results in decreased expression of RAC1 mRNA; [Poly I-C co-treated with Ivermectin] results in decreased expression of RAC1 mRNA |
CTD |
PMID:26923065 PMID:34696514 |
|
NCBI chr12:16,150,411...16,170,864
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions |
ISO |
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of RARB mRNA; [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of RARB protein; [Arsenicals co-treated with Poly I-C] affects the expression of RARB mRNA; [Arsenicals co-treated with Poly I-C] results in decreased expression of RARB protein |
CTD |
PMID:34303791 |
|
NCBI chr15:10,837,252...11,482,037
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rassf8 |
Ras association domain family member 8 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of RASSF8 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 4:180,447,050...180,528,792
Ensembl chr 4:178,719,992...178,796,690
|
|
G |
Rdm1 |
RAD52 motif containing 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of RDM1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:87,062,322...87,073,273
Ensembl chr10:86,539,553...86,573,034
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization increases phosphorylation multiple interactions |
ISO |
Poly I-C affects the localization of RELA protein Poly I-C results in increased phosphorylation of RELA protein TP53 protein affects the reaction [Poly I-C affects the localization of RELA protein] |
CTD |
PMID:18779317 PMID:24709138 PMID:27836898 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rffl |
ring finger and FYVE-like domain containing E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of RFFL mRNA |
CTD |
PMID:35688559 |
|
NCBI chr10:68,238,273...68,301,225
Ensembl chr10:67,740,712...67,824,434
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
increases expression |
ISO |
Poly I-C results in increased expression of RGS4 mRNA |
CTD |
PMID:24889602 |
|
NCBI chr13:84,469,593...84,475,884
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
[Poly I-C co-treated with Atorvastatin co-treated with Ivermectin] results in increased expression of RHOA mRNA; [Poly I-C co-treated with Atorvastatin] results in increased expression of RHOA mRNA |
CTD |
PMID:34696514 |
|
NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rig1 |
RNA sensor RIG-1 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of RIGI mRNA IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of RIGI mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of RIGI mRNA] |
CTD |
PMID:27183587 PMID:30341573 PMID:31154625 |
|
NCBI chr 5:60,117,398...60,165,995
Ensembl chr 5:55,321,235...55,370,819
|
|
G |
Rimbp2 |
RIMS binding protein 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of RIMBP2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr12:33,383,646...33,582,259
Ensembl chr12:27,747,980...27,956,763
|
|
G |
Rimoc1 |
RAB7A interacting MON1-CCZ1 complex subunit 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of RIMOC1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:54,917,383...54,931,577
Ensembl chr 2:53,189,790...53,203,821
|
|
G |
Ripor2 |
RHO family interacting cell polarization regulator 2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of RIPOR2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr17:40,751,771...40,975,611
Ensembl chr17:40,323,867...40,548,092
|
|
G |
Rnf141 |
ring finger protein 141 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of RNF141 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:174,365,789...174,391,848
Ensembl chr 1:164,931,077...164,957,118
|
|
G |
Rpl31 |
ribosomal protein L31 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of RPL31 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:49,143,044...49,147,155
Ensembl chr 9:41,647,426...41,662,129 Ensembl chr 8:41,647,426...41,662,129
|
|
G |
Rps6kb2 |
ribosomal protein S6 kinase B2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of RPS6KB2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:210,880,824...210,887,556
Ensembl chr 1:201,451,265...201,458,078
|
|
G |
RT1-DOb |
RT1 class II, locus DOb |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of HLA-DOB mRNA |
CTD |
PMID:35688559 |
|
NCBI chr20:4,621,336...4,627,537
Ensembl chr20:4,619,816...4,625,667
|
|
G |
Rtn4rl1 |
reticulon 4 receptor-like 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of RTN4RL1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:60,541,584...60,615,302
Ensembl chr10:60,043,002...60,116,978
|
|
G |
S100a3 |
S100 calcium binding protein A3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of S100A3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:178,331,856...178,387,280
Ensembl chr 2:176,049,520...176,089,702
|
|
G |
Sema6d |
semaphorin 6D |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SEMA6D mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:131,801,680...132,394,578
Ensembl chr 3:111,883,872...111,941,094
|
|
G |
Septin6 |
septin 6 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SEPTIN6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:121,018,951...121,157,677
Ensembl chr X:116,153,255...116,230,115
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions increases expression |
ISO |
Chloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; Chloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 protein]; Hydroxychloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; Hydroxychloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 protein]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of SERPINE1 mRNA] Poly I-C results in increased expression of SERPINE1 mRNA; Poly I-C results in increased expression of SERPINE1 protein |
CTD |
PMID:30341573 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
increases expression |
ISO |
Poly I-C results in increased expression of SESN2 mRNA |
CTD |
PMID:25637945 |
|
NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Sgms2 |
sphingomyelin synthase 2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of SGMS2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 2:222,567,661...222,641,804
Ensembl chr 2:219,893,572...219,967,546
|
|
G |
Sgtb |
small glutamine rich tetratricopeptide repeat co-chaperone beta |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SGTB mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:36,966,840...37,003,318
Ensembl chr 2:35,233,042...35,269,518
|
|
G |
Sh3rf1 |
SH3 domain containing ring finger 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SH3RF1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:33,746,396...33,912,127
Ensembl chr16:28,735,440...28,901,644
|
|
G |
Shroom1 |
shroom family member 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of SHROOM1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr10:38,121,971...38,134,832
Ensembl chr10:37,621,723...37,631,256
|
|
G |
Shroom2 |
shroom family member 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SHROOM2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:25,308,163...25,480,194
Ensembl chr X:21,812,469...21,984,153
|
|
G |
Sidt1 |
SID1 transmembrane family, member 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SIDT1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:69,867,758...69,965,377
Ensembl chr11:56,363,512...56,459,050
|
|
G |
Slc14a1 |
solute carrier family 14 member 1 (Kidd blood group) |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC14A1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr18:73,840,568...73,883,925
Ensembl chr18:71,565,454...71,595,146
|
|
G |
Slc17a7 |
solute carrier family 17 member 7 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC17A7 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:104,786,172...104,798,049
Ensembl chr 1:95,649,745...95,661,588
|
|
G |
Slc25a12 |
solute carrier family 25 member 12 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC25A12 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:76,504,868...76,599,536
Ensembl chr 3:56,097,269...56,192,100
|
|
G |
Slc25a14 |
solute carrier family 25 member 14 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC25A14 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:132,685,518...132,723,705
Ensembl chr X:127,807,449...127,845,823
|
|
G |
Slc2a13 |
solute carrier family 2 member 13 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC2A13 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:124,278,881...124,606,146
Ensembl chr 7:122,399,330...122,726,605
|
|
G |
Slc3a1 |
solute carrier family 3 member 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC3A1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:15,361,037...15,396,695
Ensembl chr 6:9,608,178...9,641,907
|
|
G |
Slc4a10 |
solute carrier family 4 member 10 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SLC4A10 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:67,050,925...67,367,637
Ensembl chr 3:46,665,265...46,957,268
|
|
G |
Slc7a1 |
solute carrier family 7 member 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of SLC7A1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr12:11,664,488...11,740,030
Ensembl chr12:6,628,007...6,703,849
|
|
G |
Smarcd1 |
SWI/SNF related BAF chromatin remodeling complex subunit D1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SMARCD1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:132,708,627...132,719,167
Ensembl chr 7:130,829,768...130,840,323
|
|
G |
Snd1 |
staphylococcal nuclease and tudor domain containing 1 |
affects localization |
ISO |
Poly I-C affects the localization of SND1 protein |
CTD |
PMID:22240577 |
|
NCBI chr 4:58,060,689...58,459,926
Ensembl chr 4:57,095,208...57,530,843
|
|
G |
Snrk |
SNF related kinase |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SNRK mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:130,657,204...130,711,461
Ensembl chr 8:121,793,302...121,832,323
|
|
G |
Sntb1 |
syntrophin, beta 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of SNTB1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 7:88,950,642...89,219,017
Ensembl chr 7:87,060,926...87,329,315
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of SOCS1 mRNA [TL8-506 co-treated with Poly I-C] results in increased expression of SOCS1 mRNA Progesterone promotes the reaction [Poly I-C results in increased expression of SOCS1 mRNA] |
CTD |
PMID:22546503 PMID:35688559 |
|
NCBI chr10:5,389,574...5,391,265
Ensembl chr10:4,882,560...4,884,383
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of SOCS3 mRNA [TL8-506 co-treated with Poly I-C] results in increased expression of SOCS3 mRNA |
CTD |
PMID:21195166 PMID:35688559 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression multiple interactions |
EXP ISO |
Poly I-C results in increased expression of SOD2 mRNA [TL8-506 co-treated with Poly I-C] results in increased expression of SOD2 mRNA |
CTD |
PMID:23939143 PMID:35688559 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
increases expression multiple interactions |
ISO |
Poly I-C results in increased expression of SOX2 protein Poly I-C promotes the reaction [MSI1 protein results in increased expression of SOX2 protein] |
CTD |
PMID:29486283 |
|
NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Spag6 |
sperm associated antigen 6 |
decreases expression |
EXP |
Poly I-C results in decreased expression of SPAG6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:86,258,418...86,309,922
Ensembl chr17:81,349,084...81,401,501
|
|
G |
Srsf12 |
serine and arginine rich splicing factor 12 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SRSF12 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:52,402,033...52,427,839
Ensembl chr 5:47,606,285...47,629,778
|
|
G |
Srsf7 |
serine and arginine rich splicing factor 7 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SRSF7 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:20,564,035...20,571,205
Ensembl chr 6:14,811,808...14,818,965
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions increases expression increases phosphorylation |
ISO |
sodium arsenite inhibits the reaction [Poly I-C results in increased phosphorylation of STAT1 protein] Poly I-C results in increased expression of STAT1 mRNA IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of STAT1 mRNA] |
CTD |
PMID:30726814 PMID:31154625 |
|
NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat2 |
signal transducer and activator of transcription 2 |
multiple interactions increases expression |
ISO |
IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT2 mRNA] |
CTD |
PMID:31154625 |
|
NCBI chr 7:1,287,025...1,302,858
Ensembl chr 7:702,495...718,967
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
IL6 protein affects the reaction [Poly I-C results in increased phosphorylation of and results in increased activity of STAT3 protein]; Poly I-C results in increased phosphorylation of and results in increased activity of STAT3 protein |
CTD |
PMID:21195166 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of STAT5A mRNA |
CTD |
PMID:35688559 |
|
NCBI chr10:86,285,859...86,310,187
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Stk17b |
serine/threonine kinase 17b |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of STK17B mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 9:62,801,912...62,832,511
Ensembl chr 9:55,307,668...55,338,031
|
|
G |
Stxbp6 |
syntaxin binding protein 6 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of STXBP6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:67,647,721...67,884,369
Ensembl chr 6:61,920,756...62,158,024
|
|
G |
Svip |
small VCP interacting protein |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SVIP mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:110,723,051...110,728,741
Ensembl chr 1:101,587,128...101,593,116
|
|
G |
Syt11 |
synaptotagmin 11 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of SYT11 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:176,503,845...176,530,354
Ensembl chr 2:174,206,191...174,231,964
|
|
G |
Tacstd2 |
tumor-associated calcium signal transducer 2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of TACSTD2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 4:98,037,620...98,039,320
Ensembl chr 4:96,707,951...96,709,650
|
|
G |
Tagap |
T-cell activation RhoGTPase activating protein |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of TAGAP mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:49,575,750...49,584,747
Ensembl chr 1:47,170,725...47,179,792
|
|
G |
Tbc1d9 |
TBC1 domain family member 9 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of TBC1D9 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr19:41,746,732...41,855,924
Ensembl chr19:24,842,205...24,943,129
|
|
G |
Tbk1 |
TANK-binding kinase 1 |
multiple interactions increases phosphorylation |
ISO |
APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr 7:58,963,319...58,996,357
Ensembl chr 7:57,077,830...57,110,892
|
|
G |
Tcf7 |
transcription factor 7 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of TCF7 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr10:36,924,363...36,954,279
Ensembl chr10:36,423,445...36,453,535
|
|
G |
Tcf7l2 |
transcription factor 7 like 2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of TCF7L2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:264,791,335...264,984,225
Ensembl chr 1:254,786,091...254,978,967
|
|
G |
Tcfl5 |
transcription factor like 5 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of TCFL5 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 3:188,112,037...188,131,883
Ensembl chr 3:167,734,473...167,754,282
|
|
G |
Tecrl2 |
trans-2,3-enoyl-CoA reductase like 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of TECRL2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:49,668,662...49,669,780
Ensembl chr19:24,541,615...24,568,168
|
|
G |
Tfb1m |
transcription factor B1, mitochondrial |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of TFB1M mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:46,520,510...46,567,004
Ensembl chr 1:44,119,166...44,161,709
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of TFRC mRNA |
CTD |
PMID:35688559 |
|
NCBI chr11:81,668,478...81,690,318
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases secretion |
ISO |
Poly I-C results in increased secretion of TGFB1 protein |
CTD |
PMID:34740670 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thap2 |
THAP domain containing 2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of THAP2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 7:52,879,011...52,893,680
Ensembl chr 7:50,995,793...51,008,061
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of THY1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:53,286,396...53,291,541
Ensembl chr 8:44,389,513...44,394,659
|
|
G |
Tial1 |
Tia1 cytotoxic granule-associated RNA binding protein-like 1 |
affects localization |
ISO |
Poly I-C affects the localization of TIAL1 protein |
CTD |
PMID:22240577 |
|
NCBI chr 1:192,438,794...192,475,520
Ensembl chr 1:183,009,253...183,031,637
|
|
G |
Ticam1 |
TIR domain containing adaptor molecule 1 |
increases expression |
ISO |
Poly I-C results in increased expression of TICAM1 mRNA |
CTD |
PMID:21418039 |
|
NCBI chr 9:1,189,717...1,197,730
Ensembl chr 9:1,102,366...1,123,147
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
Poly I-C results in increased expression of TIMP1 mRNA |
CTD |
PMID:21195166 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of TJP1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tlcd1 |
TLC domain containing 1 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of TLCD1 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr10:63,572,541...63,574,574
Ensembl chr10:63,074,469...63,076,501
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression |
ISO |
Poly I-C results in increased expression of TLR2 mRNA |
CTD |
PMID:17669408 |
|
NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr3 |
toll-like receptor 3 |
multiple interactions increases activity increases expression |
ISO EXP |
[[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of IL12B protein; [[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of TNF protein; [Poly I-C binds to TLR3 protein] which affects the susceptibility to 1-aminopyrene; [Poly I-C binds to TLR3 protein] which affects the susceptibility to 1-nitropyrene; [Poly I-C binds to TLR3 protein] which affects the susceptibility to pyrene; [Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of TLR3 mRNA; [Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of TLR3 protein; Chloroquine inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]; Poly I-C binds to and results in increased activity of TLR3 protein; Quinacrine inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA] MIR26A mRNA inhibits the reaction [Poly I-C results in increased activity of TLR3 protein] Poly I-C results in increased expression of TLR3 mRNA cinnamaldehyde inhibits the reaction [Poly I-C results in increased expression of TLR3 mRNA] |
CTD |
PMID:16399790 PMID:17669408 PMID:18306459 PMID:18779317 PMID:21398612 PMID:21418039 PMID:23266719 PMID:23458896 PMID:24423102 PMID:25780039 PMID:26682054 PMID:27385120 PMID:28003376 PMID:30341573 PMID:32244040 More...
|
|
NCBI chr16:53,554,916...53,572,321
Ensembl chr16:46,822,039...46,836,545
|
|
G |
Tlr7 |
toll-like receptor 7 |
increases expression |
ISO |
Poly I-C results in increased expression of TLR7 mRNA |
CTD |
PMID:17669408 |
|
NCBI chr X:30,644,324...30,670,796
Ensembl chr X:27,027,425...27,054,754
|
|
G |
Tmem266 |
transmembrane protein 266 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of TMEM266 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 8:64,603,199...64,716,770
Ensembl chr 8:55,707,122...55,820,692
|
|
G |
Tmem268 |
transmembrane protein 268 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of TMEM268 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 5:81,990,314...82,016,970
Ensembl chr 5:76,977,310...77,001,452
|
|
G |
Tmem273 |
transmembrane protein 273 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in increased expression of TMEM273 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr16:8,055,930...8,088,280
Ensembl chr16:8,049,669...8,081,981
|
|
G |
Tmprss2 |
transmembrane serine protease 2 |
decreases response to substance |
ISO |
TMPRSS2 gene mutant form results in decreased susceptibility to Poly I-C |
CTD |
PMID:30626688 |
|
NCBI chr11:50,403,707...50,443,224
Ensembl chr11:36,934,306...36,973,715
|
|
G |
Tmx1 |
thioredoxin-related transmembrane protein 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of TMX1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:94,696,699...94,707,751
Ensembl chr 6:88,960,695...88,971,301
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases secretion |
ISO EXP |
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of TNF protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of TNF protein]; [[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of TNF protein; [TL8-506 co-treated with Poly I-C] results in increased expression of TNF mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of TNF protein; CEP-11004 inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; CpG ODN 2006 inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of TNF protein]; inotodiol inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; inotodiol inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; RTKI cpd inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of TNF protein] Poly I-C results in increased expression of TNF mRNA; Poly I-C results in increased expression of TNF protein cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF protein] APPL1 protein inhibits the reaction [Poly I-C results in increased expression of TNF protein]; Citrinin inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Citrinin inhibits the reaction [Poly I-C results in increased expression of TNF protein]; Cycloheximide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Dimethyl Sulfoxide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Ethanol inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Ethanol inhibits the reaction [Poly I-C results in increased expression of TNF protein]; Ethanol inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Ethanol promotes the reaction [Hydroxamic Acids analog promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]]]; Hydroxamic Acids analog inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Hydroxamic Acids analog promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]]; Luteolin inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of TNF mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of TNF mRNA] |
CTD |
PMID:16687389 PMID:17238832 PMID:17321468 PMID:17669408 PMID:17698565 PMID:17868967 PMID:18323514 PMID:19426678 PMID:19500611 PMID:20932985 PMID:22319556 PMID:22771370 PMID:23266719 PMID:23618096 PMID:23939143 PMID:24423102 PMID:25780039 PMID:27385120 PMID:28316773 PMID:28726298 PMID:30017638 PMID:30726814 PMID:30836164 PMID:35688559 PMID:36958387 PMID:37886743 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases expression |
ISO |
Poly I-C results in increased expression of TNFSF10 mRNA; Poly I-C results in increased expression of TNFSF10 protein |
CTD |
PMID:16472598 |
|
NCBI chr 2:112,136,550...112,155,903
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf9 |
TNF superfamily member 9 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of TNFSF9 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 9:2,031,011...2,033,345
Ensembl chr 9:1,944,017...1,946,345
|
|
G |
Tnks2 |
tankyrase 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of TNKS2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 1:243,980,432...244,033,629
Ensembl chr 1:234,567,858...234,621,079
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
TP53 protein affects the reaction [Poly I-C affects the localization of RELA protein]; TP53 protein affects the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein]; TP53 results in increased susceptibility to [Poly I-C co-treated with Fluorouracil] |
CTD |
PMID:18779317 PMID:20367642 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpd52 |
tumor protein D52 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of TPD52 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:94,642,514...94,723,442
Ensembl chr 2:92,735,620...92,816,622
|
|
G |
Tpk1 |
thiamin pyrophosphokinase 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of TERF2IP mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 4:73,170,125...73,557,683
Ensembl chr 4:72,170,134...72,557,694
|
|
G |
Traf3ip2 |
Traf3 interacting protein 2 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of TRAF3IP2 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr20:44,565,992...44,609,240
Ensembl chr20:43,011,450...43,054,667
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
TRAF6 mutant form inhibits the reaction [Vehicle Emissions analog promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]] |
CTD |
PMID:16399790 |
|
NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Trim2 |
tripartite motif-containing 2 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of TRIM2 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:171,798,654...171,950,193
Ensembl chr 2:169,500,634...169,652,927
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of TSLP protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of TSLP protein]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] Poly I-C results in increased expression of TSLP mRNA; Poly I-C results in increased expression of TSLP protein |
CTD |
PMID:23688403 PMID:30017638 |
|
NCBI chr18:24,723,990...24,728,419
Ensembl chr18:24,449,844...24,453,548
|
|
G |
Tspyl5 |
TSPY-like 5 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of TSPYL5 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 7:66,766,695...66,770,702
Ensembl chr 7:64,884,225...64,885,457
|
|
G |
Ttc3 |
tetratricopeptide repeat domain 3 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of TTC3 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr11:47,158,766...47,258,612
Ensembl chr11:33,688,952...33,788,975
|
|
G |
Tubb2a |
tubulin, beta 2A class IIa |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of TUBB2A mRNA |
CTD |
PMID:35688559 |
|
NCBI chr17:31,002,186...31,006,057
Ensembl chr17:30,747,503...30,800,714
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
decreases expression |
EXP |
Poly I-C results in decreased expression of TWIST1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:50,674,678...50,677,653
|
|
G |
Twsg1 |
twisted gastrulation BMP signaling modulator 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of TWSG1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 9:112,979,972...113,014,315
Ensembl chr 9:105,533,136...105,567,479
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions increases expression |
EXP |
Diclofenac inhibits the reaction [Poly I-C results in increased expression of TXN1 mRNA] |
CTD |
PMID:23939143 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Ubl4a |
ubiquitin-like 4A |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of UBL4A mRNA |
CTD |
PMID:26923065 |
|
NCBI chr X:157,302,528...157,305,380
Ensembl chr X:152,151,460...152,154,069
|
|
G |
Ubr1 |
ubiquitin protein ligase E3 component n-recognin 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of UBR1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:128,265,160...128,377,830
Ensembl chr 3:107,811,392...107,922,204
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
decreases expression |
EXP |
Poly I-C results in decreased expression of UGT2B1 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Usp32 |
ubiquitin specific peptidase 32 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of USP32 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:70,353,310...70,538,008
Ensembl chr10:69,855,885...70,029,137
|
|
G |
Utp6 |
UTP6 small subunit processome component |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of UTP6 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr10:65,395,253...65,425,928
Ensembl chr10:64,897,328...64,927,997
|
|
G |
Vsnl1 |
visinin-like 1 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of VSNL1 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 6:39,757,721...39,878,556
Ensembl chr 6:34,038,642...34,159,479
|
|
G |
Wac |
WW domain containing adaptor with coiled-coil |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of WAC mRNA |
CTD |
PMID:26923065 |
|
NCBI chr17:60,617,702...60,677,771
Ensembl chr17:55,923,123...55,982,301
|
|
G |
Wdr47 |
WD repeat domain 47 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of WDR47 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 2:198,914,977...198,975,844
Ensembl chr 2:196,205,238...196,287,739
|
|
G |
Wnt4 |
Wnt family member 4 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of WNT4 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 5:154,797,245...154,818,565
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Wtap |
WT1 associated protein |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of WTAP mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:50,070,973...50,096,074
Ensembl chr 1:47,665,965...47,691,065
|
|
G |
Zbtb32 |
zinc finger and BTB domain containing 32 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of ZBTB32 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr 1:94,969,374...94,978,553
Ensembl chr 1:85,841,931...85,844,236
|
|
G |
Zbtb6 |
zinc finger and BTB domain containing 6 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ZBTB6 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:41,600,488...41,603,902
Ensembl chr 3:21,187,483...21,207,849
|
|
G |
Zdhhc21 |
zinc finger DHHC-type palmitoyltransferase 21 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ZDHHC21 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 5:102,273,561...102,333,174
Ensembl chr 5:97,229,345...97,286,537
|
|
G |
Zfp354c |
zinc finger protein 354C |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ZFP354C mRNA |
CTD |
PMID:26923065 |
|
NCBI chr10:35,630,738...35,647,176
Ensembl chr10:35,132,959...35,145,661
|
|
G |
Zfp663 |
zinc finger protein 663 |
multiple interactions |
EXP |
[Poly I-C co-treated with HU 211] results in decreased expression of ZFP763 mRNA |
CTD |
PMID:26923065 |
|
NCBI chr 3:174,503,851...174,522,648
Ensembl chr 3:154,085,957...154,093,160
|
|
G |
Zmynd11 |
zinc finger, MYND-type containing 11 |
multiple interactions |
ISO |
[TL8-506 co-treated with Poly I-C] results in increased expression of ZMYND11 mRNA |
CTD |
PMID:35688559 |
|
NCBI chr17:65,226,907...65,323,278
Ensembl chr17:60,543,077...60,631,902
|
|
|
G |
Pkm |
pyruvate kinase M1/2 |
multiple interactions |
ISO |
Glucose deficiency promotes the reaction [SAICAR binds to and results in increased activity of PKM protein] |
CTD |
PMID:23086999 |
|
NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:60,057,402...60,079,599
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of sedoheptulose 1,7-bisphosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Klrc1 |
killer cell lectin like receptor C1 |
decreases expression |
ISO |
sofosbuvir co-treated with ledipasvir decreased expression of NCR1 protein in natural killer cells |
RGD |
PMID:31218578 |
RGD:40400920 |
NCBI chr 4:164,828,163...164,838,446
Ensembl chr 4:163,147,189...163,152,425
|
|
G |
Ncr1 |
natural cytotoxicity triggering receptor 1 |
affects expression |
ISO |
sofosbuvir co-treated with ledipasvir affects expression of NCR1 protein in natural killer cells |
RGD |
PMID:31218578 |
RGD:40400920 |
NCBI chr 1:78,657,409...78,665,255
Ensembl chr 1:69,616,601...69,660,558
|
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
stearoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
stearoyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
stearoyl-coenzyme A binds to and results in increased activity of PPARG protein |
CTD |
PMID:11139385 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
affects hydrolysis |
ISO |
ACOT4 protein affects the hydrolysis of succinyl-coenzyme A |
CTD |
PMID:16141203 |
|
NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:103,668,753...103,673,917
|
|
|
G |
P2rx1 |
purinergic receptor P2X 1 |
affects binding |
EXP |
TNP-ATP binds to P2rx1 protein |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:58,117,107...58,132,167
Ensembl chr10:57,618,586...57,633,623
|
|
G |
P2rx2 |
purinergic receptor P2X 2 |
multiple interactions |
EXP |
TNP-ATP binds to P2rx2 protein; TNP-ATP inhibits the reaction [ATP binds to P2rx2 protein] in transfected glial cells |
RGD |
PMID:16388598 |
RGD:1642662 |
NCBI chr12:51,999,107...52,002,627
Ensembl chr12:46,339,549...46,342,891
|
|
G |
P2rx5 |
purinergic receptor P2X 5 |
affects transport |
EXP |
TNP-ATP affects transport ion flux of P2rx5 receptor |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:58,276,329...58,291,108
Ensembl chr10:57,777,819...57,789,423
|
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]]; Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein] |
CTD |
PMID:18523137 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
multiple interactions |
ISO |
[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein; montelukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; montelukast inhibits the reaction [[Uridine Diphosphate metabolite results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein; zafirlukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Uridine Diphosphate metabolite results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein] |
CTD |
PMID:20083671 |
|
NCBI chr X:75,734,281...75,762,873
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Uridine Diphosphate results in increased activity of GPR17 protein] |
CTD |
PMID:18974869 |
|
NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,577,242...23,582,966
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Uridine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] |
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of Uridine Diphosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Uridine Diphosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
MRS 2211 inhibits the reaction [Uridine Diphosphate results in increased expression of IL6 protein]; P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:18523137 PMID:24849676 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Uridine Diphosphate results in increased phosphorylation of MAPK1 protein P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15034929 PMID:18523137 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Uridine Diphosphate results in increased phosphorylation of MAPK3 protein P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15034929 PMID:18523137 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
P2ry6 |
pyrimidinergic receptor P2Y6 |
multiple interactions affects response to substance |
ISO |
P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]]; P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK1 protein]; P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK3 protein] P2RY6 gene affects the susceptibility to Uridine Diphosphate |
CTD |
PMID:18523137 |
|
NCBI chr 1:164,707,188...164,742,689
Ensembl chr 1:155,295,111...155,330,808
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Uridine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:108,169,980...108,269,822
|
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
Uridine Diphosphate Galactose binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
increases activity |
ISO |
Uridine Diphosphate Galactose results in increased activity of GPR17 protein |
CTD |
PMID:18974869 |
|
NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:740,929...818,310
Ensembl chr 9:653,659...756,334
|
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
Uridine Diphosphate Glucose binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
increases activity |
ISO |
Uridine Diphosphate Glucose results in increased activity of GPR17 protein |
CTD |
PMID:18974869 |
|
NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:740,929...818,310
Ensembl chr 9:653,659...756,334
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] |
CTD |
PMID:35101544 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
B3gat3 |
beta-1,3-glucuronyltransferase 3 |
affects binding multiple interactions |
ISO |
B3GAT3 protein binds to Uridine Diphosphate Glucuronic Acid Uridine Diphosphate Glucuronic Acid inhibits the reaction [Diacetyl results in decreased activity of B3GAT3 protein] |
CTD |
PMID:11986319 |
|
NCBI chr 1:215,246,453...215,253,033
Ensembl chr 1:205,817,378...205,837,807
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
Uridine Diphosphate Glucuronic Acid binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Uridine Diphosphate Glucuronic Acid results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucuronic Acid co-treated with UGT1A1 protein] results in increased glucuronidation of Labetalol |
CTD |
PMID:18098064 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucuronic Acid co-treated with UGT1A3 protein] results in increased metabolism of Lithocholic Acid |
CTD |
PMID:36473578 |
|
NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol; [Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased metabolism of hyodeoxycholic acid; Fluconazole inhibits the reaction [[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol] |
CTD |
PMID:18098064 PMID:36473578 |
|
NCBI chr14:21,251,535...21,274,451
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:740,929...818,310
Ensembl chr 9:653,659...756,334
|
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
Uridine Diphosphate Galactose binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
increases activity |
ISO |
Uridine Diphosphate Galactose results in increased activity of GPR17 protein |
CTD |
PMID:18974869 |
|
NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:740,929...818,310
Ensembl chr 9:653,659...756,334
|
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
Uridine Diphosphate Glucose binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
increases activity |
ISO |
Uridine Diphosphate Glucose results in increased activity of GPR17 protein |
CTD |
PMID:18974869 |
|
NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:740,929...818,310
Ensembl chr 9:653,659...756,334
|
|
|
G |
Gale |
UDP-galactose-4-epimerase |
affects binding |
ISO |
Uridine Diphosphate N-Acetylgalactosamine binds to GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:153,477,420...153,481,926
Ensembl chr 5:148,194,791...148,198,388
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Uridine Diphosphate N-Acetylglucosamine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Bsg |
basigin |
decreases expression |
ISO |
Uridine Monophosphate results in decreased expression of BSG protein |
CTD |
PMID:36574092 |
|
NCBI chr 7:10,643,788...10,651,005
Ensembl chr 7:9,993,170...10,000,387
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Uridine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
Uridine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein] |
CTD |
PMID:12044622 |
|
NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Egfr |
epidermal growth factor receptor |
increases phosphorylation |
EXP |
Uridine Triphosphate results in increased phosphorylation of EGFR protein |
CTD |
PMID:14676212 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Gnaq |
G protein subunit alpha q |
multiple interactions |
EXP |
Uridine Triphosphate inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]] |
CTD |
PMID:14676212 |
|
NCBI chr 1:222,852,453...223,098,754
Ensembl chr 1:213,424,465...213,667,672
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Uridine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] |
CTD |
PMID:32941855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hcar2 |
hydroxycarboxylic acid receptor 2 |
multiple interactions |
ISO |
[Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids]; [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids] |
CTD |
PMID:16674924 |
|
NCBI chr12:38,387,163...38,389,149
Ensembl chr12:32,726,184...32,728,504
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
NF157 compound inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein] MRS 2211 inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein] |
CTD |
PMID:24793913 PMID:24849676 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids]; [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids; Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] Uridine Triphosphate results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:14676212 PMID:15034929 PMID:16674924 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids]; [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids; Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] Uridine Triphosphate results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:14676212 PMID:15034929 PMID:16674924 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myl2 |
myosin light chain 2 |
multiple interactions |
EXP |
Uridine Triphosphate inhibits the reaction [MYL2 protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]; Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of MYL2 protein] |
CTD |
PMID:14676212 |
|
NCBI chr12:40,114,964...40,126,236
Ensembl chr12:34,454,218...34,468,983
|
|
G |
Myocd |
myocardin |
multiple interactions |
EXP |
Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of MYL2 protein]; Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of NPPA protein] |
CTD |
PMID:14676212 |
|
NCBI chr10:50,332,356...50,426,819
Ensembl chr10:49,836,641...49,927,627
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases expression |
EXP |
Uridine Triphosphate inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]; Uridine Triphosphate inhibits the reaction [MYL2 protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]; Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of NPPA protein]; Uridine Triphosphate inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] Uridine Triphosphate results in increased expression of NPPA mRNA |
CTD |
PMID:14676212 |
|
NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
P2rx1 |
purinergic receptor P2X 1 |
affects binding |
EXP |
UTP binds to P2rx1 protein |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:58,117,107...58,132,167
Ensembl chr10:57,618,586...57,633,623
|
|
G |
P2ry2 |
purinergic receptor P2Y2 |
multiple interactions |
EXP ISO |
Uridine Triphosphate binds to and results in increased activity of P2RY2 protein Endocannabinoids inhibits the reaction [Uridine Triphosphate binds to and results in increased activity of P2RY2 protein]; Uridine Triphosphate binds to and results in increased activity of P2RY2 protein |
CTD |
PMID:15654852 PMID:30102254 |
|
NCBI chr 1:164,764,119...164,779,578
Ensembl chr 1:155,351,165...155,367,632
|
|
G |
P2ry4 |
pyrimidinergic receptor P2Y4 |
multiple interactions |
EXP |
Uridine Triphosphate binds to and results in increased activity of P2RY4 protein |
CTD |
PMID:15654852 |
|
NCBI chr X:69,722,604...69,757,726
Ensembl chr X:65,683,232...65,721,748
|
|
G |
Panx1 |
Pannexin 1 |
decreases activity |
ISO |
Uridine Triphosphate results in decreased activity of PANX1 protein |
CTD |
PMID:19023039 |
|
NCBI chr 8:20,128,783...20,171,200
Ensembl chr 8:11,850,730...11,889,774
|
|
G |
Sftpb |
surfactant protein B |
increases secretion |
ISO |
Uridine Triphosphate results in increased secretion of SFTPB protein |
CTD |
PMID:14565945 |
|
NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:104,359,396...104,368,436
|
|
G |
Sftpc |
surfactant protein C |
increases secretion |
ISO |
Uridine Triphosphate results in increased secretion of SFTPC protein |
CTD |
PMID:14565945 |
|
NCBI chr15:52,006,274...52,009,324
Ensembl chr15:45,596,574...45,610,777
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Uridine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:32941855 |
|
NCBI chr 3:128,620,320...128,724,716
Ensembl chr 3:108,169,980...108,269,822
|
|
G |
Trpc3 |
transient receptor potential cation channel, subfamily C, member 3 |
multiple interactions increases activity |
ISO |
ethyl-1-(4-(2*3*3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate inhibits the reaction [Uridine Triphosphate results in increased activity of TRPC3 protein] |
CTD |
PMID:19289841 |
|
NCBI chr 2:121,409,436...121,487,095
Ensembl chr 2:119,481,400...119,558,855
|
|
G |
Trpc5 |
transient receptor potential cation channel, subfamily C, member 5 |
increases activity |
ISO |
Uridine Triphosphate results in increased activity of TRPC5 protein |
CTD |
PMID:19289841 |
|
NCBI chr X:112,742,828...113,027,638
Ensembl chr X:107,939,131...108,230,991
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
increases activity |
ISO |
Uridine Triphosphate results in increased activity of TRPC6 protein |
CTD |
PMID:19289841 |
|
NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Trpc7 |
transient receptor potential cation channel, subfamily C, member 7 |
increases activity |
ISO |
Uridine Triphosphate results in increased activity of TRPC7 protein |
CTD |
PMID:19289841 |
|
NCBI chr17:7,707,954...7,839,064
Ensembl chr17:7,709,583...7,833,435
|
|